9h-pyrimido [4,5-b]indoles and related analogs as bet bromodomain inhibitors

ABSTRACT

The present disclosure provides substituted 9H-pyrimido[4,5-b]indoles and 5H-pyrido[4,3-b]indoles and related analogs represented by Formula I: 
     
       
         
         
             
             
         
       
     
     and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R 1a , A, B 1 , B 2 , G, X 1 , Y 1 , Y 2 , and Y 3  are as defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a condition or disorder responsive to inhibition of BET bromodomains. Compounds of the present disclosure are especially useful for treating cancer.

This invention was made with government support under CA111275 andCA069568 awarded by the National Institutes of Health. The Governmenthas certain rights in the invention.

BACKGROUND OF THE INVENTION

Field of the Invention

The present disclosure provides BET bromodomain inhibitors andtherapeutic methods of treating conditions and diseases whereininhibition of one or more BET bromodomains provides a benefit.

Background Art

The genomes of eukaryotic organisms are highly organized within thenucleus of the cell. The long strands of duplex DNA are wrapped aroundan octamer of histone proteins (usually comprising two copies ofhistones H2A, H2B, H3, and H4) to form a nucleosome, which then isfurther compressed to form a highly condensed chromatin structure. Arange of different condensation states are possible, and the tightnessof this structure varies during the cell cycle. The chromatin structureplays a critical role in regulating gene transcription, which cannotoccur efficiently from highly condensed chromatin. The chromatinstructure is controlled by a series of post translational modificationsto histone proteins, notably histones H3 and H4. These modificationsinclude acetylation, methylation, phosphorylation, ubiquitinylation, andSUMOylation.

Histone acetylation usually is associated with the activation of genetranscription, as the modification loosens the interaction of the DNAand the histone octamer by changing the electrostatics. In addition tothis physical change, specific proteins bind to acetylated lysineresidues within histones to read the epigenetic code. Bromodomains aresmall (about 110 amino acids) distinct domains within proteins that bindto acetylated lysine resides commonly, but not exclusively, in thecontext of histones. There is a family of about 50 proteins known tocontain bromodomains, which have a range of functions within the cell.

The BET family of bromodomain-containing proteins (“BET bromodomains”)includes four proteins, i.e., BRD2, BRD3, BRD4, and BRD-t, which containtandem bromodomains capable of binding to two acetylated lysine residuesin close proximity, thereby increasing the specificity of theinteraction. BRD2 and BRD3 associate with histones along activelytranscribed genes and may be involved in facilitating transcriptionalelongation, while BRD4 may be involved in the recruitment of the pTEF-βcomplex to inducible genes, resulting in phosphorylation of RNApolymerase and increased transcriptional output. BRD4 or BRD3 also mayfuse with NUT (nuclear protein in testis) forming novel fusiononcogenes, BRD4-NUT or BRD3-NUT, in a highly malignant form ofepithelial neoplasia. Data suggests that BRD-NUT fusion proteinscontribute to carcinogenesis. BRD-t is uniquely expressed in the testesand ovary. All family members have been reported to have some functionin controlling or executing aspects of the cell cycle, and have beenshown to remain in complex with chromosomes during cell division, whichsuggests a role in the maintenance of epigenetic memory. In addition,some viruses make use of these proteins to tether their genomes to thehost cell chromatin as part of the process of viral replication.

A discussion of BET proteins can be found in WO 2012/075456, WO2012/075383, and WO 2011/054864. A discussion of BET bromodomaininhibitors, e.g., I-BET-151 and I-BET-762, can be found in Delmore etal., Cell 146:904-917 (2011) and Seal et al., Bioorg. Med. Chem. Lett.22:2968-2972 (2012). Small molecule inhibitors of BET bromodomains havetherapeutic potential for the treatment of many diseases and conditionsin which BET bromodomains have a role, including cancer. BET bromodomaininhibitors are disclosed in the following U.S. Pat. No. 8,044,042, U.S.Pat. No. 8,476,260, U.S. Pat. No. 8,114,995, U.S. Pat. No. 8,557,984,and U.S. Pat. No. 8,580,957; the following U.S. patent applicationpublications: US 20120059002, US 20120208800, US 2012202799, US2012252781, US 20130252331, US 20140011862, US 20130184264, US2013079335, US 20140011862, US 20140005169, US 20130331382, US20130281450, US 20130281399, US 20120157428, and US 20100286127; and thefollowing international applications: WO 1998011111, WO 2006129623, WO2008092231, WO 2009084693, WO 2009158404, WO 2010123975, WO 2011054843,WO 2011054844, WO 2011054845, WO 2011054846, WO 2011054848, WO2011143651, WO 2011143660, WO 2011143669, WO 2011161031, WO 2012075383,WO 2012116170, WO 2012151512, WO 2012174487, WO 2013024104, WO2013027168, WO 2013030150, WO 2013033268, and WO 2013097601.

Men who develop metastatic castration-resistant prostate cancer (CRPC)invariably succumb to the disease. The development and progression toCRPC following androgen ablation therapy is predominantly driven byunregulated androgen receptor (AR) signaling (Taylor, B. S. et al.,Cancer Cell 18:11-22 (2010); Chen, C. D. et al., Nat Med 10:33-39(2004); Visakorpi, T. et al., Nat Genet 9:401-406 (1995)). Despite thesuccess of recently approved therapies targeting AR signaling such asabiraterone (Stein, M. N., Goodin, S. and Dipaola, R. S., Clin CancerRes 18:1848-1854 (2012); Reid, A. H. et al. J Clin Oncol 28: 1489-1495(2010); de Bono, J. S. et al., N Engl J Med 364: 1995-2005 (2011)) andsecond generation anti-androgens MDV3100 (enzalutamide) (Mukherji, D. etal. Expert Opin Investig Drugs 21:227-233 (2012); Scher, H. I. et al., NEngl J Med 367:1187-1197 (2012)), durable responses are limited,presumably due to acquired resistance. Recently JQ1 and I-BET, twoselective small molecule inhibitors that target the amino-terminalbromodomains of BRD4, have been shown to exhibit antiproliferativeeffects in a range of malignancies (Lockwood, W. W. et al., Proc NatlAcad Sci USA 109:19 408-19413 (2012); Dawson, M. A. et al., Nature 478:529-533 (2011); Delmore, J. E. et al. Cell 146: 904-917 (2011);Puissant, A. et al. Cancer Discov 3:308-323 (2013)). BRD4 physicallyinteracts with the N-terminal domain of AR and can be disrupted by JQ1(Delmore, J. E. et al. Cell 146: 904-917 (2011); Puissant, A. et al.Cancer Discov 3:308-323 (2013); Filippakopoulos, P. et al. Nature468:1067-1073 (2010)).

The identification and therapeutic targeting of co-activators ormediators of AR transcriptional signaling should be considered asalternate strategies to treat CRPC (Attard, G. et al., Clin Cancer Res17:1649-1657 (2011)). BRD4 is a conserved member of the bromodomain andextraterminal (BET) family of chromatin readers that include BRD2/3 andBRDT. BRD4 plays a critical role in transcription by RNA PolII, byfacilitating recruitment of the positive transcription elongation factorP-TEFb (Jang, M. K. et al., Mol Cell 19:523-534 (2005); Yang, Z. et al.,Mol Cell 19: 535-545 (2005). Similar to other BET-family proteins, BRD4contains two conserved bromodomains, BD1 and BD2. Competitive binding ofJQ1 or I-BET to the bromodomain pocket results in the displacement BRD4from active chromatin and subsequent removal of RNA PolII from targetgenes (Dawson, M. A. et al., Nature 478: 529-533 (2011); Delmore, J. E.et al., Cell 146: 904-917 (2011); Puissant, A. et al., Cancer Discov3:308-323 (2013); Filippakopoulos, P. et al., Nature 468:1067-1073(2010); Loven, J. et al., 153:320-334 (2013)) Although most cancer cellsexpress BET-family proteins, it is not clear why only a subset of celllines from diverse cancers respond to BET-inhibitors (Lockwood, W. W. etal. Proc Natl Acad Sci USA 109:19408-19413 (2012); Mertz, J. A. et al.,Proc Natl Acad Sci USA 108:16669-16674 (2011)). Recently, BRD4 was shownto interact with sequence-specific DNA-binding transcription factors ina gene-specific manner (Wu, S. Y. et al., Mol Cell 49:843-857 (2013)).As the genetic and epigenetic landscape differs between tumor types, itis possible that distinct transcriptional regulators that associate withBRD4 might influence the action of BET-inhibitors.

Breast cancer accounts for more than 20% of all cancers in womenworldwide. The expression of androgen receptor (AR) is widespread bothin ER (estrogen receptor)-positive and ER-negative breast cancers. In ERpositive breast cancer adjuvant therapy with ER antagonist tamoxifen oraromatase inhibitors (AIs)—which block conversion of androgen toestrogens, has shown to be effective in inhibiting disease progression.Moreover, direct AR antagonist Enzalutamide (MDV3100) has recently beenproposed as a therapeutic modality for AR positive breast cancers.

Despite research directed to BET bromodomains and BET bromodomaininhibitors, the design of potent, non-peptide inhibitors of BETbromodomains remains a significant challenge in modern drug discovery.Accordingly, a need still exists in the art for BET bromodomaininhibitors having physical and pharmacological properties that permituse of the inhibitors in therapeutic applications, especially in humans.The present disclosure provides compounds that bind to BET bromodomainsand inhibit BET bromodomain activity.

BRIEF SUMMARY OF THE INVENTION

In one aspect, the present disclosure provides9H-pyrimido[4,5-b]indoles, 5H-pyrido[4,3-b]indoles, and related analogsrepresented by Formulae I-VI and IX-XVII, below, and thepharmaceutically acceptable salts, hydrates, and solvates thereof,collectively referred to herein as “Compounds of the Disclosure.”Compounds of the Disclosure are potent and specific inhibitors of BETbromodomains that bind to BET bromodomains and function as potentantagonists of BET bromodomains. Thus, Compounds of the Disclosure areuseful in treating diseases or conditions wherein inhibition of BETbromodomains, e.g., BRD2, BRD3, BRD4, BRD-t, or an isoform or mutantthereof, provides a benefit.

In another aspect, the present disclosure provides methods of treating acondition or disease by administering a therapeutically effective amountof a Compound of the Disclosure to an individual, e.g., a human, in needthereof. The disease or condition of interest is treatable by inhibitionof BET bromodomains, for example, a cancer, a chronic autoimmunedisorder, an inflammatory condition, a proliferative disorder, sepsis,or a viral infection. Also provided are methods of preventing theproliferation of unwanted proliferating cells, such as cancer, in asubject, the methods comprising administering a therapeuticallyeffective amount of a Compound of the Disclosure to a subject at risk ofdeveloping a condition characterized by unwanted proliferating cells. Insome embodiments, the Compounds of the Disclosure reduce theproliferation of unwanted cells by inducing apoptosis in those cells.

In another aspect, the present disclosure provides a method ofinhibiting BET bromodomains in an individual, comprising administeringto the individual an effective amount of at least one Compound of theDisclosure.

In another aspect, the present disclosure provides a pharmaceuticalcomposition comprising a Compound of the Disclosure and an excipientand/or pharmaceutically acceptable carrier.

In another aspect, the present disclosure provides a compositioncomprising a Compound of the Disclosure and an excipient and/orpharmaceutically acceptable carrier for use treating diseases orconditions wherein inhibition of BET bromodomains provides a benefit,e.g., cancer.

In another aspect, the present disclosure provides a compositioncomprising: (a) a Compound of the Disclosure; (b) a secondtherapeutically active agent; and (c) optionally an excipient and/orpharmaceutically acceptable carrier.

In another aspect, the present disclosure provides a Compound of theDisclosure for use in treatment of a disease or condition of interest,e.g., cancer.

In another aspect, the present disclosure provides a Compound of theDisclosure for use in treatment of breast cancer having active androgenreceptor (AR) signaling.

In another aspect, the present disclosure provides a Compound of theDisclosure for use in treatment of prostate cancer, e.g.,castration-resistant prostate cancer, having active AR signaling.

In another aspect, the present disclosure provides a use of a Compoundof the Disclosure for the manufacture of a medicament for treating adisease or condition of interest, e.g., cancer.

In another aspect, the present disclosure provides a kit comprising aCompound of the Disclosure, and, optionally, a packaged compositioncomprising a second therapeutic agent useful in the treatment of adisease or condition of interest, and a package insert containingdirections for use in the treatment of a disease or condition, e.g.,cancer.

In another aspect, the present disclosure provides compounds assynthetic intermediates that can be used to prepare Compounds of theDisclosure.

In another aspect, the present disclosure provides methods of preparingCompounds of the Disclosure.

Additional embodiments and advantages of the disclosure will be setforth, in part, in the description that follows, and will flow from thedescription, or can be learned by practice of the disclosure. Theembodiments and advantages of the disclosure will be realized andattained by means of the elements and combinations particularly pointedout in the appended claims.

It is to be understood that both the foregoing summary and the followingdetailed description are exemplary and explanatory only, and are notrestrictive of the invention as claimed.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 is a table showing the IC₅₀ for JQ1 in each cell line is listed.

FIG. 2 is an illustration showing the induction of apoptosis in VCaPprostate cancer cells by JQ1. Cleaved PARP (cPARP) immunoblot analysis.GAPDH served as a loading control.

FIG. 3 is a bar graph showing colony formation assays of prostate celllines. Cells were cultured in the presence or absence of 100 and 500 nMof JQ1 for 12 days, followed by staining and quantification.

FIG. 4 is a bar graph showing QRT-PCR analysis of indicated genes inVCaP treated with different concentrations of JQ1 for 24 h.

FIG. 5 is an illustration showing immunoblot analyses of AR, PSA and ERGlevels in VCaP treated with JQ1.

FIG. 6 is four illustrations showing GSEA of the AR target genesignature in VCaP, LNCaP, 22RV1, and DU145 cells. NS, not-significant,*P≦0.05, **P≦0.005 by t-test.

FIG. 7 is an illustration showing VCaP nuclear extracts fractionated ona Superose-6 column and AR, BRD4 and RNA PolII and analysis byimmunoblotting.

FIG. 8 is two illustrations showing endogenous association of AR andBRD2/3/4. VCaP and LNCaP nuclear extracts were subjected toimmunoprecipitation using an anti-AR antibody. Immunoprecipitates wereanalyzed for the presence of BRD2/3/4 by immunoblotting (upper panel).The immunoblot was stripped and reprobed for AR (lower panel). 5% totallysate was used as input control.

FIG. 9 is a schematic of BRD4 and AR constructs used forco-immunoprecipitation experiments (BD1, bromodomain 1; BD2, bromodomain2; ET, Extraterminal domain. CTD; C-terminal domain; NTD, N-terminaldomain; DBD, DNA-binding domain; and LBD, ligand-binding domain).

FIG. 10 is an illustration showing the N-terminal domain of BRD4interacts with AR. Proteins from 293T cells co-transfected withdifferent His-tag-BRD4 deletion and Halo-tag-AR constructs weresubjected to immunoprecipitation with Halo-beads followed byimmunoblotting with His-tag antibody. Inputs are shown in the bottompanel.

FIG. 11 is an illustration as in FIG. 10 but with the indicated saltconcentrations.

FIG. 12 is an illustration showing representative sensorgrams forAR:BRD4 (BD1-BD2) by an OctetRED biolayer interferometry showing directinteraction. Real-time binding was measured by immobilizing biotinylatedAR protein on the super streptavidin biosensor and subsequentinteraction with different concentrations of BRD4 (BD1-BD2) protein. Theplots show the response versus protein concentration curves derived fromthe raw binding data. Right, Dissociation constant (Kd) represents theBRD4 (BD1-BD2) concentration yielding half-maximal binding to AR.Protein RNF2 was used as negative control.

FIG. 13 is an illustration showing in vitro binding analysis of AR andindicated domains of BRD4. Equal amounts of in vitro translatedfull-length Halo-tag-AR protein and GST-tag-BRD4 domains were combinedand immunoprecipitated using Halo beads followed by immunoblot analysiswith anti-GST antibody.

FIG. 14 is an illustration showing the NTD domain of AR interacts withBD1 of BRD4. As in FIG. 8, immunoprecipitation with different domains ofHalo-AR followed by immunoblot analysis with anti-GST antibody.

FIG. 15 is an illustration showing the NTD domain of AR interacts withBD1 of BRD4. As in FIG. 8, immunoprecipitation with different domains ofHalo-AR followed by immunoblot analysis with anti-GST antibody.

FIG. 16 is an illustration showing JQ1 disrupts AR-BD1 interactions.Varying concentrations of JQ1 were incubated to the AR-BD1, NTD1b-BD1,and AR-BD2 complex prior to immunoprecipitation followed by immunoblotanalysis.

FIG. 17 is an illustration showing AR ChIP-seq in VCaP cells treated for12 h with vehicle, DHT (10 nM), DHT+JQ1 (500 nM), DHT+MDV3100 (10M) orDHT+Bicalutamide (25 μM). Summary plot of AR enrichment (averagecoverage) across ARBs (AR Binding sites) in different treatment groupsis shown.

FIG. 18 is a Venn diagram illustrating the overlap of AR and BRD4enriched peaks in DHT treated sample.

FIG. 19 is an illustration showing AR and BRD4 enrichment for theAR-BRD4 overlapping (2031) regions.

FIG. 20 is an illustration showing AR and BRD4 enrichment for theAR-BRD4 overlapping (2031) regions.

FIG. 21 is an illustration showing a genome browser representation ofAR, BRD4 and RNA PolII binding events on a putative “super-enhancer” ofthe AR-regulated BMPR1B gene. They-axis denotes reads per million perbase pair (rpm/bp). The x-axis denotes the genomic position with a scalebar on top right. The putative super-enhancer region enriched for AR,BRD4 and RNA PolII is depicted with a black bar on the top left.

FIG. 22 is a line graph comparison of JQ1 and MDV3100 treatment on VCaPcell viability in vitro. VCaP cells were treated with MDV3100 or JQ1 for8 days and assayed for viability with Cell-titerGLO.

FIG. 23 is a line graph comparison of JQ1 and MDV3100VCaP. Cells wereimplanted subcutaneously in mice and grown until tumors reached the sizeof approximately 100 mm³. Xenografted mice were randomized and thenreceived vehicle or 50 mg/kg JQ1 or 10 mg/kg MDV3100 as indicated 5days/week. Caliper measurements were taken bi-weekly. Mean tumorvolume±SEM is shown.

FIG. 24 is an illustration of individual tumor volume and weight fromdifferent treatment groups with p-values is shown.

FIG. 25 is an illustration of individual tumor volume and weight fromdifferent treatment groups with p-values is shown.

FIG. 26 is a schematic illustrating the VCaP CRPC mouse xenograftexperimental design (top panel). Castrated mice bearing VCaP CRPCxenograft received vehicle or 50 mg/kg JQ1 as indicated 5 days/week(bottom panel).

FIG. 27 is a schematic depicting varying mechanisms to blockAR-signaling in CRPC. 1) Abiraterone inhibits androgen biosynthesis byblocking the enzyme CYP17A1. 2) MDV3100 competitively antagonizesandrogen binding to AR preventing nuclear translocation and recruitmentto target gene loci. 3) JQ1 (or BET-inhibitors) blocks AR and BRD2/3/4interaction and co-recruitment to target gene loci as well as thefunctional activity and/or expression of ETS and MYC.

DETAILED DESCRIPTION OF THE INVENTION

Compounds of the Disclosure are inhibitors of BET bromodomain proteins.In view of this property, Compounds of the Disclosure are useful fortreating conditions or disorders responsive to BET bromodomaininhibition.

In one embodiment, Compounds of the Disclosure are compounds representedby Formula I:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein:

B¹ is —N═ or —C(R^(1b))—;

B² is —N═ or —C(R^(1c))—;

Y¹ is selected from the group consisting of —C(R^(2a))═ and —N═;

Y² is selected from the group consisting of —C(R^(2b))═ and —N═;

Y³ is selected from the group consisting of —C(R^(2c))═ and —N═;

G is selected from the group consisting of halo, hydroxy, cyano,optionally substituted cycloalkyl, optionally substituted heterocyclo,optionally substituted aryl, optionally substituted heteroaryl, aralkyl,(heteroaryl)alkyl, —OS(═O)CF₃, and —Z—R³

R^(1a) and R^(1b) are each independently selected from the groupconsisting of hydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio,amino, and halo;

R^(1c) is selected from the group consisting of hydrogen, hydroxy,alkyl, haloalkyl, alkoxy, alkylthio, amino, carboxamido, and fluoro;

R^(2a) and R^(2c) are independently selected from the group consistingof hydrogen, halo, alkyl, and carboxamido;

R^(2b) is selected from the group consisting of hydrogen, amino,optionally substituted alkyl, hydroxyalkyl, alkoxyalkyl, heteroalkyl,(heterocyclo)alkyl, (amino)alkyl, optionally substituted cycloalkyl,optionally substituted heterocyclo, and carboxamido;

R³ is selected from the group consisting of optionally substitutedcycloalkyl, optionally substituted aryl, optionally substitutedheteroaryl, and optionally substituted heterocyclo;

A is optionally substituted 5-membered heteroaryl;

X¹ is selected from the group consisting of —O—, —S—, and —N(R^(5a1))—;

Z is selected from the group consisting of —C(═O)—, —O—, —S—, —SO₂—, and—N(R^(5b1))—;

R^(5a1) is selected from the group consisting of hydrogen and alkyl, and

R^(5b1) is selected from the group consisting of hydrogen and alkyl,

with the proviso that A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, with the provisos that:

a) when G is halo, hydroxy, cyano, optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl, aralkyl,(heteroaryl)alkyl, or —OS(═O)₂CF₃, then either B¹ or B², or both, is—N═; or

b) when G is halo, hydroxy, cyano, optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl, aralkyl,(heteroaryl)alkyl, or —OS(═O)₂CF₃, then either R^(1b) or R^(1c), orboth, is hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino,carboxamido, or fluoro.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, with the provisos that:

c) at least one of Y¹, Y², and Y³ is —N═; and

d) at least one of Y¹, Y², and Y³ is not —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula II:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein:

R¹ is selected from the group consisting of hydrogen, hydroxy, alkyl,haloalkyl, alkoxy, alkylthio, amino, and halo;

R² is selected from the group consisting of hydrogen, amino, alkyl,hydroxyalkyl, alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, optionallysubstituted cycloalkyl, optionally substituted heterocyclo, andcarboxamido;

R³ is selected from the group consisting of optionally substitutedcycloalkyl, optionally substituted aryl, optionally substitutedheteroaryl, and optionally substituted heterocyclo;

A is optionally substituted 5-membered heteroaryl;

X¹ is selected from the group consisting of —O—, —S—, and —N(R^(5a1))—;

Y¹ is selected from the group consisting of —CH═ and —N═;

Z is selected from the group consisting of —O—, —S—, —SO₂—, and—N(R^(5b1))—;

R^(5a1) is selected from the group consisting of hydrogen and alkyl; and

R^(5b1) is selected from the group consisting of hydrogen and alkyl,

with the proviso that A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula II, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein:

R¹ is selected from the group consisting of hydrogen, hydroxy, alkyl,haloalkyl, alkoxy, alkylthio, amino, and halo;

R² is selected from the group consisting of hydrogen, alkyl,hydroxyalkyl, alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, optionallysubstituted cycloalkyl, optionally substituted heterocyclo, andcarboxamido;

R³ is selected from the group consisting of optionally substituted aryl,optionally substituted heteroaryl, and optionally substitutedheterocyclo;

A is optionally substituted 5-membered heteroaryl;

X¹ is selected from the group consisting of —O—, —S—, and —N(R^(5a1))—;

Y¹ is selected from the group consisting of —CH═ and —N═;

Z is selected from the group consisting of —O—, —S—, —SO₂—, and—N(R^(5b1))—;

R^(5a1) is selected from the group consisting of hydrogen and alkyl; and

R^(5b1) is selected from the group consisting of hydrogen and alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I and II, and the pharmaceutically acceptablesalts, hydrates, and solvates thereof, wherein:

A is optionally substituted 5-membered heteroaryl selected from thegroup consisting of:

R^(4a), R^(4b), and R^(4c) are each independently selected from thegroup consisting of hydrogen, halo, haloalkyl, and alkyl;

X² is selected from the group consisting of —O—, —S—, and —N(R^(5c1))—;and

R^(5c1) is selected from the group consisting of hydrogen and alkyl. Inanother embodiment, R^(4a), R^(4b), and R^(4c) are each independentlyselected from the group consisting of hydrogen and alkyl, and X isselected from the group consisting of —O— and —N(R^(5c1))—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I and II, and the pharmaceutically acceptablesalts, hydrates, and solvates thereof, wherein A is A-3 and X² is—N(R^(5c1))—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I and II, and the pharmaceutically acceptablesalts, hydrates, and solvates thereof, wherein A is A-9, R^(4a) isalkyl, and R^(4b) is alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula III:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R¹, R², R³, X¹, Y¹, and Z are as defined above inconnection with Formula II, and R^(4a), R^(4b), and X² is as definedabove in connection with groups A-1 to A-9.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(1a) is C₁₋₄ alkoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae II and III, and the pharmaceutically acceptablesalts, hydrates, and solvates thereof, wherein R is C₁₋₄ alkoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula III, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(4a) and R^(4b) are eachindependently selected from the group consisting of hydrogen and C₁₋₄alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula III, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein X² is O.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein Y² is —C(R^(2b))— and R^(2b) isC₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae II and III, and the pharmaceutically acceptablesalts, hydrates, and solvates thereof, wherein R² is C₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I, II, and III, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein X¹ is —NH—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I, II, and III, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein X is—N(R^(5a1))—, wherein R^(5a1) is C₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I, II, and III, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein X⁴ is—N(CH₃)—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formulae I, II and III, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Z is —NH—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IV:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R², R³, Z, and Y¹ are as defined above in connectionwith Formula II.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula V:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R², R³, Y¹, and Z are as defined above in connectionwith Formula II.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula VI:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R², R³, Y¹, and Z are as defined above in connectionwith Formula II.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein G is selected from the groupconsisting of halo, hydroxy, optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl, aralkyl,and (heteroaryl)alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein G is —Z—R³.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Z is —NH—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Z is —O—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Z is —S—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Z is —SO₂—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein Y² is —C(R^(2b))— and R^(2b) ishydrogen.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae II-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein R is hydrogen.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein Y² is —C(R^(2b))— and R^(2b) isC₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae II-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein R² is alkyl.In another embodiment, R² is C₁₋₆ alkyl. In another embodiment, R² isC₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein Y² is —C(R^(2b))— and R^(2b) isoptionally substituted heterocyclo.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae II-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein R isoptionally substituted heterocyclo.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Y¹ is —CH═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein Y¹ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted aryl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted aryl selected from the group consisting ofoptionally substituted phenyl and optionally substituted naphthyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted phenyl selected from the group consisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted naphthyl selected from the group consisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted heteroaryl. In one embodiment, the optionallysubstituted heteroaryl is selected from the group consisting of:

In another embodiment, the optionally substituted heteroaryl is selectedfrom the group consisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted 6-membered heteroaryl. In one embodiment, theoptionally substituted 6-membered heteroaryl is selected from the groupconsisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted 5-membered heteroaryl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula I-VI, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein:

G or R³ is optionally substituted 5-membered heteroaryl selected fromthe group consisting of:

R^(5a), R^(5b), and R⁵ are each independently selected from the groupconsisting of hydrogen, halo, cyano, alkylcarbonyl, alkoxycarbonyl,haloalkyl, optionally substituted alkyl, hydroxyalkyl, alkoxyalkyl,alkenyl, aralkyl, optionally substituted cycloalkyl, optionallysubstituted heterocyclo, optionally substituted aryl, optionallysubstituted heteroaryl, and carboxamido;

X³ is selected from the group consisting of —O—, —S—, and —N(R^(5d))—;

R^(5d) is selected from the group consisting of hydrogen, optionallysubstituted alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, (amino)alkyl,aralkyl, (heterocyclo)alkyl, optionally substituted cycloalkyl,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, carboxamido, (carboxamido)alkyl, and—C(═O)R^(5e); and

R^(5e) is selected from the group consisting of alkyl and alkoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein:

G or R³ is optionally substituted 5-membered heteroaryl selected fromthe group consisting of:

R^(5a), R^(5b), and R^(5c) are each independently selected from thegroup consisting of hydrogen, halo, cyano, alkylcarbonyl,alkoxycarbonyl, haloalkyl, optionally substituted alkyl, hydroxyalkyl,alkoxyalkyl, alkenyl, aralkyl, optionally substituted cycloalkyl,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, and carboxamido;

X³ is selected from the group consisting of —O—, —S—, and —N(R^(5d))—;

R^(5d) is selected from the group consisting of hydrogen, alkyl,haloalkyl, hydroxyalkyl, alkoxyalkyl, (amino)alkyl, aralkyl, optionallysubstituted cycloalkyl, optionally substituted heterocyclo, optionallysubstituted aryl, optionally substituted heteroaryl, carboxamido,(carboxamido)alkyl, and —C(═O)R^(5e); and

R^(5e) is selected from the group consisting of alkyl and alkoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein:

G or R³ is optionally substituted heteroaryl selected from the groupconsisting of:

X⁴ is selected from the group consisting of —O—, —S—, and —N(R^(f))—;

R^(5f) is selected from the group consisting of hydrogen, alkyl,haloalkyl, hydroxyalkyl, aralkyl, optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl, andcarboxamido; and

n is 1, 2, or 3. In another embodiment, X⁴ is —N(R^(5f))— and n is 1 or2.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-1.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-2.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-3.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-4.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-5.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-6.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-7.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-8.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-9.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein R³ is R3-10.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-11.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isR3-12.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isoptionally substituted 5-membered heteroaryl selected from the groupconsisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-V, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein G or R³ isselected from the group consisting of:

In another embodiment, Compounds of the Disclosure are compoundsrepresented by any one of Formulae I-VI, and the pharmaceuticallyacceptable salts, hydrates, and solvates thereof, wherein R isoptionally substituted cycloalkyl. In another embodiment, R³ is selectedfrom the group consisting of cyclopentyl and cyclohexyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(1a) is selected from thegroup consisting of hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino,and halo; R^(1b) is halo; and R^(1c) is hydrogen.

In another embodiment, Compounds of the Disclosure are compoundsrepresented Formula I, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(1a) is selected from thegroup consisting of hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino,and halo; R^(1b) is hydrogen; and R^(1c) is fluoro.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R¹, R², R^(a1), R^(5a), R^(5c), R^(5d), A, Z, and Y¹are as defined above in connection with Formula II, with the provisothat A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(5a1) is hydrogen. In anotherembodiment, R^(5a1) is C₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R¹ is alkoxy. In anotherembodiment, R¹ is methoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein A is selected from the groupconsisting of A-3 and A-9. In another embodiment, A is A-3. In anotherembodiment, X is —O—, and R^(4a) and R^(4b) are independently C₁₋₄alkyl. In another embodiment, R^(4a) and R^(4b) are methyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein, Z is —NH—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein, Y¹ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula IX, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(5a), R^(5c), and R^(5d) areindependently selected from the group consisting of hydrogen, C₁₋₆alkyl, and C₃₋₆ cycloalkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula X:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a), A, G, X¹, Y¹, Y², and Y³ are as defined abovein connection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl. Inanother embodiment, G is selected from the group consisting ofoptionally substituted aryl, optionally substituted heteroaryl, aralkyl,and (heteroaryl)alkyl. In another embodiment, G is —Z—R³. In anotherembodiment, Y¹ is —N═; Y² is —C(R^(2b))=; and Y³ is —C(R^(2c))=. Inanother embodiment, Y¹ is —C(R^(2a))═; Y² is —N═; and Y³ is —C(R²)═. Inanother embodiment, Y¹ is —C(R^(2a))═; Y² is —C(R^(2b))═; and Y³ is —N═.In another embodiment, Y¹ is —N═; Y² is —C(R^(2b))═; and Y³ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XI:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a), A, G, X¹, Y¹, Y², and Y³ are as defined abovein connection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl. Inanother embodiment, G is selected from the group consisting ofoptionally substituted aryl, optionally substituted heteroaryl, aralkyl,and (heteroaryl)alkyl. In another embodiment, G is —Z—R. In anotherembodiment, Y¹ is —N═; Y² is —C(R^(2b))=; and Y³ is —C(R^(2c))=. Inanother embodiment, Y¹ is —C(R^(2a))=; Y² is —N═; and Y³ is —C(R^(2c))═.In another embodiment, Y¹ is —C(R^(2a))═; Y² is —C(R^(2b))═; and Y³ is—N═. In another embodiment, Y¹ is —N═; Y² is —C(R^(2b))═; and Y³ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XII:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) and R^(1b) are independently selected from thegroup consisting of hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino,and halo; and A, G, X¹, Y¹, Y², and Y³ are as defined above inconnection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl. Inanother embodiment, G is selected from the group consisting ofoptionally substituted aryl, optionally substituted heteroaryl, aralkyl,and (heteroaryl)alkyl. In another embodiment, G is —Z—R³. In anotherembodiment, Y¹ is —N═; Y² is —C(R^(2b))═; and Y³ is —C(R^(2c))═. Inanother embodiment, Y¹ is —C(R^(2a))=; Y² is —N═; and Y³ is —C(R^(2c))═.In another embodiment, Y¹ is —C(R^(2a))═; Y² is —C(R^(2b))═; and Y³ is—N═. In another embodiment, Y¹ is —N═; Y² is —C(R^(2b))═; and Y³ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XIII:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) and R^(1c) are independently selected from thegroup consisting of hydroxy, optionally substituted heterocyclo, alkyl,haloalkyl, alkoxy, alkylthio, amino, and fluoro; and A, G, X¹, Y¹, Y²,and Y³ are as defined above in connection with Formula I, with theproviso that A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted aryl, optionally substituted heteroaryl, aralkyl,and (heteroaryl)alkyl. In another embodiment, G is selected from thegroup consisting of optionally substituted aryl, optionally substitutedheteroaryl, aralkyl, and (heteroaryl)alkyl. In another embodiment, G is—Z—R³. In another embodiment, Y¹ is —N═; Y² is —C(R^(2b))═; and Y³ is—C(R^(2c))═. In another embodiment, Y¹ is —C(R^(2a))═; Y² is —N═; and Y³is —C(R^(2c))═. In another embodiment, Y¹ is —C(R^(2a))═; Y² is—C(R^(2b))═; and Y³ is —N═. In another embodiment, Y¹ is —N═; Y² is—C(R^(2b))═; and Y³ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XIV:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) is selected from the group consisting ofhydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, and halo; andR^(1b), R^(1c), R^(2b), R^(2c), A, G, and X¹ are as defined above inconnection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted aryl, optionally substituted heterocyclo,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl; andeither R^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is selected fromthe group consisting of optionally substituted aryl, optionallysubstituted heteroaryl, aralkyl, and (heteroaryl)alkyl; and eitherR^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is —Z—R³.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XV:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) is selected from the group consisting ofhydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, and halo; andR^(1b), R^(1c), R^(2a), R^(2c), A, G, and X¹ are as defined above inconnection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl; andeither R^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is selected fromthe group consisting of optionally substituted aryl, optionallysubstituted heteroaryl, aralkyl, and (heteroaryl)alkyl; and eitherR^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is —Z—R³.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVI:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) is selected from the group consisting ofhydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, and halo; andR^(1b), R^(1c), R^(2a), R^(2b), A, G, and X¹ are as defined above inconnection with Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl; andeither R^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is —Z—R³.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVII:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R^(1a) is selected from the group consisting ofhydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, and halo; andR^(1b), R^(1c), R^(2b), A, G, and X¹ are as defined above in connectionwith Formula I, with the proviso that A is not1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—. In anotherembodiment, G is selected from the group consisting of halo, hydroxy,optionally substituted heterocyclo, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, and (heteroaryl)alkyl; andeither R^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is selected fromthe group consisting of optionally substituted aryl, optionallysubstituted heteroaryl, aralkyl, and (heteroaryl)alkyl; and eitherR^(1b) or R^(1c), or both, is hydroxy, alkyl, haloalkyl, alkoxy,alkylthio, amino, or fluoro. In another embodiment, G is —Z—R³.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII:

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof, wherein R¹, R², R^(5a1), R^(5a), R^(5c), R^(5d), A, Z, and Y¹are as defined above in connection with Formula II, with the provisothat A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein:

R^(4a) and R^(4b) are each independently selected from the groupconsisting of hydrogen, halo, haloalkyl, and alkyl; and

X⁵ is selected from the group consisting of —O— and —S—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(5a1) is hydrogen. In anotherembodiment, R^(5a1) is C₁₋₄ alkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R¹ is alkoxy. In anotherembodiment, R¹ is methoxy.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein A is selected from the groupconsisting of A-3 and A-9. In another embodiment, A is A-3. In anotherembodiment, X is —O—, and R^(4a) and R^(4b) are independently C₁₋₄alkyl. In another embodiment, R^(4a) and R^(4b) are methyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein, Z is —NH—.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein, Y¹ is —N═.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(5a), R^(5c), and R^(5d) areindependently selected from the group consisting of hydrogen, C₁₋₆alkyl, and C₃₋₆ cycloalkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein R^(5a1) is hydrogen, and R^(5f)is selected from the group consisting of C₁₋₆ alky land C₃₋₆ cycloalkyl.

In another embodiment, Compounds of the Disclosure are compoundsrepresented by Formula XVIII, and the pharmaceutically acceptable salts,hydrates, and solvates thereof, wherein; R¹ is —OCH₃, R² is selectedfrom the group consisting of —CH₃ and —CH₂OCH₃; and Z is —N(H)—.

In one aspect, the present disclosure provides the following specificembodiments:

Embodiment I

A method of treating a cancer selected from the group consisting ofprostate cancer and breast cancer in a subject, the method comprisingadministering to the subject an effective amount of a compound thatinhibits one or more BET bromodomain proteins.

Embodiment II

The method of Embodiment I, wherein the cancer is prostate cancer.

Embodiment III

The method of Embodiment II, wherein the prostate cancer has active ARsignaling.

Embodiment IV

The method of Embodiments II or III, wherein the prostate cancer iscastration resistant prostate cancer.

Embodiment V

The method of Embodiment I, wherein the cancer is breast cancer.

Embodiment VI

The method of Embodiment V, wherein the breast cancer has active ARsignaling.

Embodiment VII

A method of identifying a patient sensitive to a compound that inhibitsBET bromodomain proteins, the method comprising evaluating AR-signalingstatus in a patient having prostate cancer or breast cancer tumors.

Embodiment VIII

The method of any one of Embodiments I-VII, wherein the compoundinhibits BRD2, BRD3, BRD4, and/or BRD-t.

Embodiment IX

The method of Embodiment VIII, wherein the compound inhibits BRD4.

Embodiment X

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XI

The method of any of Embodiments I-IX, wherein the compound is:

Embodiment XII

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XIII

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XIV

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XV

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XVI

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XVII

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XVIII

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XIX

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XX

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XXI

The method of any one of Embodiments I-IX, wherein the compound is:

Embodiment XXII

The method of any one of Embodiments I-IV or VII-XXI, wherein thecompound is administered as a single agent or in combination withstandard therapy for prostate cancer.

Embodiment XXIII

The method of Embodiment XXII, wherein the standard therapy for prostatecancer is an inhibitor of AR signaling selected from the groupconsisting of biclutamide, abiraterone, and enzalutamide.

Embodiment XXIV

The method of any one of Embodiments I, V, 6VI, or VIII-XXI, wherein thecompound is administered as a single agent or in combination withstandard therapy for breast cancer.

Embodiment XXV

The method of Embodiment XXIV, wherein the standard therapy for breastcancer is selected from the group consisting of Herceptin, Taxol,Taxotere, Perjeta, Adriamycin, Cytoxan, Paraplatin, and Kadcyla.

Embodiment XXVII

The method of any one of Embodiments I-IX, wherein the compound any oneof Formula I-XVII, or a pharmaceutically acceptable salt, hydrate, orsolvates thereof.

Embodiment XXVIII

The method of any one of Embodiments I-IX, wherein the compound is anyone of Cpd. Nos. 1-81, 83-113, 115-127, 129, 131-163, 166, 169-178,181-183, 185-188, 190, 192-203, 205-207, 210-243, 247-274, 277-295,304-331, or 333 of Table 1.

In another embodiment, Compounds of the Disclosure are compounds ofTable 1, and the pharmaceutically acceptable salts, hydrates, andsolvates thereof.

TABLE 1 Cpd. No. Structure Name 1

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(3-methyl-1-phenyl-1H-pyrazol-5- yl)-9H-pyrimido[4,5-b]indol-4- amine 2

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(3-phenyl-1H-pyrazol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 3

4-(4-((4-Isopropyl-5-methyl- 4H-1,2,4-triazol-3-yl)thio)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 4

7-(3,5-Dimethylisoxazol-4-yl)- N-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 5

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(5-methyl-4-phenyl-1H-pyrazol-3- yl)-9H-pyrimido[4,5-b]indol-4- amine 6

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2- (oxazol-2-yl)-4-phenylthiazol- 5-amine 7

N-(1-(3-Chlorophenyl)-3- methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 8

N-(1,3-Dimethyl-1H-pyrazol-5- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 9

7-(3,5-Dimethylisoxazol-4-yl)- N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 10

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[3,4- b]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine11

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3- c]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine12

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-indazol-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 13

N-(5-Chloro-1-methyl-1H- indazol-3-yl)-7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 14

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyridin-3-yl)- 9H-pyrimido[4,5-b]indol-4- amine 15

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2-methylpyrazolo[1,5-a]pyridin- 3-yl)-9H-pyrimido[4,5-b]indol- 4-amine 16

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyrimidin-3- yl)-9H-pyrimido[4,5-b]indol-4- amine 17

7-(3,5-Dimethylisoxazol-4-yl)-6- methoxy-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4- amine 18

7-(3,5-Dimethylisoxazol-4-yl)-2- isopropyl-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 19

7-(3,5-Dimethylisoxazol-4-yl)-6- methoxy-N-(6-methoxy-1-methyl-1H-indazol-3-yl)-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 20

7-(3,5-Dimethylisoxazol-4-yl)-6- methoxy-N-(1-methyl-1H-indazol-3-yl)-2-(tetrahydro-2H-pyran-4- yl)-9H-pyrimido[4,5-b]indol-4- amine 21

7-(3,5-Dimethylisoxazol-4-yl)-6- methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5- yl)-9H-pyrimido[4,5-b]indol-4- amine 22

7-(3,5-Dimethylisoxazol-4-yl)-N- (1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5-b]indol- 4-amine 23

4-(4-((2-chlorophenyl)thio)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 24

4-(4-((3-chlorophenyl)thio)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 25

4-(4-((2-isopropylphenyl)thio)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 26

4-(4-((1H-indol-3-yl)thio)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 27

4-(4-((3-(tert-butyl)phenyl)thio)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 28

(R)-N-(chroman-4-yl)-7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 29

7-(3,5-dimethylisoxazol-4-yl)-N- (1-isopropyl-1H-1,2,4-triazol-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 30

N-(3-(tert-butyl)-1,5-dimethyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 31

N-(5-(tert-butyl)-1,3-dimethyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 32

7-(3,5-dimethylisoxazol-4-yl)-N- (4-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 33

4-(tert-butyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)thiazol- 5-amine 34

N-(1,3-dimethyl-1H-pyrazol-4-yl)- 7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 35

7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 36

7-(3,5-dimethylisoxazol-4-yl)-N- (1-isopropyl-3,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5-b]indol- 4-amine 37

7-(3,5-dimethylisoxazol-4-yl)-N- (1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5-b]indol- 4-amine 38

3-(4-chlorophenyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-yl)-5-methylisoxazol-4-amine 39

3-(3-chlorophenyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-yl)-5-methylisoxazol-4-amine 40

4-(3-chlorophenyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)thiazol-5-amine 41

4-(4-chlorophenyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)thiazol-5-amine 42

7-(3,5-dimethylisoxazol-4-yl)- N-(1H-indol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 43

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2- isopropyl-4-phenylthiazol-5- amine 44

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(5-methyl-2-phenyl-1H-pyrrol-3- yl)-9H-pyrimido[4,5-b]indol-4- amine 45

N-(2-(3-chlorophenyl)-5- methyl-1H-pyrrol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 46

4-((7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-N,2-dimethyl-5- phenyl-1H-pyrrole-3-carboxamide 47

(4-((7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-2-methyl-5-phenyl- 1H-pyrrol-3-yl)(morpholino)methanone 48

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(5-methoxy-[1,1′-biphenyl]-2-yl)-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 49

N-(4′-chloro-5-methoxy-[1,1′- biphenyl]-2-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 50

N-(4-((dimethylamino)methyl)- 5-methoxy-[1,1′-biphenyl]-2-yl)-7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 51

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(7- phenyl-2,3-dihydrobenzo[b][1,4]dioxin-6- yl)-9H-pyrimido[4,5-b]indol-4- amine 52

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4- methyl-7-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6- amine 53

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(6-methoxy-4-phenylpyridin-3-yl)-2-methyl- 9H-pyrimido[4,5-b]indol-4- amine 54

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(4-methoxy-2-(pyridin-2-yl)phenyl)-2-methyl- 9H-pyrimido[4,5-b]indol-4- amine 55

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(4-methoxy-2-(pyridin-4-yl)phenyl)-2-methyl- 9H-pyrimido[4,5-b]indol-4- amine 56

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(4-methoxy-2-(oxazol-2-yl)phenyl)-2-methyl- 9H-pyrimido[4,5-b]indol-4- amine 57

7-(3,5-dimethylisoxazol-4-yl)- N-(4-ethoxynaphthalen-1-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 58

7-(3,5-dimethylisoxazol-4-yl)- N-(1H-indazol-3-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 59

7-(3,5-dimethylisoxazol-4-yl)- N-(6-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 60

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(5-methoxy-1-methyl-1H-indazol-3-yl)-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 61

7-(3,5-dimethylisoxazol-4-yl)- N-(1H-indol-3-yl)-2-isopropyl-6-methoxy-9H-pyrimido[4,5- b]indol-4-amine 62

N-(1-(tert-butyl)-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 64

7-(3,5-dimethylisoxazol-4-yl)- 2-isopropyl-N-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5- yl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine 65

7-(3,5-dimethylisoxazol-4-yl)- N-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 66

2-(5-((7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-3-methyl-1H- pyrazol-1-yl)ethan-1-ol67

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(3-methyl-1-(pyridin-4-yl)-1H- pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine 68

N-(1,3-dimethyl-1H-pyrazol-5- yl)-7-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 69

7-(3,5-dimethyl-4H-1,2,4- triazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H- indazol-3-yl)-9H-pyrimido[4,5- b]indol-4-amine 70

7-(3,5-dimethyl-4H-1,2,4- triazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5- a]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine71

7-(3,5-dimethyl-1H-pyrazol-4- yl)-N-(1,3-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 72

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-8-methoxy-5H- pyrido[4,3-b]indol-1-amine 73

7-(3,5-dimethylisoxazol-4-yl)- 2-isopropyl-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6- methoxy-9H-pyrimido[4,5- b]indol-4-amine 74

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2- (tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-4-amine 75

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-9H- pyrimido[4,5-b]indol-4-amine 76

N-(1,4-dimethyl-1H-pyrazol-5- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 77

N-(1,4-dimethyl-1H-pyrazol-3- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 78

7-(3,5-dimethylisoxazol-4-yl)- N-(4-isopropyl-1-methyl-1H-pyrazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 79

7-(3,5-dimethylisoxazol-4-yl)- N-(4-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 80

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1,3,4-trimethyl-1H-pyrazol-5-yl)-9H- pyrimido[4,5-b]indol-4-amine 81

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 83

N-(1,3-diisopropyl-1H-pyrazol- 5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 84

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4- isopropyl-2-methylthiazol-5- amine 85

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4- methylthiazol-2-amine 86

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5- methylthiazol-2-amine 87

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-5-methyl-1H-imidazol-2-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 88

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-4-methyl-1H-imidazol-2-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 89

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-1H-imidazol-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 90

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5- isopropyl-3-methylisoxazol-4- amine 91

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3- isopropyl-5-methylisoxazol-4- amine 92

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4- isopropyl-2-methyloxazol-5- amine 93

4-(4-((3- chlorophenyl)sulfonyl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 94

4-(4-((4-isopropyl-4H-1,2,4- triazol-3-yl)sulfonyl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole95

4-(4-(3-chlorophenoxy)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 96

4-(6-methoxy-2-methyl-4- (pyridin-3-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 97

N-(3-chlorophenyl)-7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 98

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5- methyl-3-phenylisoxazol-4- amine 99

7-(3,5-dimethylisoxazol-4-yl)- N-(imidazo[1,2-a]pyridin-3-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 100

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(4-methoxynaphthalen-1-yl)-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 101

N-([1,2,4]triazolo[4,3- a]pyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 102

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 103

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)thieno[2,3-b]pyridin-3-amine 104

4-(6-methoxy-2-methyl-4- (quinolin-4-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5- dimethylisoxazole 105

4-(4-(5-bromopyridin-3- yl)oxy)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)- 3,5-dimethylisoxazole 106

N-(5-chloropyridin-3-yl)-7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 107

N-(3-chloro-4-fluorophenyl)-7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 108

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(5-methylpyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 109

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(4-methylpyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 110

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(4-methylpyridin-2-yl)-9H- pyrimido[4,5-b]indol-4-amine 111

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(6-methylpyridin-2-yl)-9H- pyrimido[4,5-b]indol-4-amine 112

N-cyclohexyl-7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 113

N-cyclopentyl-7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 115

N-(1,5-Dimethyl-1H-pyrazol-3- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 116

7-(3,5-Dimethylisoxazol-4-yl)- N-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 117

N-(1-(tert-Butyl)-3- (trifluoromethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 118

N-(1-Cyclopentyl-3-methyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 119

N-(1-Cyclobutyl-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 120

N-(3-tert-Butyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 121

N-(3-Cyclopropyl-1-methyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 122

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2- methyl-2,4,5,6-tetrahydrocyclopenta- [c]pyrazol-3-yl)-9H- pyrimido[4,5-b]indol-4-amine123

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3- b]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine124

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-4,5,6,7-tetrahydro-1H- indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine 125

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2-methyl-4,5,6,7-tetrahydro-2H- indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine 126

N-(3-(tert-Butyl)-1H-pyrazol-5- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 127

7-(3,5-Dimethylisoxazol-4-yl)- N-(5-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 129

7-(3,5-Dimethylisoxazol-4-yl)- N-(7-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 131

2-(3-((7-(3,5-Dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-1H-indazol-1- yl)ethanol 132

7-(3,5-Dimethylisoxazol-4-yl)- N-(4-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 133

3-(tert-Butyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)isothiazol-5-amine 134

N-(5,6-Dihydro-4H- pyrrolo[1,2-b]pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 135

N-(1-Cyclopentyl-4-methyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 136

N-(3-Cyclobutyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 137

7-(3,5-Dimethylisoxazol-4-yl)- N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol- 3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 138

7-(3,5-Dimethylisoxazol-4-yl)- N-(2-isopropyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 139

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N- (4,5,6,7-tetrahydropyrazolo[1,5- a]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine140

N-(4-Cyclopropyl-1,3- dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 141

7-(3,5-Dimethylisoxazol-4-yl)- N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol- 3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 142

7-(3,5-Dimethylisoxazol-4-yl)- N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine143

N-(4-Cyclopropyl-1-ethyl-3- methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 144

N-(3-Cyclopropyl-1-ethyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 145

N-(3-Cyclopropyl-1-ethyl-4- methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 146

7-(3,5-Dimethylisoxazol-4-yl)- N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine147

N-(3-Cyclopropyl-1,4- dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 148

N-(2-Cyclopropyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)-7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 149

N-(3-Cyclopropyl-1-isopropyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 150

2-(3-((7-(3,5-Dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-5,6- dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol 151

7-(3,5-Dimethylisoxazol-4-yl)- N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol- 3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 152

N-(1,3-Dicyclopropyl-1H- pyrazol-5-yl)-7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 153

N-(3-Cyclopropyl-1H-pyrazol- 5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 154

1-(3-Cyclopropyl-5-((7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- yl)amino)-1H-pyrazol-1-yl)ethanone 155

Ethyl 3-cyclopropyl-5-((7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- yl)amino)-1H-pyrazole-1-carboxylate 156

N-(3-Cyclopropyl-1-(2,2,2- trifluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 157

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)-9H-pyrimido[4,5-b]indol- 4-amine 158

2-(3-Cyclopropyl-5-((7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- yl)amino)-1H-pyrazol-1-yl)ethanol 159

N-(3-Cyclopropyl-1-(2- fluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 160

N-(3-Cyclopropyl-1-(2- (dimethylamino)ethyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 161

7-(3,5-Dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-3-(1,1,1-trifluoro-2- methylpropan-2-yl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5- b]indol-4-amine 162

tert-butyl 3-(5-amino-3- cyclopropyl-1H-pyrazol-1-yl)azetidine-1-carboxylate 163

N-(1-(Azetidin-3-yl)-3- cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 166

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-imidazol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 169

7-(3,5-dimethylisoxazol-4-yl)- N-(3-ethyl-1,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 170

N-(1,5-dimethyl-1H-pyrazol-4- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 171

N-(1,2-dimethyl-1H-imidazol- 5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 172

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-9H- pyrimido[4,5-b]indol-4-amine 173

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 174

5-((7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)amino)-1-methyl-1H- pyrazole-4-carbonitrile175

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 176

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 177

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2,4- dimethylthiazol-5-amine 178

N-(1-cyclopentyl-1H-pyrazol- 5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 179

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H- pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine 181

7-(3,5-dimethylisoxazol-4-yl)- N-(3-isopropyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 182

7-(3,5-dimethylisoxazol-4-yl)- N-(3-ethyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 183

N-(1-(tert-butyl)-1H-pyrazol-5- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 185

N-(1-(tert-butyl)-3,4-dimethyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 186

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 187

N-(1-cyclobutyl-3,4-dimethyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 188

N-(1-cyclopropyl-3,4-dimethyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 190

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2- isopropyl-4-methylthiazol-5- amine 192

N-(1-cyclopropyl-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 193

N-(3-(tert-butyl)-1-methyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 194

7-(3,5-dimethylisoxazol-4-yl)- N-(3-isopropyl-1,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine195

N-(3-cyclopropyl-1-methyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 196

N-(1-(tert-butyl)-4-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 197

N-(1-cyclopropyl-4-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 198

N-(1-cyclobutyl-4-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 199

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-3-isopropyl-1H-pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 200

N-(3-cyclobutyl-1-methyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 201

N-(3-cyclobutyl-1-ethyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 202

2-(tert-butyl)-N-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4- methylthiazol-5-amine 203

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-3-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 205

N-(1-cyclopropyl-3-isopropyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 206

N4-(3-cyclopropyl-1-methyl- 1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-9H-pyrimido[4,5- b]indole-2,4-diamine207

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-4- amine 210

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N- (quinolin-8-yl)-9H-pyrimido[4,5-b]indol-4-amine 211

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N- (quinolin-5-yl)-9H-pyrimido[4,5-b]indol-4-amine 212

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-m-tolyl-9H-pyrimido[4,5-b]indol- 4-amine 213

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(3-methoxyphenyl)-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 214

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(3-(trifluoromethyl)phenyl)-9H- pyrimido[4,5-b]indol-4-amine 215

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,5- dimethylisoxazol-4-amine 216

7-(3,5-dimethylisoxazol-4-yl)- N-(3-ethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 217

N-(3-chloro-2-fluorophenyl)-7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 218

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(3-methoxy-5-methylphenyl)-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 219

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,4- dimethylisoxazol-5-amine 220

7-(3,5-dimethylisoxazol-4-yl)- N-(1H-indol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 221

7-(3,5-dimethylisoxazol-4-yl)- N-(isoquinolin-5-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 222

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4,5- dimethylisoxazol-3-amine 223

7-(3,5-dimethylisoxazol-4-yl)- N-(isoquinolin-8-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 224

N-(5-chloro-2-fluorophenyl)-7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 225

N-(3-chloro-5-fluorophenyl)-7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 226

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-phenyl-9H-pyrimido[4,5-b]indol-4- amine 227

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrrolo[2,3- b]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine228

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2-methylquinolin-5-yl)-9H- pyrimido[4,5-b]indol-4-amine 229

N-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- yl)benzo[d]thiazol-7-amine 230

N1-(7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)- N3,N3-dimethylbenzene-1,3- diamine 231

7-(3,5-dimethylisoxazol-4-yl)- N-(indolin-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 232

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methylindolin-6-yl)-9H- pyrimido[4,5-b]indol-4-amine 233

7-(3,5-dimethylisoxazol-4-yl)- N-(1H-indol-6-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 234

N-(2,3-dihydrobenzofuran-4- yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 235

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-indazol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 236

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-indol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 237

7-(3,5-dimethylisoxazol-4-yl)- N-(3,5-dimethylphenyl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 238

7-(3,5-dimethylisoxazol-4-yl)- N-(2,5-dimethylphenyl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 239

N-(3,5-dicyclopropyl-1-methyl- 1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 240

N-(3,5-diethyl-1-methyl-1H- pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 241

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1,3,5-triethyl-1H-pyrazol-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 242

N-(3,5-diisopropyl-1-methyl- 1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 243

7-(3,5-dimethylisoxazol-4-yl)- N-(2-isopropylphenyl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-amine 247

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N- (quinolin-4-yl)-9H-pyrimido[4,5-b]indol-4-amine 248

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(2-methylpyridin-4-yl)-9H- pyrimido[4,5-b]indol-4-amine 249

N-(3-cyclopropyl-4-fluoro-1- methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 250

N-(3-cyclopropyl-1-ethyl-4- fluoro-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 251

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1- methyl-3-(1-methylcyclopropyl)-1H- pyrazol-5-yl)-9H-pyrimido[4,5- b]indol-4-amine252

7-(3,5-dimethylisoxazol-4-yl)- N-(1-ethyl-3-(1- methylcyclopropyl)-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 253

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-3-(1-methylcyclopropyl)-1H- pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5- b]indol-4-amine 254

N-(3-cyclopropyl-4-fluoro-1- isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 255

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8- methoxy-5H-pyrido[4,3- b]indol-1-amine 256

N-(1-cyclopentyl-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8- methoxy-5H-pyrido[4,3- b]indol-1-amine 257

7-(3,5-dimethylisoxazol-4-yl)- 8-methoxy-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)- 5H-pyrido[4,3-b]indol-1-amine 258

N-(3-cyclopropyl-1-(1- methylazetidin-3-yl)-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-N,2,9-trimethyl-9H-pyrimido[4,5-b]indol-4-amine 259

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1H-pyrrolo[2,3-c]pyridin-3-yl)-9H- pyrimido[4,5-b]indol-4-amine 260

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N-(3-(1- methoxycyclopropyl)-1-methyl-1H-pyrazol-5-yl)-2- methyl-9H-pyrimido[4,5- b]indol-4-amine 261

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1- methyl-3-(1-(trifluoromethyl)cyclopropyl)- 1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine 262

2-(3-cyclopropyl-5-((7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)-N- ethylacetamide 263

N-(3-cyclopropyl-1-(piperidin- 4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 264

N-(3-cyclopropyl-1-(1- ethylpiperidin-4-yl)-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 265

1-(4-(3-cyclopropyl-5-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- ylamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone 266

N-(3-cyclopropyl-1-(2- methoxyethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4- yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 267

N-(3-cyclopropyl-1-(1- methylpiperidin-4-yl)-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 268

1-(4-(7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- ylamino)-1-methyl-1H-pyrazol- 3-yl)ethanone 269

2-(4-(7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- ylamino)-1-methyl-1H-pyrazol- 3-yl)propan-2-ol270

N-(3-tert-butyl-1,5-dimethyl- 1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 271

methyl 5-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- ylamino)-1-methyl-1H- pyrazole-3-carboxylate 272

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-3-(prop-1-en-2-yl)-1H- pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine 273

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4- amine 274

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-((2- methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-amine 277

1-(3-(3-cyclopropyl-5-(7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- ylamino)-1H-pyrazol-1-yl)azetidin-1-yl)ethanone 278

methyl 3-(3-cyclopropyl-5-(7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- ylamino)-1H-pyrazol-1-yl)azetidine-l-carboxylate 279

N-(3-cyclopropyl-1-(1- ethylazetidin-3-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 280

(2S)-4-(3-cyclopropyl-5-(7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- ylamino)-1H-pyrazol-1-yl)butane-1,2-diol 281

(S)-3-(3-cyclopropyl-5-((7- (3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- yl)amino)-1H-pyrazol-1-yl)propane-1,2-diol 282

N-(1-((1,4-dioxan-2- yl)methyl)-3-cyclopropyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 283

N-(3-cyclopropyl-1- (tetrahydro-2H-pyran-4-yl)-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 284

N-(3-cyclopropyl-1-(2- morpholinoethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 285

N-(3-cyclopropyl-1-ethyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8- methoxy-5H-pyrido[4,3- b]indol-1-amine 286

7-(3,5-dimethylisoxazol-4-yl)- N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol- 3-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine 287

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4- amine 288

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-((2- methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-amine 289

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2- ((methylsulfonyl)methyl)-9H-pyrimido[4,5-b]indol-4-amine 290

N4-(3-cyclopropyl-1-ethyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-9H-pyrimido[4,5- b]indole-2,4-diamine291

N4-(1,3-dicyclopropyl-1H pyrazol-5-yl)-7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5 b]indole-2,4-diamine 292

7-(3,5-dimethylisoxazol-4-yl)- N4-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol- 3-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4- diamine 293

3-(3-cyclopropyl-5-((7-(3,5- dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H- pyrimido[4,5-b]indol-4- yl)amino)-1H-pyrazol-1-yl)azetidine-1-carbaldehyde 294

N-(3-cyclopropyl-1-(oxetan-3- ylmethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 295

N-(3-cyclopropyl-1-(2- (methylsulfonyl)ethyl)-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine 304

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[3′,2′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 305

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5- fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- amine 306

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5- fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5- b]indol-4-amine 307

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8- fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4- amine 308

N-(3-cyclopropyl-1-methyl- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8- fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5- b]indol-4-amine 309

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- fluoro-8-methoxy-5H-pyrido[4,3-b]indol-1-amine 310

N-(1-(tert-butyl)-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 311

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[3,4- b]pyridin-3-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 312

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2- methyl-9H- pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine 313

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-2-methyl-N-(m- tolyl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 314

N-(3-(tert-butyl)-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 315

N-(3-(tert-butyl)-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 316

N-(1-(tert-butyl)-3-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 317

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N,2-dimethyl-N-(m- tolyl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 318

7-(3,5-dimethylisoxazol-4-yl)- 6-methoxy-N,2-dimethyl-N-(1-methyl-1H-pyrazolo[3,4- b]pyridin-3-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 319

7-(3,5-dimethylisoxazol-4-yl)- N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-N,2- dimethyl-9H- pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine 320

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 321

N-cyclopentyl-7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 322

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-amine 323

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-9H-pyrido[3,4- b]indol-4-amine 324

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6- methoxy-9H-pyrido[2,3- b]indol-4-amine 325

4-(6-methoxy-2-methyl-4- (quinolin-4-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-7-yl)-3,5- dimethylisoxazole326

methyl 4-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-yl)-1-naphthoate 327

2-(3-(7-(3,5-dimethylisoxazol- 4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4- yl)phenyl)propan-2-ol 328

4-(4-(3,5-diethyl-1-methyl-1H- pyrazol-4-yl)-6-methoxy-2- methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-7-yl)-3,5- dimethylisoxazole329

5-cyclopropyl-4-(7-(3,5- dimethylisoxazol-4-yl)-6- methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3- d]pyrimidin-4-yl)-3- methylisoxazole 330

4-(4-(5-cyclopropyl-1,3- dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H- pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5- dimethylisoxazole 331

4-(4-(3-cyclopropyl-1,5- dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H- pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5- dimethylisoxazole 333

N-(3-cyclopropyl-1-methyl-1H- pyrazol-5-yl)-6-methoxy-2-methyl-7-(1,3,5-trimethyl-1H- pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine

In another embodiment, Compounds of the Disclosure are compoundsselected from the group consisting of:

-   N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;-   N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;    and-   N-(1,3-dicyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine,

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof.

In another embodiment, Compounds of the Disclosure are compoundsselected from the group consisting of:

-   N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;-   N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;    and-   N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,    5-b]indol-4-amine,

and the pharmaceutically acceptable salts, hydrates, and solvatesthereof.

In another embodiment, the present disclosure provides methods ofpreparing Compounds of the Disclosure. In one embodiment, the method ofpreparing Compounds of the Disclosure comprises reacting a compound ofFormula VII:

wherein:

L is a leaving group, e.g., Cl, I, Br, or OSO₂R⁶, wherein R⁶ is selectedfrom the group consisting of alkyl, haloalkyl, and optionallysubstituted aryl;

R¹ is selected from the group consisting of hydrogen, hydroxy, alkyl,haloalkyl, alkoxy, alkylthio, amino, and halo;

R² is selected from the group consisting of hydrogen, amino, alkyl,hydroxyalkyl, alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, optionallysubstituted cycloalkyl, optionally substituted heterocyclo, andcarboxamido;

A is optionally substituted 5-membered heteroaryl;

X¹ is selected from the group consisting of —O—, —S—, and —N(R^(5a1))—;

Y¹ is selected from the group consisting of —CH═ and —N═; and

R^(5a1) is selected from the group consisting of hydrogen and alkyl,

with a compound having Formula VIII:

H—Z—R³  VIII

wherein:

Z is selected from the group consisting of —O—, —S—, and —N(R^(5b1))—;

R³ is selected from the group consisting of optionally substitutedcycloalkyl, optionally substituted aryl, optionally substitutedheteroaryl, and optionally substituted heterocyclo; and

R^(5b1) is selected from the group consisting of hydrogen and alkyl.

In another embodiment, the method further comprises isolating theCompound of the Disclosure, e.g., free from starting materials,reagents, solvents, and/or reaction side-products. In anotherembodiment, the reaction is carried out in a solvent, e.g., onecontaining dimethylformamide, acetonitrile, dimethyl sulfoxide, and/orN-methyl-2-pyrrolidone. In another embodiment, the reaction is carriedout at a temperature of about 50° C. to about 200° C., e.g., at about50° C., about 60° C., about 70° C., about 80° C., about 90° C., about100° C., about 110° C., about 120° C., about 130° C., about 140° C.,about 150° C., about 160° C., about 170° C., about 180° C., about 190°C., or about 200° C.

Compounds of the Disclosure inhibit BET bromodomains and are useful inthe treatment of a variety of diseases and conditions. In particular,Compounds of the Disclosure are useful in methods of treating a diseaseor condition wherein inhibition of BET bromodomains provides a benefit,for example, cancers and proliferative diseases. Methods of thedisclosure comprise administering a therapeutically effective amount ofa Compound of the Disclosure to an individual in need thereof. Thepresent methods also encompass administering a second therapeutic agentto the individual in addition to the Compound of the Disclosure. Thesecond therapeutic agent is selected from drugs known as useful intreating the disease or condition afflicting the individual in needthereof, e.g., a chemotherapeutic agent and/or radiation known as usefulin treating a particular cancer.

Salts, hydrates, and solvates of the Compounds of the Disclosure canalso be used in the methods disclosed herein. The present disclosurefurther includes all possible stereoisomers and geometric isomers ofCompounds of the Disclosure to include both racemic compounds andoptically active isomers. When a Compound of the Disclosure is desiredas a single enantiomer, it can be obtained either by resolution of thefinal product or by stereospecific synthesis from either isomericallypure starting material or use of a chiral auxiliary reagent, forexample, see Z. Ma et al., Tetrahedron: Asymmetry, 8(6), pages 883-888(1997). Resolution of the final product, an intermediate, or a startingmaterial can be achieved by any suitable method known in the art.Additionally, in situations where tautomers of the Compounds of theDisclosure are possible, the present disclosure is intended to includeall tautomeric forms of the compounds.

The present disclosure encompasses the preparation and use of salts ofCompounds of the Disclosure. As used herein, the pharmaceutical“pharmaceutically acceptable salt” refers to salts or zwitterionic formsof Compounds of the Disclosure. Salts of Compounds of the Disclosure canbe prepared during the final isolation and purification of the compoundsor separately by reacting the compound with an acid having a suitablecation. The pharmaceutically acceptable salts of Compounds of theDisclosure can be acid addition salts formed with pharmaceuticallyacceptable acids. Examples of acids which can be employed to formpharmaceutically acceptable salts include inorganic acids such asnitric, boric, hydrochloric, hydrobromic, sulfuric, and phosphoric, andorganic acids such as oxalic, maleic, succinic, and citric. Nonlimitingexamples of salts of compounds of the disclosure include, but are notlimited to, the hydrochloride, hydrobromide, hydroiodide, sulfate,bisulfate, 2-hydroxyethansulfonate, phosphate, hydrogen phosphate,acetate, adipate, alginate, aspartate, benzoate, bisulfate, butyrate,camphorate, camphorsulfonate, digluconate, glycerolphsphate,hemisulfate, heptanoate, hexanoate, formate, succinate, fumarate,maleate, ascorbate, isethionate, salicylate, methanesulfonate,mesitylenesulfonate, naphthylenesulfonate, nicotinate,2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate,3-phenylproprionate, picrate, pivalate, propionate, trichloroacetate,trifluoroacetate, phosphate, glutamate, bicarbonate,paratoluenesulfonate, undecanoate, lactate, citrate, tartrate,gluconate, methanesulfonate, ethanedisulfonate, benzene sulfonate, andp-toluenesulfonate salts. In addition, available amino groups present inthe compounds of the disclosure can be quaternized with methyl, ethyl,propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl,dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and sterylchlorides, bromides, and iodides; and benzyl and phenethyl bromides. Inlight of the foregoing, any reference Compounds of the Disclosureappearing herein is intended to include compounds of Compounds of theDisclosure as well as pharmaceutically acceptable salts, hydrates, orsolvates thereof.

The present disclosure encompasses the preparation and use of solvatesof Compounds of the Disclosure. Solvates typically do not significantlyalter the physiological activity or toxicity of the compounds, and assuch may function as pharmacological equivalents. The term “solvate” asused herein is a combination, physical association and/or solvation of acompound of the present disclosure with a solvent molecule such as, e.g.a disolvate, monosolvate or hemisolvate, where the ratio of solventmolecule to compound of the present disclosure is about 2:1, about 1:1or about 1:2, respectively. This physical association involves varyingdegrees of ionic and covalent bonding, including hydrogen bonding. Incertain instances, the solvate can be isolated, such as when one or moresolvent molecules are incorporated into the crystal lattice of acrystalline solid. Thus, “solvate” encompasses both solution-phase andisolatable solvates. Compounds of the Disclosure can be present assolvated forms with a pharmaceutically acceptable solvent, such aswater, methanol, ethanol, and the like, and it is intended that thedisclosure includes both solvated and unsolvated forms of Compounds ofthe Disclosure. One type of solvate is a hydrate. A “hydrate” relates toa particular subgroup of solvates where the solvent molecule is water.Solvates typically can function as pharmacological equivalents.Preparation of solvates is known in the art. See, for example, M. Cairaet al., J. Pharmaceut. Sci., 93(3):601-611 (2004), which describes thepreparation of solvates of fluconazole with ethyl acetate and withwater. Similar preparation of solvates, hemisolvates, hydrates, and thelike are described by E. C. van Tonder et al., AAPS Pharm. Sci. Tech.,5(1):Article 12 (2004), and A. L. Bingham et al., Chem. Commun. 603-604(2001). A typical, non-limiting, process of preparing a solvate wouldinvolve dissolving a Compound of the Disclosure in a desired solvent(organic, water, or a mixture thereof) at temperatures above 20° C. toabout 25° C., then cooling the solution at a rate sufficient to formcrystals, and isolating the crystals by known methods, e.g., filtration.Analytical techniques such as infrared spectroscopy can be used toconfirm the presence of the solvent in a crystal of the solvate.

The present disclosure provides Compounds of the Disclosure as BETbromodomain inhibitors for the treatment of a variety of diseases andconditions wherein inhibition of BET bromodomains has a beneficialeffect. Compounds of the Disclosure typically have a binding affinity(IC₅₀) to BET bromodomains of less than 100 μM, e.g., less than 50 μM,less than 25 μM, and less than 5 μM, less than about 1 μM, less thanabout 0.5 μM, or less than about 0.1 μM. In one embodiment, the presentdisclosure relates to a method of treating an individual suffering froma disease or condition wherein inhibition of the BET bromodomainsprovides a benefit comprising administering a therapeutically effectiveamount of a Compound of the Disclosure to an individual in need thereof.

Since Compounds of the Disclosure are inhibitors of one or more BETbromodomains, a number of diseases and conditions mediated by BETbromodomain proteins can be treated by employing these compounds. Thepresent disclosure is thus directed generally to a method for treating acondition or disorder responsive to inhibition of BRD2, BRD3, BRD4,BRD-t, or an isoform or mutant thereof, in an animal, e.g., a human,suffering from, or at risk of suffering from, the condition or disorder,the method comprising administering to the animal an effective amount ofone or more Compounds of the Disclosure.

The present disclosure is further directed to a method of inhibiting BETbromodomains in an animal in need thereof, said method comprisingadministering to the animal an effective amount of at least one Compoundof the Disclosure.

The methods of the present disclosure can be accomplished byadministering a Compound of the Disclosure as the neat compound or as apharmaceutical composition. Administration of a pharmaceuticalcomposition, or neat compound of a Compound of the Disclosure, can beperformed during or after the onset of the disease or condition ofinterest. Typically, the pharmaceutical compositions are sterile, andcontain no toxic, carcinogenic, or mutagenic compounds that would causean adverse reaction when administered. Further provided are kitscomprising a Compound of the Disclosure and, optionally, a secondtherapeutic agent useful in the treatment of diseases and conditionswherein inhibition of BET bromodomains provides a benefit, packagedseparately or together, and an insert having instructions for usingthese active agents.

In one embodiment, a Compound of the Disclosure is administered inconjunction with a second therapeutic agent useful in the treatment of adisease or condition wherein inhibition of BET bromodomains provides abenefit. The second therapeutic agent is different from the Compound ofthe Disclosure. A Compound of the Disclosure and the second therapeuticagent can be administered simultaneously or sequentially to achieve thedesired effect. In addition, the Compound of the Disclosure and secondtherapeutic agent can be administered from a single composition or twoseparate compositions.

The second therapeutic agent is administered in an amount to provide itsdesired therapeutic effect. The effective dosage range for each secondtherapeutic agent is known in the art, and the second therapeutic agentis administered to an individual in need thereof within such establishedranges.

A Compound of the Disclosure and the second therapeutic agent can beadministered together as a single-unit dose or separately as multi-unitdoses, wherein the Compound of the Disclosure is administered before thesecond therapeutic agent or vice versa. One or more doses of theCompound of the Disclosure and/or one or more dose of the secondtherapeutic agent can be administered. The Compound of the Disclosuretherefore can be used in conjunction with one or more second therapeuticagents, for example, but not limited to, anticancer agents.

Diseases and conditions treatable by the methods of the presentdisclosure include, but are not limited to, cancer and otherproliferative disorders, inflammatory diseases, sepsis, autoimmunedisease, and viral infection. In one embodiment, a human patient istreated with a Compound of the Disclosure, or a pharmaceuticalcomposition comprising a Compound of the Disclosure, wherein thecompound is administered in an amount sufficient to inhibit BETbromodomain activity in the patient.

In one embodiment, the disease to be treated by the Compound of theDisclosure is cancer. Examples of treatable cancers include, but are notlimited to, adrenal cancer, acinic cell carcinoma, acoustic neuroma,acral lentigious melanoma, acrospiroma, acute eosinophilic leukemia,acute erythroid leukemia, acute lymphoblastic leukemia, acutemegakaryoblastic leukemia, acute monocytic leukemia, acute promyelocyticleukemia, adenocarcinoma, adenoid cystic carcinoma, adenoma, adenomatoidodontogenic tumor, adenosquamous carcinoma, adipose tissue neoplasm,adrenocortical carcinoma, adult T-cell leukemia/lymphoma, aggressiveNK-cell leukemia, AIDS-related lymphoma, alveolar rhabdomyosarcoma,alveolar soft part sarcoma, ameloblastic fibroma, anaplastic large celllymphoma, anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoidtumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocyticleukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer,bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor,Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma insitu, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma,chondroma, chordoma, choriocarcinoma, choroid plexus papilloma,clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-celllymphoma, cervical cancer, colorectal cancer, Degos disease,desmoplastic small round cell tumor, diffuse large B-cell lymphoma,dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonalcarcinoma, endocrine gland neoplasm, endodermal sinus tumor,enteropathy-associated T-cell lymphoma, esophageal cancer, fetus infetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroidcancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor,gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumorof the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosiscerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,gynandroblastoma, gallbladder cancer, gastric cancer, hairy cellleukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma,hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma,Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma,intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna,lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lungcancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma,acute lymphocytic leukemia, acute myelogeous leukemia, chroniclymphocytic leukemia, liver cancer, small cell lung cancer, non-smallcell lung cancer, MALT lymphoma, malignant fibrous histiocytoma,malignant peripheral nerve sheath tumor, malignant triton tumor, mantlecell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia,mediastinal germ cell tumor, medullary carcinoma of the breast,medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkelcell cancer, mesothelioma, metastatic urothelial carcinoma, mixedMullerian tumor, mucinous tumor, multiple myeloma, muscle tissueneoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma,nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma,neuroma, nodular melanoma, ocular cancer, oligoastrocytoma,oligodendroglioma, oncocytoma, optic nerve sheath meningioma, opticnerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor,papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma,polyembryoma, precursor T-lymphoblastic lymphoma, primary centralnervous system lymphoma, primary effusion lymphoma, preimary peritonealcancer, prostate cancer, pancreatic cancer, pharyngeal cancer,pseudomyxoma periotonei, renal cell carcinoma, renal medullarycarcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter'stransformation, rectal cancer, sarcoma, Schwannomatosis, seminoma,Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cellcarcinoma, skin cancer, small blue round cell tumors, small cellcarcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinaltumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovialsarcoma, Sezary's disease, small intestine cancer, squamous carcinoma,stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroidcancer, transitional cell carcinoma, throat cancer, urachal cancer,urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer,verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginalcancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms'tumor.

In another embodiment, the cancer is a leukaemia, for example aleukaemia selected from acute monocytic leukemia, acute myelogenousleukemia, chronic myelogenous leukemia, chronic lymphocytic leukemia andmixed lineage leukaemia (MLL). In another embodiment the cancer isNUT-midline carcinoma. In another embodiment the cancer is multiplemyeloma. In another embodiment the cancer is a lung cancer such as smallcell lung cancer (SCLC). In another embodiment the cancer is aneuroblastoma. In another embodiment the cancer is Burkitt's lymphoma.In another embodiment the cancer is cervical cancer. In anotherembodiment the cancer is esophageal cancer. In another embodiment thecancer is ovarian cancer. In another embodiment the cancer is colorectalcancer. In another embodiment, the cancer is prostate cancer. In anotherembodiment, the cancer is breast cancer.

In another embodiment, the present disclosure provides a method oftreating a benign proliferative disorder, such as, but are not limitedto, benign soft tissue tumors, bone tumors, brain and spinal tumors,eyelid and orbital tumors, granuloma, lipoma, meningioma, multipleendocrine neoplasia, nasal polyps, pituitary tumors, prolactinoma,pseudotumor cerebri, seborrheic keratoses, stomach polyps, thyroidnodules, cystic neoplasms of the pancreas, hemangiomas, vocal cordnodules, polyps, and cysts, Castleman disease, chronic pilonidaldisease, dermatofibroma, pilar cyst, pyogenic granuloma, and juvenilepolyposis syndrome.

Compounds of the Disclosure can also treat infectious and noninfectiousinflammatory events and autoimmune and other inflammatory diseases byadministration of an effective amount of a present compound to a mammal,in particular a human in need of such treatment. Examples of autoimmuneand inflammatory diseases, disorders, and syndromes treated using thecompounds and methods described herein include inflammatory pelvicdisease, urethritis, skin sunburn, sinusitis, pneumonitis, encephalitis,meningitis, myocarditis, nephritis, osteomyelitis, myositis, hepatitis,gastritis, enteritis, dermatitis, gingivitis, appendictitis,pancreatitis, cholocystitus, agammaglobulinemia, psoriasis, allergy,Crohn's disease, irritable bowel syndrome, ulcerative colitis, Sjogren'sdisease, tissue graft rejection, hyperacute rejection of transplantedorgans, asthma, allergic rhinitis, chronic obstructive pulmonary disease(COPD), autoimmune polyglandular disease (also known as autoimmunepolyglandular syndrome), autoimmune alopecia, pernicious anemia,glomerulonephritis, dermatomyositis, multiple sclerosis, scleroderma,vasculitis, autoimmune hemolytic and thrombocytopenic states,Goodpasture's syndrome, atherosclerosis, Addison's disease, Parkinson'sdisease, Alzheimer's disease, Type I diabetes, septic shock, systemiclupus erythematosus (SLE), rheumatoid arthritis, psoriatic arthritis,juvenile arthritis, osteoarthritis, chronic idiopathic thrombocytopenicpurpura, Waldenstrom macroglobulinemia, myasthenia gravis, Hashimoto'sthyroiditis, atopic dermatitis, degenerative joint disease, vitiligo,autoimmune hypopituatarism, Guillain-Barre syndrome, Behcet's disease,scleracierma, mycosis fungoides, acute inflammatory responses (such asacute respiratory distress syndrome and ischemia/reperfusion injury),and Graves' disease.

In another embodiment, the present disclosure provides a method oftreating systemic inflammatory response syndromes, such as LPS-inducedendotoxic shock and/or bacteria-induced sepsis by administration of aneffective amount of a Compound of the Disclosure to a mammal, inparticular a human in need of such treatment.

In another embodiment, the present disclosure provides a method fortreating viral infections and diseases. Examples of viral infections anddiseases treated using the compounds and methods described hereininclude episome-based DNA viruses including, but not limited to, humanpapillomavirus, Herpesvirus, Epstein-Barr virus, human immunodeficiencyvirus, hepatis B virus, and hepatitis C virus.

In another embodiment, the present disclosure provides therapeuticmethod of modulating protein methylation, gene expression, cellproliferation, cell differentiation and/or apoptosis in vivo in diseasesmentioned above, in particular cancer, inflammatory disease, and/orviral disease is provided by administering a therapeutically effectiveamount of a Compound of the Disclosure to a subject in need of suchtherapy.

In another embodiment, the present disclosure provides a method ofregulating endogenous or heterologous promoter activity by contacting acell with a Compound of the Disclosure.

In methods of the present disclosure, a therapeutically effective amountof a Compound of the Disclosure, typically formulated in accordance withpharmaceutical practice, is administered to a human being in needthereof. Whether such a treatment is indicated depends on the individualcase and is subject to medical assessment (diagnosis) that takes intoconsideration signs, symptoms, and/or malfunctions that are present, therisks of developing particular signs, symptoms and/or malfunctions, andother factors.

A Compound of the Disclosure can be administered by any suitable route,for example by oral, buccal, inhalation, sublingual, rectal, vaginal,intracisternal or intrathecal through lumbar puncture, transurethral,nasal, percutaneous, i.e., transdermal, or parenteral (includingintravenous, intramuscular, subcutaneous, intracoronary, intradermal,intramammary, intraperitoneal, intraarticular, intrathecal, retrobulbar,intrapulmonary injection and/or surgical implantation at a particularsite) administration. Parenteral administration can be accomplishedusing a needle and syringe or using a high pressure technique.

Pharmaceutical compositions include those wherein a Compound of theDisclosure is administered in an effective amount to achieve itsintended purpose. The exact formulation, route of administration, anddosage is determined by an individual physician in view of the diagnosedcondition or disease. Dosage amount and interval can be adjustedindividually to provide levels of a Compound of the Disclosure that issufficient to maintain therapeutic effects.

Toxicity and therapeutic efficacy of the Compounds of the Disclosure canbe determined by standard pharmaceutical procedures in cell cultures orexperimental animals, e.g., for determining the maximum tolerated dose(MTD) of a compound, which defines as the highest dose that causes notoxicity in animals. The dose ratio between the maximum tolerated doseand therapeutic effects (e.g. inhibiting of tumor growth) is thetherapeutic index. The dosage can vary within this range depending uponthe dosage form employed, and the route of administration utilized.Determination of a therapeutically effective amount is well within thecapability of those skilled in the art, especially in light of thedetailed disclosure provided herein.

A therapeutically effective amount of a Compound of the Disclosurerequired for use in therapy varies with the nature of the conditionbeing treated, the length of time that activity is desired, and the ageand the condition of the patient, and ultimately is determined by theattendant physician. Dosage amounts and intervals can be adjustedindividually to provide plasma levels of the BET bromodomain inhibitorthat are sufficient to maintain the desired therapeutic effects. Thedesired dose conveniently can be administered in a single dose, or asmultiple doses administered at appropriate intervals, for example asone, two, three, four or more subdoses per day. Multiple doses often aredesired, or required. For example, a Compound of the Disclosure can beadministered at a frequency of: four doses delivered as one dose per dayat four-day intervals (q4d×4); four doses delivered as one dose per dayat three-day intervals (q3d×4); one dose delivered per day at five-dayintervals (qd×5); one dose per week for three weeks (qwk3); five dailydoses, with two days rest, and another five daily doses (5/2/5); or, anydose regimen determined to be appropriate for the circumstance.

A Compound of the Disclosure used in a method of the present disclosurecan be administered in an amount of about 0.005 to about 500 milligramsper dose, about 0.05 to about 250 milligrams per dose, or about 0.5 toabout 100 milligrams per dose. For example, a Compound of the Disclosurecan be administered, per dose, in an amount of about 0.005, 0.05, 0.5,5, 10, 20, 30, 40, 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500milligrams, including all doses between 0.005 and 500 milligrams.

The dosage of a composition containing a Compound of the Disclosure, ora composition containing the same, can be from about 1 ng/kg to about200 mg/kg, about 1 μg/kg to about 100 mg/kg, or about 1 mg/kg to about50 mg/kg. The dosage of a composition can be at any dosage including,but not limited to, about 1 μg/kg. The dosage of a composition may be atany dosage including, but not limited to, about 1 μg/kg, about 10 μg/kg,about 25 μg/kg, about 50 μg/kg, about 75 μg/kg, about 100 μg/kg, about125 μg/kg, about 150 μg/kg, about 175 μg/kg, about 200 μg/kg, about 225μg/kg, about 250 μg/kg, about 275 μg/kg, about 300 μg/kg, about 325μg/kg, about 350 μg/kg, about 375 μg/kg, about 400 μg/kg, about 425μg/kg, about 450 μg/kg, about 475 μg/kg, about 500 μg/kg, about 525μg/kg, about 550 μg/kg, about 575 μg/kg, about 600 μg/kg, about 625μg/kg, about 650 μg/kg, about 675 μg/kg, about 700 μg/kg, about 725μg/kg, about 750 μg/kg, about 775 μg/kg, about 800 μg/kg, about 825μg/kg, about 850 μg/kg, about 875 μg/kg, about 900 μg/kg, about 925μg/kg, about 950 μg/kg, about 975 μg/kg, about 1 mg/kg, about 5 mg/kg,about 10 mg/kg, about 15 mg/kg, about 20 mg/kg, about 25 mg/kg, about 30mg/kg, about 35 mg/kg, about 40 mg/kg, about 45 mg/kg, about 50 mg/kg,about 60 mg/kg, about 70 mg/kg, about 80 mg/kg, about 90 mg/kg, about100 mg/kg, about 125 mg/kg, about 150 mg/kg, about 175 mg/kg, about 200mg/kg, or more. The above dosages are exemplary of the average case, butthere can be individual instances in which higher or lower dosages aremerited, and such are within the scope of this disclosure. In practice,the physician determines the actual dosing regimen that is most suitablefor an individual patient, which can vary with the age, weight, andresponse of the particular patient.

As stated above, a Compound of the Disclosure can be administered incombination with a second therapeutically active agent. In someembodiments, the second therapeutic agent is an epigenetic drug. As usedherein, the term “epigenetic drug” refers to a therapeutic agent thattargets an epigenetic regulator. Examples of epigenetic regulatorsinclude the histone lysine methyltransferases, histone arginine methyltransferases, histone demethylases, histone deacetylases, histoneacetylases, and DNA methyltransferases. Histone deacetylase inhibitorsinclude, but are not limited to, vorinostat.

In another embodiment, chemotherapeutic agents or otheranti-proliferative agents can be combined with Compound of theDisclosure to treat proliferative diseases and cancer. Examples oftherapies and anticancer agents that can be used in combination withCompounds of the Disclosure include surgery, radiotherapy (e.g.,gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy,proton therapy, brachytherapy, and systemic radioactive isotopes),endocrine therapy, a biologic response modifier (e.g., an interferon, aninterleukin, tumor necrosis factor (TNF), hyperthermia and cryotherapy,an agent to attenuate any adverse effect (e.g., an antiemetic), and anyother approved chemotherapeutic drug.

Examples of antiproliferative compounds include, but are not limited to,an aromatase inhibitor; an anti-estrogen; an anti-androgen; agonadorelin agonist; a topoisomerase I inhibitor; a topoisomerase IIinhibitor; a microtubule active agent; an alkylating agent; a retinoid,a carontenoid, or a tocopherol; a cyclooxygenase inhibitor; an MMPinhibitor; an mTOR inhibitor; an antimetabolite; a platin compound; amethionine aminopeptidase inhibitor; a bisphosphonate; anantiproliferative antibody; a heparanase inhibitor; an inhibitor of Rasoncogenic isoforms; a telomerase inhibitor; a proteasome inhibitor; acompound used in the treatment of hematologic malignancies; a Flt-3inhibitor; an Hsp90 inhibitor; a kinesin spindle protein inhibitor; aMEK inhibitor; an antitumor antibiotic; a nitrosourea; a compoundtargeting/decreasing protein or lipid kinase activity, a compoundtargeting/decreasing protein or lipid phosphatase activity, or anyfurther anti-angiogenic compound.

Nonlimiting exemplary aromatase inhibitors include, but are not limitedto, steroids, such as atamestane, exemestane, and formestane, andnon-steroids, such as aminoglutethimide, roglethimide,pyridoglutethimide, trilostane, testolactone, ketokonazole, vorozole,fadrozole, anastrozole, and letrozole.

Nonlimiting anti-estrogens include, but are not limited to, tamoxifen,fulvestrant, raloxifene, and raloxifene hydrochloride. Anti-androgensinclude, but are not limited to, bicalutamide. Gonadorelin agonistsinclude, but are not limited to, abarelix, goserelin, and goserelinacetate.

Exemplary topoisomerase I inhibitors include, but are not limited to,topotecan, gimatecan, irinotecan, camptothecin and its analogues,9-nitrocamptothecin, and the macromolecular camptothecin conjugatePNU-166148. Topoisomerase II inhibitors include, but are not limited to,anthracyclines, such as doxorubicin, daunorubicin, epirubicin,idarubicin, and nemorubicin; anthraquinones, such as mitoxantrone andlosoxantrone; and podophillotoxines, such as etoposide and teniposide.

Microtubule active agents include microtubule stabilizing, microtubuledestabilizing compounds, and microtubulin polymerization inhibitorsincluding, but not limited to, taxanes, such as paclitaxel anddocetaxel; vinca alkaloids, such as vinblastine, vinblastine sulfate,vincristine, and vincristine sulfate, and vinorelbine; discodermolides;cochicine and epothilones and derivatives thereof.

Exemplary nonlimiting alkylating agents include cyclophosphamide,ifosfamide, melphalan, and nitrosoureas, such as carmustine andlomustine.

Exemplary nonlimiting cyclooxygenase inhibitors include Cox-2inhibitors, 5-alkyl substituted 2-arylaminophenylacetic acid andderivatives, such as celecoxib, rofecoxib, etoricoxib, valdecoxib, or a5-alkyl-2-arylaminophenylacetic acid, such as lumiracoxib.

Exemplary nonlimiting matrix metalloproteinase inhibitors (“MMPinhibitors”) include collagen peptidomimetic and nonpeptidomimeticinhibitors, tetracycline derivatives, batimastat, marimastat,prinomastat, metastat, BMS-279251, BAY 12-9566, TAA211, MMI270B, andAAJ996.

Exemplary nonlimiting mTOR inhibitors include compounds that inhibit themammalian target of rapamycin (mTOR) and possess antiproliferativeactivity such as sirolimus, everolimus, CCI-779, and ABT578.

Exemplary nonlimiting antimetabolites include 5-fluorouracil (5-FU),capecitabine, gemcitabine, DNA demethylating compounds, such as5-azacytidine and decitabine, methotrexate and edatrexate, and folicacid antagonists, such as pemetrexed.

Exemplary nonlimiting platin compounds include carboplatin, cis-platin,cisplatinum, and oxaliplatin.

Exemplary nonlimiting methionine aminopeptidase inhibitors includebengamide or a derivative thereof and PPI-2458.

Exemplary nonlimiting bisphosphonates include etridonic acid, clodronicacid, tiludronic acid, pamidronic acid, alendronic acid, ibandronicacid, risedronic acid, and zoledronic acid.

Exemplary nonlimiting antiproliferative antibodies include trastuzumab,trastuzumab-DMI, cetuximab, bevacizumab, rituximab, PR064553, and 2C4.The term “antibody” is meant to include intact monoclonal antibodies,polyclonal antibodies, multispecific antibodies formed from at least twointact antibodies, and antibody fragments, so long as they exhibit thedesired biological activity.

Exemplary nonlimiting heparanase inhibitors include compounds thattarget, decrease, or inhibit heparin sulfate degradation, such as PI-88and OGT2115.

The term “an inhibitor of Ras oncogenic isoforms,” such as H-Ras, K-Ras,or N-Ras, as used herein refers to a compound which targets, decreases,or inhibits the oncogenic activity of Ras, for example, a farnesyltransferase inhibitor, such as L-744832, DK8G557, tipifarnib, andlonafarnib.

Exemplary nonlimiting telomerase inhibitors include compounds thattarget, decrease, or inhibit the activity of telomerase, such ascompounds that inhibit the telomerase receptor, such as telomestatin.

Exemplary nonlimiting proteasome inhibitors include compounds thattarget, decrease, or inhibit the activity of the proteasome including,but not limited to, bortezomid.

The phrase “compounds used in the treatment of hematologic malignancies”as used herein includes FMS-like tyrosine kinase inhibitors, which arecompounds targeting, decreasing or inhibiting the activity of FMS-liketyrosine kinase receptors (Flt-3R); interferon,I-β-D-arabinofuransylcytosine (ara-c), and bisulfan; and ALK inhibitors,which are compounds which target, decrease, or inhibit anaplasticlymphoma kinase.

Exemplary nonlimiting Flt-3 inhibitors include PKC412, midostaurin, astaurosporine derivative, SU11248, and MLN518.

Exemplary nonlimiting HSP90 inhibitors include compounds targeting,decreasing, or inhibiting the intrinsic ATPase activity of HSP90; ordegrading, targeting, decreasing or inhibiting the HSP90 client proteinsvia the ubiquitin proteosome pathway. Compounds targeting, decreasing orinhibiting the intrinsic ATPase activity of HSP90 are especiallycompounds, proteins, or antibodies that inhibit the ATPase activity ofHSP90, such as 17-allylamino,17-demethoxygeldanamycin (17AAG), ageldanamycin derivative; other geldanamycin related compounds; radicicoland HDAC inhibitors.

The phrase “a compound targeting/decreasing a protein or lipid kinaseactivity; or a protein or lipid phosphatase activity; or any furtheranti-angiogenic compound” as used herein includes a protein tyrosinekinase and/or serine and/or threonine kinase inhibitor or lipid kinaseinhibitor, such as a) a compound targeting, decreasing, or inhibitingthe activity of the platelet-derived growth factor-receptors (PDGFR),such as a compound that targets, decreases, or inhibits the activity ofPDGFR, such as an N-phenyl-2-pyrimidine-amine derivatives, such asimatinib, SU1O1, SU6668, and GFB-111; b) a compound targeting,decreasing, or inhibiting the activity of the fibroblast growthfactor-receptors (FGFR); c) a compound targeting, decreasing, orinhibiting the activity of the insulin-like growth factor receptor I(IGF-IR), such as a compound that targets, decreases, or inhibits theactivity of IGF-IR; d) a compound targeting, decreasing, or inhibitingthe activity of the Trk receptor tyrosine kinase family, or ephrin B4inhibitors; e) a compound targeting, decreasing, or inhibiting theactivity of the Axl receptor tyrosine kinase family; f) a compoundtargeting, decreasing, or inhibiting the activity of the Ret receptortyrosine kinase; g) a compound targeting, decreasing, or inhibiting theactivity of the Kit/SCFR receptor tyrosine kinase, such as imatinib; h)a compound targeting, decreasing, or inhibiting the activity of thec-Kit receptor tyrosine kinases, such as imatinib; i) a compoundtargeting, decreasing, or inhibiting the activity of members of thec-Abl family, their gene-fusion products (e.g. Bcr-Abl kinase) andmutants, such as an N-phenyl-2-pyrimidine-amine derivative, such asimatinib or nilotinib; PD180970; AG957; NSC 680410; PD173955; ordasatinib; j) a compound targeting, decreasing, or inhibiting theactivity of members of the protein kinase C (PKC) and Raf family ofserine/threonine kinases, members of the MEK, SRC, JAK, FAK, PDK1,PKB/Akt, and Ras/MAPK family members, and/or members of thecyclin-dependent kinase family (CDK), such as a staurosporine derivativedisclosed in U.S. Pat. No. 5,093,330, such as midostaurin; examples offurther compounds include UCN-01, safingol, BAY 43-9006, bryostatin 1,perifosine; ilmofosine; RO 318220 and RO 320432; GO 6976; Isis 3521;LY333531/LY379196; a isochinoline compound; a farnesyl transferaseinhibitor; PD184352 or QAN697, or AT7519; k) a compound targeting,decreasing or inhibiting the activity of a protein-tyrosine kinase, suchas imatinib mesylate or a tyrphostin, such as Tyrphostin A23/RG-50810;AG 99; Tyrphostin AG 213; Tyrphostin AG 1748; Tyrphostin AG 490;Tyrphostin B44; Tyrphostin B44 (+) enantiomer; Tyrphostin AG 555; AG494; Tyrphostin AG 556, AG957 and adaphostin(4-{[(2,5-dihydroxyphenyl)methyl]amino}-benzoic acid adamantyl ester;NSC 680410, adaphostin); 1) a compound targeting, decreasing, orinhibiting the activity of the epidermal growth factor family ofreceptor tyrosine kinases (EGFR, ErbB2, ErbB3, ErbB4 as homo- orheterodimers) and their mutants, such as CP 358774, ZD 1839, ZM 105180;trastuzumab, cetuximab, gefitinib, erlotinib, OSI-774, Cl-1033, EKB-569,GW-2016, antibodies E1.1, E2.4, E2.5, E6.2, E6.4, E2.11, E6.3 andE7.6.3, and 7H-pyrrolo-[2,3-d]pyrimidine derivatives; and m) a compoundtargeting, decreasing, or inhibiting the activity of the c-Met receptor.

Exemplary compounds that target, decrease, or inhibit the activity of aprotein or lipid phosphatase include inhibitors of phosphatase 1,phosphatase 2A, or CDC25, such as okadaic acid or a derivative thereof.

Further anti-angiogenic compounds include compounds having anothermechanism for their activity unrelated to protein or lipid kinaseinhibition, e.g., thalidomide and TNP-470.

Additional, nonlimiting, exemplary chemotherapeutic compounds, one ormore of which may be used in combination with a present BET bromodomaininhibitor, include: daunorubicin, adriamycin, Ara-C, VP-16, teniposide,mitoxantrone, idarubicin, carboplatinum, PKC412, 6-mercaptopurine(6-MP), fludarabine phosphate, octreotide, SOM230, FTY720,6-thioguanine, cladribine, 6-mercaptopurine, pentostatin, hydroxyurea,2-hydroxy-1H-isoindole-1,3-dione derivatives,1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine or a pharmaceuticallyacceptable salt thereof,1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine succinate,angiostatin, endostatin, anthranilic acid amides, ZD4190, ZD6474,SU5416, SU6668, bevacizumab, rhuMAb, rhuFab, macugon; FLT-4 inhibitors,FLT-3 inhibitors, VEGFR-2 IgGI antibody, RPI 4610, bevacizumab, porfimersodium, anecortave, triamcinolone, hydrocortisone, 11-a-epihydrocotisol,cortex olone, 17a-hydroxyprogesterone, corticosterone,desoxycorticosterone, testosterone, estrone, dexamethasone,fluocinolone, a plant alkaloid, a hormonal compound and/or antagonist, abiological response modifier, such as a lymphokine or interferon, anantisense oligonucleotide or oligonucleotide derivative, shRNA, andsiRNA.

Other examples of second therapeutic agents, one or more of which apresent BET bromodomain inhibitor also can be combined, include, but arenot limited to: a treatment for Alzheimer's Disease, such as donepeziland rivastigmine; a treatment for Parkinson's Disease, such asL-DOPA/carbidopa, entacapone, ropinrole, pramipexole, bromocriptine,pergolide, trihexephendyl, and amantadine; an agent for treatingmultiple sclerosis (MS) such as beta interferon e.g., AVONEX® andREBIF®), glatiramer acetate, and mitoxantrone; a treatment for asthma,such as albuterol and montelukast; an agent for treating schizophrenia,such as zyprexa, risperdal, seroquel, and haloperidol; ananti-inflammatory agent, such as a corticosteroid, a TNF blocker, IL-1RA, azathioprine, cyclophosphamide, and sulfasalazine; animmunomodulatory agent, including immunosuppressive agents, such ascyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, aninterferon, a corticosteroid, cyclophosphamide, azathioprine, andsulfasalazine; a neurotrophic factor, such as an acetylcholinesteraseinhibitor, an MAO inhibitor, an interferon, an anti-convulsant, an ionchannel blocker, riluzole, or an anti-Parkinson's agent; an agent fortreating cardiovascular disease, such as a beta-blocker, an ACEinhibitor, a diuretic, a nitrate, a calcium channel blocker, or astatin; an agent for treating liver disease, such as a corticosteroid,cholestyramine, an interferon, and an anti-viral agent; an agent fortreating blood disorders, such as a corticosteroid, an anti-leukemicagent, or a growth factor; or an agent for treating immunodeficiencydisorders, such as gamma globulin.

The above-mentioned second therapeutically active agents, one or more ofwhich can be used in combination with a Compound of the Disclosure, areprepared and administered as described in the art.

Compound of the Disclosure typically are administered in admixture witha pharmaceutical carrier selected with regard to the intended route ofadministration and standard pharmaceutical practice. Pharmaceuticalcompositions for use in accordance with the present disclosure areformulated in a conventional manner using one or more physiologicallyacceptable carriers comprising excipients and/or auxiliaries thatfacilitate processing of Compound of the Disclosure.

These pharmaceutical compositions can be manufactured, for example, byconventional mixing, dissolving, granulating, dragee-making,emulsifying, encapsulating, entrapping, or lyophilizing processes.Proper formulation is dependent upon the route of administration chosen.When a therapeutically effective amount of the Compound of theDisclosure is administered orally, the composition typically is in theform of a tablet, capsule, powder, solution, or elixir. Whenadministered in tablet form, the composition additionally can contain asolid carrier, such as a gelatin or an adjuvant. The tablet, capsule,and powder contain about 0.01% to about 95%, and preferably from about1% to about 50%, of a Compound of the Disclosure. When administered inliquid form, a liquid carrier, such as water, petroleum, or oils ofanimal or plant origin, can be added. The liquid form of the compositioncan further contain physiological saline solution, dextrose or othersaccharide solutions, or glycols. When administered in liquid form, thecomposition contains about 0.1% to about 90%, and preferably about 1% toabout 50%, by weight, of a Compound of the Disclosure.

When a therapeutically effective amount of a Compound of the Disclosureis administered by intravenous, cutaneous, or subcutaneous injection,the composition is in the form of a pyrogen-free, parenterallyacceptable aqueous solution. The preparation of such parenterallyacceptable solutions, having due regard to pH, isotonicity, stability,and the like, is within the skill in the art. A preferred compositionfor intravenous, cutaneous, or subcutaneous injection typicallycontains, an isotonic vehicle.

Compounds of the Disclosure can be readily combined withpharmaceutically acceptable carriers well-known in the art. Standardpharmaceutical carriers are described in Remington's PharmaceuticalSciences, Mack Publishing Co., Easton, Pa., 19th ed. 1995. Such carriersenable the active agents to be formulated as tablets, pills, dragees,capsules, liquids, gels, syrups, slurries, suspensions and the like, fororal ingestion by a patient to be treated. Pharmaceutical preparationsfor oral use can be obtained by adding the Compound of the Disclosure toa solid excipient, optionally grinding the resulting mixture, andprocessing the mixture of granules, after adding suitable auxiliaries,if desired, to obtain tablets or dragee cores. Suitable excipientsinclude, for example, fillers and cellulose preparations. If desired,disintegrating agents can be added.

Compound of the Disclosure can be formulated for parenteraladministration by injection, e.g., by bolus injection or continuousinfusion. Formulations for injection can be presented in unit dosageform, e.g., in ampules or in multidose containers, with an addedpreservative. The compositions can take such forms as suspensions,solutions, or emulsions in oily or aqueous vehicles, and can containformulatory agents such as suspending, stabilizing, and/or dispersingagents.

Pharmaceutical compositions for parenteral administration includeaqueous solutions of the active agent in water-soluble form.Additionally, suspensions of a Compound of the Disclosure can beprepared as appropriate oily injection suspensions. Suitable lipophilicsolvents or vehicles include fatty oils or synthetic fatty acid esters.Aqueous injection suspensions can contain substances which increase theviscosity of the suspension. Optionally, the suspension also can containsuitable stabilizers or agents that increase the solubility of thecompounds and allow for the preparation of highly concentratedsolutions. Alternatively, a present composition can be in powder formfor constitution with a suitable vehicle, e.g., sterile pyrogen-freewater, before use.

Compounds of the Disclosure also can be formulated in rectalcompositions, such as suppositories or retention enemas, e.g.,containing conventional suppository bases. In addition to theformulations described previously, the Compound of the Disclosure alsocan be formulated as a depot preparation. Such long-acting formulationscan be administered by implantation (for example, subcutaneously orintramuscularly) or by intramuscular injection. Thus, for example, theCompound of the Disclosure can be formulated with suitable polymeric orhydrophobic materials (for example, as an emulsion in an acceptable oil)or ion exchange resins.

In particular, the Compounds of the Disclosure can be administeredorally, buccally, or sublingually in the form of tablets containingexcipients, such as starch or lactose, or in capsules or ovules, eitheralone or in admixture with excipients, or in the form of elixirs orsuspensions containing flavoring or coloring agents. Such liquidpreparations can be prepared with pharmaceutically acceptable additives,such as suspending agents. Compound of the Disclosure also can beinjected parenterally, for example, intravenously, intramuscularly,subcutaneously, or intracoronarily. For parenteral administration, theCompound of the Disclosure are typically used in the form of a sterileaqueous solution which can contain other substances, for example, saltsor monosaccharides, such as mannitol or glucose, to make the solutionisotonic with blood.

In another embodiment, the present disclosure provides kits whichcomprise a Compound of the Disclosure (or a composition comprising aCompound of the Disclosure) packaged in a manner that facilitates theiruse to practice methods of the present disclosure. In one embodiment,the kit includes a Compound of the Disclosure (or a compositioncomprising a Compound of the Disclosure) packaged in a container, suchas a sealed bottle or vessel, with a label affixed to the container orincluded in the kit that describes use of the compound or composition topractice the method of the disclosure. In one embodiment, the compoundor composition is packaged in a unit dosage form. The kit further caninclude a device suitable for administering the composition according tothe intended route of administration.

The term “BET bromodomain” as used herein means one or more of BRD2,BRD3, BRD4, and BRD-t, or an isoform or mutant thereof.

The term “a disease or condition wherein inhibition of BET bromodomainsprovides a benefit” pertains to a condition in which at least one ofBRD2, BRD3, BRD4, and BRD-t, and/or an action of at least one of BRD2,BRD3, BRD4, and BRD-t, is important or necessary, e.g., for the onset,progress, expression of that disease or condition, or a disease or acondition which is known to be treated by a BET bromodomain inhibitor.Examples of such conditions include, but are not limited to, a cancer, achronic autoimmune disease, an inflammatory disease, a proliferativedisease, sepsis, and a viral infection. One of ordinary skill in the artis readily able to determine whether a compound treats a disease orcondition mediated by a BET bromodomain for any particular cell type,for example, by assays which conveniently can be used to assess theactivity of particular compounds.

The term “second therapeutic agent” refers to a therapeutic agentdifferent from a Compound of the Disclosure and that is known to treatthe disease or condition of interest. For example when a cancer is thedisease or condition of interest, the second therapeutic agent can be aknown chemotherapeutic drug, like taxol, or radiation, for example.

The term “disease” or “condition” denotes disturbances and/or anomaliesthat as a rule are regarded as being pathological conditions orfunctions, and that can manifest themselves in the form of particularsigns, symptoms, and/or malfunctions. As demonstrated below, a Compoundof the Disclosure is a potent inhibitor of BET bromodomains and can beused in treating diseases and conditions wherein inhibition of BETbromodomains provides a benefit.

As used herein, the terms “treat,” “treating,” “treatment,” and the likerefer to eliminating, reducing, or ameliorating a disease or condition,and/or symptoms associated therewith. Although not precluded, treating adisease or condition does not require that the disease, condition, orsymptoms associated therewith be completely eliminated. As used herein,the terms “treat,” “treating,” “treatment,” and the like may include“prophylactic treatment,” which refers to reducing the probability ofredeveloping a disease or condition, or of a recurrence of apreviously-controlled disease or condition, in a subject who does nothave, but is at risk of or is susceptible to, redeveloping a disease orcondition or a recurrence of the disease or condition. The term “treat”and synonyms contemplate administering a therapeutically effectiveamount of a Compound of the Disclosure to an individual in need of suchtreatment.

Within the meaning of the disclosure, “treatment” also includes relapseprophylaxis or phase prophylaxis, as well as the treatment of acute orchronic signs, symptoms and/or malfunctions. The treatment can beorientated symptomatically, for example, to suppress symptoms. It can beeffected over a short period, be oriented over a medium term, or can bea long-term treatment, for example within the context of a maintenancetherapy.

The term “therapeutically effective amount” or “effective dose” as usedherein refers to an amount of the active ingredient(s) that is(are)sufficient, when administered by a method of the disclosure, toefficaciously deliver the active ingredient(s) for the treatment ofcondition or disease of interest to an individual in need thereof. Inthe case of a cancer or other proliferation disorder, thetherapeutically effective amount of the agent may reduce (i.e., retardto some extent and preferably stop) unwanted cellular proliferation;reduce the number of cancer cells; reduce the tumor size; inhibit (i.e.,retard to some extent and preferably stop) cancer cell infiltration intoperipheral organs; inhibit (i.e., retard to some extent and preferablystop) tumor metastasis; inhibit, to some extent, tumor growth; reduceBET bromodomain signaling in the target cells; and/or relieve, to someextent, one or more of the symptoms associated with the cancer. To theextent the administered compound or composition prevents growth and/orkills existing cancer cells, it may be cytostatic and/or cytotoxic.

The term “container” means any receptacle and closure therefore suitablefor storing, shipping, dispensing, and/or handling a pharmaceuticalproduct.

The term “insert” means information accompanying a pharmaceuticalproduct that provides a description of how to administer the product,along with the safety and efficacy data required to allow the physician,pharmacist, and patient to make an informed decision regarding use ofthe product. The package insert generally is regarded as the “label” fora pharmaceutical product.

“Concurrent administration,” “administered in combination,”“simultaneous administration,” and similar phrases mean that two or moreagents are administered concurrently to the subject being treated. By“concurrently,” it is meant that each agent is administered eithersimultaneously or sequentially in any order at different points in time.However, if not administered simultaneously, it is meant that they areadministered to an individual in a sequence and sufficiently close intime so as to provide the desired therapeutic effect and can act inconcert. For example, a Compound of the Disclosure can be administeredat the same time or sequentially in any order at different points intime as a second therapeutic agent. A Compound of the Disclosure and thesecond therapeutic agent can be administered separately, in anyappropriate form and by any suitable route. When a Compound of theDisclosure and the second therapeutic agent are not administeredconcurrently, it is understood that they can be administered in anyorder to a subject in need thereof. For example, a Compound of theDisclosure can be administered prior to (e.g., 5 minutes, 15 minutes, 30minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks,5 weeks, 6 weeks, 8 weeks, or 12 weeks before), concomitantly with, orsubsequent to (e.g., 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours,96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks,or 12 weeks after) the administration of a second therapeutic agenttreatment modality (e.g., radiotherapy), to an individual in needthereof. In various embodiments, a Compound of the Disclosure and thesecond therapeutic agent are administered 1 minute apart, 10 minutesapart, 30 minutes apart, less than 1 hour apart, 1 hour apart, 1 hour to2 hours apart, 2 hours to 3 hours apart, 3 hours to 4 hours apart, 4hours to 5 hours apart, 5 hours to 6 hours apart, 6 hours to 7 hoursapart, 7 hours to 8 hours apart, 8 hours to 9 hours apart, 9 hours to 10hours apart, 10 hours to 11 hours apart, 11 hours to 12 hours apart, nomore than 24 hours apart or no more than 48 hours apart. In oneembodiment, the components of the combination therapies are administeredat about 1 minute to about 24 hours apart.

The use of the terms “a”, “an”, “the”, and similar referents in thecontext of describing the disclosure (especially in the context of theclaims) are to be construed to cover both the singular and the plural,unless otherwise indicated. Recitation of ranges of values herein merelyare intended to serve as a shorthand method of referring individually toeach separate value falling within the range, unless otherwise indicatedherein, and each separate value is incorporated into the specificationas if it were individually recited herein. The use of any and allexamples, or exemplary language (e.g., “such as”) provided herein, isintended to better illustrate the disclosure and is not a limitation onthe scope of the disclosure unless otherwise claimed. No language in thespecification should be construed as indicating any non-claimed elementas essential to the practice of the disclosure.

The term “about,” as used herein, includes the recited number ±10%.Thus, “about 10” means 9 to 11.

For the purpose of the present disclosure, the term “alkyl” as used byitself or as part of another group refers to a straight- orbranched-chain aliphatic hydrocarbon containing one to twelve carbonatoms (i.e., C₁₋₁₂ alkyl) or the number of carbon atoms designated(i.e., a C₁ alkyl such as methyl, a C₂ alkyl such as ethyl, a C₃ alkylsuch as propyl or isopropyl, etc.). In one embodiment, the alkyl groupis chosen from a straight chain C₁₋₁₀ alkyl group. In anotherembodiment, the alkyl group is chosen from a branched chain C₃₋₁₀ alkylgroup. In another embodiment, the alkyl group is chosen from a straightchain C₁₋₆ alkyl group. In another embodiment, the alkyl group is chosenfrom a branched chain C₃₋₆ alkyl group. In another embodiment, the alkylgroup is chosen from a straight chain C₁₋₄ alkyl group. In anotherembodiment, the alkyl group is chosen from a branched chain C₃₋₄ alkylgroup. In another embodiment, the alkyl group is chosen from a straightor branched chain C₃₋₄ alkyl group. Non-limiting exemplary C₁₋₁₀ alkylgroups include methyl, ethyl, propyl, isopropyl, butyl, sec-butyl,tert-butyl, iso-butyl, 3-pentyl, hexyl, heptyl, octyl, nonyl, decyl, andthe like. Non-limiting exemplary C₁₋₄ alkyl groups include methyl,ethyl, propyl, isopropyl, butyl, sec-butyl, tert-butyl, and iso-butyl.

For the purpose of the present disclosure, the term “optionallysubstituted alkyl” as used by itself or as part of another group meansthat the alkyl as defined above is either unsubstituted or substitutedwith one, two, or three substituents independently chosen from nitro,haloalkoxy, aryloxy, aralkyloxy, alkylthio, sulfonamido, alkylcarbonyl,arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl,cycloalkyl, and the like. In one embodiment, the optionally substitutedalkyl is substituted with two substituents. In another embodiment, theoptionally substituted alkyl is substituted with one substituent.Non-limiting exemplary optionally substituted alkyl groups include—CH₂CH₂NO₂, —CH₂SO₂CH₃ CH₂CH₂CO₂H, —CH₂CH₂SO₂CH₃, —CH₂CH₂COPh, and—CH₂C₆H₁₁.

For the purpose of the present disclosure, the term “cycloalkyl” as usedby itself or as part of another group refers to saturated and partiallyunsaturated (containing one or two double bonds) cyclic aliphatichydrocarbons containing one to three rings having from three to twelvecarbon atoms (i.e., C₃₋₁₂ cycloalkyl) or the number of carbonsdesignated. In one embodiment, the cycloalkyl group has two rings. Inone embodiment, the cycloalkyl group has one ring. In anotherembodiment, the cycloalkyl group is chosen from a C₃₋₈ cycloalkyl group.In another embodiment, the cycloalkyl group is chosen from a C₃₋₆cycloalkyl group. Non-limiting exemplary cycloalkyl groups includecyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,cyclooctyl, norbornyl, decalin, adamantyl, cyclohexenyl, andcyclopentenyl, cyclohexenyl.

For the purpose of the present disclosure, the term “optionallysubstituted cycloalkyl” as used by itself or as part of another groupmeans that the cycloalkyl as defined above is either unsubstituted orsubstituted with one, two, or three substituents independently chosenfrom halo, nitro, cyano, hydroxy, amino, haloalkyl, hydroxyalkyl,alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido,sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl,carboxy, carboxyalkyl, alkyl, optionally substituted cycloalkyl,alkenyl, alkynyl, optionally substituted aryl, optionally substitutedheteroaryl, optionally substituted heterocyclo, alkoxyalkyl,(amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, and (heterocyclo)alkyl.In one embodiment, the optionally substituted cycloalkyl is substitutedwith two substituents. In another embodiment, the optionally substitutedcycloalkyl is substituted with one substituent.

For the purpose of the present disclosure, the term “alkenyl” as used byitself or as part of another group refers to an alkyl group as definedabove containing one, two or three carbon-to-carbon double bonds. In oneembodiment, the alkenyl group is chosen from a C₂₋₆ alkenyl group. Inanother embodiment, the alkenyl group is chosen from a C₂₋₄ alkenylgroup. Non-limiting exemplary alkenyl groups include ethenyl, propenyl,isopropenyl, butenyl, sec-butenyl, pentenyl, and hexenyl.

For the purpose of the present disclosure, the term “optionallysubstituted alkenyl” as used herein by itself or as part of anothergroup means the alkenyl as defined above is either unsubstituted orsubstituted with one, two or three substituents independently chosenfrom halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino,haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy,alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl,alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, cycloalkyl,alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.

For the purpose of the present disclosure, the term “alkynyl” as used byitself or as part of another group refers to an alkyl group as definedabove containing one to three carbon-to-carbon triple bonds. In oneembodiment, the alkynyl has one carbon-to-carbon triple bond. In oneembodiment, the alkynyl group is chosen from a C₂₋₆ alkynyl group. Inanother embodiment, the alkynyl group is chosen from C₂₋₄ alkynyl group.Non-limiting exemplary alkynyl groups include ethynyl, propynyl,butynyl, 2-butynyl, pentynyl, and hexynyl groups.

For the purpose of the present disclosure, the term “optionallysubstituted alkynyl” as used herein by itself or as part of anothergroup means the alkynyl as defined above is either unsubstituted orsubstituted with one, two or three substituents independently chosenfrom halo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino,haloalkyl, hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy,alkylthio, carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl,alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl, cycloalkyl,alkenyl, alkynyl, aryl, heteroaryl, or heterocyclo.

For the purpose of the present disclosure, the term “haloalkyl” as usedby itself or as part of another group refers to an alkyl groupsubstituted by one or more fluorine, chlorine, bromine and/or iodineatoms. In one embodiment, the alkyl group is substituted by one, two, orthree fluorine and/or chlorine atoms. In another embodiment, thehaloalkyl group is chosen from a C₁₋₄ haloalkyl group. Non-limitingexemplary haloalkyl groups include fluoromethyl, 2-fluoroethyl,difluoromethyl, trifluoromethyl, pentafluoroethyl, 1,1-difluoroethyl,2,2-difluoroethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl,4,4,4-trifluorobutyl, and trichloromethyl groups.

For the purpose of the present disclosure, the term “hydroxyalkyl” asused by itself or as part of another group refers to an alkyl groupsubstituted with one or more, e.g., one, two, or three, hydroxy groups.In one embodiment, the hydroxyalkyl group is a monohydroxyalkyl group,i.e., substituted with one hydroxy group. In another embodiment, thehydroxyalkyl group is a dihydroxyalkyl group, i.e., substituted with twohydroxy groups, e.g.,

In another embodiment, the hydroxyalkyl group is chosen from a C₁₋₄hydroxyalkyl group. Non-limiting exemplary hydroxyalkyl groups includehydroxymethyl, hydroxyethyl, hydroxypropyl and hydroxybutyl groups, suchas 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 2-hydroxypropyl,3-hydroxypropyl, 3-hydroxybutyl, 4-hydroxybutyl,2-hydroxy-1-methylpropyl, and 1,3-dihydroxyprop-2-yl.

For the purpose of the present disclosure, the term “alkoxy” as used byitself or as part of another group refers to an optionally substitutedalkyl, optionally substituted cycloalkyl, optionally substituted alkenylor optionally substituted alkynyl attached to a terminal oxygen atom. Inone embodiment, the alkoxy group is chosen from a C₁₋₄ alkoxy group. Inanother embodiment, the alkoxy group is chosen from a C₁₋₄ alkylattached to a terminal oxygen atom, e.g., methoxy, ethoxy, andtert-butoxy.

For the purpose of the present disclosure, the term “alkylthio” as usedby itself or as part of another group refers to a sulfur atomsubstituted by an optionally substituted alkyl group. In one embodiment,the alkylthio group is chosen from a C₁₋₄ alkylthio group. Non-limitingexemplary alkylthio groups include —SCH₃, and —SCH₂CH₃.

For the purpose of the present disclosure, the term “alkoxyalkyl” asused by itself or as part of another group refers to an alkyl groupsubstituted with an alkoxy group. Non-limiting exemplary alkoxyalkylgroups include methoxymethyl, methoxyethyl, methoxypropyl, methoxybutyl,ethoxymethyl, ethoxyethyl, ethoxypropyl, ethoxybutyl, propoxymethyl,iso-propoxymethyl, propoxyethyl, propoxypropyl, butoxymethyl,tert-butoxymethyl, isobutoxymethyl, sec-butoxymethyl, andpentyloxymethyl.

For the purpose of the present disclosure, the term “haloalkoxy” as usedby itself or as part of another group refers to a haloalkyl attached toa terminal oxygen atom. Non-limiting exemplary haloalkoxy groups includefluoromethoxy, difluoromethoxy, trifluoromethoxy, and2,2,2-trifluoroethoxy.

For the purpose of the present disclosure, the term “aryl” as used byitself or as part of another group refers to a monocyclic or bicyclicaromatic ring system having from six to fourteen carbon atoms (i.e.,C₆-C₁₄ aryl). Non-limiting exemplary aryl groups include phenyl(abbreviated as “Ph”), naphthyl, phenanthryl, anthracyl, indenyl,azulenyl, biphenyl, biphenylenyl, and fluorenyl groups. In oneembodiment, the aryl group is chosen from phenyl or naphthyl.

For the purpose of the present disclosure, the term “optionallysubstituted aryl” as used herein by itself or as part of another groupmeans that the aryl as defined above is either unsubstituted orsubstituted with one to five substituents independently chosen fromhalo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl,hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio,carboxamido, sulfonamido, alkylcarbonyl, arylcarbonyl, alkylsulfonyl,arylsulfonyl, carboxy, carboxyalkyl, alkyl, optionally substitutedcycloalkyl, alkenyl, alkynyl, optionally substituted aryl, optionallysubstituted heteroaryl, optionally substituted heterocyclo, alkoxyalkyl,(amino)alkyl, (carboxamido)alkyl, mercaptoalkyl, or (heterocyclo)alkyl.

In one embodiment, the optionally substituted aryl is an optionallysubstituted phenyl. In one embodiment, the optionally substituted phenylhas four substituents. In another embodiment, the optionally substitutedphenyl has three substituents. In another embodiment, the optionallysubstituted phenyl has two substituents. In another embodiment, theoptionally substituted phenyl has one substituent. Non-limitingexemplary substituted aryl groups include 2-methylphenyl,2-methoxyphenyl, 2-fluorophenyl, 2-chlorophenyl, 2-bromophenyl,3-methylphenyl, 3-methoxyphenyl, 3-fluorophenyl, 3-chlorophenyl,4-methylphenyl, 4-ethylphenyl, 4-methoxyphenyl, 4-fluorophenyl,4-chlorophenyl, 2,6-di-fluorophenyl, 2,6-di-chlorophenyl, 2-methyl,3-methoxyphenyl, 2-ethyl, 3-methoxyphenyl, 3,4-di-methoxyphenyl,3,5-di-fluorophenyl 3,5-di-methylphenyl, 3,5-dimethoxy, 4-methylphenyl,2-fluoro-3-chlorophenyl, and 3-chloro-4-fluorophenyl. The termoptionally substituted aryl is meant to include groups having fusedoptionally substituted cycloalkyl and fused optionally substitutedheterocyclo rings. Non-limiting examples include:

For the purpose of the present disclosure, the term “aryloxy” as used byitself or as part of another group refers to an optionally substitutedaryl attached to a terminal oxygen atom. A non-limiting exemplaryaryloxy group is PhO—.

For the purpose of the present disclosure, the term “aralkyloxy” as usedby itself or as part of another group refers to an aralkyl groupattached to a terminal oxygen atom. A non-limiting exemplary aralkyloxygroup is PhCH₂O—.

For the purpose of the present disclosure, the term “heteroalkyl” asused by itself or part of another group refers to a stable straight orbranched chain hydrocarbon radical containing 1 to 10 carbon atoms andat least two heteroatoms, which can be the same or different, selectedfrom O, N, or S, wherein: 1) the nitrogen atom(s) and sulfur atom(s) canoptionally be oxidized; and/or 2) the nitrogen atom(s) can optionally bequaternized. The heteroatoms can be placed at any interior position ofthe heteroalkyl group or at a position at which the heteroalkyl group isattached to the remainder of the molecule. In one embodiment, theheteroalkyl group contains two oxygen atoms. In one embodiment, theheteroalkyl contains one oxygen and one nitrogen atom. In oneembodiment, the heteroalkyl contains two nitrogen atoms. Non-limitingexemplary heteroalkyl groups include —CH₂OCH₂CH₂OCH₃,—OCH₂CH₂OCH₂CH₂OCH₃, —CH₂NHCH₂CH₂OCH₂, —OCH₂CH₂NH₂, —NHCH₂CH₂N(H)CH₃,—NHCH₂CH₂OCH₃ and —OCH₂CH₂OCH₃.

For the purpose of the present disclosure, the term “heteroaryl” or“heteroaromatic” refers to monocyclic and bicyclic aromatic ring systemshaving 5 to 14 ring atoms (i.e., C₅-C₁₄ heteroaryl), wherein at leastone carbon atom of one of the rings is replaced with a heteroatomindependently selected from the group consisting of oxygen, nitrogen andsulfur. In one embodiment, the heteroaryl contains 1, 2, 3, or 4heteroatoms independently selected from the group consisting of oxygen,nitrogen and sulfur. In one embodiment, the heteroaryl has threeheteroatoms. In another embodiment, the heteroaryl has two heteroatoms.In another embodiment, the heteroaryl has one heteroatom. Non-limitingexemplary heteroaryl groups include thienyl, benzo[b]thienyl,naphtho[2,3-b]thienyl, thianthrenyl, furyl, benzofuryl, pyranyl,isobenzofuranyl, benzooxazonyl, chromenyl, xanthenyl, 2H-pyrrolyl,pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl,pyridazinyl, isoindolyl, 3H-indolyl, indolyl, indazolyl, purinyl,isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, cinnolinyl,quinazolinyl, pteridinyl, 4aH-carbazolyl, carbazolyl, β-carbolinyl,phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl,thiazolyl, isothiazolyl, phenothiazolyl, isoxazolyl, furazanyl, andphenoxazinyl. In one embodiment, the heteroaryl is chosen from thienyle.g., thien-2-yl and thien-3-yl), furyl (e.g., 2-furyl and 3-furyl),pyrrolyl (e.g., 1H-pyrrol-2-yl and 1H-pyrrol-3-yl), imidazolyl (e.g.,2H-imidazol-2-yl and 2H-imidazol-4-yl), pyrazolyl e.g., 1H-pyrazol-3-yl,1H-pyrazol-4-yl, and 1H-pyrazol-5-yl), pyridyl e.g., pyridin-2-yl,pyridin-3-yl, and pyridin-4-yl), pyrimidinyl (e.g., pyrimidin-2-yl,pyrimidin-4-yl, and pyrimidin-5-yl), thiazolyl (e.g., thiazol-2-yl,thiazol-4-yl, and thiazol-5-yl), isothiazolyl (e.g., isothiazol-3-yl,isothiazol-4-yl, and isothiazol-5-yl), oxazolyl e.g., oxazol-2-yl,oxazol-4-yl, and oxazol-5-yl), isoxazolyl (e.g., isoxazol-3-yl,isoxazol-4-yl, and isoxazol-5-yl), and indazolyl (e.g.,1H-indazol-3-yl). The term “heteroaryl” is also meant to includepossible N-oxides. A non-limiting exemplary N-oxide is pyridyl N-oxide.

In one embodiment, the heteroaryl is a 5- or 6-membered heteroaryl. Inone embodiment, the heteroaryl is a 5-membered heteroaryl, i.e., theheteroaryl is a monocyclic aromatic ring system having 5 ring atomswherein at least one carbon atom of the ring is replaced with aheteroatom independently selected from nitrogen, oxygen, and sulfur.Non-limiting exemplary 5-membered heteroaryl groups include thienyl,furyl, pyrrolyl, oxazolyl, pyrazolyl, imidazolyl, thiazolyl,isothiazolyl, and isoxazolyl.

In another embodiment, the heteroaryl is a 6-membered heteroaryl, e.g.,the heteroaryl is a monocyclic aromatic ring system having 6 ring atomswherein at least one carbon atom of the ring is replaced with a nitrogenatom. Non-limiting exemplary 6-membered heteroaryl groups includepyridyl, pyrazinyl, pyrimidinyl, and pyridazinyl.

For the purpose of the present disclosure, the term “optionallysubstituted heteroaryl” as used by itself or as part of another groupmeans that the heteroaryl as defined above is either unsubstituted orsubstituted with one to four substituents, e.g., one or twosubstituents, independently chosen from halo, nitro, cyano, hydroxy,amino, alkylamino, dialkylamino, haloalkyl, hydroxyalkyl, alkoxy,haloalkoxy, aryloxy, aralkyloxy, alkylthio, carboxamido, sulfonamido,alkylcarbonyl, arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy,carboxyalkyl, alkyl, optionally substituted cycloalkyl, alkenyl,alkynyl, optionally substituted aryl, optionally substituted heteroaryl,optionally substituted heterocyclo, alkoxyalkyl, (amino)alkyl,(carboxamido)alkyl, mercaptoalkyl, or (heterocyclo)alkyl. In oneembodiment, the optionally substituted heteroaryl has one substituent.Any available carbon or nitrogen atom can be substituted. Non-limitingexemplary optionally substituted 5-membered heteroaryl groups include,but are not limited to:

The term optionally substituted heteroaryl is also meant to includegroups having fused optionally substituted cycloalkyl and fusedoptionally substituted heterocyclo rings. Non-limiting examples include:

For the purpose of the present disclosure, the term “heterocycle” or“heterocyclo” as used by itself or as part of another group refers tosaturated and partially unsaturated (e.g., containing one or two doublebonds) cyclic groups containing one, two, or three rings having fromthree to fourteen ring members (i.e., a 3- to 14-membered heterocyclo)wherein at least one carbon atom of one of the rings is replaced with aheteroatom. Each heteroatom is independently selected from the groupconsisting of oxygen, sulfur, including sulfoxide and sulfone, and/ornitrogen atoms, which can be oxidized or quaternized. The term“heterocyclo” is meant to include groups wherein a ring —CH₂— isreplaced with a —C(═O)—, for example, cyclic ureido groups such as2-imidazolidinone and cyclic amide groups such as β-lactam, γ-lactam,δ-lactam, ε-lactam, and piperazin-2-one. The term “heterocyclo” is alsomeant to include groups having fused optionally substituted aryl groups,e.g., indolinyl, chroman-4-yl. In one embodiment, the heterocyclo groupis chosen from a 5- or 6-membered cyclic group containing one ring andone or two oxygen and/or nitrogen atoms. The heterocyclo can beoptionally linked to the rest of the molecule through any availablecarbon or nitrogen atom. Non-limiting exemplary heterocyclo groupsinclude dioxanyl, tetrahydropyranyl, 2-oxopyrrolidin-3-yl,piperazin-2-one, piperazine-2,6-dione, 2-imidazolidinone, piperidinyl,morpholinyl, piperazinyl, pyrrolidinyl, and indolinyl.

For the purpose of the present disclosure, the term “optionallysubstituted heterocyclo” as used herein by itself or part of anothergroup means the heterocyclo as defined above is either unsubstituted orsubstituted with one to four substituents independently selected fromhalo, nitro, cyano, hydroxy, amino, alkylamino, dialkylamino, haloalkyl,hydroxyalkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy, alkylthio,carboxamido, sulfonamido, alkylcarbonyl, alkoxycarbonyl, CF₃C(═O)—,arylcarbonyl, alkylsulfonyl, arylsulfonyl, carboxy, carboxyalkyl, alkyl,optionally substituted cycloalkyl, alkenyl, alkynyl, optionallysubstituted aryl, optionally substituted heteroaryl, optionallysubstituted heterocyclo, alkoxyalkyl, (amino)alkyl, (carboxamido)alkyl,mercaptoalkyl, or (heterocyclo)alkyl. Substitution may occur on anyavailable carbon or nitrogen atom, or both. Non-limiting exemplaryoptionally substituted heterocyclo groups include:

For the purpose of the present disclosure, the term “amino” as used byitself or as part of another group refers to —NR^(7a)R^(7b), whereinR^(7a) and R^(7b) are each independently hydrogen, alkyl, hydroxyalkyl,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heterocyclo, or optionally substitutedheteroaryl, or R^(7a) and R^(7b) are taken together to form a 3- to8-membered optionally substituted heterocyclo. Non-limiting exemplaryamino groups include —NH₂ and —N(H)(CH₃).

For the purpose of the present disclosure, the term “(amino)alkyl” asused by itself or as part of another group refers to an alkyl groupsubstituted with an amino group. Non-limiting exemplary amino alkylgroups include —CH₂CH₂NH₂, and —CH₂CH₂N(H)CH₃, —CH₂CH₂N(CH₃)₂, and—CH₂N(H)cyclopropyl.

For the purpose of the present disclosure, the term “carboxamido” asused by itself or as part of another group refers to a radical offormula —C(═O)NR^(9a)R^(9b), wherein R^(9a) and R^(9b) are eachindependently hydrogen, optionally substituted alkyl, hydroxyalkyl,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heterocyclo, or optionally substitutedheteroaryl, or R^(9a) and R^(9b) taken together with the nitrogen towhich they are attached form a 3- to 8-membered optionally substitutedheterocyclo group. In one embodiment, R^(9a) and R^(9b) are eachindependently hydrogen or optionally substituted alkyl. In oneembodiment, R^(9a) and R^(9b) are taken together to taken together withthe nitrogen to which they are attached form a 3- to 8-memberedoptionally substituted heterocyclo group. Non-limiting exemplarycarboxamido groups include, but are not limited to, —CONH₂, —CON(H)CH₃,—CON(CH₃)₂, —CON(H)Ph,

For the purpose of the present disclosure, the term “sulfonamido” asused by itself or as part of another group refers to a radical of theformula —SO₂NR^(8a)R^(8b), wherein R^(8a) and R^(8b) are eachindependently hydrogen, optionally substituted alkyl, or optionallysubstituted aryl, or R^(8a) and R^(8b) taken together with the nitrogento which they are attached from a 3- to 8-membered heterocyclo group.Non-limiting exemplary sulfonamido groups include —SO₂NH₂, —SO₂N(H)CH₃,and —SO₂N(H)Ph.

For the purpose of the present disclosure, the term “alkylcarbonyl” asused by itself or as part of another group refers to a carbonyl group,i.e., —C(═O)—, substituted by an alkyl group. A non-limiting exemplaryalkylcarbonyl group is —COCH₃.

For the purpose of the present disclosure, the term “arylcarbonyl” asused by itself or as part of another group refers to a carbonyl group,i.e., —C(═O)—, substituted by an optionally substituted aryl group. Anon-limiting exemplary arylcarbonyl group is —COPh.

For the purpose of the present disclosure, the term “alkoxycarbonyl” asused by itself or as part of another group refers to a carbonyl group,i.e., —C(═O)—, substituted by an alkoxy group. Non-limiting exemplaryalkoxycarbonyl groups include —C(═O)OMe, —C(═O)OEt, and —C(═O)OtBu.

For the purpose of the present disclosure, the term “alkylsulfonyl” asused by itself or as part of another group refers to a sulfonyl group,i.e., —SO₂—, substituted by any of the above-mentioned optionallysubstituted alkyl groups. A non-limiting exemplary alkylsulfonyl groupis —SO₂CH₃.

For the purpose of the present disclosure, the term “arylsulfonyl” asused by itself or as part of another group refers to a sulfonyl group,i.e., —SO₂—, substituted by any of the above-mentioned optionallysubstituted aryl groups. A non-limiting exemplary arylsulfonyl group is—SO₂Ph.

For the purpose of the present disclosure, the term “mercaptoalkyl” asused by itself or as part of another group refers to any of theabove-mentioned alkyl groups substituted by a —SH group.

For the purpose of the present disclosure, the term “carboxy” as used byitself or as part of another group refers to a radical of the formula—COOH.

For the purpose of the present disclosure, the term “carboxyalkyl” asused by itself or as part of another group refers to any of theabove-mentioned alkyl groups substituted with a —COOH. A non-limitingexemplary carboxyalkyl group is —CH₂CO₂H.

For the purpose of the present disclosure, the terms “aralkyl” or“arylalkyl” as used by themselves or as part of another group refers toan alkyl group substituted with one, two, or three optionallysubstituted aryl groups. In one embodiment, the optionally substitutedaralkyl group is a C₁₋₄ alkyl substituted with one optionallysubstituted aryl group. In one embodiment, the optionally substitutedaralkyl group is a C₁ or C₂ alkyl substituted with one optionallysubstituted aryl group. In one embodiment, the optionally substitutedaralkyl group is a Q or C₂ alkyl substituted with one optionallysubstituted phenyl group. Non-limiting exemplary optionally substitutedaralkyl groups include benzyl, phenethyl, —CHPh₂, —CH₂(4-F-Ph),—CH₂(4-Me-Ph), —CH₂(4-CF₃-Ph), and —CH(4-F-Ph)₂.

For the purpose of the present disclosure, the terms“(heterocyclo)alkyl” as used by itself or part of another group refersto an alkyl group substituted with an optionally substituted heterocyclogroup. In one embodiment, the (heterocyclo)alkyl is a C₁₋₄ alkylsubstituted with one optionally substituted heterocyclo group.Non-limiting exemplary (heterocyclo)alkyl groups include:

For the purpose of the present disclosure, the term “(carboxamido)alkyl”as used by itself or as part of another group refers to an alkyl groupsubstituted with one or two carboxamido groups. In one embodiment, the(carboxamido)alkyl is a C₁₋₄ alkyl substituted with one carboxamidogroup. In another embodiment, the (carboxamido)alkyl is a C₁₋₄ alkylsubstituted with two carboxamido groups. Non-limiting exemplary(carboxamido)alkyl groups include —CH₂CONH₂, —C(H)CH₃—CONH₂,—CH₂CON(H)CH₃, and —CH(CO₂NH₂)CH-₂CH₂CO₂NH₂

EXAMPLES Example 1 Synthesis of ethyl2-amino-6-(3,5-dimethylisoxazol-4-yl)-5-methoxy-1H-indole-3-carboxylate(S6)

S3 (2.26 g, 20 mmol) was dissolved in anhydrous DMF (50 mL) and thesolution was cooled to 0° C. NaH (1.2 g, 60% in mineral oil, 30 mmol)was added in small portions. The resulting reaction mixture was stirredfor 0.5 h at 0° C. and an anhydrous DMF solution of known compounds S1and S2 (20 mmol, J. Med. Chem. 55:449-464 (2012)) was added. Theresulting solution was stirred at 0° C. for 3 h before quenching with 1N HCl. The aqueous layer was extracted with ethyl acetate and combinedorganic layers were washed with brine and dried over anhydrous Na₂SO₄.The volatile components were removed on a rotary evaporator and theresidue was purified by flash column chromatogram. The desired productS4 was isolated as colorless oil with impurity of the other regioisomer(4.17 g, 61% yield). ¹H NMR (300 MHz, CDCl₃): 8.41 (s, 1H), 7.11 (s,1H), 5.60 (s, 1H), 4.24 (q, J=7.03 Hz, 2H), 4.01 (s, 3H), 1.25 (t,J=7.14 Hz, 3H).

S4 (1.43 g, 4.2 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(2.34 g, 10.5 mmol), and K₂CO₃ (2.03 g, 14.7 mmol) were added to around-bottom flask. DME (30 mL) and water (15 mL) were added at roomtemperature. The solution was degassed, then Pd(PPh₃)₄ (242 mg, 0.21mmol) was added in one portion. The solution was again degassed, thenheated at reflux for 14 h. The aqueous layer was extracted with ethylacetate, the combined organic layers were washed with brine, then driedover anhydrous Na₂SO₄. The volatile components were removed on a rotaryevaporator and the residue was purified by flash column chromatogram.The desired product S5 was isolated in >80% yield (1.47 g, contaminatedwith isomers and pinacol components). ¹H NMR (CDCl₃, 300 MHz): 8.10 (s,1H), 7.27 (s, 1H), 5.78 (s, 1H), 4.35 (q, J=7.12 Hz, 2H), 3.99 (s, 3H),2.33 (s, 3H), 2.18 (s, 3H), 1.37 (t, J=7.14 Hz, 3H).

To an AcOH (30 mL) solution of S5 (1.47 g) at 80° C., 0.8 g Zn powderwas added in small portions. The mixture was stirred at 80° C. for 1 h,another 0.8 g Zn powder was added, and the reaction was kept at the sametemperature for 2 h. The reaction was cooled, filtered, and washed withAcOH. The AcOH solution was combined and the volatile components wereremoved on a rotary evaporator. Purification by flash columnchromatogram furnished the desired product S6 (0.55 g, ca, 40% yield).¹H NMR (CDCl₃, 300 MHz): 8.01 (br, s, 1H), 7.44 (s, 1H), 6.78 (s, 1H),5.73 (br, s, 2H), 4.40 (q, J=7.08 Hz, 2H), 3.82 (s, 3H), 2.29 (s, 3H),2.15 (s, 3H), 1.45 (t, J=7.08 Hz, 3H). ESI-MS calculated for C₁₇H₂₀N₃O₄[M+H]⁺: 330.15, Obtained: 330.25.

Example 2 Synthesis of4-(4-chloro-6-methoxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(S13)

Step 1: To a round-bottom flask, S6 (0.37 g, 1.1 mmol) and MeCN (20 mL)were added at room temperature. Dry HCl was bubbled through MeCN for 30min and the reaction mixture was warmed up to reflux (ca, 82° C.) for2.5 h. The reaction was then cooled to room temperature and the volatilecomponents were removed on a rotary evaporator. To this crude mixture,10% NaOH aqueous solution (20 mL) and EtOH (50 mL) were added and thesolution was heated at reflux for 6 h. The volatile components were thenremoved on a rotary evaporator and the aqueous residue was acidifiedwith 2N HCl aqueous solution. The product S12 was allowed to precipitateat 0° C. Filtration of the mixture furnished pure S12 in 0.278 g (78%yield, 2 steps). ¹H NMR (DMSO-d6, 300 MHz): 7.57 (s, 1H), 7.20 (s, 1H),3.81 (s, 3H), 2.37 (s, 3H), 2.27 (s, 3H), 2.08 (s, 3H).

Step 2: To a round-bottom flask, S12 (0.278 g, 0.8 mmol) and POCl₃ (8mL) were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished S13 as a brown solid in0.208 g (75% yield). ¹H NMR (DMSO-d6, 300 MHz): 7.81 (s, 1H), 7.43 (s,1H), 3.89 (s, 3H), 2.69 (s, 3H), 2.31 (s, 3H), 2.11 (s, 3H).

Example 3 Synthesis of4-(4-chloro-6-methoxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD54)

Step 1: S6 (0.45 g, 1.4 mmol), ammonium formate (1.06 g, 17 mmol), andformamide (16 mL) were heated at 175° C. for 14 h. The reaction wascooled to room temperature and water was added. Filtration of themixture yielded S7 as a brown solid (0.24 g, 0.77 mmol, 55% yield). ¹HNMR (DMSO-d6, 300 MHz): 8.09 (s, 1H), 7.57 (s, 1H), 7.24 (s, 1H), 3.81(s, 3H), 3.30 (s, 1H), 2.62 (s, 3H), 2.06 (s, 3H), ESI-MS calculated forC₁₆H₁₅N₄O₃ [M+H]⁺: 311.11, Obtained: 311.75

Step 2: S7 (0.24 g, 0.77 mmol) was dissolved in POCl₃ (10 mL) and themixture was heated at 90° C. for 5 h. The mixture was cooled to roomtemperature and the volatile components were removed on a rotaryevaporator. Ethyl acetate (20 mL) was added at 0° C., followed by NaHCO₃(20 mL) and water (20 mL). The mixture was filtered and the desired CD54product was collected as a brown solid (0.17 g). The aqueous layer wasextracted with ethyl acetate and the combined organic layers were washedwith brine and dried over anhydrous Na₂SO₄. The volatile components wereremoved on a rotary evaporator affording a brown solid (80 mg, 90 purityof CD54). ¹H NMR (DMSO-d6, 300 MHz): 8.74 (s, 1H), 7.84 (s, 1H), 7.45(s, 1H). 3.89 (s, 3H), 3.31 (br, s, 1H), 2.29 (s, 3H), 2.09 (s, 3H). ¹³CNMR (DMSO-d6, 75 MHz): 167.84, 161.17. 155.84, 122.24, 120.26, 116.96,115.15, 113.11, 105.80, 57.84, 13.36, 12.39. ESI-MS calculated forC₁₆H₁₄ ³⁵ClN₄O₂[M+H]⁺: 329.08, Obtained: 329.67

Example 4 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 17)

4-(4-Chloro-6-methoxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD54, 56 mg) and 1-methyl-1H-indazol-3-amine (60 mg) were dissolved inisopropanol (5 mL). Five drops of concentrated HCl was added via a glasspipette. The mixture was heat at reflux for overnight. The reaction wasthen concentrated on a rotary evaporator and the remaining residues waspurified by reverse phase HPLC to yield Cpd. No. 17 in 19 mg as a saltof CF₃CO₂H. ¹H NMR (300 MHz, MeOD-d4): 8.57 (s, 1H), 8.17 (s, 1H), 7.91(d, J=8.42 Hz, 1H), 7.70 (d, J=8.42 Hz, 1H), 7.62-7.54 (m, 1H), 7.54 (s,1H), 7.32 (d, J=7.40 Hz, 1H), 4.20 (s, 3H), 3.98 (s, 3H), 2.35 (s, 3H),2.18 (s, 3H). ESI-MS calculated for C₂₄H₂₂N₇O₂ [M+H]⁺=440.18, Observed:440.58

Example 5 Synthesis of4-(4-chloro-2-isopropyl-6-methoxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD177)

Step 1: S6 (400 mg) was dissolved in isobutyronitrile (2 mL). HCl gaswas bubbled into the solution for 40 min and the solution was heated at90° C. for 3 h. The solvent was concentrated in vacuum and the residuewas dissolved in ethanol (40 mL). NaOH (10%, 30 mL) was added to theethanol solution and the mixture was heated at reflux for overnight. Thesolution was cooled to room temperature and concentrated in vacuum.Ethyl acetate (20 mL) was added followed by aqueous HCl solution to setpH=4-5. The precipitate was collected by filtration and the residue waswashed with diethyl ether to furnish CD171 in 0.26 g. ¹H NMR (300 MHz,DMSO-d6): 12.05 (s, 1H), 12.00 (s, 1H), 7.54 (s, 1H), 7.18 (s, 1H), 3.81(s, 3H), 2.97 (septet, J=6.75 Hz, 1H), 2.26 (s, 3H), 2.06 (s, 3H), 1.25(d, J=6.80 Hz, 6H)

Step 2: CD171 (0.26 g) was mixed with phosphorus(V) oxychloride (5 mL)and heated at 90° C. for 6 h. The mixture was concentrated in vacuum andneutralized with excess aqueous NaHCO₃ saturated solution. Ethyl acetate(30 mL) was added and the precipitate was collected by filtration. Thesolid residue was washed with diethyl ether to furnish CD177 in 120 mg(43% yield). ¹H NMR (300 MHz, DMSO-d6): 12.52 (s, 1H), 7.79 (s, 1H),7.38 (s, 1H), 3.88 (s, 3H), 3.19 (septet, J=6.88 Hz, 1H), 2.28 (s, 3H),2.09 (s, 3H), 1.33 (d, J=6.88 Hz, 6H).

Example 6 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-2-isopropyl-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 18)

4-(4-Chloro-2-isopropyl-6-methoxy-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD177, 70 mg) and 1-methyl-1H-indazol-3-amine (60 mg) were dissolved inisopropanol (5 mL). Five drops of concentrated HCl was added via a glasspipette. The mixture was heat at reflux for overnight. The reaction wasthen concentrated on a rotary evaporator and the remaining residues waspurified by reverse phase HPLC to yield Cpd. No. 18 in 40 mg as a saltof CF₃CO₂H. ¹H NMR (300 MHz, MeOD-d4): 7.97 (d, J=8.32 Hz, 1H), 7.90 (s,1H), 7.67 (d, J=8.53 Hz, 1H), 7.62-7.55 (m, 1H), 7.49 (s, 1H), 7.31 (t,J=7.42 Hz, 1H), 4.16 (s, 3H), 3.89 (s, 3H), 3.36 (septet, J=6.78 Hz,1H), 2.33 (s, 3H), 2.16 (s, 3H), 1.50 (d, J=6.90 Hz, 6H). ESI-MScalculated for C₂₇H₂₈N₇O₂ [M+H]⁺=482.23, Observed: 482.42.

Example 7 Synthesis of4-(4-chloro-6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD197)

Step 1: S6 (300 mg), tetrahydropyranyl-4-carbonitrile (330 mg), anddioxane (10 mL) were placed in a round-bottom flask. HCl gas was bubbledinto the solution for 40 min and the solution was heated at 80° C. for 5h. The solvent was concentrated in vacuum and the residue was dissolvedin ethanol (30 mL). NaOH (10%, 30 mL) was added to the ethanol solutionand the mixture was heated at reflux for 12 h. The solution was cooledto room temperature and concentrated in vacuum. Ethyl acetate (20 mL)was added followed by addition of aqueous HCl solution to set pH=4-5.The precipitate was collected by filtration and the residue was washedwith diethyl ether to furnish CD188 in 0.12 g (33% yield). ESI-MScalculated for C₂₁H₂₃N₄O₄ [M+H]⁺=395.17, Obtained: 395.58.

Step 2: CD188 (0.12 g) was mixed with phosphorus(V) oxychloride (10 mL)and heated at 90° C. for 6 h. The mixture was concentrated in vacuum andneutralized with excess aqueous NaHCO₃ saturated solution. Ethyl acetate(20 mL) was added and the precipitate was collected by filtration. Thesolid residue was washed with diethyl ether to furnish CD197 in 80 mg(63% yield).

Example 8 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 20

4-(4-Chloro-6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(CD197, 28 mg) and 1-methyl-1H-indazol-3-amine (60 mg) were dissolved inisopropanol (5 mL). Four drops of concentrated HCl was added via a glasspipette. The mixture was heat at reflux for overnight. The reaction wasthen concentrated on a rotary evaporator and the remaining residues waspurified by reverse phase HPLC to yield Cpd. No. 21 in 13 mg as a saltof CF₃CO₂H. ¹H NMR (300 MHz, MeOD-d4): 7.93 (d, J=8.16 Hz, 1H), 7.88 (s,1H), 7.68 (d, J=8.35 Hz, 1H), 7.64-7.54 (m, 1H), 7.49 (s, 1H), 7.34-7.24(m, 1H), 4.17 (s, 3H), 4.08 (dt, J=6.13, 2.73 Hz, 2H), 3.88 (s, 3H),3.70-3.45 (m, 2H), 2.33 (s, 3H), 2.16 (s, 3H), 2.10-1.98 (m, 5H). ESI-MScalculated for C₂₉H₃₀N₇O₃ [M+H]⁺=524.24, Observed: 524.50.

Example 9 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 1)

S13 (68 mg), 3-methyl-1-phenyl-1H-pyrazol-5-amine (80 mg), NaHCO₃ (100mg) and anhydrous DMSO (3 mL) were heated at 130° C. for overnight. Themixture was then purified by reverse phase HPLC to yield Cpd. No. 1 as aCF₃CO₂H salt in 5 mg (4% yield). ¹H NMR (300 MHz, MeOD-d4): 7.56-7.46(m, 3H), 7.43 (s, 1H), 7.42-7.28 (m, 3H), 6.52 (s, 1H), 3.84 (s, 3H),2.61 (s, 3H), 2.40 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H). ESI-MScalculated for C₂₇H₂₆N₇O₂ [M+H]⁺=480.21; Observed: 480.67.

Example 10 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-phenyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 2)

S13 (70 mg), 5-phenyl-1H-pyrazol-4-amine (70 mg), NaHCO₃ (100 mg) andanhydrous DMSO (3 mL) were heated at 130° C. for 16 h. The mixture wasthen purified by reverse phase HPLC to yield Cpd. No. 2 as a CF₃CO₂Hsalt in 3 mg (3% yield). ¹H NMR (300 MHz, MeOD-d4): 8.01 (s, 1H),7.72-7.66 (m, 2H), 7.44 (s, 3H), 7.42-7.32 (m, 3H), 3.87 (s, 3H), 2.57(s, 3H), 2.32 (s, 3H), 2.15 (s, 3H). ESI-MS calculated for C₂₆H₂₄N₇O₂[M+H]⁺=466.20; observed: 466.75.

Example 11 Synthesis of4-(4-((4-Isopropyl-5-methyl-4H-1,2,4-triazol-3-yl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 3)

S13 (68 mg), 4-isopropyl-5-methyl-4H-1,2,4-triazole-3-thiol (64 mg), andK₂CO₃ (64 mg) were mixed in a round-bottom flask. Anhydrous DMSO (3 mL)was added and the reaction mixture was heated at 130° C. for overnight.The reaction was then cooled to ambient temperature and water (1 mL) wasadded. The mixture was purified on reverse phase HPLC to yield thedesired product Cpd. No. 3 as a salt of trifluoroacetic acid in 45 mg(50% yield). ¹H NMR (300 MHz, MeOD-d4): 7.70 (s, 1H), 7.42 (s, 1H),5.00-4.90 (m, 1H), 3.96 (s, 3H), 2.86 (s, 3H), 2.54 (s, 3H), 2.34 (s,3H), 2.17 (s, 3H), 1.62 (d, J=6.99 Hz, 6H). ESI-MS calculated forG₃H₂₆N₇O₂S [M+H]⁺=464.19; Observed: 464.33.

Example 12 Synthesis of 1-Isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-amine(CE261 TFA salt)

Step 1: 2-(Hydroxyimino)-1-phenylbutane-1,3-dione (1.3 g) and isopropylhydrazine (500 mg) were dissolved in ethanol. The solution was stirredat ambient temperature for overnight. The volatile components wereremoved a rotary evaporator. Ethyl acetate and water were added and theaqueous layer was extracted with ethyl acetate. The combined organiclayers were dried and concentrated on a rotary evaporator.

Step 2: The previous remaining residue was dissolved in acetic acid (20mL) followed by addition of zinc powder (1.8 g). The mixture was heat at80° C. for overnight. The mixture was filtered and the filtrate wasconcentrated. The remaining residue was purified on preparative HPLC toyield the desired product CE261 in 96 mg as a salt of trifluoroaceticacid. ¹H NMR (300 MHz, MeOD-d4): 7.65-7.57 (m, 2H), 7.54-7.38 (m, 3H),5.40-5.10 (broad singlet, 2H), 4.61 (septet, J=6.63 Hz, 1H), 2.43 (s,3H), 1.49 (d, J=6.63 Hz, 6H). ¹³C (75 MHz, MeOD-d4): 145.85, 135.02,132.56, 130.13, 129.94, 129.17, 108.85, 52.08, 22.61, 8.92. ESI-MScalculated for C₁₃H₁₈N₃ [M+H]⁺=216.15; Observed: 216.50.

Example 13 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 4)

S13 (70 mg) and 1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-amine (70 mg)were dissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction mixture was concentrated on a rotary evaporatorand the remaining residues were purified by HPLC to yield the desiredproduct Cpd. No. 4 in 38 mg as a salt of trifluoroacetic acid. ¹H NMR(300 MHz, MeOD-d4): 7.80-7.66 (m, 2H), 7.50-7.40 (m, 1H), 7.36-7.20 (m,4H), 4.80-4.60 (m, 1H), 3.92 (s, 3H), 2.56 (s, 3H), 2.46-2.30 (m, 3H),2.31 (s, 3H), 2.14 (s, 3H), 1.59 (d, J=5.75 Hz, 6H). ESI-MS calculatedfor C₃₀H₃₂N₇O₂ [M+H]⁺=522.26; Observed: 522.58.

Example 14 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(5-methyl-4-phenyl-1H-pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 5)

S13 (70 mg) and 5-methyl-4-phenyl-1H-pyrazol-3-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No 5 in 2 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.52 (s, 1H), 7.43-7.40 (m, 5H), 7.30 (s, 1H), 3.82 (s, 3H),2.72 (s, 3H), 2.45 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H). ESI-MScalculated for G₇H₂₆N₇O₂ [M+H]⁺=480.21; Observed: 480.17.

Example 15 Synthesis of 2-(Oxazol-2-yl)-4-phenylthiazol-5-amine (CE267)

Oxazole-2-carbaldehyde (1 g), sulfur (352 mg), and2-amino-2-phenylacetonitrile-HCl (1.69 g) were mixed in ethanol (50 mL).Triethyl amine (2.1 mL) was added and the mixture was heated at 50° C.for 1 h. The mixture was cooled to ambient temperature and aqueoushydroxylamine (hydroxylamine-HCl 1.90 g neutralized by sodium hydroxide)was added. The reaction was stirred at ambient temperature forovernight. The reaction mixture was filtered, concentrated, andpartitioned between ethyl acetate and water. The aqueous layer wasextracted with ethyl acetate. The combined organic layers were dried andconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to yield CE267 in 260 mg. ¹H NMR (300MHz, DMSO-d6): 8.18 (d, J=0.77 Hz, 1H), 7.77-7.71 (m, 2H), 7.41 (t,J=7.65 Hz, 2H), 7.33 (d, J=0.76 Hz, 1H), 7.24 (t, J=7.35 Hz, 1H), 6.50(s, 1H). ¹³C (75 MHz, DMSO-d6): 158.32, 150.83, 142.08, 136.92, 136.59,134.41, 130.56, 130.45, 128.39, 128.23. ESI-MS calculated for C₁₂H₁₀N₃OS[M+H]⁺=244.05; Observed: 244.42.

Example 16 Synthesis ofN-(7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)-4-phenylthiazol-5-amine(Cpd. No. 6)

S13 (230 mg) and 2-(oxazol-2-yl)-4-phenylthiazol-5-amine (260 mg) weredissolved in isopropanol (20 mL). Eleven drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 6 in 8 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,DMSO-d6): 12.00 (s, 1H), 10.08 (s, 1H), 8.34 (s, 1H), 8.08 (d, J=7.80Hz, 2H), 7.80 (s, 1H), 7.54 (t, J=7.62 Hz, 2H), 7.50 (s, 1H), 7.40 (t,J=7.33 Hz, 1H), 7.28 (s, 1H), 3.78 (s, 3H), 2.64 (s, 3H), 2.29 (s, 3H),2.09 (s, 3H). ESI-MS calculated for C₂₉H₂₄N₇O₃S [M+H]⁺=550.17; Observed:550.75.

Example 17 Synthesis of 1-(3-Chlorophenyl)-3-methyl-1H-pyrazol-5-amine(CE280)

Step 1: (3-Chlorophenyl)hydrazine (415 mg), 3-oxobutanenitrile (895 mg),and sodium acetate (415 mg) were dissolved in ethanol (20 mL). Thesolution was heated at reflux for overnight. The reaction mixture wasconcentrated and partitioned between ethyl acetate and water. Theaqueous layer was extracted with ethyl acetate. The combined organiclayers were dried and concentrated on a rotary evaporator.

Step 2: The previous remaining residue was dissolved in methanol andtrifluoroacetic acid (1 mL) was added. The mixture was left at ambienttemperature for overnight. The reaction mixture was concentrated andneutralized by sodium bicarbonate saturated solution. The aqueous layerwas extracted with ethyl acetate. The combined organic layers were driedand concentrated on a rotary evaporator. The remaining residue waspurified by flash column chromatography to yield CE280 in 0.84 g. ¹H NMR(300 MHz, CDCl₃): 7.67-7.61 (m, 1H), 7.52-7.45 (m, 1H), 7.42-7.34 (m,1H), 7.32-7.25 (m, 1H), 7.26 (s, 1H), 5.47 (s, 1H), 3.77 (s, 2H), 2.22(s, 3H). ¹³C (75 MHz, CDCl₃): 150.16, 145.46, 140.09, 135.27, 130.53,127.07, 123.88, 121.48, 91.61, 14.11. ESI-MS calculated for C₁₀H₁₁³⁵ClN₃ [M+H]⁺=208.06; Observed: 208.33.

Example 18 Synthesis ofN-(1-(3-Chlorophenyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 7)

Tris(dibenzylideneacetone)dipalladium(0) (18 mg) and2,2′-bis(diphenylphosphino)-1,1′-binaphthyl (26 mg) were mixed inanhydrous toluene. And the mixture was heated at reflux for 3-4 minutes.This mixture was transferred into a round-bottom flask containing S13(60 mg), 1-(3-chlorophenyl)-3-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄(130 mg), and toluene (1 mL). The mixture was heated at reflux forovernight before quenching with methanol. The reaction mixture wasfiltered and the mixture was purified by HPLC to yield Cpd. No. 7 as aCF₃CO₂H salt in 40 mg. ¹H NMR (300 MHz, MeOD-d4): 7.54-7.49 (m, 1H),7.45-7.42 (m, 1H), 7.43 (s, 1H), 7.42-3.80 (m, 1H), 7.34-2.25 (m, 1H),7.27 (s, 1H), 6.52 (s, 1H), 3.84 (s, 3H), 2.61 (s, 3H), 2.39 (s, 3H),2.30 (s, 3H), 2.13 (s, 3H). ESI-MS calculated for C₂₇H₂₅³⁵ClN₇O₂[M+H]⁺=514.18; Observed: 514.33.

Example 19 Synthesis ofN-(1,3-Dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 8)

Cpd. No. 8 was prepared from S13 (68 mg) and1,3-dimethyl-1H-pyrazol-5-amine (50 mg) following the same procedure forpreparation of Cpd. No. 7. Cpd. No. 8 was isolated as a CF₃CO₂H salt in40 mg. ¹H NMR (300 MHz, MeOD-d4): 7.46 (s, 1H), 7.43 (s, 1H), 6.25 (s,1H), 3.87 (s, 3H), 3.76 (s, 3H), 2.70 (s, 3H), 2.31 (s, 3H), 2.30 (s,3H), 2.14 (s, 3H). ESI-MS calculated for C₂₂H₂₄N₇O₂ [M+H]⁺=418.20;Observed: 418.92.

Example 20 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 9)

Cpd. No. 9 was prepared from S13 (70 mg) and1-isopropyl-3-methyl-1H-pyrazol-5-amine (640 mg) following the sameprocedure for preparation of Cpd. No. 7. Cpd. No. 9 was isolated as aCF₃CO₂H salt in 26 mg. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s, 1H), 7.18 (s,1H), 6.18 (s, 1H), 4.59 (septet, J=6.68 Hz, 1H), 3.83 (s, 3H), 2.70 (s,3H), 2.32 (s, 3H), 2.30 (s, 3H), 2.13 (s, 3H), 1.47 (d, J=6.66 Hz, 6H).ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.67.

Example 21 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 21)

Cpd. No. 21 was prepared from S13 (102 mg) and2-methyl-5-(trifluoromethyl)pyrazol-3-amine (100 mg) following the sameprocedure for preparation of Cpd. No. 7. Cpd. No. 21 was isolated as asalt of CF₃CO₂H in 29 mg. ¹H NMR (300 MHz, MeOD-d4): 7.83 (s, 1H), 7.47(s, 1H), 6.72 (s, 1H), 3.92 (s, 3H), 3.88 (s, 3H), 2.67 (s, 3H), 2.32(s, 3H), 2.15 (s, 3H). ESI-MS calculated for C₂₂H₂₁F₃N₇O₂ [M+H]⁺=472.17,Observed: 472.33.

Example 22 Synthesis of1-Isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-amine

(E)-4-Amino-4-ethoxy-1,1,1-trifluoro-but-3-en-2-one (1.0 g)isopropylhydrazine-HCl (1.21 g), and sodium acetate (1.4 g) were mixedin a round-bottom flask. Ethanol (20 mL) was added and the mixture washeated at reflux for overnight. The reaction mixture was concentrated onrotary evaporator and the remaining residues were dissolved in ethylacetate followed by extraction with water. The organic layer wascollected and dried over anhydrous sodium sulfate. The solid wasfiltered off and the solvent was removed on a rotary evaporator. Theremaining residue (1.12 g) was used without further purification. ¹H NMR(300 MHz, CDCl₃): 5.79 (s, 1H), 4.37 (septet, J=6.67 Hz, 1H), 1.47 (d,J=6.67 Hz, 6H). ESI-MS calculated for C₇H₁₁F₃N₃ [M+H]⁺=194.09, Observed:194.17. Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 22)

Cpd. No. 22 was prepared from S13 (102 mg) and1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-amine (174 mg) followingthe same procedure for preparation of Cpd. No. 7. Cpd. No. 22 wasisolated as a salt of CF₃CO₂H in 60 mg. ¹H NMR (300 MHz, MeOD-d4): 7.72(s, 1H), 7.48 (s, 1H), 6.45 (s, 1H), 4.65 (septet, J=6.60 Hz, 1H), 3.90(s, 1H), 2.67 (s, 1H), 2.31 (s, 1H), 2.14 (s, 1H), 1.51 (d, J=6.67 Hz,6H). ESI-MS calculated for C₂₄H₂₅F₃N₇O₂[M+H]⁺=500.20, Observed: 500.42.

Example 23 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 10)

Cpd. No. 10 was prepared from S13 (68 mg) and1-methyl-1H-pyrazolo[3,4-b]pyridin-3-amine (60 mg) following the sameprocedure for preparation of Cpd. No. 7. Cpd. No. 10 was isolated as aCF₃CO₂H salt in 32 mg. ¹H NMR (300 MHz, MeOD-d4): 8.65 (d, J=3.99 Hz,1H), 8.38 (d, J=8.15 Hz, 1H), 7.89, 7.48, 7.31 (dd, J=8.08, 4.55 Hz,1H), 4.17 (s, 3H), 3.86 (s, 3H), 2.71 (s, 3H), 2.32 (s, 3H), 2.15 (s,3H). ESI-MS calculated for C₂₄H₂₃N₈O₂ [M+H]⁺=455.19; Observed: 455.50.

Example 24 Synthesis of 1-Methyl-1H-pyrazolo[4,3-c]pyridin-3-amine(CE311)

4-Chloronicotinonitrile (500 mg) and methyl hydrazine (828 mg) weredissolved in ethanol (20 mL). The mixture was heated at reflux forovernight. The reaction mixture was concentrated and partitioned betweenethyl acetate and water. The aqueous layer was extracted with ethylacetate. The combined organic layers were dried and concentrated on arotary evaporator. The remaining residue (187 mg of CE311) was useddirectly for the next step. ¹H NMR (300 MHz, CDCl₃): 8.85 (d, J=1.01 Hz,1H), 8.31 (d, J=6.11 Hz, 1H), 7.05 (dd, J=6.12, 1.06 Hz, 1H), 4.50-4.20(br, 2H), 3.81 (s, 3H). ¹³C (75 MHz, CDCl₃): 147.93, 144.54, 143.98,143.70, 112.55, 103.50, 34.88. ESI-MS calculated for C₇H₉N₄[M+H]⁺=149.08; Observed: 149.50.

Example 25 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 11)

Cpd. No. 11 was prepared from S13 (70 mg) and1-methyl-1H-pyrazolo[4,3-c]pyridin-3-amine (60 mg) following the sameprocedure for preparation of Cpd. No. 7. Cpd. No. 11 was isolated as aCF₃CO₂H salt in 47 mg. ¹H NMR (300 MHz, CDCl₃): 9.71 (s, 1H), 8.46 (d,J=6.97 Hz, 1H), 8.12 (s, 1H), 8.08 (d, J=7.00 HZ, 1H), 7.38 (s, 1H),4.23 (s, 3H), 3.98 (s, 3H), 2.65 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H).ESI-MS calculated for C₂₄H₂₃N₈O₂ [M+H]⁺=455.19.

Example 26 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 12)

S13 (90 mg) and 1-methyl-1H-indazol-3-amine (90 mg) were dissolved inisopropanol (30 mL). Four drops of concentrated HCl was added via aglass pipette. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 12in 60 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4):8.44 (d, J=7.88 Hz, 1H), 7.84 (s, 1H), 7.68 (d, J=8.62 Hz, 1H), 7.57 (t,J=7.63 Hz, 1H), 7.47 (s, 1H), 7.30 (t, J=7.55 Hz, 1H), 4.16 (s, 3H),3.86 (s, 3H), 2.73 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H). ESI-MScalculated for C₂₅H₂₄N₇O₂ [M+H]⁺=454.20; Observed: 454.42.

Example 27 Synthesis of 5-Chloro-1-methyl-1H-indazol-3-amine (CE301)

5-Chloro-2-fluorobenzonitrile (600 mg) and methyl hydrazine (1.1 mL)were dissolved in ethanol (20 mL). The mixture was heated at reflux forovernight. The reaction mixture was concentrated and partitioned betweenethyl acetate and water. The aqueous layer was extracted with ethylacetate. The combined organic layers were dried and concentrated on arotary evaporator. The remaining residue (717 mg of CE301) was useddirectly for the next step. ¹H NMR (300 MHz, CDCl₃): 7.48 (s, 1H), 7.26(dd, J=8.86, 1.63 Hz, 1H), 7.11 (d, J=8.89 Hz, 1H), 4.20-3.90 (br, 2H),3.82 (s, 3H). ESI-MS calculated for C₈H₉ClN₃ [M+H]⁺=182.05; Observed:182.67.

Example 28 Synthesis ofN-(5-Chloro-1-methyl-1H-indazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 13)

S13 (70 mg) and 5-chloro-1-methyl-1H-indazol-3-amine (100 mg) weredissolved in isopropanol (5 mL). Five drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 13 in 18 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.92 (s, 2H), 7.69 (d, J=9.01 Hz, 1H), 7.52 (d, J=9.01 Hz,1H), 7.48 (s, 1H), 4.15 (s, 3H), 3.89 (s, 3H), 2.71 (s, 3H), 2.34 (s,3H), 2.16 (s, 3H). ESI-MS calculated for C₂₅H₂₃ ³⁵ClN₇O₂[M+H]⁺=488.16;Observed: 488.58.

Example 29 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-N-(6-methoxy-1-methyl-1H-indazol-3-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 19)

S13 (68 mg) and 1-methyl-6-methoxy-1H-indazol-3-amine (80 mg) weredissolved in isopropanol (5 mL). Six drops of concentrated HCl was addedvia a glass pipette. The mixture was heat at reflux for overnight. Thereaction was then concentrated on a rotary evaporator and the remainingresidues was purified by reverse phase HPLC to yield Cpd. No. 19 in 24mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-d4): 7.89 (s, 1H), 7.75(d, J=8.92 Hz, 1H), 7.47 (s, 1H), 7.07 (d, J=1.95 Hz, 1H), 6.92 (dd,J=8.86, 2.13 Hz, 1H), 4.11 (s, 3H), 3.95 (s, 3H), 3.90 (s, 3H), 2.77 (s,3H), 2.33 (s, 3H), 2.16 (s, 3H). ESI-MS calculated for C₂₆H₂₆N₇O₃[M+H]⁺=484.21, Observed: 484.75.

Example 30 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 14)

S13 (68 mg) and pyrazolo[1,5-a]pyridin-3-amine (84 mg) were dissolved inisopropanol (5 mL). Five drops of concentrated HCl was added via a glasspipette. The mixture was heated at reflux for overnight. The reactionwas concentrated on a rotary evaporator and the remaining residues werepurified by HPLC to yield the desired product Cpd. No. 14 in 55 mg as asalt of trifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4): 8.67 (d, J=7.06Hz, 1H), 8.22 (s, 1H), 8.10-7.80 (br, 1H), 7.68 (d, J=8.99 Hz, 1H), 7.47(s, 1H), 7.43-7.33 (m, 1H), 7.06 (t, J=6.79 Hz, 1H), 3.89 (s, 3H), 2.60(s, 3H), 2.33 (s, 3H), 2.15 (s, 3H). ESI-MS calculated for C₂₄H₂₂N₇O₂[M+H]⁺=440.18; Observed: 440.18.

Example 31 Synthesis of tert-Butyl(2-methylpyrazolo[1,5-a]pyridin-3-yl)carbamate (CE298)

Step 1: 1-Aminopyridinium iodide (10 g), ethyl but-2-ynoate (6.05 g),potassium carbonate (7.45 g) were mixed in anhydrous DMF (50 mL). Thereaction mixture was stirred at ambient temperature for 3 days. Amixture of water (100 mL), ethyl acetate (100 mL) and hexane (100 mL)was added and the product was collected by filtration. The filter cakewas washed with a mixture of ethyl acetate:hexane=1:1, affording 6.4 gof ethyl 2-methylpyrazolo[1,5-a]pyridine-3-carboxylate (70% yield).

Step 2: 6.4 g of ethyl 2-methylpyrazolo[1,5-a]pyridine-3-carboxylate wasdissolved in a mixture of methanol (40 mL) and THF (40 mL). To thismixture, 8 N NaOH (20 mL) was added and the mixture was heated at refluxfor 70° C. for overnight. Acid-base work-up of the reaction mixtureyielded CD157 in 4.1 g (75% yield), which was used without furtherpurification.

Step 3: CD157 (350 mg) and triethylamine (0.5 mL) were dissolved intert-butanol (5 mL). Diphenyl phosphoryl azide (DPPA, 0.65 mL) was addedvia a syringe. The reaction mixture was stirred at ambient temperaturefor overnight followed by heat-up at reflux for 24 hours. The reactionmixture was then filtered and washed with tert-butanol. The mixture wasconcentrated and purified by flash column chromatography to yield CE298in 116 mg. ¹H NMR (300 MHz, CDCl₃): 8.19 (d, J=6.77 Hz, 1H), 7.29 (d,J=7.99 Hz, 1H), 6.99 (t, J=7.68 Hz, 1H), 6.58 (t, J=6.68 Hz, 1H), 6.29(s, 1H), 2.32 (s, 3H), 1.48 (s, 9H). ESI-MS calculated for C₁₃H₁₈N₃O₂[M+H]⁺=248.14; Observed: 248.00.

Example 32 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 15)

CE298 (116 mg) and triethylsilane (0.1 mL) were dissolved indichloromethane (4 mL). Trifluoroacetic acid (6 mL) was added and themixture was stirred at ambient temperature for 3 h. The volatilecomponents were then removed on a rotary evaporator. S13 (70 mg) andisopropanol (5 mL) were added followed by addition of six drops ofconcentrated HCl. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 15in 93 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4):8.56 (d, J=6.96 Hz, 1H), 8.25 (broad singlet, 1H), 7.57 (d, J=8.80 Hz,1H), 7.47 (s, 1H), 7.40-7.30 (m, 1H), 6.99 (t, J=6.74 Hz, 1H), 3.95 (s,3H), 2.61 (s, 3H), 2.44 (s, 3H), 2.33 (s, 3H), 2.15 (s, 3H). ESI-MScalculated for C₂₅H₂₄N₇O₂ [M+H]⁺=454.20; Observed: 454.42.

Example 33 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyrimidin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 16)

S13 (120 mg) and pyrazolo[1,5-a]pyrimidin-3-amine (60 mg) were dissolvedin isopropanol (5 mL). Six drops of concentrated HCl was added via aglass pipette. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 16in 33 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4):9.07 (dd, J=7.16, 1.64 Hz, 1H), 8.64 (dd, J=4.20, 1.69 Hz, 1H), 8.47 (s,1H), 8.07 (s, 1H), 7.47 (s, 1H), 7.18 (dd, J=7.20, 4.17 Hz, 1H), 3.93(s, 3H), 2.59 (s, 3H), 2.34 (s, 3H), 2.16 (s, 3H). ESI-MS calculated forC₂₃H₂₁N₈O₂ [M+H]⁺=441.18; Observed: 441.67.

Example 34 Synthesis of4-(4-((3-chlorophenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 23)

S13 (68 mg), 3-chlorobenzenethiol (85 mg), and K₂CO₃ (64 mg) were mixedin a round-bottom flask. Anhydrous DMSO (3 mL) was added and thereaction mixture was heated at 60° C. for overnight. The reaction wasthen cooled to ambient temperature and water (1 mL) was added. Themixture was purified on reverse phase HPLC to yield the desired productCpd. No. 23 as a salt of trifluoroacetic acid in 38 mg. ESI-MScalculated for C₂₃H₂₀ClN₄O₂S [M+H]⁺=451.09; Observed: 451.23. ¹H NMR(300 MHz, MeOD) δ 7.77-7.71 (m, 2H), 7.59 (d, J=6.9 Hz, 1H), 7.53-7.43(m, 3H), 3.92 (s, 3H), 2.66 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H).

Example 35 Synthesis of4-(4-((2-chlorophenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 24)

S13 (68 mg), 2-chlorobenzenethiol (85 mg), and K₂CO₃ (64 mg) were mixedin a round-bottom flask. Anhydrous DMSO (3 mL) was added and thereaction mixture was heated at 60° C. for overnight. The reaction wasthen cooled to ambient temperature and water (1 mL) was added. Themixture was purified on reverse phase HPLC to yield the desired productCpd. No. 24 as a salt of trifluoroacetic acid in 44 mg. ESI-MScalculated for C₂₃H₂₀ClN₄O₂S [M+H]⁺=451.09; Observed: 451.13. ¹H NMR(300 MHz, MeOD) δ 7.74 (s, 1H), 7.69 (dd, J=7.8, 1.6 Hz, 1H), 7.63 (dd,J=8.0, 1.3 Hz, 1H), 7.48 (td, J=7.7, 1.7 Hz, 1H), 7.42-7.35 (m, 2H),3.93 (s, 3H), 2.56 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H).

Example 36 Synthesis of4-(4-((2-isopropylphenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 25)

S13 (68 mg), 2-isopropylbenzenethiol (85 mg), and K₂CO₃ (64 mg) weremixed in a round-bottom flask. Anhydrous DMSO (3 mL) was added and thereaction mixture was heated at 60° C. for overnight. The reaction wasthen cooled to ambient temperature and water (1 mL) was added. Themixture was purified on reverse phase HPLC to yield the desired productCpd. No. 25 as a salt of trifluoroacetic acid in 40 mg. ESI-MScalculated for C₂₆H₂₇N₄O₂S [M+H]⁺=459.18; Observed: 459.25. ¹H NMR (300MHz, MeOD) δ 7.83 (s, 1H), 7.65-7.59 (m, 1H), 7.57-7.48 (m, 2H), 7.40(s, 1H), 7.28 (ddd, J=7.8, 6.2, 2.7 Hz, 1H), 3.96 (s, 3H), 3.52 (dt,J=13.8, 6.8 Hz, 1H), 2.51 (s, 3H), 2.37 (s, 3H), 2.20 (s, 3H), 1.26 (d,J=6.9 Hz, 6H).

Example 37 Synthesis of4-(4-((1H-indol-3-yl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 26)

S13 (68 mg), 3-mercaptoindole (90 mg), and K₂CO₃ (64 mg) were mixed in around-bottom flask. Anhydrous DMSO (3 mL) was added and the reactionmixture was heated at 60° C. for overnight. The reaction was then cooledto ambient temperature and water (1 mL) was added. The mixture waspurified on reverse phase HPLC to yield the desired product Cpd. No. 26as a salt of trifluoroacetic acid in 30 mg. ESI-MS calculated forC₂₅H₂₂N₅O₂S [M+H]⁺=456.14; Observed: 456.25. ¹H NMR (300 MHz, DMSO) δ12.08 (s, 1H), 11.75 (s, 1H), 7.88-7.81 (m, 2H), 7.52 (d, J=8.1 Hz, 1H),7.42 (d, J=7.9 Hz, 1H), 7.38 (s, 1H), 7.20 (t, J=7.6 Hz, 1H), 7.07 (t,J=7.5 Hz, 1H), 3.93 (s, 3H), 2.35 (s, 3H), 2.33 (s, 3H), 2.14 (s, 3H).

Example 38 Synthesis of4-(4-((3-(tert-butyl)phenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 27)

S13 (68 mg), 3-tert-butylthiophenol (90 mg), and K₂CO₃ (64 mg) weremixed in a round-bottom flask. Anhydrous DMSO (3 mL) was added and thereaction mixture was heated at 60° C. overnight. The reaction was thencooled to ambient temperature and water (1 mL) was added. The mixturewas purified on reverse phase HPLC to yield the desired product Cpd. No.27 as a salt of trifluoroacetic acid in 40 mg. ESI-MS calculated forC₂₇H₂₉N₄O₂S [M+H]⁺=473.20; Observed: 473.44. ¹H NMR (300 MHz, DMSO) δ12.17 (s, 1H), 7.84-7.29 (m, 6H), 3.88 (s, 3H), 2.51 (s, 3H), 2.32 (s,3H), 2.12 (s, 3H), 1.31 (s, 9H).

Example 39 Synthesis of(R)—N-(chroman-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 28)

S13 (68 mg), (R)-chroman-4-ylamine (75 mg), and Cs₂CO₃ (244 mg) weremixed in a round-bottom flask. Anhydrous DMSO (3 mL) was added and thereaction mixture was heated at 60° C. overnight. The reaction was thencooled to ambient temperature and water (1 mL) was added. The mixturewas purified on reverse phase HPLC to yield the desired product Cpd. No.28 as a salt of trifluoroacetic acid in 1.5 mg. ESI-MS calculated forC₂₆H₂₆N₅O₃ [M+H]⁺=456.20; Observed: 456.44.

Example 40 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-1H-1,2,4-triazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 29)

S13 (68 mg), 1-isopropyl-1H-1,2,4-triazol-5-amine (75 mg), and Cs₂CO₃(244 mg) were mixed in a round-bottom flask. Anhydrous DMSO (3 mL) wasadded and the reaction mixture was heated at 60° C. overnight. Thereaction was then cooled to ambient temperature and water (1 mL) wasadded. The mixture was purified on reverse phase HPLC to yield thedesired product Cpd. No. 29 as a salt of trifluoroacetic acid in 4 mg.ESI-MS calculated for C₂₂H₂₅N₈O₂ [M+H]⁺=433.21; Observed: 433.32. ¹H NMR(300 MHz, MeOD) δ 8.24 (s, 1H), 7.50 (s, 1H), 7.39 (s, 1H), 5.07 (dt,J=13.3, 6.5 Hz, 1H), 3.86 (s, 3H), 2.71 (s, 3H), 2.34 (s, 3H), 2.17 (s,3H), 1.61 (d, J=6.7 Hz, 6H).

Example 41 Synthesis ofN-(3-(tert-butyl)-1,5-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 30)

S13 (70 mg) and 3-tert-butyl-1,5-dimethylpyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux overnight.The reaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 30in 30 mg as a salt of trifluoroacetic acid. Aq. NaHCO₃ was added to thecompound and the mixture was extracted by ethyl acetate. The combinedorganic layers were washed with brine and dried over anhydrous Na₂SO₄.The volatile components were removed on a rotary evaporator affording asolid. ESI-MS calculated for C₂₆H₃₂N₇O₂ [M+H]⁺=474.26; Observed: 474.44.¹H NMR (300 MHz, MeOD) δ 7.97 (brs, 1H), 7.30 (s, 1H), 3.88 (brs, 3H),3.80 (brs, 3H), 2.52 (s, 3H), 2.34 (s, 3H), 2.17 (s, 6H), 1.36 (s, 9H).

Example 42 Synthesis ofN-(5-(tert-butyl)-1,3-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 31)

S13 (70 mg) and 5-tert-butyl-1,3-dimethylpyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 31 in 30 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₆H₃₂N₇O₂ [M+H]⁺=474.26; Observed: 474.34.

Example 43 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(4-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 32)

S13 (70 mg) and 4-isopropyl-1H-pyrazol-3-amine (88 mg) were dissolved inisopropanol (5 mL). Four drops of concentrated HCl was added via a glasspipette. The mixture was heated at reflux overnight. The reaction wasconcentrated on a rotary evaporator and the remaining residues werepurified by HPLC to yield the desired product Cpd. No. 32 in 2 mg as asalt of trifluoroacetic acid. ESI-MS calculated for C₂₃H₂₆N₇O₂[M+H]⁺=432.21; Observed: 432.44. ¹H NMR (300 MHz, MeOD) δ 7.76 (s, 1H),7.46 (s, 1H), 7.28 (s, 1H), 3.87 (s, 3H), 3.04 (td, J=13.4, 6.6 Hz, 1H),2.77 (s, 3H), 2.34 (s, 3H), 2.16 (s, 3H), 1.31 (d, J=6.9 Hz, 6H).

Example 44 Synthesis of4-(tert-butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)thiazol-5-amine(Cpd. No. 33)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),4-tert-butyl-1,3-thiazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (1mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 33 as a CF₃CO₂H salt in 4 mg. ESI-MScalculated for C₂₄H₂₇N₆O₂S [M+H]⁺=463.19; Observed: 463.25. ¹H NMR (300MHz, MeOD) δ 9.02 (s, 1H), 7.76 (brs, 1H), 7.49 (s, 1H), 3.92 (s, 3H),2.71 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H), 1.46 (s, 9H).

Example 45 Synthesis ofN-(1,3-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 34)

S13 (70 mg) and 1,3-dimethyl-1H-pyrazol-4-ylamine (88 mg) were dissolvedin isopropanol (5 mL). Four drops of concentrated HCl was added via aglass pipette. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 34in 30 mg as a salt of trifluoroacetic acid. ESI-MS calculated forC₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed: 418.45. ¹H NMR (300 MHz, MeOD) δ8.0-7.7 (m, 2H), 7.47 (s, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 2.70 (s, 3H),2.34 (s, 3H), 2.24 (s, 3H), 2.17 (s, 3H).

Example 46 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 35)

S13 (70 mg) and 1,3,5-trimethyl-1H-pyrazol-4-amine (88 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux overnight.The reaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 35in 40 mg as a salt of trifluoroacetic acid. ESI-MS calculated forC₂₃H₂₆N₇O₂ [M+H]⁺=432.21; Observed: 432.44. ¹H NMR (300 MHz, MeOD) δ8.20 (s, 1H), 7.48 (s, 1H), 3.97 (s, 3H), 3.85 (s, 3H), 2.70 (s, 3H),2.34 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H), 2.16 (s, 3H).

Example 47 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 36)

S13 (70 mg) and 1-isopropyl-3,5-dimethyl-1H-pyrazol-4-amine (88 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux overnight.The reaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 36in 20 mg as a salt of trifluoroacetic acid. ESI-MS calculated forC₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.35. ¹H NMR (300 MHz, MeOD) δ8.20 (s, 1H), 7.49 (s, 1H), 4.70-4.52 (m, 1H), 3.97 (s, 3H), 2.70 (s,3H), 2.33 (s, 3H), 2.31 (brs, 1H), 2.25 (s, 3H), 2.16 (s, 3H), 1.53 (d,J=6.4 Hz, 6H).

Example 48 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 37)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-isopropyl-4-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (1 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 37 as a CF₃CO₂H salt in 2mg. ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.44. ¹HNMR (300 MHz, MeOD) δ 7.57 (s, 1H), 7.48 (s, 1H), 7.07 (brs, 1H), 4.64(dt, J=13.2, 6.7 Hz, 1H), 3.84 (s, 3H), 2.73 (s, 3H), 2.33 (s, 3H), 2.15(s, 3H), 1.95 (s, 3H), 1.48 (d, J=6.7 Hz, 6H).

Example 49 Synthesis of4-(4-(3-chlorophenoxy)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 95)

S13 (50 mg, 0.146 mmol), 3-chlorophenol (38 mg, 0.292 mmol), andpotassium carbonate (61 mg, 0.438 mmol) were dissolved in DMSO (2 mL)and heated to 90° C. After overnight, the reaction was cooled to roomtemperature, brine was added and the resulting solution was extractedwith ethyl acetate. The combined ethyl acetate extracts were washedtwice with water, once with brine, and the ethyl acetate was removed byrotoevaporation. The resulting oil was purified by preparative HPLC andlyophilized to give the TFA salt of the title compound as a powder.¹H-NMR (300 MHz, CD₃OD) δ ppm 7.66 (s, 1H), 7.53-7.26 (m, 5H), 3.88 (s,3H), 2.60 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H); ESI-MS m/z 435.25 (M+H)⁺.

Example 50 Synthesis of4-(6-methoxy-2-methyl-4-(pyridin-3-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 96)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 95. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.93 (s, 1H),8.67 (d, J=5.52 Hz, 1H), 8.31 (d, J=8.55 Hz, 1H), 7.89 (dd, J=5.12, 8.36Hz, 1H), 7.77 (s, 1H), 7.41 (s, 1H), 3.91 (s, 3H), 2.58 (s, 3H), 2.34(s, 3H), 2.18 (s, 3H); ESI-MS m/z 402.58 (M+H)⁺.

Example 51 Synthesis ofN-(3-chlorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 97)

Concentrated hydrochloric acid (5 drops) was added to a solution of S13(100 mg, 0.292 mmol) and 3-chloroaniline (82 mg, 0.642 mmol) inisopropanol (3 mL). After refluxing overnight, the reaction was cooled,the solvent was removed with a rotoevaporator and the crude was purifiedby preparative HPLC and lyophilized to give the TFA salt of the titlecompound as a powder. ¹H-NMR (300 MHz, CD₃OD) δ ppm 7.69-7.66 (m, 1H),7.65 (s, 1H), 7.56-7.46 (m, 2H), 7.43 (s, 1H), 7.38 (dt, J=1.92, 7.06Hz, 1H), 3.84 (s, 3H), 2.69 (s, 3H), 2.33 (s, 3H), 2.15 (s, 3H); ESI-MSm/z 434.42 (M+H)⁺.

Example 52 Synthesis ofN-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-methyl-3-phenylisoxazol-4-amine(Cpd. No. 98)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.09-7.91 (m,1H), 7.77-7.67 (m, 2H), 7.47 (s, 1H), 7.44-7.34 (m, 3H), 3.92 (s, 3H),2.58 (s, 3H), 2.52 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H); ESI-MS m/z481.50 (M+H)⁺.

Example 53 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(imidazo[1,2-a]pyridin-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 99)

The title compound was prepared in a similar manner as described for thepreparation of Cpd, No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.58 (dt,J=0.95. 6.88 Hz, 1H), 8.21 (s, 1H), 8.13-8.02 (m, 3H), 7.53 (td, J=1.89,6.40 Hz, 1H), 7.43 (s, 1H), 3.97 (s, 3H), 2.42 (s, 3H), 2.35 (s, 3H),2.18 (s, 3H); ESI-MS m/z 440.67 (M+H)⁺.

Example 54 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(4-methoxynaphthalen-1-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 100)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.44-8.38 (m,1H), 8.04-7.98 (m, 1H), 7.68-7.58 (m, 3H), 7.49-7.31 (m, 1H), 7.43 (s,1H), 7.09 (d, J=8.26 Hz, 1H), 4.12 (s, 3H), 3.63 (s, 3H), 2.59 (s, 3H),2.31 (s, 3H), 2.13 (s, 3H); ESI-MS m/z 480.58 (M+H)⁺.

Example 55 Synthesis ofN-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd, No. 101)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 95. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.73 (d,J=6.56 Hz, 1H), 8.05 (s, 1H), 7.97-7.82 (m, 2H), 7.45-7.36 (m, 2H), 4.02(s, 3H), 2.74 (s, 3H), 2.35 (s, 3H), 2.19 (s, 3H); ESI-MS m/z 441.58(M+H)⁺.

Example 56 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 102)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.40 (d,J=4.31 Hz, 1H), 8.14 (dd, J=1.35, 7.94, 1H), 7.97-7.78 (m, 1H), 7.82 (s,1H), 7.46 (s, 1H), 7.30 (dd, J=4.94, 7.95 Hz, 1H), 3.85 (s, 3H), 2.61(s, 3H), 2.33 (s, 3H), 2.16 (s, 3H); ESI-MS m/z 440.33 (M+H)⁺.

Example 57 Synthesis ofN-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)thieno[2,3-b]pyridin-3-amine(Cpd. No. 103)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.68 (dd,J=1.44, 4.64 Hz, 1H), 8.22 (dd, J=1.50, 8.17 Hz, 1H), 8.01 (s, 1H), 7.91(s, 1H), 7.52 (dd, J=4.67, 8.16 Hz, 1H), 7.48 (s, 1H), 3.86 (s, 3H),2.60 (s, 3H), 2.34 (s, 3H), 2.16 (s, 3H); ESI-MS m/z 457.50 (M+H)⁺.

Example 58 Synthesis of4-(6-methoxy-2-methyl-4-(quinolin-4-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 104)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 95. ¹H-NMR (300 MHz, CD₃OD and 10% CDCl₃) δ ppm9.12 (d, J=6.26 Hz, 1H), 8.69 (d, J=8.71 Hz, 1H), 8.27 (d, J=8.83 Hz,1H), 8.23-8.14 (m, 1H), 8.04-7.96 (m, 2H), 7.65 (s, 1H), 7.45 (s, 1H),3.78 (s, 3H), 2.68 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H); ESI-MS m/z452.67 (M+H)⁺.

Example 59 Synthesis of4-(4-(5-bromopyridin-3-yloxy)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(Cpd. No. 105)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 95. ¹H-NMR (300 MHz, CD₃OD and 10% CDCl₃) δ ppm8.64-8.60 (m, 2H), 8.13 (t, J=2.18 Hz, 1H), 7.72 (s, 1H), 7.38 (s, 1H),3.91 (s, 3H), 2.59 (s, 3H), 2.34 (s, 3H), 2.18 (s, 3H); ESI-MS m/z480.25 (M+HJ.

Example 60 Synthesis ofN-(5-chloropyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 106)

The title compound was prepared in a similar manner as described for thepreparation of Cpd. No. 97. ¹H-NMR (300 MHz, CD₃OD) δ ppm 8.86 (d,J=1.88 Hz, 1H), 8.52 (s, 1H), 8.31 (t, J=2.10 Hz, 1H), 8.04 (s, 1H),7.47 (s, 1H), 3.96 (s, 3H), 2.71 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H);ESI-MS m/z 435.33 (M+H)⁺.

Example 61 Synthesis of4-(1-Chloro-8-methoxy-5H-pyrido[4,3-b]indol-7-yl)-3,5-dimethylisoxazole(RX3)

7-Bromo-1-chloro-8-methoxy-5H-pyrido[4,3-b]indole (157 mg, 0.5 mmol),3,5-dimethylisoxazole-4-boronic acid pinacol ester (655 mg, 2.0 mmol),and K₂CO₃ (345 mg, 2.5 mmol) were dissolved in DME/H₂O (50 mL/25 mL)system. Then vacuumed, and refilled with N₂. After that,tetrakis(triphenylphosphine)palladium (0) was added, followed byvacuuming and refilling with N₂. The reaction mixture was heated toreflux for overnight, when cooled to room temperature, it was extractedwith EtOAc, and the combined organic fractions were concentrated beforepurification in prep-HPLC. 57 mg (34.6%) of the titled compound wasobtained after being lyophilized for 24 hours as a pale yellow powder.¹HNMR (300 MHz, MeOD-d₄) δ 8.26 (d, 1H, J=6.0 Hz), 8.09 (s, 1H), 7.60(d, 1H, J=6.3 Hz), 7.49 (s, 1H), 3.98 (s, 3H), 2.63 (s, 3H), 2.20 (s,3H). ESIMSm/z [M+H]⁺ calculated=328.77; found=328.83.

7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-N-(1-methyl-1H-indazol-3-yl)-5H-pyrido[4,3-b]indol-1-aminecan be synthesized from4-(1-chloro-8-methoxy-5H-pyrido[4,3-b]indol-7-yl)-3,5-dimethylisoxazoleand 1-methyl-1H-indazol-3-amine following the same method for thepreparation of Cpd. No. 255.

Example 62 Synthesis ofN-cyclohexyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 112)

In a round-bottomed flask, S13 (70 mg), NaHCO₅ (84 mg) and anhydrousDMSO (3 mL) were added. Cyclohexylamine (0.1 mL) was subsequently addedvia a syringe and the mixture was heated at 120° C. for overnight. Thereaction mixture was then purified by reverse phase HPLC to yield thetitle product as a salt of trifluoroacetic acid in 32 mg. ¹H NMR (300MHz, MeOD-d4): 8.02 (s, 1H), 7.41 (s, 1H), 4.50-4.30 (m, 1H), 3.96 (s,3H), 2.73 (s, 3H), 2.31 (s, 3H), 2.20-2.00 (m, 2H), 2.14 (s, 3H),1.98-1.84 (m, 2H), 1.84-1.60 (m, 3H), 1.60-1.40 (m, 2H), 1.40-1.20 (m,1H). ESI-MS calculated for C₂₃H₂₈N₅O₂ [M+H]⁺=406.22; Observed: 406.42.

Example 63 Synthesis ofN-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 113)

In a round-bottomed flask, S13 (68 mg), NaHCO₅ (100 mg) and anhydrousDMSO (3 mL) were added. Cyclopentylamine (0.1 mL) was subsequently addedvia a syringe and the mixture was heated at 120° C. for overnight. Thereaction mixture was then purified by reverse phase HPLC to yield thetitle product as a salt of trifluoroacetic acid in 60 mg. ¹H NMR (300MHz, MeOD-d4): 8.02 (s, 1H), 7.41 (s, 1H), 4.86-4.70 (m, 1H), 3.96 (s,3H), 2.73 (s, 3H), 2.32 (s, 3H), 2.32-2.18 (m, 2H), 2.15 (s, 3H),2.00-1.70 (m, 6H). ESI-MS calculated for C₂₂H₂₆N₅O₂ [M+H]⁺=392.21;Observed: 392.25.

Example 64 Synthesis of 3-Isopropyl-1-methyl-1H-pyrazol-5-amine (CF24)

4-Methyl-3-oxopentanenitrile (1 g) was dissolved in ethanol (30 mL).Methyl hydrazine (26 mL) was added and the mixture was heated at refluxfor overnight. The mixture was concentrated on a rotary evaporatorfollowed by addition of ethyl acetate and water. The aqueous layer wasextracted with ethyl acetate and the organic layers were combined,dried, and concentrated on a rotary evaporator. The remaining residuewas purified by flash column chromatography and the desired product wasobtained in 0.98 g. ¹H NMR (300 MHz, CDCl₃): 5.37 (s, 1H), 3.61 (s, 3H),3.43 (br, s, 1H), 2.83 (septet, J=6.89 Hz, 1H), 1.21 (d, J=6.93 Hz, 6H).¹³C NMR (75 MHz, CDCl₃): 158.17, 144.75, 88.24, 34.18, 28.35, 23.10.ESI-MS calculated for C₇H₁₄N₃[M+H]⁺=140.12, Observed: 140.33.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 65)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),3-isopropyl-1-methyl-1H-pyrazol-5-amine (84 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 65 in 49mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 7.46 (s, 1H), 7.42 (s,1H), 6.25 (s, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 2.97 (septet, J=6.92 Hz,1H), 2.71 (s, 3H), 2.31 (s, 3H), 2.13 (s, 3H), 1.28 (d, J=6.95 Hz, 6H).ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23, Observed: 446.42.

Example 65 Synthesis ofN-(1,5-Dimethyl-1H-pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 115)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1,5-dimethyl-1H-pyrazol-3-amine (70 mg, 0.6 mmol), K₃PO₄ (212 mg, 1.0mmol), and anhydrous toluene (5 mL). The mixture was heated at refluxfor overnight before quenching with methanol. The reaction mixture wasfiltered through a pad of Celite® and the organic layer was collected,concentrated, and purified by HPLC to yield Cpd. No. 115 in 31 mg as aCF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 8.24 (s, 1H), 7.46 (s, 1H),6.25 (s, 1H), 3.98 (s, 3H), 3.90 (s, 3H), 2.84 (s, 3H), 2.39 (s, 3H),2.33 (s, 3H), 2.16 (s, 3H). ESI-MS calculated for C₂₂H₂₄N₇O₂[M+H]⁺=418.20, Observed: 418.50.

Example 66 Synthesis of 1-Ethyl-3-methyl-1H-pyrazol-5-amine (CF35)

3-Aminocrotononitrile (2.0 g, 24.3 mmol) was dissolved in ethanol (40mL). Ethyl hydrazine oxalate (5 g, 33.3 mmol) and sodium acetate (6 g,73 mmol) were added and the mixture was heated at reflux for overnight.The mixture was concentrated on a rotary evaporator followed by additionof ethyl acetate and water. The aqueous layer was extracted with ethylacetate and the organic layers were combined, dried, and concentrated ona rotary evaporator. The remaining residues were purified by flashcolumn chromatography and the desired product was obtained in 1.277 g.¹H NMR (300 MHz, CDCl₃): 5.34 (s, 1H), 3.91 (q, J=7.26 Hz, 2H), 2.16 (s,3H), 1.36 (t, J=7.26 Hz, 3H). ESI-MS calculated forC₆H₁₂N₃[M+H]⁺=126.10, Observed: 126.33.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1-ethyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 116)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-ethyl-3-methyl-1H-pyrazol-5-amine (75 mg, 0.6 mmol), K₃PO₄ (212 mg,1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 116 in19 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s, 1H), 7.28(s, 1H), 6.21 (s, 1H), 4.11 (q, J=7.22 Hz, 2H), 3.85 (s, 3H), 2.70 (s,3H), 2.31 (s, 6H), 2.13 (s, 3H), 1.44 (t, J=7.23 Hz, 3H). ESI-MScalculated for C₂₃H₂₆N₇O₂ [M+H]⁺=432.21, Observed: 432.92.

Example 67 Synthesis of1-(tert-Butyl)-3-(trifluoromethyl)-1H-pyrazol-5-amine (CF39)

(E)-4-Amino-4-ethoxy-1,1,1-trifluorobut-3-en-2-one (2 g, 10.9 mmol) wasdissolved in ethanol (40 mL). Tert-butyl hydrazine-HCl salt (2.74 g, 22mmol) and sodium acetate (2.71 g, 33 mmol) were added and the mixturewas heated at reflux for overnight. The mixture was concentrated on arotary evaporator followed by addition of ethyl acetate and water. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residues were purified by flash column chromatography and thedesired product was obtained in 1.0 g. ¹H NMR (300 MHz, CDCl₃): 5.77 (s,1H), 1.59 (s, 9H). ESI-MS calculated for C₈H₁₃F₃N₃ [M+H]⁺=208.11,Observed: 208.42.

Synthesis ofN-(1-(tert-Butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 117)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-(tert-Butyl)-3-(trifluoromethyl)-1H-pyrazol-5-amine (120 mg, 0.6mmol), K₃PO₄ (212 mg, 1.0 mmol), and anhydrous toluene (5 mL). Themixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was filtered through a pad of Celite® andthe organic layer was collected, concentrated, and purified by HPLC toyield Cpd. No. 117 in 10 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz,MeOD-d4): 7.44 (s, 2H), 6.70 (s, 1H), 3.87 (s, 3H), 2.66 (s, 3H), 2.32(s, 3H), 2.15 (s, 3H), 1.71 (s, 3H). ESI-MS calculated forC₂₅H₂₇F₃N₇O₂[M+H]⁺=514.22, Observed: 514.17.

Example 68 Synthesis ofN-(1-Cyclopentyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 118)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-cyclopentyl-3-methyl-1H-pyrazol-5-amine (100 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 118 in60 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 7.44 (s, 1H), 7.19(s, 1H), 6.18 (s, 1H), 4.69 (quintet, J=7.95 Hz, 1H), 3.83 (s, 3H), 2.70(s, 3H), 2.31 (s, 3H), 2.13 (s, 3H), 2.10-2.00 (m, 4H), 2.00-1.80 (m,2H), 1.70-1.50 (m, 2H). ESI-MS calculated for C₂₆H₃₀N₇O₂ [M+H]⁺=472.25,Observed: 472.42.

Example 69 Synthesis of 1-Cyclobutyl-3-methyl-1H-pyrazol-5-amine (CF44)

3-Aminocrotononitrile (670 mg, 8.16 mmol) was dissolved in ethanol (40mL). Cyclobutyl hydrazine-HCl salt (1 g, 8.16 mmol) and sodium acetate(1.6 g, 20 mmol) were added and the mixture was heated at reflux forovernight. The mixture was concentrated on a rotary evaporator followedby addition of ethyl acetate and water. The aqueous layer was extractedwith ethyl acetate and the organic layers were combined, dried, andconcentrated on a rotary evaporator. The remaining residues werepurified by flash column chromatography and the desired product wasobtained in 100 mg. ¹H NMR (300 MHz, CDCl₃): 5.31 (s, 1H), 4.60-4.40 (m,1H), 3.50 (br, 2H, NH₂), 2.80-2.50 (m, 2H), 2.40-2.20 (m, 2H), 2.16 (s,3H), 1.90-1.70 (m, 2H). ESI-MS calculated for C₈H₁₄N₃[M+H]⁺=152.12,Observed:152.08.

Synthesis ofN-(1-Cyclobutyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 119)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-cyclobutyl-3-methyl-1H-pyrazol-5-amine (100 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 119 in58 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s, 1H), 7.22(s, 1H), 6.20 (s, 1H), 4.90-4.70 (m, 1H), 3.84 (s, 3H), 2.70-2.50 (m,2H), 2.69 (s, 3H), 2.40-2.20 (m, 2H), 2.34 (s, 3H), 2.31 (s, 3H), 2.13(s, 3H), 1.90-1.60 (m, 2H). ESI-MS calculated for C₂₅H₂₈N₇O₂[M+H]⁺=458.23, Observed: 548.58.

Example 70 Synthesis ofN-(3-tert-Butyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 120)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),3-tert-butyl-1-methyl-1H-pyrazol-5-amine (100 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (4 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 120 as aCF₃CO₂H salt in 49 mg. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s, 1H), 6.26 (s,1H), 3.88 (s, 3H), 3.82 (s, 3H), 2.71 (s, 3H), 2.31 (s, 3H), 2.14 (s,3H), 1.32 (s, 9H). ESI-MS calculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.25,Observed: 460.33.

Example 71 Synthesis ofN-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 121)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (90 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (4 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 121 as aCF₃CO₂H salt in 49 mg. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s, 1H), 7.25 (s,1H), 6.09 (s, 1H), 3.86 (s, 3H), 3.75 (s, 3H), 2.71 (s, 3H), 2.31 (s,3H), 2.14 (s, 3H), 2.00-1.80 (m, 1H), 1.00-0.90 (m, 2H), 0.76-0.68 (m,2H). ESI-MS calculated for C₂₄H₂₆N₇O₂ [M+H]⁺=444.21, Observed: 444.33.

Example 72 Synthesis of2-Methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine

2-Oxocyclopentanecarbonitrile (1.5 g, 14 mmol) was dissolved in ethanol(30 mL). Methyl hydrazine (3.0 mL, 56 mmol) was added via a syringe andthe reaction mixture was heated at reflux for overnight. The reactionmixture was cooled to ambient temperature and the solvent was removed ona rotary evaporator. Ethyl acetate and water was added and the aqueouslayer was extracted with ethyl acetate. The organic layers werecombined, dried, and concentrated on a rotary evaporator. The remainingresidues were purified by flash column chromatography and the desiredproduct was obtained in 0.64 g (the desired product was washed out at40% methanol in ethyl acetate). At the eluent gradient of 80% ethylacetate in hexane, we also isolated a hydrazone, partially condensedproduct, which was converted to2-methyl-2,4,5,6-tetrahydrocyclo-penta[c]pyrazol-3-amine upon treatmentof CF₃CO₂H in methanol for overnight. ¹H NMR (300 MHz, CDCl₃): 3.70-3.50(m, 2H, NH₂), 3.51 (s, 3H), 2.52 (t, J=7.13 Hz, 2H), 2.46-2.34 (m, 2H),2.32-2.18 (m, 2H). ESI-MS calculated for C₇H₁₂N₃[M+H]⁺=138.10, Observed:138.08.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methyl-2,4,5,6-tetrahydrocyclopenta-[c]pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 122)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),2-methyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (90 mg, 0.6mmol), K₃PO₄ (212 mg, 1.0 mmol), and anhydrous toluene (4 mL). Themixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was filtered through a pad of Celite® andthe organic layer was collected, concentrated, and purified by HPLC toyield Cpd. No. 122 as a CF₃CO₂H salt in 38 mg. ¹H NMR (300 MHz,MeOD-d4): 7.46 (s, 1H), 7.27 (s, 1H), 3.85 (s, 3H), 3.82 (s, 3H),2.80-2.70 (m, 2H), 2.73 (s, 3H), 2.56-2.34 (m, 4H), 2.31 (s, 3H), 2.14(s, 3H). ESI-MS calculated for C₂₄H₂₆N₇O₂ [M+H]⁺=444.21, Observed:444.42.

Example 73 Synthesis of 1-Methyl-1H-pyrazolo[4,3-b]pyridin-3-amine(CF55)

3-Fluoro-2-pyridinecarbonitrile (1.5 g, 12.3 mmol) was dissolved inethanol (30 mL). Methyl hydrazine (2.63 mL, 50 mmol) was added and themixture was heated at reflux for overnight. The mixture was concentratedon a rotary evaporator followed by addition of ethyl acetate and water.The aqueous layer was extracted with ethyl acetate and the organiclayers were combined, dried, and concentrated on a rotary evaporator.The remaining residue (1.28 g) was used directly for the next stepwithout further purification. ¹H NMR (300 MHz, CDCl₃): 8.37 (d, J=4.33Hz, 1H), 7.54 (d, J=8.56 Hz, 1H), 7.28-7.20 (m, 1H), 4.40 (br, 2H),NH₂), 3.84 (s, 3H). ESI-MS calculated for C₇H₉N₄ [M+H]⁺=149.08,Observed: 149.08.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 123)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-methyl-1H-pyrazolo[4,3-b]pyridin-3-amine (90 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 123 in27.9 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 8.69 (d, J=3.63Hz, 1H), 8.32 (dd, J=8.69, 0.79 Hz, 1H), 8.26 (s, 1H), 7.67 (dd, J=8.74,4.41 Hz, 1H), 7.49 (s, 1H), 4.22 (s, 3H), 4.01 (s, 3H), 2.84 (s, 3H),2.35 (s, 3H), 2.18 (s, 3H). ESI-MS calculated for C₂₄H₂₃N₈O₂[M+H]⁺=455.19, Observed: 455.42

Example 74 Synthesis of 1-Methyl-4, 5,6,7-tetrahydro-1H-indazol-3-amine(CF58)

Step 1: LiHMDS (10 mL of 1.0 M in THF) was cooled to −78° C. for 10 min.Cyclohexanone (0.52 mL, 5.0 mmol) was added via a syringe and themixture was stirred at −78° C. for 10 min. Ethoxycarbonylisothiocyanate(0.60 mL, 5.0 mmol) was added via a syringe and the reaction was allowedto stir at −78° C. for 3 h before warm up to ambient temperatureovernight. Water was then added and the aqueous layer was extracted withethyl acetate, and the organic layers were combined, dried, andconcentrated on a rotary evaporator. The remaining residue was usedwithout purification.

Step 2: The residue from step 1 was dissolved in ethanol and methylhydrazine (0.8 mL, 16 mmol) was added via a syringe. The solution wasstirred at ambient temperature for 6 h then heated at reflux forovernight. The reaction mixture was cooled to ambient temperature andthe solvent was removed on a rotary evaporator. Ethyl acetate and waterwas added and the aqueous layer was extracted with ethyl acetate. Theorganic layers were combined, dried, and concentrated on a rotaryevaporator. The remaining residue was purified by flash columnchromatography and the desired product was obtained in 0.22 g. ¹H NMR(300 MHz, CDCl₃): 3.50 (s, 3H), 2.43 (t, J=5.87 Hz, 2H), 2.26 (t, J=5.76Hz, 2H), 1.80-1.60 (m, 4H). ESI-MS calculated for C₈H₁₄N₃[M+H]⁺=152.12,Observed: 152.50.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 124)

Pd₂(dba)₃ (64 mg, 0.07 mmol) and BINAP (88 mg, 0.14 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (240 mg, 0.7 mmol),1-methyl-4,5,6,7-tetrahydro-1H-indazol-3-amine (220 mg, 1.4 mmol), K₃PO₄(600 mg, 3.0 mmol), and anhydrous toluene (10 mL). The mixture washeated at reflux for overnight before quenching with methanol. Thereaction mixture was filtered through a pad of Celite® and the organiclayer was collected, concentrated, and purified by HPLC to yield Cpd.No. 124 in 100 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 7.71 (s,1H), 7.45 (s, 1H), 3.90 (s, 3H), 3.81 (s, 3H), 2.77 (s, 3H), 2.71 (t,J=6.06 Hz, 2H), 2.53 (t, J=5.95 Hz, 2H), 2.32 (s, 3H), 2.15 (s, 3H),1.98-1.84 (m, 2H), 1.84-1.70 (m, 2H). ESI-MS calculated for C₂₅H₂₈N₇O₂[M+H]⁺=458.23, Observed: 458.75.

Example 75 Synthesis of 2-Methyl-4,5,6,7-tetrahydro-2H-indazol-3-amine

2-Oxocyclohexanecarbonitrile (2.0 g, 16 mmol) was dissolved in ethanol(40 mL). Methyl hydrazine (1.7 mL, 32 mmol) was added via a syringe andthe reaction mixture was heated at reflux for overnight. The reactionmixture was cooled to ambient temperature and the solvent was removed ona rotary evaporator. Ethyl acetate and water was added and the aqueouslayer was extracted with ethyl acetate. The organic layers werecombined, dried, and concentrated on a rotary evaporator. The remainingresidues were purified by flash column chromatography (the desiredproduct was washed out at 40% methanol in ethyl acetate). The desiredproduct was obtained in 1.58 g. ¹H NMR (300 MHz, CDCl₃): 3.50 (s, 3H),2.416 (t, J=5.54 Hz, 2H), 2.21 (t, J=5.49 Hz, 2H), 1.76-1.56n (m, 4H).¹³C NMR (75 MHz, CDCl₃):147.63, 140.71, 99.76, 33.91, 23.49, 23.36,23.32, 19.56.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 125)

Pd₂(dba)₃ (37 mg, 0.04 mmol) and BINAP (50 mg, 0.08 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (136 mg, 0.4 mmol),2-methyl-4,5,6,7-tetrahydro-2H-indazol-3-amine (144 mg, 1.0 mmol), K₃PO₄(320 mg, 1.5 mmol), and anhydrous toluene (10 mL). The mixture washeated at reflux for overnight before quenching with methanol. Thereaction mixture was filtered through a pad of Celite® and the organiclayer was collected, concentrated, and purified by HPLC to yield Cpd.No. 125 as a CF₂CO₂H salt in 25 mg. ¹H NMR (300 MHz, MeOD-d4): 7.45 (s,1H), 7.14 (s, 1H), 3.83 (s, 3H), 3.80 (s, 3H), 2.80-2.60 (m, 2H), 2.71(s, 3H), 2.40-2.20 (m, 2H), 2.31 (s, 3H), 2.13 (s, 3H), 1.90-1.76 (m,2H), 1.76-1.60 (m, 2H). ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23,Observed: 458.50.

Example 76 Synthesis ofN-(3-(tert-Butyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 126)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),5-amino-3-tert-butylpyrazole (84 mg, 0.6 mmol), K₃PO₄ (212 mg, 1.0mmol), and anhydrous toluene (5 mL). The mixture was heated at refluxfor overnight before quenching with methanol. The reaction mixture wasfiltered through a pad of Celite® and the organic layer was collected,concentrated, and purified by HPLC to yield Cpd. No. 126 in 31 mg as aCF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-d4): 8.29 (s, 1H), 7.46 (s, 1H),6.30 (s, 1H), 3.99 (s, 3H), 2.83 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),1.41 (s, 9H). ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23, Observed:446.42.

Example 77 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(5-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 127)

5-Fluoro-1-methyl-1H-indazol-3-ylamine (100 mg, 0.6 mol) and S13 (102mg, 0.3 mmol) were mixed in anhydrous isopropanol (5 mL). ConcentratedHCl (5 drops) was added via a glass pipette. The reaction was heated atreflux for overnight. The reaction was diluted with methanol and filterthrough a pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 127 wasisolated in 17 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.93 (s, 1H), 7.71 (dd, J=9.05, 3.80 Hz, 1H), 7.56 (dd,J=8.80, 2.24 Hz, 1H), 7.48 (s, 1H), 7.44-7.32 (m, 1H), 4.16 (s, 3H),3.89 (s, 3H), 2.71 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H). ESI-MScalculated for C₂₅H₂₃FN₇O₂[M+H]⁺=472.19, Observed: 472.42.

Example 78 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(6-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 59)

6-Fluoro-1-methyl-1H-indazol-3-ylamine (100 mg, 0.6 mol) and S13 (102mg, 0.3 mmol) were mixed in anhydrous isopropanol (5 mL). ConcentratedHCl (5 drops) was added via a glass pipette. The reaction was heated atreflux for overnight. The reaction was diluted with methanol and filterthrough a pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 59 wasisolated in 77 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 8.06 (s, 1H), 7.66 (t, J=7.97 Hz, 1H), 7.49 (s, 1H), 7.16-7.00(m, 2H), 3.94 (s, 3H), 3.49 (s, 3H), 2.76 (s, 3H), 2.32 (s, 3H), 2.14(s, 3H). ESI-MS calculated for C₂₅H₂₃FN₇O₂[M+H]⁺=472.19, Observed:472.67.

Example 79 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(7-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 129)

7-Fluoro-1-methyl-1H-indazol-3-ylamine (100 mg, 0.6 mol) and S13 (102mg, 0.3 mmol) were mixed in anhydrous isopropanol (5 mL). ConcentratedHCl (5 drops) was added via a glass pipette. The reaction was heated atreflux for overnight. The reaction was diluted with methanol and filterthrough a pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 129 wasisolated in 50 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.83 (s, 1H), 7.63 (d, J=7.94 Hz, 1H), 7.48 (s, 1H), 7.30-7.12(m, 2H), 4.27 (s, 3H), 3.86 (s, 3H), 2.69 (s, 3H), 2.33 (s, 3H), 2.15(s, 3H). ESI-MS calculated for C₂₅H₂₃FN₇O₂[M+H]⁺=472.19, Observed:472.50.

Example 80 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 58)

1H-indazol-3-ylamine (84 mg, 0.6 mol) and S13 (102 mg, 0.3 mmol) weremixed in anhydrous isopropanol (5 mL). Concentrated HCl (5 drops) wasadded via a glass pipette. The reaction was heated at reflux forovernight. The reaction was diluted with methanol and filter through apad of Celite®. The solution was concentrated and subsequently purifiedon a reverse phase HPLC. The desired product Cpd. No. 58 was isolated in27 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4): 7.92(d, J=8.29 Hz, 1H), 7.74 (s, 1H), 7.64 (d, J=8.55 Hz, 1H), 7.57-7.50 (m,1H), 7.47 (s, 1H), 7.32-7.25 (m, 1H), 3.84 (s, 3H), 2.76 (s, 3H), 2.32(s, 3H), 2.15 (s, 3H). ESI-MS calculated for C₂₄H₂₂N₇O₂ [M+H]⁺=440.18,Observed: 440.33.

Example 81 Synthesis of 2-(3-Amino-1H-indazol-1-yl)ethanol (CF40)

2-Fluorobenzonitrile (1 g, 8.25 mmol) was dissolved in n-butanol (30mL). 2-Hydrazinoethanol (2.5 g, 33 mmol) was added and the mixture washeated at reflux for two days. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and water. The aqueouslayer was extracted with ethyl acetate and the organic layers werecombined, dried, and concentrated on a rotary evaporator. The remainingresidue (1.11 g) was used directly for the next step without furtherpurification. ESI-MS calculated for C₉H₁₂N₃O [M+H]⁺=178.10, Observed:178.50.

Synthesis of2-(3-((7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-indazol-1-yl)ethanol(Cpd. No. 131)

2-(3-Amino-1H-indazol-1-yl)ethanol (290 mg, 1.6 mol) and S13 (170 mg,0.5 mmol) were mixed in anhydrous isopropanol (15 mL). Concentrated HCl(6 drops) was added via a glass pipette. The reaction was heated atreflux for overnight. The reaction was diluted with methanol and filterthrough a pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 131 wasisolated in 107 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.91 (d, J=8.25 Hz, 1H), 7.84 (s, 1H), 7.70 (d, J=8.65 Hz,1H), 7.54 (t, J=7.58 Hz, 1H), 7.47 (s, 1H), 7.27 (t, J=7.50 Hz, 1H),4.57 (t, J=5.10 Hz, 2H), 4.05 (t, J=5.10 Hz, 2H), 3.83 (s, 3H), 2.71 (s,3H), 2.32 (s, 3H), 2.15 (s, 3H). ESI-MS calculated for C₂₆H₂₆N₇O₃[M+H]⁺=484.21, Observed: 484.25.

Example 82 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(4-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 132)

4-Fluoro-1-methyl-1H-indazol-3-ylamine (102 mg, 0.6 mol) and S13 (102mg, 0.3 mmol) were mixed in anhydrous isopropanol (5 mL). ConcentratedHCl (5 drops) was added via a glass pipette. The reaction was heated atreflux for overnight. The reaction was diluted with methanol and filterthrough a pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 132 wasisolated in 75 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 7.82 (s, 1H), 7.54-7.45 (m, 2H), 7.49 (s, 1H), 6.98-6.87 (m,1H), 4.16 (s, 3H), 3.87 (s, 3H), 2.72 (s, 3H), 2.33 (s, 3H), 2.15 (s,3H). ESI-MS calculated for C₂₅H₂₃FN₇O₂[M+H]⁺=472.19, Observed: 472.33.

Example 83 Synthesis of3-(tert-Butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)isothiazol-5-amine(Cpd. No. 133)

3-Tert-butylisothiazol-5-amine (90 mg, 0.6 mol) and S13 (102 mg, 0.3mmol) were mixed in anhydrous isopropanol (5 mL). Concentrated HCl (5drops) was added via a glass pipette. The reaction was heated at refluxfor overnight. The reaction was diluted with methanol and filter througha pad of Celite®. The solution was concentrated and subsequentlypurified on a reverse phase HPLC. The desired product Cpd. No. 133 wasisolated in 22 mg as a salt of trifluoroacetic acid. ¹H NMR (300 MHz,MeOD-d4): 8.26 (s, 1H), 7.40 (s, 1H), 7.31 (s, 1H), 3.98 (s, 3H), 2.81(s, 3H), 2.34 (s, 3H), 2.17 (s, 3H), 1.47 (s, 3H). ESI-MS calculated forC₂₄H₂₇N₆O₂S [M+H]⁺=463.19, Observed: 463.42.

Example 84

Step 1: Synthesis of methyl5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylate (CF66-2)

3a,4,5,6-Tetrahydro-3-oxo-3H-pyrrolo[1,2-c][1,2,3]oxadiazol-7-ium ylidewas prepared according to literature procedures (Organic ProcessResearch & Development 2006, 10, 712-716).3a,4,5,6-Tetrahydro-3-oxo-3H-pyrrolo[1,2-c][1,2,3]oxadiazol-7-ium ylide(21.6 mmol) was dissolved in 1,2-diethoxyethane (40 mL). The solutionwas heated at 120° C. Methyl propiolate (1.68 g, 20 mmol) was added viaa syringe and the mixture was held at reflux overnight. The reactionmixture was concentrated on a rotary evaporator and the remainingresidues were purified by flash column chromatography. CF66-2 wasisolated in 315 mg and CF66-1 was isolated in 500 mg. ¹H NMR (300 MHz,CDCl₃): 7.80 (s, 1H), 4.07 (t, J=7.32 Hz, 2H), 3.71 (s, 3H), 2.99 (t,J=7.34 Hz, 2H), 2.66-2.50 (m, 2H). ¹³C NMR (75 MHz, CDCl₃): 163.84,149.91, 145.21, 107.69, 51.12, 48.20, 25.96, 23.84. ESI-MS calculatedfor C₈H₁₁N₂O₂ [M+H]⁺=167.08, Observed: 167.25.

Step 2: Synthesis of 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole-3-carboxylicacid (CF70)

CF66-2 (315 mg) was dissolved in THF (5 mL). Water (5 mL) and LiOH—H₂O(2 g) were added subsequently and the solution was stirred at ambienttemperature for overnight. The aqueous was extracted with diethyl etherand subsequently acidified with 1 N HCl. The aqueous layer was extractedwith ethyl acetate. The organic layers were combined, dried, andconcentrated on a rotary evaporator. The remaining residue containingCF70 (280 mg) was used without further purification. ¹H NMR (300 MHz,MeOD-d4): 7.83 (s, 1H), 4.14 (t, J=7.30 Hz, 2H), 3.07 (t, J=7.38 Hz,2H), 2.74-2.60 (m, 4H). ¹³C NMR (75 MHz, MeOD-d4): 164.99, 150.21,144.61, 107.63, 47.51, 25.24, 23.08. ESI-MS calculated forC₇H₉N₂O₂[M+H]⁺=153.07, Observed: 153.08.

Step 3: Synthesis of tert-butyl(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)carbamate (CF72)

CF70 (280 mg, 1.84 mmol) was mixed with tert-butanol (6 mL) and triethylamine (0.8 mL, 4 mmol). Diphenyl phosphoryl azide (0.71 mL, 3.31 mmol)was added via a syringe and the mixture was stirred at ambienttemperature for overnight. The solution was heated at reflux for 24 h.The volatile components were removed on a rotary evaporator and theresidue was purified by flash column chromatography. CF72 was isolatedin 224 mg. ¹H NMR (300 MHz, CDCl₃): 7.36 (s, 1H), 6.24 (s, 1H), 4.05 (t,J=7.31 Hz, 2H), 2.98-2.82 (m, 2H), 2.60-2.44 (m, 4H), 1.46 (s, 9H). ¹³CNMR (75 MHz, CDCl₃): 153.76, 137.82, 137.01, 114.08, 80.10, 48.23,28.48, 26.26, 23.63. ESI-MS calculated for C₁₁H₁₈N₃O₂ [M+H]⁺=224.14,Observed: 224.58.

Step 4: Synthesis of 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-amine

CF72 (224 mg, 1.0 mmol) was dissolved in CH₂Cl₂ (4 mL). Triethylsilane(0.05 mL) and trifluoroacetic acid (6 mL) was added via syringes. Thereaction was stirred at ambient temperature for 2 h before concentratedon a rotary evaporator. The remaining residue containing5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-amine was used for the next stepwithout further purification. ESI-MS calculated for C₆H₁₀N₃[M+H]⁺=124.09, Observed: 124.42.

Synthesis ofN-(5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 134)

5,6-Dihydro-4H-pyrrolo[1,2-b]pyrazol-3-amine prepared for previous step4 and S13 (342 mg, 1.0 mmol) were mixed in anhydrous isopropanol (10mL). Concentrated HCl (6 drops) was added via a glass pipette. Thereaction was heated at reflux for overnight. The reaction was dilutedwith methanol and filter through a pad of Celite®. The solution wasconcentrated and subsequently purified on a reverse phase HPLC. Thedesired product Cpd. No. 134 was isolated in 175 mg as a salt oftrifluoroacetic acid. ¹H NMR (300 MHz, MeOD-d4): 8.00 (s, 1H), 7.60 (s,1H), 7.32 (s, 1H), 4.14 (t, J=7.26 Hz, 2H), 3.87 (s, 3H), 2.87 (t,J=7.20 Hz, 2H), 2.60-2.50 (m, 2H), 2.54)s, 3H), 2.28 (s, 3H), 2.08 (s,3H). ESI-MS calculated for G₃H₂₄N₇O₂ [M+H]⁺=430.20, Observed: 430.42.

Example 85 Synthesis ofN-(1-Cyclopentyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 135)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-cyclopentyl-4-methyl-1H-pyrazol-5-amine (100 mg, 0.6 mmol), tBuONa(120 mg, 1.2 mmol), and anhydrous toluene (5 mL). The mixture was heatedat reflux for overnight before quenching with methanol. The reactionmixture was concentrated, filtered, and purified by HPLC to yield Cpd.No. 135 in 26 mg as a CF₃CO₂H salt. ¹H NMR (300 MHz, MeOD-D4): 7.53 (s,1H), 7.45 (s, 1H), 4.80-4.70 (m, 1H), 3.83 (s, 3H), 2.70 (s, 3H), 2.31(s, 3H), 2.14 (s, 3H), 2.10-2.00 (m, 4H), 2.00-1.80 (m, 2H), 1.93 (s,3H), 1.70-1.50 (m, 2H). ESI-MS calculated for G₆H₃₀N₇O₂ [M+H]⁺=472.25;Observed: 472.58.

Example 86

Synthesis of 3-Cyclobutyl-1-methyl-1H-pyrazol-5-amine (CF78)

3-Cyclobutyl-3-oxopropanenitrile (1.0 g, 8.1 mmol) and methyl hydrazine(0.90 mL, 17 mmol) were dissolved in ethanol, and the mixture was heatedat reflux for overnight. The reaction mixture was cooled to roomtemperature and ethanol was removed on a rotary evaporator. Water wasadded and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield CF78 in0.986 g. ¹H NMR (300 MHz, CDCl₃): 5.42 (s, 1H), 3.59 (s, 3H), 3.60-3.40(br, 2H, NH), 3.50-3.30 (m, 1H), 2.34-2.20 (m, 2H), 2.20-2.04 (m, 2H),2.041-1.90 (m, 1H), 1.90-1.74 (m, 1H). ESI-MS calculated forC₈H₁₄N₃[M+H]⁺=152.12; Observed: 152.25.

Synthesis ofN-(3-Cyclobutyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 136)

Pd₂(dba)₃ (27 mg, 0.03 mmol) and BINAP (37 mg, 0.06 mmol) were mixed inanhydrous toluene (5 mL). The mixture was heated at reflux for 3-4minutes. This clear, orange-red color solution was transferred into around-bottom flask containing S13 (102 mg, 0.3 mmol),1-methyl-3-cyclobutyl-1H-pyrazol-5-amine (90 mg, 0.6 mmol), K₃PO₄ (212mg, 1.0 mmol), and anhydrous toluene (5 mL). The mixture was heated atreflux for overnight before quenching with methanol. The reactionmixture was filtered through a pad of Celite® and the organic layer wascollected, concentrated, and purified by HPLC to yield Cpd. No. 136 as aCF₃CO₂H salt in 49 mg. ¹H NMR (300 MHz, MeOD-D4): 7.45 (s, 1H), 7.34 (s,1H), 6.31 (s, 1H), 3.85 (s, 3H), 3.78 (s, 3H), 3.65-3.50 (m, 1H), 2.71(s, 3H), 2.50-2.30 (m, 2H), 2.31 (s, 3H), 2.30-2.15 (m, 2H), 2.15-2.00(m, 1H), 2.14 (s, 3H), 2.00-1.80 (m, 1H). ESI-MS calculated forC₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed: 458.50.

Example 87

Synthesis of 2-Isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine(CF83)

2-Oxocyclopentanecarbonitrile (2.0 g, 18.3 mmol), sodium acetate (3.04g, 37 mmol), and isopropyl hydrazine-HCl (2.5 g, 22 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF83 in 2.60 g. ¹H NMR (300 MHz, CDCl₃): 4.21(septet, J=6.63 Hz, 1H), 2.60 (t, J=7.26 Hz, 2H), 2.40-2.38 (m, 2H),2.38-2.20 (m, 2H), 1.39 (d, J=6.67 Hz, 6H). ¹³C NMR (75 MHz, CDCl₃):159.89, 137.22, 109.30, 48.44, 30.01, 25.24, 22.59, 22.41. ESI-MScalculated for C₉H₁₆N₃[M+H]⁺=166.13; Observed: 166.25. Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine (Cpd. No. 137)

Cpd. No. 137 was prepared from S13 (102 mg) and2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (107 mg)following the same procedure for preparation of Cpd. No. 135. Cpd. No.137 was obtained in 27 mg as a salt of CF₃CO₂H. 1H NMR (300 MHz,MeOD-D4): 7.44 (s, 1H), 6.88 (s, 1H), 4.70-4.55 (m, 1H), 3.79 (s, 3H),2.80-2.60 (m, 2H), 2.72 (s, 3H), 2.44-2.30 (m, 4H), 2.31 (s, 3H), 2.13(s, 3H), 1.50 (d, J=6.65 Hz, 6H). ESI-MS calculated for C₂₆H₃₀N₇O₂[M+H]⁺=472.25; Observed: 472.83.

Example 88

Synthesis of 2-Isopropyl-4,5,6,7-tetrahydro-2H-indazol-3-amine (CF82)

2-Oxocyclohexanecarbonitrile (2.0 g, 16.2 mmol), sodium acetate (2.7 g,33 mmol), and isopropyl hydrazine-HCl (2.13 g, 19.4 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF82 in 2.47 g. ¹H NMR (300 MHz, CDCl₃): 4.32(septet, J=6.69 Hz, 1H), 2.60 (t, J=5.80 Hz, 2H), 2.31 (t, J=5.59 Hz,2H), 1.80-1.66 (m, 4H), 1.44 (d, J=6.69 Hz, 6H). ESI-MS calculated forC₁₀H₁₈N₃[M+H]⁺=180.15; Observed: 180.25.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(2-isopropyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 138)

Cpd. No. 138 was prepared from S13 (102 mg) and2-isopropyl-4,5,6,7-tetrahydro-2H-indazol-3-amine (115 mg) following thesame procedure for preparation of Cpd. No. 135. Cpd. No. 138 wasobtained in 42 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.44(s, 1H), 6.78 (s, 1H), 4.78-4.62 (m, 1H), 3.78 (s, 3H), 2.75-2.65 (m,2H), 2.72 (s, 3H), 2.30 (s, 3H), 2.24-2.15 (m, 2H), 2.12 (s, 3H),1.85-1.72 (m, 2H), 1.72-1.60 (m, 2H), 1.49 (d, J=6.65 Hz, 6H). ESI-MScalculated for C₂₇H₃₂N₇O₂ [M+H]⁺=486.26; Observed: 486.42.

Example 89

Synthesis of tert-Butyl(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)carbamate (CF84)

4,5,6,7-Tetrahydropyrazolo[1,5-a]pyridine-3-carboxylic acid (1.0 g, 6.0mmol) and EtN(i-Pr)₂ (3 mL, 18 mmol) were mixed in t-BuOH (20 mL) atroom temperature. Diphenyl phosphoryl azide (DPPA, 2.33 mL, 10.8 mmol)was added via a syringe and the mixture was stirred at room temperaturefor overnight followed by heating at reflux for 24 hours. The mixturewas concentrated on a rotary evaporator and the remaining residue waspurified by flash column chromatography to yield CF84 in 0.72 g. ¹H NMR(300 MHz, CDCl₃): 7.43 (s, 1H), 5.99 (s, 1H), 4.10-4.00 (m, 2H),2.70-2.55 (m, 2H), 2.05-1.90 (m, 2H), 1.90-1.75 (m, 2H), 1.46 (s, 9H).¹³C NMR (75 MHz, CDCl₃): 154.09, 133.87, 129.79, 120.51, 80.11, 48.12,28.44, 23.35, 21.09, 20.06. ESI-MS calculated for C₁₂H₂₀N₃O₂[M+H]⁺=238.16; Observed: 238.42.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 139)

Step 1: CF84 (100 mg) and TES-H (0.1 mL) were dissolved indichloromethane (5 mL). TFA (5 mL) was added via a syringe and themixture was stirred at ambient temperature for 1 hour. The volatilecomponents were removed on a rotary evaporator and the remaining residuewas used for the next step without further purification.

Step 2: 4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-amine obtained fromstep 1 and S13 (136 mg, 0.4 mmol) were mixed in anhydrous isopropanol (5mL). Concentrated HCl (5 drops) was added via a glass pipette. Thereaction was heated at reflux for overnight. The reaction was dilutedwith methanol and filter through a pad of Celite®. The solution wasconcentrated and subsequently purified on a reverse phase HPLC. Thedesired product Cpd. No. 139 was isolated in 90 mg as a salt oftrifluoroacetic acid. ¹H NMR (300 MHz, MeOD-D4): 8.00-7.50 (br, 1H),7.67 (s, 1H), 7.45 (s, 1H), 4.20 (t, J=6.01 Hz, 2H), 3.89 (s, 3H),2.78-2.68 (m, 2H), 2.68 (s, 3H), 2.31 (s, 3H), 2.18-2.05 (m, 2H), 2.14(s, 3H), 1.98-1.85 (m, 2H). ESI-MS calculated for C₂₄H₂₆N₇O₂[M+H]⁺=444.21; Observed: 444.82.

Example 90

Synthesis of 2-Cyclopropyl-3-oxobutanenitrile (CF85)

Step 1: 2-Cyclopropylacetonitrile (4.86 g, 60 mmol) was dissolved inanhydrous THF (60 mL) and the solution was cooled to −78° C. LDA (96 mL,1.0 M in THF, 96 mmol) was added via a syringe over 20 minutes and themixture was stirred at −78° C. for 20 min. Acetic anhydride (2.83 mL, 30mmol) was added dropwise via a syringe and the mixture was stirred at−78° C. for 20 minutes. The reaction was quenched with 1 N HCl andextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF85 in 0.98 g. ¹H NMR (300 MHz, CDCl₃): 3.17(d, J=7.63 Hz, 1H), 2.40 (s, 3H), 1.30-1.20 (m, 1H), 0.85-0.70 (m, 2H),0.60-0.45 (m, 2H).

Synthesis of 4-Cyclopropyl-1,3-dimethyl-1H-pyrazol-5-amine (CF88)

Step 2: 2-Cyclopropyl-3-oxobutanenitrile (0.50 g, 4.1 mmol) and methylhydrazine (0.42 mL, 8.2 mmol) were dissolved in ethanol, and the mixturewas heated at reflux for overnight. The reaction mixture was cooled toroom temperature and ethanol was removed on a rotary evaporator. Waterwas added and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield CF88 in0.47 g. ¹H NMR (300 MHz, CDCl₃): 3.55 (s, 3H), 2.15 (s, 3H), 1.45-1.30(m, 1H), 1.80-1.65 (m, 2H), 1.45-1.30 (m, 2H). ESI-MS calculated forC₈H₁₄N₃[M+H]⁺=152.12; Observed: 152.42.

Synthesis ofN-(4-Cyclopropyl-1,3-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 140)

Cpd. No. 140 was prepared from S13 (102 mg) and4-cyclopropyl-1,3-dimethyl-1H-pyrazol-5-amine (90 mg) following the sameprocedure for preparation of Cpd. No. 135. Cpd. No. 140 was obtained in8 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.46 (s, 1H),7.30-7.00 (br, 1H), 3.84 (s, 3H), 3.76 (s, 3H), 2.72 (s, 3H), 2.32 (s,3H), 2.29 (s, 3H), 2.14 (s, 3H), 1.40-1.20 (m, 1H), 0.70-0.50 (m, 2H),0.50-0.30 (m, 2H). ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23;Observed: 458.58.

Example 91

2-Ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (CF91)

2-Oxocyclopentanecarbonitrile (1.5 g, 14 mmol), sodium acetate (3.4 g,42 mmol), and ethyl hydrazine-oxalate (4.2 g, 28 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF91 in 1.03 g. ¹H NMR (300 MHz, CDCl₃): 3.92(q, J=7.23 Hz, 2H), 3.40-3.20 (m, 2H, NH), 2.62 (t, J=7.19 Hz, 2H),2.54-2.44 (m, 2H), 2.40-2.28 (m, 2H), 1.38 (t, J=7.24 Hz, 3H). ESI-MScalculated for C₈H₁₄N₃[M+H]⁺=152.12; Observed: 152.33

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 141)

Cpd. No. 141 was prepared from S13 (102 mg) and2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (90 mg) followingthe same procedure for preparation of Cpd. No. 135. Cpd. No. 141 wasobtained in 39 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.45(s, 1H), 7.00 (s, 1H), 4.17 (q, J=7.16 Hz, 1H), 3.80 (s, 3H), 2.80-2.60(m, 2H), 2.73 (s, 3H), 2.45-2.25 (m, 4H), 2.30 (s, 3H), 2.13 (s, 3H),1.46 (t, J=7.19 Hz, 3H). ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23;Observed: 458.75.

Example 92

Synthesis of 2-Ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine (CF93)

2-Oxocyclohexanecarbonitrile (2.0 g, 16.2 mmol), sodium acetate (3.94 g,48 mmol), and ethyl hydrazine-oxalate (4.8 g, 32 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF93 in 3.94 g. ¹H NMR (300 MHz, CDCl₃): 3.94(q, J=7.26 Hz, 2H), 3.40-3.10 (m, 2H, NH), 2.58 (t, J=5.94 Hz, 2H), 2.31(t, J=5.64 Hz, 2H), 1.80-1.60 (m, 4H), 1.39 (t, J=7.26 Hz, 3H). ¹³C NMR(75 MHz, CDCl₃): 147.94, 139.61, 100.67, 42.16, 23.80, 23.65, 23.57,19.82, 15.27. ESI-MS calculated for C₉H₁₆N₃[M+H]⁺=166.13; Observed:166.33

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 142)

Cpd. No. 142 was prepared from S13 (102 mg) and2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-amine (90 mg) following the sameprocedure for preparation of Cpd. No. 135. Cpd. No. 142 was obtained in49 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.44 (s, 1H),6.90 (s, 1H), 4.17 (q, J=7.16 Hz, 2H), 3.80 (s, 3H), 2.80-2.60 (m, 2H),2.72 (s, 3H), 2.30 (s, 3H), 2.25-2.15 (m, 2H), 2.13 (s, 3H), 1.90-1.70(m, 2H), 1.70-1.50 (m, 2H), 1.45 (t, J=7.17 Hz, 3H). ESI-MS calculatedfor G₆H₃₀N₇O₂ [M+H]⁺=472.25; Observed: 472.33.

Example 93

Synthesis of 4-Cyclopropyl-1-ethyl-3-methyl-1H-pyrazol-5-amine (CF89)

CF85 (0.50 g, 4.1 mmol), ethyl hydrazine-oxalate (1.35 g, 9 mmol), andsodium acetate (1 g, 12 mmol) were dissolved in ethanol, and the mixturewas heated at reflux for overnight. The reaction mixture was cooled toroom temperature and ethanol was removed on a rotary evaporator. Waterwas added and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield CF89 in 171mg. ¹H NMR (300 MHz, CDCl₃): 3.88 (q, J=7.24 Hz, 2H), 3.60-3.40 (br, 2H,NH), 2.16 (s, 3H), 1.40-1.30 (m, 1H), 1.34 (t, J=7.22 Hz, 3H), 0.80-0.70(m, 2H), 0.44-0.36 (m, 2H). ESI-MS calculated for C₉H₁₆N₃[M+H]⁺=166.13;Observed: 166.17.

Synthesis ofN-(4-Cyclopropyl-1-ethyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 143)

Cpd. No. 143 was prepared from S13 (170 mg) and4-cyclopropyl-1-ethyl-3-methyl-1H-pyrazol-5-amine (170 mg) following thesame procedure for preparation of Cpd. No. 135. Cpd. No. 143 wasobtained in 76 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.45(s, 1H), 7.00-6.50 (br, 1H), 4.13 (q, J=7.15 Hz, 2H), 3.78 (s, 3H), 2.74(s, 3H), 2.30 (s, 6H), 2.12 (s, 3H), 1.43 (t, J=7.19 Hz, 3H), 1.30-1.10(m, 1H), 0.70-0.54 (m, 2H), 0.54-0.40 (m, 2H). ESI-MS calculated forG₆H₃₀N₇O₂ [M+H]⁺=472.25; Observed: 472.33.

Example 94

Synthesis of 3-Cyclopropyl-1-ethyl-1H-pyrazol-5-amine (CF96)

3-Cyclopropyl-3-oxopropanenitrile (2.0 g, 18.3 mmol), sodium acetate(5.4 g, 54 mmol), and ethyl hydrazine-oxalate (5.4 g, 36 mmol) weremixed in ethanol, and the mixture was heated at reflux for overnight.The reaction mixture was cooled to room temperature and ethanol wasremoved on a rotary evaporator. Water was added and the aqueous layerwas extracted with ethyl acetate. The combined organic layers werewashed with brine, dried over anhydrous sodium sulfate, and concentratedon a rotary evaporator. The remaining residue was purified by flashcolumn chromatography to yield CF96 in 1.32 g. ¹H NMR (300 MHz, CDCl₃):5.17 (s, 1H), 3.91 (q, J=7.25 Hz, 2H), 3.50-3.30 (m, 2H, NH), 1.90-1.76(m, 1H), 1.36 (t, J=7.20 Hz, 3H), 0.90-0.80 (m, 2H), 0.66-0.58 (m, 2H).ESI-MS calculated for C₈H₁₄N₃[M+H]⁺=152.12; Observed: 152.17.

Synthesis ofN-(3-Cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 144)

Cpd. No. 144 was prepared from S13 (180 mg) and3-cyclopropyl-1-ethyl-1H-pyrazol-5-amine (140 mg) following the similarprocedure for preparation of Cpd. No. 135. Cpd. No. 144 was obtained in83 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.44 (s, 1H),6.92 (s, 1H), 6.03 (s, 1H), 4.11 (q, J=7.20 Hz, 2H), 3.83 (s, 3H), 2.71(s, 3H), 2.29 (s, 3H), 2.12 (s, 3H), 2.00-1.85 (m, 1H), 1.44 (t, J=7.20Hz, 3H), 1.00-0.90 (m, 2H), 0.75-0.65 (m, 2H). ESI-MS calculated forC₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed: 458.33.

Example 95

Synthesis of 3-Cyclopropyl-1-ethyl-4-methyl-1H-pyrazol-5-amine (CF101)

3-Cyclopropyl-2-methyl-3-oxopropanenitrile (2.0 g, 16 mmol), sodiumacetate (2.62 g, 32 mmol), and ethyl hydrazine-oxalate (2.4 g, 16 mmol)were mixed in ethanol, and the mixture was heated at reflux forovernight. The reaction mixture was cooled to room temperature andethanol was removed on a rotary evaporator. Water was added and theaqueous layer was extracted with ethyl acetate. The combined organiclayers were washed with brine, dried over anhydrous sodium sulfate, andconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to yield CF101 in 0.52 g. ¹H NMR (300MHz, CDCl₃): 3.93 (q, J=7.23 Hz, 2H), 3.60-3.00 (br, 2H, NH), 1.91 (s,3H), 1.80-1.60 (m, 1H), 1.31 (t, J=7.24 Hz, 3H), 0.85-0.75 (m, 4H).ESI-MS calculated for CH₁₆N₃[M+H]⁺=166.13; Observed: 166.33

Synthesis ofN-(3-Cyclopropyl-1-ethyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 145)

Cpd. No. 145 was prepared from S13 (202 mg) and3-cyclopropyl-1-ethyl-4-methyl-1H-pyrazol-5-amine (132 mg) following thesimilar procedure for preparation of Cpd. No. 135. Cpd. No. 145 wasobtained in 87 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.45(s, 1H), 7.20-6.80 (br, 1H), 4.09 (q, J=7.19 Hz, 2H), 3.82 (s, 3H), 2.72(s, 3H), 2.31 (s, 3H), 2.13 (s, 3H), 1.90 (s, 3H), 2.00-1.80 (m, 1H),1.38 (t, J=7.21 Hz, 3H), 1.00-0.80 (m, 4H). ESI-MS calculated forC₂₆H₃₀N₇O₂ [M+H]⁺=472.25; Observed: 472.58.

Example 96

Synthesis of 1-Ethyl-3-(trifluoromethyl)-1H-pyrazol-5-amine (CF102)

(E)-4-Amino-4-ethoxy-1,1,1-trifluorobut-3-en-2-one (1.0 g, 5.5 mmol),sodium acetate (1.50 g, 18 mmol), and ethyl hydrazine-oxalate (1.7 g, 11mmol) were mixed in ethanol, and the mixture was heated at reflux forovernight. The reaction mixture was cooled to room temperature andethanol was removed on a rotary evaporator. Water was added and theaqueous layer was extracted with ethyl acetate. The combined organiclayers were washed with brine, dried over anhydrous sodium sulfate, andconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to yield CF102 in 0.51 g. ¹H NMR (300MHz, CDCl₃): 5.80 (s, 1H), 4.04 (q, J=7.42 Hz, 2H), 3.70-3.45 (br, 2H,NH), 1.42 (t, J=7.25 Hz, 3H). ESI-MS calculated forC₆H₉F₃N₃[M+H]⁺=180.07; Observed: 180.33.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 146)

Cpd. No. 146 was prepared from S13 (136 mg) and1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-amine (143 mg) following thesimilar procedure for preparation of Cpd. No. 135. Cpd. No. 146 wasobtained in 26 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.72(s, 1H), 7.49 (s, 1H), 6.70 (s, 1H), 4.21 (q, J=7.17 Hz, 2H), 3.90 (s,3H), 2.68 (s, 3H), 2.30 (s, 3H), 2.13 (s, 3H), 1.50 (t, J=7.20 Hz, 3H).ESI-MS calculated for C₂₃H₂₃F₃N₇O₂[M+H]⁺=486.19; Observed: 486.33.

Example 97

Synthesis of 3-Cyclopropyl-1,4-dimethyl-1H-pyrazol-5-amine (CF105)

3-Cyclopropyl-2-methyl-3-oxopropanenitrile (1.5 g, 12 mmol) and methylhydrazine (1.26 mL, 24 mmol) were mixed in ethanol, and the mixture washeated at reflux for overnight. The reaction mixture was cooled to roomtemperature and ethanol was removed on a rotary evaporator. Water wasadded and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield CF105 in0.70 g. ¹H NMR (300 MHz, CDCl₃): 3.58 (s, 3H), 3.40-3.10 (br, 2H, NH),1.92 (s, 3H), 1.80-1.60 (m, 2H), 1.85-1.70 (m, 4H). ESI-MS calculatedfor C₈H₁₄N₃[M+H]⁺=152.12; Observed: 152.25.

Synthesis ofN-(3-Cyclopropyl-1,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 147)

Cpd. No. 147 was prepared from S13 (136 mg) and3-cyclopropyl-1,4-dimethyl-1H-pyrazol-5-amine (120 mg) following thesimilar procedure for preparation of Cpd. No. 135. Cpd. No. 147 wasobtained in 16 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.45(s, 1H), 7.30-7.00 (br, 1H), 3.84 (s, 3H), 3.72 (s, 3H), 2.71 (s, 3H),2.31 (s, 3H), 2.13 (s, 3H), 1.94 (s, 3H), 2.00-1.80 (m, 2H), 1.00-0.75(m, 4H). ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed:458.50.

Example 98

Synthesis of2-Cyclopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (CF108)

2-Oxocyclopentanecarbonitrile (1.0 g, 9 mmol), sodium acetate (1.6 g, 20mmol), and isopropyl hydrazine-HCl (1.0 g, 10 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF108 in 0.56 g. ¹H NMR (300 MHz, CDCl₃):4.00-3.50 (br, 2H, NH), 3.20-3.00 (m, 1H), 2.70-2.50 (m, 2H), 2.50-2.35(m, 2H), 2.35-2.20 (m, 2H), 1.20-0.90 (m, 4H). ESI-MS calculated forC₉H₁₄N₃[M+H]⁺=164.12; Observed: 164.50

Synthesis ofN-(2-Cyclopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 148)

Cpd. No. 148 was prepared from S13 (136 mg) and2-cyclopropyl-2,4,5,6-tetrahydro-cyclopenta[c]pyrazol-3-amine (162 mg)following the similar procedure for preparation of Cpd. No. 135. Cpd.No. 148 was obtained in 84 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz,MeOD-D4): 7.46 (s, 1H), 7.09 (s, 1H), 3.81 (s, 3H), 3.50-3.30 (m, 1H),2.80-2.60 (m, 2H), 2.74 (s, 3H), 2.60-2.40 (m, 2H), 2.40-2.20 (m, 2H),2.31 (s, 3H), 2.13 (s, 3H), 1.20-1.10 (m, 2H), 1.10-0.90 (m, 2H). ESI-MScalculated for C₂₆H₂₈N₇O₂ [M+H]⁺=470.23; Observed: 470.50.

Example 99

Synthesis of 3-Cyclopropyl-1-isopropyl-1H-pyrazol-5-amine (CF110)

3-Cyclopropyl-3-oxopropanenitrile (1.0 g, 9 mmol), sodium acetate (2.0g, 20 mmol), and isopropyl hydrazine-HCl (1.6 g, 15 mmol) were mixed inethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF110 in 1.27 g. ¹H NMR (300 MHz, CDCl₃): 5.08(s, 1H), 5.00-4.20 (br, 2H, NH), 4.35-4.10 (m, 1H), 1.94-1.80 (m, 1H),1.42 (d, J=6.69 Hz, 6H), 0.90-0.80 (m, 2H), 0.62-0.52 (m, 2H). ¹³C NMR(75 MHz, CDCl₃): 154.07, 143.79, 86.80, 48.21, 22.05, 9.72, 7.99. ESI-MScalculated for C₉H₁₆N₃[M+H]⁺=166.13; Observed: 166.17.

Synthesis ofN-(3-Cyclopropyl-1-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 149)

Cpd. No. 149 was prepared from S13 (273 mg) and3-cyclopropyl-1-isopropyl-1H-pyrazol-5-amine (320 mg) following thesimilar procedure for preparation of Cpd. No. 135. Cpd. No. 149 wasobtained in 119 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.43(s, 1H), 6.86 (s, 1H), 5.95 (s, 1H), 4.70-4.50 (m, 1H), 3.82 (s, 3H),2.71 (s, 3H), 2.30 (s, 3H), 2.13 (s, 3H), 2.10-1.90 (m, 1H), 1.47 (d,J=6.64 Hz, 6H), 1.10-0.90 (m, 2H), 0.80-0.60 (m, 2H). ESI-MS calculatedfor C₂₆H₃₀N₇O₂ [M+H]⁺=472.25; Observed: 472.58

Example 100

Synthesis of 2-(3-Amino-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol(CF106)

2-Oxocyclopentanecarbonitrile (1.0 g, 9 mmol) and 2-hydrazinylethanol(1.3 mL, 18 mmol) were mixed in ethanol, and the mixture was heated atreflux for overnight. The reaction mixture was cooled to roomtemperature and ethanol was removed on a rotary evaporator. Water wasadded and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield CF106 in0.347 g. ¹H NMR (300 MHz, CDCl₃): 4.00-3.90 (m, 2H), 3.90-3.70 (m, 2H),2.65-2.50 (m, 2H), 2.50-2.35 (m, 2H), 2.35-2.20 (m, 2H). ESI-MScalculated for C₈H₁₄N₃O [M+H]⁺=168.11; Observed: 168.33.

Synthesis of2-(3-((7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol(Cpd. No. 150)

Cpd. No. 150 was prepared from S13 (136 mg) and2-(3-amino-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol (120 g)following the similar procedure for preparation of Cpd. No. 135. Cpd.No. 150 was obtained in 106 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz,MeOD-D4): 7.54 (s, 1H), 7.47 (s, 1H), 4.37 (t, J=4.53 Hz, 2H), 4.00 (t,J=4.51 Hz, 2H), 3.88 (s, 3H), 2.90-2.70 (m, 2H), 2.75 (s, 3H), 2.65-2.50(m, 2H), 2.50-2.30 (m, 2H), 2.31 (s, 3H), 2.14 (s, 3H). ESI-MScalculated for C₂₅H₂₈N₇O₃ [M+H]⁺=474.23; Observed: 474.92.

Example 101 Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine (Cpd. No. 151)

Cpd. No. 150 (30 mg, 0.05 mmol) was mixed with anhydrous dichloromethane(4 mL) and the mixture was cooled to −78° C. for 10 minutes. Adichloromethane solution of DAST (40 mg, 0.25 mmol) was added via asyringe and the mixture was stirred at −78° C. for 20 minutes. Themixture was then warmed up to ambient temperature and stirred for 3 hbefore quenching with sodium bicarbonate saturated solution. Methanolwas added and the mixture was concentrated on a rotary evaporator. Theremaining residue was purified on reverse phase HPLC and Cpd. No. 151was obtained in 21 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4):7.44 (s, 1H), 7.13 (s, 1H), 4.73 (t, J=4.65 Hz, 1H), 4.49 (t, J=4.64 Hz,1H), 4.40 (t, J=4.54, 1H), 3.82 (s, 3H), 2.80-2.60 (m, 2H), 2.72 (s,3H), 2.45-2.25 (m, 4H), 2.31 (s, 3H), 2.14 (s, 3H). ESI-MS calculatedfor C₂₅H₂₇FN₇O₂[M+H]⁺=476.22; Observed: 476.58.

Example 102

Synthesis of 1,3-Dicyclopropyl-1H-pyrazol-5-amine (CF118)

3-Cyclopropyl-3-oxopropanenitrile (1.0 g, 9 mmol), sodium acetate (1.6g, 20 mmol), and cyclopropyl hydrazine-HCl (1.0 g, 9.2 mmol) were mixedin ethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue was purified by flash columnchromatography to yield CF118 in 0.88 g. ¹H NMR (300 MHz, CDCl₃): 5.05(s, 1H), 3.80-3.70 (br, 2H, NH), 3.12-3.00 (m, 1H), 1.88-1.76 (m, 1H),1.16-1.06 (m, 2H), 1.06-0.94 (m, 2H), 0.88-0.80 (m, 2H), 0.66-0.56 (m,2H). ESI-MS calculated for C₉H₁₄N₃ [M+H]⁺=164.12; Observed: 164.17.

Synthesis ofN-(1,3-Dicyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 152)

Cpd. No. 152 was prepared from S13 (136 mg) and1,3-dicyclopropyl-1H-pyrazol-5-amine (130 mg) following the similarprocedure for preparation of Cpd. No. 135. Cpd. No. 152 was obtained in140 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.44 (s, 1H),7.08 (s, 1H), 6.10 (s, 1H), 3.83 (s, 3H), 3.40-3.20 (m, 1H), 2.73 (s,3H), 2.31 (s, 3H), 2.14 (s, 3H), 2.05-1.85 (m, 1H), 1.20-1.00 (m, 2H),1.00-0.80 (m, 4H), 0.80-0.60 (m, 2H). ESI-MS calculated for C₂₆H₂₈N₇O₂[M+H]⁺=470.23; Observed: 470.58.

Example 103 Synthesis ofN-(3-Cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 153)

Cpd. No. 153 was prepared from S13 (170 mg) and3-cyclopropyl-1H-pyrazol-5-amine (162 mg) following the similarprocedure for preparation of Cpd. No. 135. Cpd. No. 153 was obtained in37.5 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 8.21 (s, 1H),7.45 (s, 1H), 6.12 (s, 1H), 3.97 (s, 3H), 2.81 (s, 3H), 2.33 (s, 3H),2.16 (s, 3H), 2.10-1.95 (m, 1H), 1.80-1.00 (m, 2H), 0.90-0.70 (m, 2H).ESI-MS calculated for C₂₃H₂₄N₇O₂ [M+H]⁺=430.20; Observed: 430.42.

Example 104 Synthesis of1-(3-Cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)ethanone(Cpd. No. 154)

Cpd. No. 153 (20 mg) and NaHCO₃ (200 mg) were mixed with anhydrous THF(4 mL). Acetic chloride (0.2 mL) was added via a syringe and the mixturewas stirred at ambient temperature for overnight. The reaction mixturewas concentrated on a rotary evaporator and the remaining residue waspurified by reverse phase HPLC. Cpd. No. 154 was obtained in 3 mg as asalt of CF₃CO₂H. ESI-MS calculated for C₂₅H₂₆N₇O₃ [M+H]⁺=472.21;Observed: 472.33.

Example 105 Synthesis of Ethyl3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazole-1-carboxylate(Cpd. No. 155)

Cpd. No. 153 (20 mg, 0.037 mmol) and NaHCO₃ (500 mg, excess) were mixedwith anhydrous THF (5 mL). Ethyl chloroformate (0.2 mL, 2 mmol) wasadded via a syringe and the mixture was stirred at ambient temperaturefor overnight. The reaction mixture was concentrated on a rotaryevaporator and the remaining residue was purified by reverse phase HPLC.Cpd. No. 155 was obtained in 10 mg as a salt of CF₃CO₂H. ESI-MScalculated for C₂₆H₂₈N₇O₄ [M+H]⁺=502.22; Observed: 502.67.

Example 106

Synthesis of 3-Cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-amine(CF127)

3-Cyclopropyl-3-oxopropanenitrile (1.0 g, 9.2 mmol) and(2,2,2-trifluoroethyl)hydrazine (2.9 mL, 70% in water, 23 mmol) weremixed in ethanol, and the mixture was heated at reflux for overnight.The reaction mixture was cooled to room temperature and ethanol wasremoved on a rotary evaporator. Water was added and the aqueous layerwas extracted with ethyl acetate. The combined organic layers werewashed with brine, dried over anhydrous sodium sulfate, and concentratedon a rotary evaporator. The remaining residue was purified by flashcolumn chromatography to yield CF127 in 1.04 g. ¹H NMR (300 MHz, CDCl₃):5.27 (s, 1H), 4.51 (q, J=8.72 Hz, 2H), 3.55-3.40 (m, 2H, NH), 1.90-1.76(m, 1H), 0.94-0.82 (m, 2H), 0.70-0.60 (m, 2H). ESI-MS calculated forC₈H₁₁F₃N₃ [M+H]⁺=206.09; Observed: 206.50.

Synthesis ofN-(3-Cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 156)

Cpd. No. 156 was prepared from S13 (170 mg) and3-cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-amine (200 mg)following the similar procedure for preparation of Cpd. No. 135. Cpd.No. 156 was obtained in 30 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz,MeOD-D4): 7.44 (s, 1H), 7.19 (s, 1H), 6.09 (s, 1H), 5.00-4.80 (m, 2H),3.84 (s, 3H), 2.70 (s, 3H), 2.31 (s, 3H), 2.13 (s, 3H), 2.05-1.90 (m,1H), 1.05-0.90 (m, 2H), 0.80-0.60 (m, 2H). ESI-MS calculated forC₂₅H₂₅F₃N₇O₂ [M+H]⁺=512.20; Observed: 512.58.

Example 107

Synthesis of2-(2,2,2-Trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine(CF128)

2-Oxocyclopentanecarbonitrile (1.0 g, 9.2 mmol) and(2,2,2-trifluoroethyl)hydrazine (2.9 mL, 70% in water, 23 mmol) weremixed in ethanol, and the mixture was heated at reflux for overnight.The reaction mixture was cooled to room temperature and ethanol wasremoved on a rotary evaporator. Water was added and the aqueous layerwas extracted with ethyl acetate. The combined organic layers werewashed with brine, dried over anhydrous sodium sulfate, and concentratedon a rotary evaporator. The remaining residue was purified by flashcolumn chromatography to yield CF128 in 1.66 g. ¹H NMR (300 MHz, CDCl₃):4.53 (q, J=8.76 Hz, 2H), 3.40-3.30 (br, 2H, NH), 2.65 (t, J=7.27 Hz,2H), 2.56-2.46 (m, 2H), 2.40-2.30 (m, 2H). ESI-MS calculated forC₈H₁₁F₃N₃ [M+H]⁺=206.09; Observed: 206.33.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 157)

Cpd. No. 157 was prepared from S13 (170 mg) and2-(2,2,2-Trifluoroethyl)-2,4,5,6-tetrahydro-cyclopenta[c]pyrazol-3-amine(200 mg) following the similar procedure for preparation of Cpd. No.135. Cpd. No. 157 was obtained in 9 mg as a salt of CF₃CO₂H. ¹H NMR (300MHz, MeOD-D4): 7.44 (s, 1H), 7.28 (s, 1H), 3.83 (s, 3H), 2.80-2.70 (m,2H), 2.70 (s, 3H), 2.50-2.30 (m, 4H), 2.32 (s, 3H), 2.14 (s, 3H). ESI-MScalculated for C₂₅H₂₅F₃N₇O₂[M+H]⁺=512.20; Observed: 512.83.

Example 108

Synthesis of 2-(5-Amino-3-cyclopropyl-1H-pyrazol-1-yl)ethanol (CF137)

3-Cyclopropyl-3-oxopropanenitrile (5.0 g, 46 mmol) and2-hydrazinylethanol (4.7 mL, 92 mmol) were mixed in ethanol, and themixture was heated at reflux for overnight. The reaction mixture wascooled to room temperature and ethanol was removed on a rotaryevaporator. Water was added and the aqueous layer was extracted withethyl acetate. The combined organic layers were washed with brine, driedover anhydrous sodium sulfate, and concentrated on a rotary evaporator.The remaining residue was washed with dichloromethane and filtered toyield CF137 in 4.52 g as a white solid. ¹H NMR (300 MHz, CDCl₃): 5.10(s, 1H), 3.98-3.88 (m, 2H), 3.80 (t, J=4.95 Hz, 2H), 1.80-1.66 (m, 1H),0.88-0.72 (m, 2H), 0.64-0.52 (m, 2H). ESI-MS calculated for C₈H₁₄N₃O[M+H]⁺=168.11; Observed: 168.58.

Synthesis of2-(3-Cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)ethanol(Cpd. No. 158)

Cpd. No. 158 was prepared from S13 (800 mg) and2-(5-amino-3-cyclopropyl-1H-pyrazol-1-yl)ethanol (640 mg) following thesimilar procedure for preparation of Cpd. No. 135. Cpd. No. 158 wasobtained in 253 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.48(s, 1H), 7.46 (s, 1H), 6.27 (s, 1H), 4.33 (t, J=4.61, 2H), 3.99 (t,J=4.67, 2H), 3.89 (s, 3H), 2.74 (s, 3H), 2.30 (s, 3H), 2.13 (s, 3H),2.04-1.90 (s, 1H), 1.04-0.90 (m, 2H), 0.80-0.70 (m, 2H). ESI-MScalculated for C₂₅H₂₈N₇O₃ [M+H]⁺=474.23; Observed: 474.50.

Example 109 Synthesis ofN-(3-Cyclopropyl-1-(2-fluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 159)

Cpd. No. 158 (20 mg) was mixed with anhydrous dichloromethane (4 mL) andthe mixture was cooled to −78° C. for 10 minutes. A dichloromethanesolution of DAST (20 mg) was added via a syringe and the mixture wasstirred at −78° C. for 20 minutes. The mixture was then warmed up toambient temperature and stirred for 3 hours before quenching with sodiumbicarbonate saturated solution. Methanol was added and the mixture wasconcentrated on a rotary evaporator. The remaining residue was purifiedon reverse phase HPLC and Cpd. No. 159 was obtained in 13 mg as a saltof CF₃CO₂H. ¹H NMR (300 MHz, MeOD-D4): 7.44 (s, 1H), 7.12 (s, 1H), 6.08(s, 1H), 4.87 (t, J=4.67 Hz, 1H), 4.71 (t, J=4.63 Hz, 1H), 4.44 (t,J=4.45 Hz, 1H), 4.35 (t, J=4.70 Hz, 1H), 3.84 (s, 1H), 2.72 (s, 1H),2.31 (s, 1H), 2.14 (s, 1H), 2.24-1.90 (m, 1H), 1.04-0.90 (m, 2H),0.80-0.66 (m, 2H). ESI-MS calculated for C₂₅H₂₇FN₇O₂[M+H]⁺=476.22;Observed: 476.58.

Example 110

Synthesis of 3-Cyclopropyl-1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-amine(CF148)

3-Cyclopropyl-3-oxopropanenitrile (1.0 g, 9.1 mmol) and2-hydrazinyl-N,N-dimethylethanamine-2 HCl (1.76 g, 9.0 mmol) were mixedin ethanol, and the mixture was heated at reflux for overnight. Thereaction mixture was cooled to room temperature and ethanol was removedon a rotary evaporator. Water was added and the aqueous layer wasextracted with ethyl acetate. The combined organic layers were washedwith brine, dried over anhydrous sodium sulfate, and concentrated on arotary evaporator. The remaining residue (CF148, 2.50 g) was used fornext step without further purification. ¹H NMR (300 MHz, DMSO-D6):5.40-5.30 (m, 1H), 4.50-4.35 (m, 2H), 3.50-3.40 (m, 2H), 2.79 (s, 6H),1.90-1.80 (m, 1H), 1.05-0.90 (m, 2H), 0.90-0.75 (m, 2H). ESI-MScalculated for C₁₀H₁₉N₄[M+H]⁺=195.16; Observed: 195.25.

Synthesis ofN-(3-Cyclopropyl-1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 160)

Cpd. No. 160 was prepared from S13 (100 mg) and3-cyclopropyl-1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-amine (160 mg)following the similar procedure for preparation of Cpd. No. 135. Cpd.No. 160 was obtained in 43 mg as a salt of CF₃CO₂H. ¹H NMR (300 MHz,MeOD-D4): 7.51 (s, 1H), 7.43 (s, 1H), 6.07 (s, 1H), 4.45 (t, J=5.47 Hz,2H), 3.67 (t, J=5.57 Hz, 2H), 3.89 (s, 3H), 2.99 (s, 6H), 2.68 (s, 3H),2.32 (s, 3H), 2.14 (s, 3H), 2.02-1.90 (m, 1H), 1.04-0.90 (m, 2H),0.80-0.70 (m, 2H). ESI-MS calculated for C₂₇H₃₃N₈O₂ [M+H]⁺=501.27;Observed: 501.67

Example 111

Synthesis of1-Methyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-amine(CF141 TFA salt)

Step 1: 3,3,3-trifluoro-2,2-dimethylpropanoic acid (1.5 g, 10 mmol) andDMF (one drop) were dissolved in anhydrous dichloromethane (15 mL).Oxalyl chloride (1.0 mL, 12 mmol) was added via a syringe at ambienttemperature and the mixture was stirred for overnight. Dichloromethanewas removed on a rotary evaporator with 0° C. water bath. The remainingresidues were used for next step without further purification.

Step 2: Acetonitrile (1.56 mL, 30 mmol) was dissolved in anhydrous THF(30 mL) and the solution was cooled to −78° C. LiHMDS (30 mL, 1.0 M inTHF, 30 mmol) was added via a syringe over 10 minutes and the mixturewas stirred at −78° C. for 20 min. THF solution of3,3,3-trifluoro-2,2-dimethylpropanoyl chloride prepare from step 1 wasadded via a syringe and the mixture was stirred at −78° C. for 2 hours.The reaction was quenched with 1 N HCl and extracted with ethyl acetate.The combined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was used for next step without further purification.

Step 3: 5,5,5-trifluoro-4,4-dimethyl-3-oxopentanenitrile prepared fromstep 2 was dissolved in ethanol (30 mL). Methyl hydrazine (1.1 mL, 20mmol) was added via a syringe and the mixture was heated at reflux forovernight. The reaction mixture was cooled to room temperature andethanol was removed on a rotary evaporator. Water was added and theaqueous layer was extracted with ethyl acetate. The combined organiclayers were washed with brine, dried over anhydrous sodium sulfate, andconcentrated on a rotary evaporator. The remaining residue was purifiedon flash chromatography to yield CF141 in 0.22 g. ¹H NMR (300 MHz,MeOD-d4): 5.54 (s, 1H), 3.61 (s, 3H), 3.60-3.40 (m, 2H, NH), 1.45 (s,6H). ESI-MS calculated for C₈H₁₃F₃N₃ [M+H]⁺=208.11; Observed: 208.25.

Synthesis of7-(3,5-Dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 161)

Cpd. No. 161 was prepared from S13 (102 mg) and1-methyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-amine (120mg) following the similar procedure for preparation of Cpd. No. 135.Cpd. No. 161 was obtained in 48 mg as a salt of CF₃CO₂H. 1H NMR (300MHz, MeOD-D4): 7.67 (s, 1H), 7.46 (s, 1H), 6.41 (s, 1H), 3.90 (s, 1H),3.83 (s, 3H), 2.69 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 1.55 (s, 6H).ESI-MS calculated for C₂₅H₂₇F₃N₇O₂[M+H]⁺=514.22; Observed: 514.67.

Example 112

Synthesis of tert-butyl3-(5-amino-3-cyclopropyl-1H-pyrazol-1-yl)azetidine-1-carboxylate (CF178)

3-Cyclopropyl-3-oxopropanenitrile (2.16 g, 20 mmol) and1-Boc-3-hydrazinylazetidine-(3.83 g, 20.0 mmol, prepared according to WO2012/004706 A2) were mixed in ethanol, and the mixture was heated atreflux for overnight. The reaction mixture was cooled to roomtemperature and ethanol was removed on a rotary evaporator. Water wasadded and the aqueous layer was extracted with ethyl acetate. Thecombined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was washed with dichloromethane and filtered to yield CF178 in2.67 g. ¹H NMR (300 MHz, CDCl₃): 5.21 (s, 1H), 4.95-4.80 (m, 1H),4.50-4.35 (m, 2H), 4.30-4.15 (m, 2H), 1.90-1.80 (m, 1H), 1.45 (s, 9H),0.95-0.80 (m, 2H), 0.70-0.60 (m, 2H). ESI-MS calculated for C₁₋₄H₂₃N₄O₂[M+H]⁺=279.18; Observed: 279.58.

Synthesis of tert-butyl3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carboxylate(Cpd. No. 162)

Cpd. No. 162 was prepared from S13 (205 mg) and tert-butyl3-(5-amino-3-cyclopropyl-1H-pyrazol-1-yl)azetidine-1-carboxylate (348mg) following the similar procedure for preparation of Cpd. No. 135.Cpd. No. 162 was used in the next reaction without purification.

Example 113 Synthesis ofN-(1-(Azetidin-3-yl)-3-cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 163)

Cpd. No. 162 (crude product) and triethylsilane (0.2 mL) were dissolvedin CF₃CO₂H-dichloromethane (1:1, 12 mL) and the mixture was stirred atroom temperature for 1 h. The reaction mixture was concentrated on arotary evaporator and the remaining residue was purified on reverse HPLCto yield 126 mg of Cpd. No. 163 as a salt of CF₃CO₂H. ¹H NMR (300 MHz,MeOD-D4): 7.54 (s, 1H), 7.46 (s, 1H), 6.09 (s, 1H), 5.40-5.20 (m, 1H),5.70-5.50 (m, 2H), 5.50-5.30 (m, 2H), 3.89 (s, 3H), 2.65 (s, 3H), 2.30(s, 3H), 2.12 (s, 3H), 2.10-1.95 (m, 1H), 1.05-0.90 (m, 2H), 0.90-0.75(m, 2H). ESI-MS calculated for C₂₆H₂₉N₈O₂ [M+H]⁺=485.24; Observed:485.67.

Example 114 Synthesis ofN-(1-(tert-butyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 62)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-(tert-butyl)-3-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 62 as a CF₃CO₂H salt in15 mg. ESI-MS calculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.55.¹H NMR (300 MHz, MeOD) δ 7.44 (s, 1H), 6.59 (s, 1H), 6.24 (s, 1H), 3.80(s, 3H), 2.74 (s, 3H), 2.31 (s, 3H), 2.30 (s, 3H), 2.14 (s, 3H), 1.72(s, 9H).

Example 115 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-imidazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 166)

Pd₂(dba)₃ (53 mg) and Xantphos (100 mg) were mixed in toluene (8 mL) and2 M Na₂CO₃ (0.58 mL). Then S13 (100 mg), 1-methyl-1H-imidazol-4-amine(100 mg), was added. The mixture was heated at reflux for overnight. Thereaction mixture was filtered and the mixture was purified by HPLC toyield Cpd. No. 166 as a CF₃CO₂H salt in 4.5 mg. ESI-MS calculated forC₂₁H₂₂N₇O₂ [M+H]⁺=404.18; Observed: 404.44. ¹H NMR (300 MHz, MeOD) δ8.16 (s, 2H), 7.45 (s, 1H), 7.41 (s, 1H), 4.00 (s, 3H), 3.93 (s, 3H),2.78 (s, 3H), 2.35 (s, 3H), 2.19 (s, 3H).

Example 116 Synthesis ofN-(1,4-dimethyl-1H-pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 77)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1,4-dimethyl-1H-pyrazol-3-amine (84 mg), K₃PO₄ (130 mg), and toluene (2mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 77 as a CF₃CO₂H salt in 20 mg. ESI-MScalculated for C₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed: 418.44. ¹H NMR (300MHz, MeOD) δ 7.65 (s, 1H), 7.62 (s, 1H), 7.47 (s, 1H), 3.93 (s, 3H),3.91 (s, 3H), 2.75 (s, 3H), 2.35 (s, 3H), 2.17 (s, 3H), 2.12 (s, 3H).

Example 117 Synthesis ofN-(1,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 76)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 76 as a CF₃CO₂H salt in 20 mg. ESI-MScalculated for C₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed: 418.64. ¹H NMR (300MHz, MeOD) δ 7.52 (s, 1H), 7.48 (s, 1H), 7.37 (brs, 1H), 3.88 (s, 3H),3.83 (s, 3H), 2.72 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H), 1.98 (s, 3H).

Example 118 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethyl-1,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 169)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),3-ethyl-1,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 169 as a CF₃CO₂H salt in20 mg. ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.67.¹H NMR (300 MHz, MeOD) δ 7.46 (s, 1H), 7.37 (brs, 1H), 3.88 (s, 3H),3.78 (s, 3H), 2.74-2.60 (m, 5H), 2.34 (s, 3H), 2.17 (s, 3H), 1.89 (s,3H), 1.27 (t, J=7.6 Hz, 3H).

Example 119 Synthesis ofN-(1,5-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 170)

S13 (70 mg) and 1,5-dimethyl-1H-pyrazol-4-amine (68 mg) were dissolvedin isopropanol (5 mL). Four drops of concentrated HCl was added via aglass pipette. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 170in 50 mg as a salt of trifluoroacetic acid. ESI-MS calculated forC₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed: 418.46. ¹H NMR (300 MHz, MeOD) δ7.95 (brs, 1H), 7.65 (s, 1H), 7.47 (s, 1H), 3.92 (s, 3H), 3.91 (s, 3H),2.70 (s, 3H), 2.33 (s, 3H), 2.31 (s, 3H), 2.16 (s, 3H).

Example 120 Synthesis ofN-(1,2-dimethyl-1H-imidazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 171)

Pd₂(dba)₃ (53 mg) and Xantphos (100 mg) were mixed in toluene (8 mL) and2 M Na₂CO₃ (0.58 mL). Then S13 (100 mg),1,2-dimethyl-1H-imidazol-5-amine (100 mg), was added. The mixture washeated at reflux for overnight. The reaction mixture was filtered andthe mixture was purified by HPLC to yield Cpd. No. 171 as a CF₃CO₂H saltin 7.5 mg. ESI-MS calculated for C₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed:418.42. ¹H NMR (300 MHz, MeOD) δ 8.10 (s, 1H), 7.60 (s, 1H), 7.47 (s,1H), 3.98 (s, 3H), 3.70 (s, 3H), 2.77 (s, 3H), 2.63 (s, 3H), 2.36 (s,3H), 2.19 (s, 3H).

Example 121 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 172)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2 mL).The mixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was filtered and the mixture was purifiedby HPLC to yield Cpd. No. 172 as a CF₃CO₂H salt in 22 mg. ESI-MScalculated for C₂₁H₂₂N₇O₂ [M+H]⁺=404.18; Observed: 404.45. ¹H NMR (300MHz, MeOD) δ 7.63 (d, J=2.1 Hz, 1H), 7.49 (s, 1H), 7.48 (s, 1H), 6.43(d, J=2.1 Hz, 1H), 3.90 (s, 3H), 3.85 (s, 3H), 2.71 (s, 3H), 2.33 (s,3H), 2.15 (s, 3H).

Example 122 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 173)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-ethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2 mL).The mixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was filtered and the mixture was purifiedby HPLC to yield Cpd. No. 173 as a CF₃CO₂H salt in 22 mg. ESI-MScalculated for C₂₂H₂₄N₇O₂ [M+H]⁺=418.19; Observed: 418.66. ¹H NMR (300MHz, MeOD) δ 7.67 (d, J=2.0 Hz, 1H), 7.50 (s, 1H), 7.45 (s, 1H), 6.39(d, J=2.0 Hz, 1H), 4.17 (q, J=7.3 Hz, 2H), 3.90 (s, 3H), 2.67 (s, 3H),2.34 (s, 3H), 2.17 (s, 3H), 1.48 (t, J=7.2 Hz, 3H).

Example 123 Synthesis of5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1-methyl-1H-pyrazole-4-carbonitrile(Cpd. No. 174)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),5-amino-1-methyl-1H-pyrazole-4-carbonitrile (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 174 as a CF₃CO₂H salt in26 mg. ESI-MS calculated for C₂₂H₂₁N₈O₂ [M+H]⁺=429.17; Observed: 429.44.¹H NMR (300 MHz, MeOD) δ 8.01 (s, 1H), 7.94 (s, 1H), 7.49 (s, 1H), 3.96(s, 3H), 3.87 (s, 3H), 2.68 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H).

Example 124 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 175)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-isopropyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 175 as a CF₃CO₂H salt in 22 mg.ESI-MS calculated for C₂₃H₂₆N₇O₂ [M+H]⁺=432.21; Observed: 432.44. ¹H NMR(300 MHz, MeOD) δ 7.69 (d, J=1.9 Hz, 1H), 7.46 (s, 1H), 7.28 (s, 1H),6.37 (d, J=2.0 Hz, 1H), 4.65 (dq, J=13.2, 6.6 Hz, 1H), 3.87 (s, 3H),2.70 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 1.51 (d, J=6.6 Hz, 6H).

Example 125 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 176)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-ethyl-4-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 176 as a CF₃CO₂H salt in 22 mg.ESI-MS calculated for C₂₃H₂₆N₇O₂ [M+H]⁺=432.21; Observed: 432.48. ¹H NMR(300 MHz, MeOD) δ 7.54 (s, 1H), 7.48 (s, 1H), 7.06 (brs, 1H), 4.18 (q,J=7.2 Hz, 2H), 3.85 (s, 3H), 2.73 (s, 3H), 2.32 (s, 3H), 2.14 (s, 3H),1.95 (s, 3H), 1.45 (t/=7.2 Hz, 3H).

Example 126 Synthesis ofN-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2,4-dimethylthiazol-5-amine(Cpd. No. 177)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),2,4-dimethylthiazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2 mL).The mixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was filtered and the mixture was purifiedby HPLC to yield Cpd. No. 177 as a CF₃CO₂H salt in 14 mg. ESI-MScalculated for C₂₂H₂₃N₆O₂S [M+H]⁺=435.16; Observed: 435.44. ¹H NMR (300MHz, MeOD) δ 7.98 (s, 1H), 7.48 (s, 1H), 3.97 (s, 3H), 2.78 (s, 3H),2.73 (s, 3H), 2.41 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H).

Example 127 Synthesis ofN-(1-cyclopentyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 178)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclopentyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene (2mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 178 as a CF₃CO₂H salt in 20 mg.ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed: 458.55. ¹H NMR(300 MHz, MeOD) δ 7.67 (d, J=1.8 Hz, 1H), 7.45 (s, 1H), 7.35 (s, 1H),6.37 (d, J=2.0 Hz, 1H), 4.78 (p, J=7.6 Hz, 1H), 3.87 (s, 3H), 2.68 (s,3H), 2.33 (s, 3H), 2.16 (s, 3H), 2.14-2.04 (m, 4H), 2.00-1.86 (m, 2H),1.72-1.57 (m, 2H).

Example 128 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 179)

S13 (70 mg) and 1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-amine (68 mg)were dissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 179 in 50 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₂H₂₁F₃N₇O₂[M+H]⁺=472.17; Observed: 472.44. ¹H NMR (300MHz, MeOD) δ 8.15 (s, 1H), 7.97 (s, 1H), 7.49 (s, 1H), 4.08 (s, 3H),3.96 (s, 3H), 2.70 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H).

Example 129 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,4-trimethyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 80)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1,3,4-trimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 80 as a CF₃CO₂H salt in 20 mg. ESI-MScalculated for C₂₃H₂₆N₇O₂ [M+H]⁺=432.21; Observed: 432.65. ¹H NMR (300MHz, MeOD) δ 7.47 (s, 1H), 7.29 (brs, 1H), 3.87 (s, 3H), 3.77 (s, 3H),2.71 (s, 3H), 2.33 (s, 3H), 2.26 (s, 3H), 2.16 (s, 3H), 1.90 (s, 3H).

Example 130 Synthesis of 3-isopropyl-1-methyl-1H-pyrazol-4-amine(ZBB153)

The mixture of 3-isopropyl-1-methyl-1H-pyrazole (500 mg), conc. H₂SO₄ (1mL) and fuming HNO₃ (1 mL) was heated at 60° C. overnight. Then themixture was poured into cooled aq. NaOH water solution and extractedwith Ethyl acetate. The organic phase was concentrated on a rotaryevaporator and was dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature underI-overnight. The mixture was filtered and concentrated on a rotaryevaporator to give ZBB153 (300 mg). ESI-MS calculated forC₇H₁₄N₃[M+H]⁺=140.11; Observed: 140.44.

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(3-isopropyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 181)

S13 (70 mg) and 3-isopropyl-1-methyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 181 in 45 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.44. ¹H NMR (300MHz, MeOD) δ 7.85 (s, 1H), 7.60 (brs, 1H), 7.47 (s, 1H), 3.95 (s, 3H),3.89 (s, 3H), 3.02 (hept, J=6.7 Hz, 1H), 2.71 (s, 3H), 2.33 (s, 3H),2.16 (s, 3H), 1.30 (d, J=7.0 Hz, 6H).

Example 131 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 182)

S13 (70 mg) and 3-ethyl-1-methyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 182 in 45 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₃H₂₆N₇O₂ [M+H]⁺=432.21; Observed: 432.55.

Example 132 Synthesis ofN-(1-(tert-butyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 183)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-(tert-butyl)-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 183 as a CF₃CO₂H salt in 20 mg.ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.65.

Example 133 1-isopropyl-3,4-dimethyl-1H-pyrazol-5-amine (ZBB159)

2-methyl-3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).isopropylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 1.3 g. ESI-MS calculated forC₈H₁₆N₃[M+H]⁺=154.13; Observed: 154.66.

Example 134 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 81)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-isopropyl-3,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 81 as a CF₃CO₂H salt in20 mg. ESI-MS calculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.44.

Example 135 Synthesis of 1-(tert-butyl)-3,4-dimethyl-1H-pyrazol-5-amine(ZBB160)

2-methyl-3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).tert-butylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 1.3 g. ESI-MS calculated forC₉H₁₈N₃[M+H]⁺=168.15; Observed: 168.44.

Example 136 Synthesis ofN-(1-(tert-butyl)-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 185)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-(tert-butyl)-3,4-dimethyl-1H-pyrazol-5-amine (84 mg), t-BuOK (100 mg),and toluene (2 mL). The mixture was heated at reflux for overnightbefore quenching with methanol. The reaction mixture was filtered andthe mixture was purified by HPLC to yield Cpd. No. 185 as a CF₃CO₂H saltin 20 mg. ESI-MS calculated for C₂₆H₃₂N₇O₂ [M+H]⁺=474.26; Observed:474.44.

Example 137 Synthesis of 1-ethyl-3,4-dimethyl-1H-pyrazol-5-amine(ZBB164)

2-methyl-3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).ethylhydrazine. HCl salt (5 g) was added and the mixture was heated atreflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 1.3 g. ESI-MS calculated forC₇H₁₄N₃[M+H]⁺=140.11; Observed: 140.34.

Example 138 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 186)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-ethyl-3,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 186 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.36.

Example 139 Synthesis of 1-cyclobutyl-3,4-dimethyl-1H-pyrazol-5-amine(ZBB165)

2-methyl-3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).cyclobutylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 1.3 g. ESI-MS calculated forC₉H₁₆N₃[M+H]⁺=166.13; Observed: 166.64.

Synthesis ofN-(1-cyclobutyl-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 187)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclobutyl-3,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg),and toluene (2 mL). The mixture was heated at reflux for overnightbefore quenching with methanol. The reaction mixture was filtered andthe mixture was purified by HPLC to yield Cpd. No. 187 as a CF₃CO₂H saltin 30 mg. ESI-MS calculated for C₂₆H₃₀N₇O₂ [M+H]⁺=472.24; Observed:472.66.

Example 140 Synthesis of 1-cyclopropyl-3,4-dimethyl-1H-pyrazol-5-amine(ZBB170)

2-methyl-3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).cyclopropylhydrazine. HCl salt (5 g) was added and the mixture washeated at reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 1.3 g. ESI-MS calculated forC₈H₁₄N₃[M+H]⁺=152.11; Observed: 152.44.

Example 141 Synthesis ofN-(1-cyclopropyl-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 188)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclopropyl-3,4-dimethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg),and toluene (2 mL). The mixture was heated at reflux for overnightbefore quenching with methanol. The reaction mixture was filtered andthe mixture was purified by HPLC to yield Cpd. No. 188 as a CF₃CO₂H saltin 25 mg. ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed:458.56.

Example 142 Synthesis of 4-isopropyl-1-methyl-1H-pyrazol-5-amine(ZBB171)

2-formyl-3-methylbutanenitrile (1 g) was dissolved in ethanol (30 mL).methylhydrazine (5 g) was added and the mixture was heated at reflux forovernight. The mixture was concentrated on a rotary evaporator followedby addition of ethyl acetate and aq. NaHCO₃. The aqueous layer wasextracted with ethyl acetate and the organic layers were combined,dried, and concentrated on a rotary evaporator. The remaining residuewas purified by flash column chromatography and the desired product wasobtained in 0.4 g. ESI-MS calculated for C₇H₁₄N₃[M+H]⁺=140.11; Observed:140.43.

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(4-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 79)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),4-isopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 79 as a CF₃CO₂H salt in12 mg. ESI-MS calculated for C₂₄H₂₈N₇O₂ [M+H]⁺=446.23; Observed: 446.43.¹H NMR (300 MHz, MeOD) δ 7.60 (s, 1H), 7.49 (s, 1H), 3.86 (s, 3H), 3.81(s, 3H), 2.87-2.75 (m, 1H), 2.73 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H),1.20 (d, J=6.9 Hz, 6H).

Example 143 Synthesis of 2-isopropyl-4-methylthiazol-5-amine (ZBB179)

The mixture of 2-isopropyl-4-methylthiazole (500 mg), conc. H₂SO₄ (1 mL)and fuming HNO₃ (1 mL) was heated at 100° C. overnight. Then the mixturewas poured into cooled aq. NaOH water solution and extracted with Ethylacetate. The organic phase was concentrated on a rotary evaporator andwas dissolved in MeOH (10 mL). 500 mg 10% Pd/C was added. the reactionmixture was degassed 2 times, each time replacing the vacuum withhydrogen, then stirred at room temperature under H₂ overnight. Themixture was filtered and concentrated on a rotary evaporator to giveZBB179 (300 mg). ESI-MS calculated for C₇H₁₃N₂S[M+H]⁺=157.07; Observed:157.44. ¹H NMR (300 MHz, CDCl₃) δ 3.23 (hept, J=6.8 Hz, 1H), 2.79 (s,3H), 1.40 (d, J=6.9 Hz, 6H).

Synthesis ofN-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-isopropyl-4-methylthiazol-5-amine(Cpd. No. 190)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),2-isopropyl-4-methylthiazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 190 as a CF₃CO₂H salt in 35 mg.ESI-MS calculated for C₂₄H₂₇N₆O₂S [M+H]⁺=463.19; Observed: 463.44.

Example 144 Synthesis of 4-isopropyl-2-methylthiazol-5-amine (ZBB181)

The mixture of 4-isopropyl-2-methylthiazole (500 mg), conc. H₂SO₄ (1 mL)and fuming HNO₃ (1 mL) was heated at 100° C. overnight. Then the mixturewas poured into cooled aq. NaOH water solution and extracted with Ethylacetate. The organic phase was concentrated on a rotary evaporator andwas dissolved in MeOH (10 mL). 500 mg 10% Pd/C was added. the reactionmixture was degassed 2 times, each time replacing the vacuum withhydrogen, then stirred at room temperature under H₂ overnight. Themixture was filtered and concentrated on a rotary evaporator to giveZBB181 (400 mg). ESI-MS calculated for C₇H₁₃N₂S[M+H]⁺=157.07; Observed:157.34.

Synthesis ofN-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-isopropyl-2-methylthiazol-5-amine(Cpd. No. 84)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene, andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),4-isopropyl-2-methylthiazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 84 as a CF₃CO₂H salt in 35 mg. ESI-MScalculated for C₂₄H₂₇N₆O₂S [M+H]⁺=463.19; Observed: 463.45. ¹H NMR (300MHz, MeOD) δ 7.84 (brs, 1H), 7.49 (s, 1H), 3.93 (s, 3H), 3.13 (dt,J=13.7, 6.8 Hz, 1H), 2.78 (s, 3H), 2.72 (s, 3H), 2.34 (s, 3H), 2.17 (s,3H), 1.32 (d, J=6.9 Hz, 6H).

Example 145 Synthesis of 1-cyclopropyl-3-methyl-1H-pyrazol-5-amine(ZBB182)

3-oxobutanenitrile (1 g) was dissolved in ethanol (30 mL).cyclopropylhydrazine (5 g) was added and the mixture was heated atreflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.4 g. ESI-MS calculated forC₇H₁₂N₃[M+H]⁺=138.10; Observed: 138.33.

Synthesis ofN-(1-cyclopropyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 192)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclopropyl-3-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 192 as a CF₃CO₂H salt in30 mg. ESI-MS calculated for C₂₄H₂₆N₇O₂ [M+H]⁺=444.21; Observed: 444.65.

Example 146 Synthesis of 3-(tert-butyl)-1-methyl-1H-pyrazol-4-amine(ZBB186)

The mixture of 3-(tert-butyl)-1-methyl-1H-pyrazol-5-amine (500 g),t-BuONO (2 mL) in THF (10 mL) was heated at 90° C. for 3 h. Then themixture was concentrated on a rotary evaporator and was dissolved inconc. H₂SO₄ (1 mL) and fuming HNO₃ (1 mL). And the mixture was heated at60° C. overnight. Then the mixture was poured into cooled aq. NaOH watersolution and extracted with Ethyl acetate. The organic phase wasconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to give ZBB184. ¹H NMR (300 MHz, CDCl₃) δ8.18 (s, 1H), 3.86 (s, 3H), 1.41 (s, 9H).

ZBB184 (200 mg) was dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature under H₂overnight. The mixture was filtered and concentrated on a rotaryevaporator to give ZBB186 (150 mg). ESI-MS calculated forC₈H₁₆N₃[M+H]⁺=154.13; Observed: 154.44.

Synthesis ofN-(3-(tert-butyl)-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 193)

S13 (70 mg) and 3-(tert-butyl)-1-methyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 193 in 45 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.55. ¹H NMR (300MHz, MeOD) δ 7.85 (s, 1H), 7.46 (s, 1H), 3.94 (s, 3H), 3.88 (s, 3H),2.71 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H), 1.38 (s, 9H).

Example 147 Synthesis of 3-isopropyl-1,5-dimethyl-1H-pyrazol-4-amine(ZBB192)

The mixture of 1-(1,5-dimethyl-1H-pyrazol-3-yl)ethan-1-one (1 g), t-BuOK(1.1 g) and CH₃PPh₃Br (3.9 g) in THF (10 mL) was stirred at roomtemperature for 5 h. Then aq. NaHCO₃ was added. The aqueous layer wasextracted with ethyl acetate and the organic layers were combined,dried, and concentrated on a rotary evaporator. The remaining residuewas purified by flash column chromatography and the desired productZBB185 was obtained in 0.8 g.

ZBB185 (0.5 g) was dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature under H₂overnight. The mixture was filtered and concentrated on a rotaryevaporator to give a crude product which was dissolved in conc. H₂SO₄ (1mL) and fuming HNO₃ (1 mL). And the mixture was heated at 60° C.overnight. Then the mixture was poured into cooled aq. NaOH watersolution and extracted with Ethyl acetate. The organic phase wasconcentrated on a rotary evaporator to give the nitro intermediate whichwas dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added. the reactionmixture was degassed 2 times, each time replacing the vacuum withhydrogen, then stirred at room temperature under H₂ overnight. Themixture was filtered and concentrated on a rotary evaporator to giveZBB192 (0.4 g). ESI-MS calculated for C₈H₁₆N₃[M+H]⁺=154.13; Observed:154.45.

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(3-isopropyl-1,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 194)

S13 (70 mg) and 3-isopropyl-1,5-dimethyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 194 in 45 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.45.

Example 148 Synthesis of tert-butyl(3-cyclopropyl-1-methyl-1H-pyrazol-4-yl)carbamate (ZBB195)

The mixture of 3-cyclopropyl-1-methyl-1H-pyrazole-4-carboxylic acid (0.5g), DPPA (1.16 mL) and Et₃N (1.25 mL) in t-BuOH (10 mL) was stirred atroom temperature for 3 h. Then the mixture was refluxed for 1 day andthen concentrated on a rotary evaporator. The remaining residue waspurified by flash column chromatography and the desired product ZBB195was obtained in 0.3 g.

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 195)

tert-butyl (3-cyclopropyl-1-methyl-1H-pyrazol-4-yl)carbamate (0.15 g)was dissolved in DCM/TFA (10 mL, 1:1) and the mixture was stirred atroom temperature for 3 h. Then the mixture was concentrated on a rotaryevaporator to give the crude amine which was dissolved in isopropanol (5mL). Four drops of concentrated HCl and S13 (70 mg) was added via aglass pipette. The mixture was heated at reflux for overnight. Thereaction was concentrated on a rotary evaporator and the remainingresidues were purified by HPLC to yield the desired product Cpd. No. 195in 47 mg as a salt of trifluoroacetic acid. ESI-MS calculated forC₂₄H₂₆N₇O₂ [M+H]⁺=444.21; Observed: 444.34. ¹H NMR (300 MHz, MeOD) δ8.0-7.7 (m, 2H), 7.47 (s, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 2.72 (s, 3H),2.34 (s, 3H), 2.17 (s, 3H), 1.79 (tt, J=7.9, 5.5 Hz, 1H), 0.95-0.79 (m,4H).

Example 149 Synthesis of 1-(tert-butyl)-4-methyl-1H-pyrazol-5-amine(ZBB197)

2-methyl-3-oxopropanenitrile (1 g) was dissolved in ethanol (30 mL).tert-butylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.3 g. ESI-MS calculated forC₈H₁₆N₃[M+H]⁺=154.13; Observed: 154.44. ¹H NMR (300 MHz, CDCl₃) δ 7.12(s, 1H), 3.29 (s, 2H), 1.90 (s, 3H), 1.64 (s, 9H).

Synthesis ofN-(1-(tert-butyl)-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 196)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-(tert-butyl)-4-methyl-1H-pyrazol-5-amine (84 mg), t-BuOK (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 196 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.44.¹H NMR (300 MHz, MeOD) δ 7.51 (s, 1H), 7.45 (s, 1H), 3.80 (s, 3H), 2.75(s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 1.85 (s, 3H), 1.69 (s, 9H).

Example 150 Synthesis of 1-cyclopropyl-4-methyl-1H-pyrazol-5-amine(ZBB198)

2-methyl-3-oxopropanenitrile (1 g) was dissolved in ethanol (30 mL).cyclopropylhydrazine. HCl salt (5 g) was added and the mixture washeated at reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.3 g. ESI-MS calculated for C₇H₁₂N₃[M+H]⁺=138.10; Observed: 138.44.

Synthesis ofN-(1-cyclopropyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 197)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclopropyl-4-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 197 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₄H₂₆N₇O₂ [M+H]⁺=444.21; Observed: 444.54.¹H NMR (300 MHz, MeOD) δ 7.73 (s, 1H), 7.49 (s, 1H), 7.47 (s, 1H), 3.89(s, 3H), 3.77-3.62 (m, 1H), 2.77 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H),2.14 (s, 3H), 1.17-0.96 (m, 4H).

Example 151 Synthesis of 1-cyclobutyl-4-methyl-1H-pyrazol-5-amine(ZBB200)

2-methyl-3-oxopropanenitrile (1 g) was dissolved in ethanol (30 mL).cyclobutylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.3 g. ESI-MS calculated forCH₁₄N₃[M+H]⁺=152.11; Observed: 152.54. ¹H NMR (300 MHz, CDCl₃) δ 7.21(s, 1H), 4.72-4.52 (m, 1H), 3.23 (brs, 2H), 2.76-2.58 (m, 2H), 2.45-2.28(m, 2H), 2.03-1.67 (m, 5H).

Synthesis ofN-(1-cyclobutyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 198)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclobutyl-4-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 198 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed: 458.55.¹H NMR (300 MHz, MeOD) δ 7.60 (s, 1H), 7.48 (s, 1H), 4.98-4.79 (m, 1H),3.86 (s, 3H), 2.81-2.57 (m, 5H), 2.40-2.25 (m, 5H), 2.16 (s, 3H), 1.97(s, 3H), 1.90-1.70 (m, 2H).

Example 152 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-isopropyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 199)

S13 (70 mg) and 1-ethyl-3-isopropyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 199 in 45 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.55.

Example 153 Synthesis of 3-cyclobutyl-1-methyl-1H-pyrazol-4-amine(ZBB214-1)

The mixture of 3-cyclobutyl-1-methyl-1H-pyrazol-5-amine (500 mg),t-BuONO (2 mL) in THF (10 mL) was heated at 90° C. for 3 h. Then themixture was concentrated on a rotary evaporator and was dissolved inconc. H₂SO₄ (1 mL) and fuming HNO₃ (1 mL). And the mixture was heated at60° C. overnight. Then the mixture was poured into cooled aq. NaOH watersolution and extracted with Ethyl acetate. The organic phase wasconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to give ZBB210 (250 mg). ¹H NMR (300 MHz,CDCl₃) δ 8.10 (s, 1H), 4.07-3.93 (m, 1H), 3.91 (s, 3H), 2.48-2.22 (m,4H), 2.16-1.81 (m, 2H).

ZBB210 (200 mg) was dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature under H₂overnight. The mixture was filtered and concentrated on a rotaryevaporator to give ZBB214-1 (150 mg). ESI-MS calculated forC₈H₁₄N₃[M+H]⁺=152.11; Observed: 152.34.

Synthesis ofN-(3-cyclobutyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd No. 200)

S13 (70 mg) and 3-cyclobutyl-1-methyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 200 in 40 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₅H₂₈N₇O₂ [M+H]⁺=458.23; Observed: 458.66.

Example 154 Synthesis of 3-cyclobutyl-1-ethyl-1H-pyrazol-4-amine(ZBB221)

The mixture of 3-cyclobutyl-1-ethyl-1H-pyrazol-5-amine (500 mg), t-BuONO(2 mL) in THF (10 mL) was heated at 90° C. for 3 h. Then the mixture wasconcentrated on a rotary evaporator and was dissolved in conc. H₂SO₄ (1mL) and fuming HNO₃ (1 mL). And the mixture was heated at 60° C.overnight. Then the mixture was poured into cooled aq. NaOH watersolution and extracted with Ethyl acetate. The organic phase wasconcentrated on a rotary evaporator. The remaining residue was purifiedby flash column chromatography to give ZBB220.

ZBB220 (200 mg) was dissolved in MeOH (10 mL). 50 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature under H₂overnight. The mixture was filtered and concentrated on a rotaryevaporator to give ZBB221(150 mg). ESI-MS calculated forC₉H₁₆N₃[M+H]⁺=166.13; Observed: 166.55.

Synthesis ofN-(3-cyclobutyl-1-ethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 201)

S13 (70 mg) and 3-cyclobutyl-1-ethyl-1H-pyrazol-4-amine (68 mg) weredissolved in isopropanol (5 mL). Four drops of concentrated HCl wasadded via a glass pipette. The mixture was heated at reflux forovernight. The reaction was concentrated on a rotary evaporator and theremaining residues were purified by HPLC to yield the desired productCpd. No. 201 in 40 mg as a salt of trifluoroacetic acid. ESI-MScalculated for C₂₆H₃₀N₇O₂ [M+H]⁺=472.24; Observed: 472.66.

Example 155 Synthesis of 2-(tert-butyl)-4-methylthiazol-5-amine(ZBB222-2)

The mixture of 2-(tert-butyl)-4-methylthiazole (500 mg), conc. H₂SO₄ (1mL) and fuming HNO₃ (1 mL) was heated at 100° C. overnight. Then themixture was poured into cooled aq. NaOH water solution and extractedwith Ethyl acetate. The organic phase was concentrated on a rotaryevaporator and was dissolved in MeOH (10 mL). 500 mg 10% Pd/C was added.the reaction mixture was degassed 2 times, each time replacing thevacuum with hydrogen, then stirred at room temperature under H₂overnight. The mixture was filtered and concentrated on a rotaryevaporator to give ZBB222-2 (300 mg). ESI-MS calculated forC₈H₁₅N₂S[M+H]⁺=171.09; Observed: 171.44.

Synthesis of2-(tert-butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-methylthiazol-5-amine(Cpd. No. 202)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),2-(tert-butyl)-4-methylthiazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 202 as a CF₃CO₂H salt in35 mg. ESI-MS calculated for C₂₅H₂₉N₆O₂S [M+H]⁺=477.20; Observed:477.44. ¹H NMR (300 MHz, MeOD) δ 8.02 (s, 1H), 7.49 (s, 1H), 3.96 (s,3H), 2.73 (s, 3H), 2.40 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H), 1.51 (s,9H).

Example 156 Synthesis of 1-ethyl-3-isopropyl-1H-pyrazol-5-amine (ZBB243)

4-methyl-3-oxopentanenitrile (1 g) was dissolved in ethanol (30 mL).Ethylhydrazine. HCl salt (5 g) was added and the mixture was heated atreflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.9 g. ESI-MS calculated forC₈H₁₆N₃[M+H]⁺=154.13; Observed: 154.44.

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 203)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-ethyl-3-isopropyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 203 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₅H₃₀N₇O₂ [M+H]⁺=460.24; Observed: 460.66.

Example 157 Synthesis of 1,3-diisopropyl-1H-pyrazol-5-amine (ZBB246)

4-methyl-3-oxopentanenitrile (1 g) was dissolved in ethanol (30 mL).isopropylhydrazine. HCl salt (5 g) was added and the mixture was heatedat reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.9 g. ESI-MS calculated forC₉H₁₈N₃[M+H]⁺=168.15; Observed: 168.44.

Synthesis ofN-(1,3-diisopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 83)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1,3-diisopropyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), and toluene(2 mL). The mixture was heated at reflux for overnight before quenchingwith methanol. The reaction mixture was filtered and the mixture waspurified by HPLC to yield Cpd. No. 83 as a CF₃CO₂H salt in 25 mg. ESI-MScalculated for C₂₆H₃₂N₇O₂ [M+H]⁺=474.26; Observed: 474.44.

Example 158 Synthesis of 1-cyclopropyl-3-isopropyl-1H-pyrazol-5-amine(ZBB247)

4-methyl-3-oxopentanenitrile (1 g) was dissolved in ethanol (30 mL).cyclopropylhydrazine. HCl salt (5 g) was added and the mixture washeated at reflux for overnight. The mixture was concentrated on a rotaryevaporator followed by addition of ethyl acetate and aq. NaHCO₃. Theaqueous layer was extracted with ethyl acetate and the organic layerswere combined, dried, and concentrated on a rotary evaporator. Theremaining residue was purified by flash column chromatography and thedesired product was obtained in 0.9 g. ESI-MS calculated forC₉H₁₆N₃[M+H]⁺=166.13; Observed: 166.56.

Synthesis ofN-(1-cyclopropyl-3-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 205)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing S13 (60 mg),1-cyclopropyl-3-isopropyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg),and toluene (2 mL). The mixture was heated at reflux for overnightbefore quenching with methanol. The reaction mixture was filtered andthe mixture was purified by HPLC to yield Cpd. No. 205 as a CF₃CO₂H saltin 25 mg. ESI-MS calculated for C₂₆H₃₀N₇O₂ [M+H]⁺=472.24; Observed:472.44.

Example 159 Synthesis of2-amino-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-ol(ZBB251)

To a round-bottom flask, S6 (1 g), NH₂CN (0.2 g) conc. HCl (0.2 mL) anddioxane (30 ml) were added at room temperature. The reaction mixture waswarmed up to reflux (ca, 90° C.) for 2 day. The reaction was then cooledto room temperature and the volatile components were removed on a rotaryevaporator. To this crude mixture, 10% NaOH aqueous solution (20 mL)were added and the solution was heated at reflux for 8 h. The volatilecomponents were then removed on a rotary evaporator and the aqueousresidue was acidified with 2N HCl aqueous solution. The product ZBB251was allowed to precipitate at 0° C. Filtration of the mixture furnishedpure ZBB251 in 0.5 g. ESI-MS calculated for C₁₆H₁₆N₅O₃ [M+H]⁺=326.12;Observed: 326.44. ¹H NMR (300 MHz, DMSO) δ 11.31 (s, 1H), 10.64 (s, 1H),7.39 (s, 1H), 7.04 (s, 1H), 6.66 (s, 2H), 3.78 (s, 3H), 2.27 (s, 3H),2.07 (s, 3H).

Example 160 Synthesis of4-chloro-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indol-2-amine(ZBB253)

To a round-bottom flask, ZBB251 (0.278 g, 0.8 mmol) and POCl₃ (8 mL)were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished ZBB253 as a brown solid in0.208 g. ESI-MS calculated for C₆H₁₅ClN₅O₂[M+H]⁺=344.09; Observed:344.44.

Example 161 Synthesis ofN4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine(Cpd. No. 206)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB253 (60 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 206 as a CF₃CO₂H salt in15 mg. ESI-MS calculated for C₂₃H₂₅N₈O₂ [M+H]⁺=445.21; Observed: 445.54.¹H NMR (300 MHz, MeOD) δ 7.70 (s, 1H), 7.35 (s, 1H), 6.09 (s, 1H), 3.92(s, 3H), 3.74 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H), 1.98-1.88 (m, 1H),1.03-0.93 (m, 2H), 0.78-0.71 (m, 2H).

Example 162 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-4-ol(ZBB256)

To a round-bottom flask, S6 (1 g), MeOCH₂CN (4 mL) and hydrogen chloridesolution, 4 M in dioxane (4 mL) were added at room temperature. Thereaction mixture was stirred overnight. The volatile components wereremoved on a rotary evaporator. To this crude mixture, 10% NaOH aqueoussolution (10 mL) and EtOH (20 mL) were added and the solution was heatedat reflux for 8 h. The volatile components were then removed on a rotaryevaporator and the aqueous residue was acidified with 2 N HCl aqueoussolution. The product ZBB256 was allowed to precipitate at 0° C.Filtration of the mixture furnished pure ZBB256 in 0.8 g. ESI-MScalculated for C₁₈H₁₉N₄O₄ [M+H]⁺=355.14; Observed: 355.44. ¹H NMR (300MHz, DMSO) δ 12.15 (s, 1H), 12.09 (s, 1H), 7.59 (s, 1H), 7.26 (s, 1H),4.39 (s, 2H), 3.84 (s, 3H), 3.38 (s, 3H), 2.29 (s, 3H), 2.09 (s, 3H).

Example 163 Synthesis of4-(4-chloro-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(ZBB257)

To a round-bottom flask, ZBB256 (0.278 g, 0.8 mmol) and POCl₃ (8 mL)were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished ZBB257 as a brown solid in0.22 g. ESI-MS calculated for C₁₈H₁₈ClN₄O₃[M+H]⁺=373.10; Observed:373.44. ¹H NMR (300 MHz, DMSO) δ 7.83 (s, 1H), 7.48 (s, 1H), 4.62 (s,2H), 3.90 (s, 3H), 3.42 (s, 3H), 2.32 (s, 3H), 2.12 (s, 3H).

Example 164 Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 207)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB257 (60 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (2 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield ZBB259 as a CF₃CO₂H salt in 15 mg.ESI-MS calculated for C₂₅H₂₈N₇O₃ [M+H]⁺=474.22; Observed: 474.67. ¹H NMR(300 MHz, MeOD) δ 7.50 (s, 1H), 7.38 (s, 1H), 6.11 (s, 1H), 4.69 (s,2H), 3.90 (s, 3H), 3.76 (s, 3H), 3.59 (s, 3H), 2.34 (s, 3H), 2.17 (s,3H), 2.05-1.86 (m, 1H), 1.04-0.95 (m, 2H), 0.78-0.72 (m, 2H).

Example 165

The following compounds were prepared as described for Cpd. No. 97 inEXAMPLE 51:

N-(3-chloro-4-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 107)

¹H-NMR (300 MHz, CD₃OD) ppm 7.85-7.77 (m, 2H), 7.62-7.54 (m, 1H),7.47-7.36 (m, 2H), 3.90 (s, 3H), 2.68 (s, 3H), 2.33 (s, 3H), 2.16 (d,3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(5-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 108)

¹H-NMR (300 MHz, CD₃OD) δ ppm 9.47 (s, 1H), 8.56 (s, 1H), 8.42 (s, 1H),8.04 (s, 1H), 7.41 (s, 1H), 3.98 (s, 3H), 2.70 (s, 3H), 2.60 (s, 3H),2.34 (s, 3H), 2.18 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-8-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 210)

¹H-NMR (300 MHz, CDCl₃) δ ppm 13.36 (s, 1H), 11.10 (s, 1H), 9.19 (dd,J=2.25, 6.67 Hz, 1H), 8.93 (dd, J=1.51, 4.24 Hz, 1H), 8.34 (dd, J=1.38,8.22 Hz, 1H), 8.11 (s, 1H), 7.78-7.66 (m, 2H), 7.65-7.54 (m, 2H), 4.17(s, 3H), 2.98 (s, 3H), 2.39 (s, 3H), 2.25 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 211)

¹H-NMR (300 MHz, CD₃OD) δ ppm 9.14-9.05 (m, 1H), 8.80 (d, J=7.79 Hz,1H), 8.25 (d, J=8.65 Hz, 1H), 8.06 (t, J=7.96 Hz, 1H), 7.90 (d, J=7.15Hz, 1H), 7.84-7.73 (m, 2H), 7.48 (s, 1H), 3.78 (s, 3H), 2.54 (s, 3H),2.33 (s, 3H), 2.16 (s, 3H);7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-m-tolyl-9H-pyrimido[4,5-b]indol-4-amine (Cpd. No. 212)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.48-7.22 (m, 6H), 3.75 (s, 3H), 2.69 (s,3H), 2.42 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-methoxyphenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 213)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.51-7.28 (m, 3H), 7.15-6.98 (m, 3H), 3.83(s, 3H), 3.74 (s, 3H), 2.71 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-(trifluoromethyl)phenyl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 214)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.97 (s, 1H), 7.87 (d, J=7.56 Hz, 1H),7.75-7.61 (m, 3H), 7.45 (s, 1H), 3.85 (s, 3H), 2.69 (s, 3H), 2.33 (s,3H), 2.15 (s, 3H).

N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,5-dimethylisoxazol-4-amine(Cpd. No. 215)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.02 (s, 1H), 7.49 (s, 1H), 3.96 (s, 3H),2.69 (s, 3H), 2.44 (s, 3H), 2.34 (s, 3H), 2.26 (s, 3H), 2.16 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 216)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.52-7.40 (m, 2H), 7.37-7.27 (m, 3H), 7.16(s, 1H), 3.69 (s, 3H), 2.78-2.64 (m, 5H), 2.30 (s, 3H), 2.13 (s, 3H),1.21 (t, J=7.59 Hz, 3H);

N-(3-chloro-2-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 217)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.92 (s, 1H), 7.61-7.53 (m, 2H), 7.46 (s,1H), 7.37-7.29 (m, 1H) 3.91 (s, 3H), 2.67 (s, 3H), 2.34 (s, 3H), 2.17(s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-methoxy-5-methylphenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 218)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.40 (s, 1H), 7.14 (s, 1H), 6.92-6.81 (m,3H), 3.79 (s, 3H), 3.70 (s, 3H), 2.71 (s, 3H), 2.36 (s, 3H), 2.31 (s,3H), 2.13 (s, 3H);

N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,4-dimethylisoxazol-5-amine(Cpd. No. 219)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.74 (s, 1H), 7.40 (s, 1H), 3.90 (s, 3H),2.64 (s, 3H), 2.33 (s, 3H), 2.30 (s, 3H), 2.16 (s, 3H), 1.92 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 220)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.57 (d, J=8.13 Hz, 1H), 7.39 (s, 1H),7.37 (d, J=3.18 Hz, 1H), 7.29 (t, J=7.82 Hz, 1H), 7.18 (d, J=6.85 Hz,1H), 7.12 (br. s., 1H), 6.40 (dd, J=0.78, 3.20 Hz, 1H), 3.57 (s, 3H),2.64 (s, 3H), 2.29 (s, 3H), 2.11 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(isoquinolin-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 221)

¹H-NMR (300 MHz, CD₃OD) δ ppm 9.66 (s, 1H), 8.60-8.52 (m, 1H), 8.43 (d,J=8.60 Hz, 1H), 8.31-8.13 (m, 2H), 8.02 (t, J=7.87 Hz, 1H), 7.92 (s,1H), 7.47 (s, 1H), 3.84 (s, 3H), 2.48 (s, 3H), 2.34 (s, 3H), 2.17 (s,3H);

N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4,5-dimethylisoxazol-3-amine(Cpd. No. 222)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.85 (s, 1H), 7.44 (s, 1H), 3.92 (s, 3H),2.70 (s, 3H), 2.45 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H), 1.99 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(isoquinolin-8-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 223)

¹H-NMR (300 MHz, CD₃OD) δ ppm 9.75 (s, 1H), 8.68-8.58 (m, 1H), 8.40 (d,J=6.43 Hz, 1H), 8.28-8.14 (m, 2H), 8.01 (d, J=6.82 Hz, 1H), 7.80 (s,1H), 7.46 (s, 1H), 3.80 (s, 3H), 2.51 (s, 3H), 2.34 (s, 3H), 2.16 (s,3H);

N-(5-chloro-2-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 224)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.88 (s, 1H), 7.84-7.78 (m, 1H), 7.49-7.30(m, 3H), 3.91 (s, 3H), 2.66 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H);

N-(3-chloro-5-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 225)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.82 (s, 1H), 7.57 (s, 1H), 7.51 (d,J=10.68 Hz, 1H), 7.43 (s, 1H), 7.15 (d, J=7.91 Hz, 1H), 3.91 (s, 3H),2.71 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-phenyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 226)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.60-7.51 (m, 4H), 7.48-7.37 (m, 3H), 3.75(s, 3H), 2.69 (s, 3H), 2.31 (s, 3H), 2.14 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-H-pyrrolo[2,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 227)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.43 (dd, J=1.42, 4.83 Hz, 1H), 8.07 (dd,J=1.44, 7.95 Hz, 1H), 7.93 (br. s., 1H), 7.79 (s, 1H), 7.47 (s, 1H),7.27 (dd, J=4.82, 7.93 Hz, 1H), 4.02 (s, 3H), 3.86 (s, 3H), 2.60 (s,3H), 2.33 (s, 3H), 2.16 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylquinolin-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 228)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.93 (d, J=8.71 Hz, 1H), 8.21-8.11 (m,2H), 7.95 (dd, J=2.17, 6.41 Hz, 1H), 7.89 (s, 1H), 7.83 (d, J=8.81 Hz,1H), 7.47 (s, 1H), 3.84 (s, 3H), 2.98 (s, 3H), 2.49 (s, 3H), 2.34 (s,3H), 2.17 (s, 3H);

N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)benzo[d]thiazol-7-amine(Cpd. No. 229)

¹H-NMR (300 MHz, CD₃OD) δ ppm 9.31 (s, 1H), 8.19 (dd, J=1.11, 8.04 Hz,1H), 7.75 (t, J=7.88 Hz, 1H), 7.67 (d, J=7.69 Hz, 1H), 7.54 (s, 1H),7.46 (s, 1H), 3.74 (s, 3H), 2.62 (s, 3H), 2.32 (s, 3H), 2.14 (s, 3H);

N1-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-N3,N3-dimethylbenzene-1,3-diamine(Cpd. No. 230)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.44 (m, 2H), 7.20 (s, 1H), 7.03-6.87 (m,3H), 3.70 (s, 3H), 3.01 (s, 3H), 2.71 (s, 3H), 2.31 (s, 3H), 2.13 (s,3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(indolin-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 231)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.45 (br. s., 1H), 7.43 (s, 1H), 7.38 (t,J=7.93 Hz, 1H), 7.17 (d, J=7.56 Hz, 1H), 7.11 (d, J=7.72 Hz, 1H), 3.79(s, 3H), 3.71 (t, J=8.04 Hz, 2H), 3.09 (t, J=7.89 Hz, 2H), 2.68 (s, 3H),2.32 (s, 3H), 2.14 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methylindolin-6-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 232)

ESI-MS m/z 455.83 (M+H)⁺;

7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-6-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 233)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.74 (d, J=8.40 Hz, 1H), 7.57 (s, 1H),7.40 (d, J=3.17 Hz, 1H), 7.36 (s, 1H), 7.18 (dd, J=1.93, 8.37 Hz, 1H),6.70 (br. s., 1H), 6.58 (dd, J=0.85, 3.17 Hz, 1H), 3.29 (s, 3H), 2.69(s, 3H), 2.27 (s, 3H), 2.08 (s, 3H);

N-(2,3-dihydrobenzofuran-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 234)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.43 (s, 1H), 7.28 (t, J=8.02 Hz, 1H),7.25 (s, 1H), 6.96 (dd, J=0.68, 7.95 Hz, 1H), 6.86 (d, J=7.74 Hz, 1H),4.60 (t, J=8.67 Hz, 2H), 3.73 (s, 3H), 3.15 (t, J=8.66 Hz, 2H), 2.71 (s,3H), 2.31 (s, 3H), 2.13 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 235

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.02 (d, J=0.82 Hz, 1H), 7.68 (d, J=8.53Hz, 1H), 7.57 (dd, J=7.30, 8.48 Hz, 1H), 7.43 (s, 1H), 7.34 (s, 1H),7.29 (dd, J=0.47, 7.17 Hz, 1H), 4.15 (s, 3H), 3.65 (s, 3H), 2.65 (s,3H), 2.30 (s, 3H), 2.13 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 236)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.58 (d, J=8.22 Hz, 1H), 7.40 (s, 1H),7.40-7.28 (m, 2H), 7.22 (dd, J=0.57, 7.48 Hz, 1H), 7.17 (br. s., 1H),6.39 (dd, J=0.73, 3.19 Hz, 1H), 3.90 (s, 3H), 3.58 (s, 3H), 2.63 (s,3H), 2.30 (s, 3H), 2.12 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(3,5-dimethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 237)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.42 (s, 1H), 7.21-7.09 (m, 4H), 3.70 (s,3H), 2.70 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 2.13 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-N-(2,5-dimethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 238)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.43 (s, 1H), 7.38 (d, J=8.12 Hz, 1H),7.34-7.23 (m, 3H), 3.74 (s, 3H), 2.67 (s, 3H), 2.36 (s, 3H), 2.31 (s,3H), 2.14 (s, 3H);

N-(3,5-dicyclopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 239)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.18 (br. s., 1H), 7.47 (s, 1H), 3.96 (br.s., 3H), 3.90 (s, 3H), 2.70 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),1.84-1.67 (m, 2H), 1.01-0.67 (m, 8H);

N-(3,5-diethyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 240)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.17 (s, 1H), 7.47 (s, 1H), 3.96 (br. s.,3H), 3.88 (s, 3H), 2.82-2.49 (m, 7H), 2.32 (s, 3H), 2.15 (s, 3H),1.36-1.01 (m, 6H);7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,5-triethyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 241)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.16 (s, 1H), 7.47 (s, 1H), 4.28-4.12 (m,2H), 3.96 (s, 3H), 2.85-2.52 (m, 7H), 2.33 (s, 3H), 2.15 (s, 3H),1.57-1.38 (m, 3H), 1.34-0.96 (m, 6H);N-(3,5-diisopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 242)

ESI-MS m/z 488.67 (M+H)⁺; and

7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 243)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.63 (d, J=7.83 Hz, 1H), 7.56-7.47 (m,1H), 7.45-7.39 (m, 3H), 6.89 (br. s., 1H), 3.64 (s, 3H), 2.69 (s, 3H),2.29 (s, 3H), 2.12 (s, 3H), 1.31 (d, J=6.82 Hz, 6H).

Example 166 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 109)

A solution of Pd₂(dba)₃ (18.3 mg, 0.02 mmol) and BINAP (25 mg, 0.04mmol) in anhydrous toluene were refluxed for 5 minutes in a pre-heatedoil bath (temp. 120° C.). After briefly cooling, the mixture wastransferred to a round bottom flask containing S13 (68 mg, 0.2 mmol),4-methylpyridin-3-amine (43 mg, 0.4 mmol), K₃PO₄ (127 mg, 0.6 mmol), andtoluene (1 mL) and the mixture was refluxed. After refluxing overnightthe reaction was cooled to RT, quenched with methanol, and concentratedto dryness. The crude solid was re-dissolved in 3:1 methanol:water,acidified, filtered and purified by HPLC to yield the title compound asits TFA salt. ¹H-NMR (300 MHz, CD₃OD) δ ppm 9.12 (s, 1H), 8.63 (d,J=4.92 Hz, 1H), 8.00-7.92 (m, 2H), 7.46 (s, 1H), 3.95 (s, 3H), 2.64 (s,3H), 2.62 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H).

Example 167

The following compounds were prepares as described for Cpd. No. 109 inEXAMPLE 166. In some cases, NaOt-Bu was used instead of K₃PO₄.

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4-methylpyridin-2-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 110)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.42 (d, J=5.53 Hz, 1H), 8.22 (s, 1H),7.58 (s, 1H), 7.46 (s, 1H), 7.29 (d, J=5.67 Hz, 1H), 4.02 (s, 3H), 2.88(s, 3H), 2.56 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(6-methylpyridin-2-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 111)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.25 (s, 1H), 8.02 (t, J=8.02 Hz, 1H),7.53 (d, J=8.28 Hz, 1H), 7.48 (s, 1H), 7.28 (d, J=7.67 Hz, 1H), 4.01 (s,3H), 2.90 (s, 3H), 2.74 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 247)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.74 (d, J=7.83 Hz, 1H), 8.30-8.23 (m 1H),8.03-7.71 (m, 3H), 7.41 (s, 1H), 6.95-6.75 (m, 2H), 3.41 (s, 3H), 2.77(s, 3H), 2.29 (s, 3H), 2.11 (s, 3H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylpyridin-4-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 248)

¹H-NMR (300 MHz, CD₃OD) δ ppm 8.39 (d, J=7.07 Hz, 1H), 8.20 (dd, J=2.39,7.03 Hz, 1H), 8.05 (d, J=2.16 Hz, 1H), 7.89 (s, 1H), 7.40 (s, 1H), 3.95(s, 3H), 2.76 (s, 3H), 2.71 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H);

N-(3-cyclopropyl-4-fluoro-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 249)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.96 (s, 1H), 7.45 (s, 1H), 3.94 (s, 6H),2.71 (s, 3H), 2.34 (s, 3H), 2.17 (s, 3H), 1.96-1.80 (m, 1H), 1.18-1.03(m, 2H), 0.99-0.84 (m, 2H);

N-(3-cyclopropyl-1-ethyl-4-fluoro-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 250)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.66 (br. s., 1H), 7.44 (s, 1H), 4.01 (q,J=7.07 Hz, 2H), 3.91 (s, 3H), 2.65 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),2.01-1.86 (m, 1H), 1.39 (t, J=7.19 Hz, 3H), 1.05-0.83 (m, 4H);

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-m-methyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 251)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.44 (s, 1H), 7.38 (br. s., 1H), 6.14 (s,1H), 3.88 (s, 3H), 3.75 (s, 3H), 2.69 (s, 3H), 2.32 (s, 3H), 2.15 (s,3H), 1.45 (s, 3H), 0.99-0.90 (m, 2H), 0.84-0.72 (m, 2H);

7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 252)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.43 (s, 1H), 7.12 (br. s., 1H), 6.10 (s,1H), 4.12 (q, J=7.22 Hz, 2H), 3.84 (s, 3H), 2.70 (s, 3H), 2.32 (s, 3H),2.14 (s, 3H), 1.50-1.38 (m, 6H), 0.99-0.91 (m, 2H), 0.81-0.74 (m, 2H);

7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 253)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.40 (s, 1H), 7.09 (br. s., 1H), 6.03 (s,1H), 4.62-4.43 (m, 1H), 3.84 (s, 3H), 2.66 (s, 3H), 2.32 (s, 3H), 2.14(s, 3H), 1.47 (d, J=6.79 Hz, 6H), 1.44 (s, 3H), 0.99-0.88 (m, 2H),0.79-0.68 (m, 2H); and

N-(3-cyclopropyl-4-fluoro-1-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 254)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.60 (br. s., 1H), 7.44 (s, 1H), 4.52-4.38(m, 1H), 3.91 (s, 3H), 2.65 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),1.99-1.88 (m, 1H), 1.44 (d, J=6.57 Hz, 6H), 1.01-0.85 (m, 4H).

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-(1-methoxycyclopropyl)-1-methyl-1H-pyrazol-5-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 260)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.60 (s, 1H), 7.43 (s, 1H), 6.33 (s, 1H),3.90 (s, 3H), 3.79 (s, 3H), 3.34 (s, 3H), 2.66 (s, 3H), 2.33 (s, 3H),2.15 (s, 3H), 1.22-1.11 (m, 2H), 1.11-1.01 (m, 2H).

7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-m-methyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 261)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.72 (s, 1H), 7.43 (s, 1H), 6.43 (s, 1H),3.91 (s, 3H), 3.78 (s, 3H), 2.65 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),1.41-1.25 (m, 4H)

2-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)-N-ethylacetamide(Cpd. No. 262)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.86 (s, 1H), 7.44 (s, 1H), 6.28 (s, 1H),4.95-4.84 (m, 2H), 3.95 (s, 3H), 3.30-3.21 (m, 2H), 2.72 (s, 3H), 2.33(s, 3H), 2.16 (s, 3H), 2.01-1.88 (m, 1H), 1.14 (t, J=7.30 Hz, 3H),1.02-0.92 (m, 2H), 0.80-0.71 (m, 2H)

N-(3-cyclopropyl-1-(piperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 263)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.39 (s, 1H), 7.33 (s, 1H), 5.93 (s, 1H),4.59-4.41 (m, 1H), 3.87 (s, 3H), 3.62-3.48 (m, 2H), 3.16-3.00 (m, 2H),2.61 (s, 3H), 2.48-2.19 (m, 7H), 2.15 (s, 3H), 2.03-1.88 (m, 1H),1.00-0.91 (m, 2H), 0.74-0.66 (m, 2H)

N-(3-cyclopropyl-1-(1-ethylpiperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 264)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.40 (s, 1H), 7.31 (s, 1H), 5.94 (s, 1H),4.59-4.40 (m, 1H), 3.86 (s, 3H), 3.76-3.61 (m, 2H), 3.15 (q, J=7.34 Hz,2H), 3.10-2.94 (m, 2H), 2.62 (s, 3H), 2.55-2.23 (m, 7H), 2.15 (s, 3H),2.03-1.87 (m, 1H), 1.33 (t, J=7.32 Hz, 3H), 1.01-0.88 (m, 2H), 0.76-0.64(m, 2H)

1-(4-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone(Cpd. No. 265)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.39 (s, 1H), 7.25 (s, 1H), 5.90 (s, 1H),4.66-4.55 (m, 1H), 4.50-4.33 (m, 1H), 4.10-3.98 (m, 1H), 3.86 (s, 3H),3.24-3.01 (m, 2H), 2.62 (s, 3H), 2.32 (s, 3H), 2.23-1.87 (m, 11H),0.99-0.86 (m, 2H), 0.73-0.62 (m, 2H); ESI-MS m/z 555.58 (M+H)⁺;

(2S)-4-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)butane-1,2-diol(Cpd. No. 280)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.53 (s, 1H), 7.44 (s, 1H), 6.12 (s, 1H),4.31-4.18 (m, 2H), 3.91 (s, 3H), 3.57-3.34 (m, 3H), 2.70 (s, 3H), 2.32(s, 3H), 2.15 (s, 3H), 2.04-1.76 (m, 3H), 1.05-0.91 (m, 2H), 0.80-0.68(m, 2H);

(S)-3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)propane-1,2-diol(Cpd. No. 281)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.62 (s, 1H), 7.46 (s, 1H), 6.34 (s, 1H),4.44-4.23 (m, 2H), 4.19-4.04 (m, 1H), 3.93 (s, 3H), 3.68-3.52 (m, 2H),2.75 (s, 3H), 2.33 (s, 3H), 2.15 (s, 3H), 2.03-1.90 (m, 1H), 1.04-0.93(m, 2H), 0.81-0.68 (m, 2H);

N-(1-((1,4-dioxan-2-yl)methyl)-3-cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 282)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.43 (s, 1H), 7.00 (s, 1H), 6.12 (s, 1H),4.25-4.17 (m, 2H), 4.07-3.95 (m, 1H), 3.89-3.79 (m, 4H), 3.71-3.39 (m,5H), 2.73 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 2.03-1.89 (m, 1H),1.02-0.93 (m, 2H), 0.74-0.65 (m, 2H);

N-(3-cyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 283)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.43 (s, 1H), 7.06 (s, 1H), 5.96 (s, 1H),4.50-4.35 (m, 1H), 4.02 (dd, J=3.96, 11.84 Hz, 2H), 3.85 (s, 3H),3.52-3.38 (m, 2H), 2.69 (s, 3H), 2.38-2.19 (m, 5H), 2.14 (s, 3H),2.06-1.83 (m, 3H), 1.01-0.90 (m, 2H), 0.73-0.63 (m, 2H);

N-(3-cyclopropyl-1-(2-morpholinoethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 284)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.56 (s, 1H), 7.44 (s, 1H), 6.11 (s, 1H),4.50 (t, J=6.03 Hz, 2H), 4.01-3.87 (m, 7H), 3.70 (t, J=6.03 Hz, 2H),3.52-3.36 (m, 4H), 2.69 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 2.05-1.91(m, 1H), 1.04-0.91 (m, 2H), 0.82-0.70 (m, 2H);

Example 168 Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 255)

In a round bottom flask,4-(1-chloro-8-methoxy-5H-pyrido[4,3-b]indol-7-yl)-3,5-dimethylisoxazole(10 mg, 0.03 mmol), 3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (9.06 mg,0.06 mmol) and sodium tert-butoxide (11.5 mg, 0.12 mmol) were dissolvedin dry toluene (10 mL). A solution of Pd₂(dba)₃ (10.8 mg, 0.012 mmol)and Dave Phos (9.4 mg, 0.024 mmol) in dry toluene (5 mL) was heated toreflux for 5 mins in a two-neck container before it was transferred intothe round bottom flask by needle syringe. The resulting mixture wasvacuumed and protected with nitrogen balloon, and heated to refluxovernight. As the reaction reach completion, the system were acidifiedwith trifluoroacetic acid and concentrated in vacuum. The residue weredissolved in MeOH/H₂O (3:1) system, filtered and purified by prep-HPLC.The product was lyophilized to give the title compound as a color-lesspowder (2.4 mg, yield 18.7%). ¹HNMR (300 MHz, MeOD-d₄) δ 8.01 (s, 1H),7.80 (d, 1H, J=7.2 Hz), 7.56 (s, 1H), 7.37 (d, 1H, J=7.2 Hz), 6.24 (s,1H), 3.98 (s, 3H), 3.80 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H), 2.00 (m,1H), 1.00 (m, 2H), 0.81 (m, 2H). ESIMSm/z [M+H]⁺ calcd.=429.49;found=430.17.

The following compounds were prepared in similar fashion:

N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 285)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.90 (s, 1H), 7.08 (d, J=7.03 Hz, 1H),7.55 (s, 1H), 7.37 (d, J=7.05 Hz, 1H), 6.17 (s, 1H), 4.14 (q, J=7.23 Hz,2H), 3.94 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H), 2.05-1.91 (m, 1H), 1.43(t, J=7.23 Hz, 3H), 1.04-0.93 (m, 2H), 0.83-0.72 (m, 2H); and

7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 286)

¹H-NMR (300 MHz, CD₃OD) δ ppm 7.93 (s, 1H), 7.81 (d, J=7.04 Hz, 1H),7.56 (s, 1H), 7.37 (d, J=7.03 Hz, 1H), 4.61 (hept., J=6.55 Hz, 1H), 3.94(s, 3H), 2.81 (t, J=7.19 Hz, 2H), 2.63-2.39 (m, 4H), 2.34 (s, 3H), 2.17(s, 3H), 1.49 (d, J=6.65 Hz, 6H).

Example 169

The following compounds were prepared as described for Cpd. No. 255 inEXAMPLE 168.

N-(1-cyclopentyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 256)

¹HNMR (300 MHz, MeOD-d₄) δ 8.08 (s, 1H), 7.78 (d, 1H, J=7.2 Hz), 7.57(s, 1H), 7.36 (d, 1H, J=7.2 Hz), 6.34 (s, 1H), 3.98 (s, 3H), 2.38 (s,3H), 2.36 (s, 3H), 2.19 (s, 3H), 2.07 (m, 4H), 1.95 (m, 2H), 1.66 (m,2H), missing one proton. ESIMSm/z [M+H]⁺ calcd.=457.55; found=457.83;

7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 257)

¹HNMR (300 MHz, MeOD-d₄) δ 8.73 (d, 1H, J=3.9 Hz), 8.46 (d, 1H, J=8.4Hz), 8.21 (s, 1H), 8.05 (d, 1H, J=6.6 Hz), 7.59 (s, 1H), 7.46 (d, J=7.2Hz), 7.39 (m, 1H), 4.25 (s, 3H), 4.05 (s, 3H), 2.38 (s, 3H), 2.21 (s,3H). ESIMSm/z [M+H]⁺ calcd.=440.48; found=440.50;

N-(3-Cyclopropyl-1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethyl-isoxazol-4-yl)-6-methoxy-N,2,9-trimethyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd No. 258)

In a round-bottom flask, compound No. 163 (13 mg) was added.Paraformaldehyde (30 mg), NaBH(OAc)₃ (212 mg), and 1,2-dichloromethane(5 mL) were added followed by addition of acetic acid (0.1 mL) via asyringe. The reaction mixture was stirred at room temperature forovernight followed by purification using reverse phase HPLC to yield thetitled compound Cpd 258 in 2 mg as a salt of trifluoroacetic acid.ESI-MS calculated for C₂₉H₃₅N₈O₂ [M+H]⁺=527.29; Observed: 527.67;

N-(3-Cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd No. 266)

Step 1: 3-Cyclopropyl-3-oxopropanenitrile (1.4 g, 8 mmol) and2-methoxyethyl hydrazine-HCl (1.0 g, 8.0 mmol) were mixed in ethanol (20mL) and heated at reflux for overnight. The reaction mixture was cooledto room temperature and ethanol was removed on a rotary evaporator.Water was added and the aqueous layer was extracted with ethyl acetate.The combined organic layers were washed with brine, dried over anhydroussodium sulfate, and concentrated on a rotary evaporator. The remainingresidue was purified by flash column chromatography to yield3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-amine in 0.89 g (4.92mmol, 62% yield). ¹H NMR (CDCl₃, 300 MHz): 5.12 (s, 1H), 4.12-4.06 (m,2H), 3.95 (s, 2H), 3.70-3.64 (m, 2H), 3.32 (s, 3H), 1.95-1.70 (m, 1H),0.90-0.80 (m, 2H), 0.70-0.60 (m, 2H). ESI-MS calculated for C₉H₁₆N₃O[M+H]⁺=182.13, Observed: 182.50.

Step 2: Cpd. No. 266 was prepared from S13 (444 mg) and3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-amine (456 mg, 2.51 mmol)following the similar procedure for preparation of Cpd. No. 135. Cpd.No. 266 was obtained in 241 mg as a salt of CF₃CO₂H. ¹H NMR (MeOD-d4,300 MHz): 7.44 (s, 1H), 6.90 (s, 1H), 6.11 (s, 1H), 4.34 (t, J=4.62 Hz,2H), 3.83 (s, 3H), 3.78 (t, J=4.81 Hz, 2H), 3.23 (s, 3H), 2.74 (s, 3H),2.30 (s, 3H), 2.12 (s, 3H), 2.00-1.85 (m, 1H), 1.00-0.90 (m, 2H),0.75-0.65 (m, 2H). ESI-MS calculated for C₂₆H₃₀N₇O₃ [M+H]⁺=488.24;Observed: 488.58;

N-(3-Cyclopropyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethyl-isoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd No. 267)

Step 1: 3-Cyclopropyl-3-oxopropanenitrile (900 mg, 5 mmol) and4-hydrazinyl-1-methyl-piperidine-HCl (1.0 g, 4.9 mmol) were mixed inethanol (20 mL) and heated at reflux for overnight. The reaction mixturewas cooled to room temperature and ethanol was removed on a rotaryevaporator. Water was added and the aqueous layer was extracted withethyl acetate. The combined organic layers were washed with brine, driedover anhydrous sodium sulfate, and concentrated on a rotary evaporator.The remaining residue was purified by flash column chromatography toyield 3-cyclopropyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-5-amine in0.81 g (74% yield). ¹H NMR (CDCl₃, 300 MHz): 5.11 (s, 1H), 3.90-3.40 (m,1H), 3.60 (s, 2H), 3.10-2.85 (m, 2H), 2.40-2.20 (m, 2H), 2.28 (s, 3H),2.20-2.00 (m, 2H), 1.95-1.70 (m, 3H), 0.90-0.80 (m, 2H), 0.70-0.50 (m,2H). ESI-MS calculated for C₁₂H₂₁N₄[M+H]⁺=221.18, Observed: 221.50.

Step 2: Cpd. No. 267 was prepared from S13 (650 mg) and3-cyclopropyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-5-amine (810 mg,3.67 mmol) following the similar procedure for preparation of Cpd. No.135. Cpd. No. 267 was obtained in 414 mg as a salt of CF₃CO₂H. ¹H NMR(MeOD-d4, 300 MHz): 7.44 (s, 1H), 6.90 (s, 1H), 5.98 (s, 1H), 5.70-5.50(m, 1H), 3.82 (s, 3H), 3.70-3.65 (m, 2H), 3.20-3.00 (m, 2H), 2.86 (s,3H), 2.71 (s, 3H), 2.60-2.40 (m, 2H), 2.30 (s, 3H), 2.30-2.20 (m, 2H),2.12 (s, 3H), 2.00-1.85 (m, 1H), 1.00-0.90 (m, 2H), 0.80-0.60 (m, 2H).ESI-MS calculated for C₂₉H₃₅N₈O₂ [M+H]⁺=527.29; Observed: 527.50;

1-(3-(3-Cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)azetidin-1-yl)ethan-1-one(Cpd No. 277)

In a round-bottom flask, compound No. 163 (40 mg) was added. Triethylamine (0.3 mL) and THF (5 mL) were added followed by addition of aceticanhydride (0.1 mL). The reaction mixture was stirred at room temperaturefor overnight and the mixture was purified using reverse phase HPLC toyield Cpd. No. 277 in 19 mg as a salt of CF₃CO₂H. ¹H NMR (MeOD-d4, 300MHz): 7.50 (s, 1H), 7.46 (s, 1H), 6.06 (s, 1H), 5.20-5.05 (m, 1H), 4.63(dd, J=9.00, 5.36 Hz, 1H), 4.51 (t, J=8.69 Hz, 1H), 4.33 (dd, J=9.98,5.53 Hz, 1H), 4.25 (t, J=9.07 Hz, 1H), 3.89 (s, 3H), 2.68 (s, 3H), 2.31(s, 3H), 2.14 (s, 3H), 2.10-1.96 (m, 1H), 1.91 (s, 3H), 1.05-0.95 (m,2H), 0.80-0.70 (m, 2H). ESI-MS calculated for C₂₈H₃₁N₈O₃ [M+H]⁺=527.25;Observed: 527.50.

Methyl3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido-[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carboxylate(Cpd No. 278)

In a round-bottom flask, compound No. 163 (30 mg) was added. Triethylamine (0.3 mL) and THF (5 mL) were added followed by addition of methylcarbonochloridate (0.1 mL). The reaction mixture was stirred at roomtemperature for overnight and the mixture was purified using reversephase HPLC to yield Cpd. No. 278 in 6 mg as a salt of CF₃CO₂H. ¹H NMR(MeOD-d4, 300 MHz): 7.52 (s, 1H), 7.46 (s, 1H), 6.05 (s, 1H), 5.15-5.05(m, 1H), 4.50-4.35 (m, 1H), 4.35-4.20 (m, 1H), 3.89 (s, 3H), 3.66 (s,3H), 2.66 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 2.10-2.00 (m, 1H), 2.03(s, 3H), 1.05-0.95 (m, 2H), 0.80-0.70 (m, 2H). ESI-MS calculated forC₂₈H₃₁N₈O₄ [M+H]⁺=543.25; Observed: 543.67; and

N-(3-Cyclopropyl-1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd No. 279)

In a round-bottom flask, compound No. 163 (40 mg) was added.Acetaldehyde (0.1 mL), NaBH(OAc)₃ (424 mg) and 1,2-dichloroethane (5 mL)were added followed by addition of acetic acid (0.05 mL) via a syringe.The reaction mixture was stirred at room temperature for overnight andthe mixture was purified using reverse phase HPLC to yield Cpd. No. 279in 40 mg as a salt of CF₃CO₂H. ¹H NMR (MeOD-d4, 300 MHz): 7.66 (s, 1H),7.47 (s, 1H), 6.08 (s, 1H), 5.50-5.30 (m, 1H), 4.80-4.60 (m, 2H),4.55-4.30 (m, 2H), 3.90 (s, 3H), 3.54 (q, J=7.43 Hz, 2H), 2.66 (s, 3H),2.31 (s, 3H), 2.14 (s, 3H), 2.10-2.00 (m, 1H), 1.28 (t, J=7.43 Hz, 3H),1.05-0.95 (m, 2H), 0.85-0.75 (m, 2H). ESI-MS calculated for C₂₈H₃₃N₈O₂[M+H]⁺=513.27; Observed: 513.58.

Example 170

Step 1: Synthesis of 6-bromo-5-methoxy-2-nitropyridin-3-amine

To a stirred solution of 5-methoxy-2-nitropyridin-3-amine (1.32 g, 7.8mmol) in DMF (15 mL) at r.t. was added NBS (1.46 g, 8.2 mmol) inportions. The resulting mixture was stirred for 1 h at r.t. Water (30mL) was added. The yellow precipitate was filtered, washed with water,and dried to give title compound (1.9 g, 90%). ¹H NMR (300 MHz, DMSO):7.60 (s, 2H), 7.00 (s, 1H), 3.91 (s, 3H); ESI-MS calculated for[M+H]⁺=248.0, observed: 248.1.

Step 2: Synthesis of 2-bromo-5-chloro-3-methoxy-6-nitropyridine

A solution of amyl nitrite (7.5 mmol, 1 mL) and CuCl2 (0.8 g, 6 mmol) inCH3CN (20 mL) was warmed to 55° C. Solid6-bromo-5-methoxy-2-nitropyridin-3-amine (1.35 g, 5.5 mmol) was slowlyadded to the reaction mixture with the observance of the gas evolution.Once the addition was complete, the reaction temperature was raised to65° C. and stirred for another 1 h. The reaction mixture was cooled tor.t. and the solvent was removed under vacuum. The residue was dilutedwith water and EtOAc. The organic layer was separated, dried overNa₂SO₄, and concentrated under vacuum. The residue was purified throughcolumn chromatography (eluent: hexanes/EtOAc=1/1) to afford YH2 as solid(1.2 g, 79%). ¹H NMR (300 MHz, CDCl₃ ppm) 7.30 (s, 1H), 4.02 (s, 3H).

Step 3: Synthesis of4-(5-chloro-3-methoxy-6-nitropyridin-2-yl)-3,5-dimethylisoxazole

To a round-bottom flask was charged with YH2 (1.2 g, 4.3 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(1.45 g, 6.5 mmol), Pd(dppf)CH₂Cl₂(175 mg, 0.2 mmol), dioxane (20 mL)and Na2CO3 (2 M, 5 mL). The reaction mixture was heated up under N at100° C. for 12 h. The solution was cooled prior to being extracted withEtOAc (2×100 mL). The organic layers were combined and washed with brine(50 mL). The organic layer was separated, dried over Na₂SO₄, andconcentrated under vacuum. The residue was purified through columnchromatography (eluent: DCM/EtOAc=15:1) to afford YH3 as a solid (610mg, 50%). ¹H NMR (300 MHz, CDCl₃) 7.47 (s, 1H), 4.01 (s, 3H), 2.43 (s,3H), 2.30 (s, 3H).

Step 4: Synthesis of ethyl2-cyano-2-(6-(3,5-dimethylisoxazol-4-yl)-5-methoxy-2-nitropyridin-3-yl)acetate

To a suspension of NaH (60% in mineral oil, 176 mg, 4.4 mmol) in DMF (8mL) at 0° C. was added ethyl cyanoacetate (452 mg, 4 mmol) dropwise. Thesolution was allowed to warm to r.t. and stirred for 15 minutes. Thenthe reaction mixture was cooled back to 0° C. prior to the dropwiseaddition of a solution of YH3 (530 mg, 1.9 mmol) in THF/DMF (2 mL/2 mL).The reaction was stirred for 1 h at r.t. prior to being neutralized by 1M HCl. The reaction mixture was extracted with EtOAc (2×20 mL). Theorganic layers were combined and washed with brine (3×20 mL). Theorganic layer was separated, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified through column chromatography (eluent:hexanes/EtOAc=1/1) to afford YH4 as oil (648 mg, 95%). ¹H NMR (300 MHz,CDCl₃): 7.67 (s, 1H), 5.80 (s, 1H), 4.38 (q, J=7.1 Hz, 2H), 4.09 (s,3H), 2.47 (s, 3H), 2.35 (s, 3H), 1.39 (t, J=7.1 Hz, 3H).

Step 5: Synthesis of ethyl2-amino-6-(3,5-dimethylisoxazol-4-yl)-5-methoxy-1H-pyrrolo[2,3-b]pyridine-3-carboxylate

To a solution of YH4 (648 mg, 1.8 mmol) in acetic acid (10 mL) was addediron powder (360 mg, 6.4 mmol). The reaction was stirred at r.t for 6 hprior to the addition of DCM/MeOH (4:1, 20 mL) and the suspension wasfiltered. The filtrate was evaporated under vacuum and the residue wastreated with EtOAc (100 mL) and water (100 mL). The organic layer wasseparated, washed successively with NaHCO₃ and brine. The organic layerwas separated, dried over Na₂SO₄, and concentrated under vacuum. Theresidue was purified through column chromatography (eluent:DCM/MeOH=9/1) to afford YH5 as a solid (430 mg, 72%). ¹H NMR (300 MHz,CDCl₃): 12.50 (s, 1H), 7.74 (s, 1H), 5.72-4.79 (m, 2H), 4.40 (q, J=7.0Hz, 2H), 3.89 (s, 3H), 2.40 (s, 3H), 2.29 (s, 3H), 1.45 (t, J=7.0 Hz,3H).

Step 6: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-3,9-dihydro-4H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-4-one

Naphthalen-2-ylmethyl ethanimidothioate hydrobromide (3.55 g, 12 mmol)was added to a vigorously stirred solution of K₂CO₃ (1.6 g, 12 mmol) inwater (10 mL) and DCM (10 mL). After 10 minutes, the organic layer wasseparated and dried over Mg₂SO₄. The clear solution was decanted to aflask where it contained YH5 (400 mg, 1.2 mmol). To this solution wasadded acetic acid (0.34 mL, 6 mmol) and the reaction mixture was stirredfor 12 h. The solution was evaporated to give a crude oil. A solution ofNaOH (1 M, 10 mL) was added to the crude oil followed by the addition ofethanol (30 mL). The reaction mixture was heated up to 80° C. for 2 h.After the solution was cooled, the ethanol was evaporated under vacuumand the aqueous solution was cooled to 0° C. and 1 M HCl was addedslowly until PH=4. The mixture was extracted with ethyl acetate. Theorganic layer was separated, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified through column chromatography (eluent:DCM/MeOH=9/1) to afford YH6 as a solid (34 mg, 8%). ¹H NMR (300 MHz,DMSO): 12.56 (s, 1H), 7.90 (s, 1H), 3.90 (s, 3H), 2.43 (s, 3H), 2.35 (s,3H), 2.20 (s, 3H).

Step 7: Synthesis of4-(4-chloro-6-methoxy-2-methyl-9H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole

A suspension of YH6 (34 mg, 0.1 mmol) in POCl₃ (4 mL) was heated at 90°C. for 1 h prior to the removal of the volatile under vacuum. Theresidue was taken up by the ethyl acetate (4 mL) and a saturatedsolution of NaHCO₃ was added until pH=9. The precipitate was filteredand washed with water and ethyl acetate to give title compound (30 mg,88%). ESI-MS calculated for [M+H]=344.1, observed: 344.4.

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine(Cpd. No. 304)

YH7 (12 mg), 3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (20 mg),Pd₂(dba)₃ (5 mg), binap (6 mg), K3PO4 (30 mg), and anhydrous toluene (2mL) were mixed and the reaction mixture was heated at reflux for 12 h.The crude mixture was diluted with EtOAc and the organic layer waswashed with water. The solvent was removed and the residue was purifiedvia reverse phase HPLC to yield the titled compound in 3 mg. ¹H NMR (300MHz, CD3OD): 7.40 (s, 1H), 6.09 (s, 1H), 3.93 (s, 3H), 3.76 (s, 3H),2.70 (s, 3H), 2.41 (s, 3H), 2.29 (s, 3H), 2.02-1.90 (m, 1H), 1.08-0.92(m, 2H), 0.85-0.70 (m, 2H).

Step 1: Synthesis of 1-bromo-3,4-difluoro-2-methoxybenzene

6-bromo-2,3-difluorophenol (3 g, 14 mmol) was slowly added to asuspension of NaH (60%, 672 mg, 16.8 mmol) in DMF (14 mL) at 0° C. Afterthe gas evolution was ceased, MeI (3.0 g, 21 mmol) was added slowly tothe reaction mixture. After the addition is completed, the reactionmixture was allowed to warm to r.t. The reaction mixture was stirred for12 h prior to being quenched with brine. The solution was extracted withEtOAc (2×20 mL). The organic layers were combined, separated, dried overNa₂SO₄, and concentrated under vacuum. The residue was purified throughcolumn chromatography (eluent: hexanes/EtOAc=16/1) to afford YH9 as oil(2.4 g, 77%). ¹H NMR (300 MHz, CDCl₃): 7.26 (dt, J=7.5, 2.4 Hz, 1H),6.82 (dt, J=9.2, 7.5 Hz, 1H), 4.00 (d, J=1.5 Hz, 3H).

Step 2: Synthesis of 1-bromo-3,4-difluoro-2-methoxy-5-nitrobenzene

Under a N₂ gas blanket at room temperature, a solution of Tf₂O (1 M inDCM, 7.5 mL) was added dropwise to a stirred suspension oftetramethylammonium nitrate (1.02 g, 7.5 mmol) in 7.5 mL of DCM. Afterstirring 1.5 h at room temperature, the stirred suspension was cooled to−78° C. To the stirred nitronium triflate suspension was added dropwise3 dissolved in 2 mL of DCM. The cooling bath was then removed andallowed to warm to room temperature. The reaction mixture was quenchedwith saturated solution of NaHCO₃. The solution was extracted with DCM(2×20 mL). The organic layers were combined, separated, dried overNa₂SO₄, and concentrated under vacuum. The residue was purified throughcolumn chromatography (eluent: hexanes/EtOAc=32/1) to afford YH10 as oil(720 mg, 54%). ¹H NMR (300 MHz, CDCl₃): 8.12 (ddd, J=5.0, 4.0, 2.5 Hz,1H), 4.19 (d, J=1.2 Hz, 3H).

Step 3: Synthesis of4-(3,4-difluoro-2-methoxy-5-nitrophenyl)-3,5-dimethylisoxazole

To a round-bottom flask was charged with YH10 (1.4 g, 5 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(1.4 g, 6 mmol), Pd(dppf)CH₂Cl₂ (408 mg, 0.5 mmol), KF (696 mg, 12mmol), toluene (10 mL) and water (10 mL). The reaction mixture washeated up under N₂ at 100° C. for 12 h. The solution was cooled prior tobeing extracted with EtOAc (2×100 mL). The organic layers were combinedand washed with brine (50 mL). The organic layer was separated, driedover Na₂SO₄, and concentrated under vacuum. The residue was purifiedthrough column chromatography (eluent: hexanes/EtOAc=4/1 to 2:1) toafford YH11 as a red solid, which was triturated with diethyl ether,followed by filtration to give YH11 as a yellow solid (1.0 g, 70%). ¹HNMR (300 MHz, CDCl₃): 7.80-7.64 (m, 1H), 4.05 (s, 3H), 2.35 (s, 3H),2.18 (s, 3H).

Step 4: Synthesis of ethyl2-cyano-2-(4-(3,5-dimethylisoxazol-4-yl)-2-fluoro-3-methoxy-6-nitrophenyl)acetate

To a suspension of NaH (60% in mineral oil, 88 mg, 2.2 mmol) in DMF (4mL) at 0° C. was added ethyl cyanoacetate (226 mg, 2 mmol) dropwise. Thesolution was allowed to warm to r.t. and stirred for 15 minutes. Thenthe reaction mixture was cooled back to 0° C. prior to the dropwiseaddition of a solution of YH11 (284 mg, 1 mmol) in DMF (1 mL). Thereaction was stirred for 1 h at 0° C. prior to being neutralized by 1 MHCl. The reaction mixture was extracted with EtOAc (2×20 mL). Theorganic layers were combined and washed with brine (3×10 mL). Theorganic layer was separated, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified through column chromatography (eluent:hexanes/EtOAc=4/1, then 2/1) to afford YH12 as oil (377 mg, 99%). ¹H NMR(300 MHz, CDCl₃): 7.94 (d, J=1.7 Hz, 1H), 5.62 (d, J=1.9 Hz, 1H),4.45-4.25 (m, 2H), 4.00 (s, 3H), 2.37 (s, 3H), 2.21 (s, 3H), 1.39 (q,J=7.2 Hz, 3H).

Step 5: Synthesis of ethyl2-amino-6-(3,5-dimethylisoxazol-4-yl)-4-fluoro-5-methoxy-1H-indole-3-carboxylate

To a solution of YH12 (614 mg, 1.6 mmol) in acetic acid (6 mL) was addediron powder (537 mg, 9.6 mmol). The reaction mixture was stirred for 4 hprior to being filtered and washed with acetic acid (2 mL) and solvent(DCM/Methanol 9:1). The volatiles were removed under vacuum and theresidue was treated with solvent (DCM/Methanol 9:1) and water (10 mL).The mixture was extracted with EtOAc and the organic layer wasseparated, washed successively with NaOH (1 M, 5 mL), NaHCO₃, and brine.The organic layer was separated, dried over Na₂SO₄, and concentratedunder vacuum. The residue was triturated in EtOAc and filtered to affordYH13 as a solid (360 mg, 63%). ¹H NMR (300 MHz, DMSO): 10.92 (m, 1H),6.94 (s, 1H), 6.78 (s, 1H), 4.20 (q, J=7.1 Hz, 2H), 3.49 (s, 3H), 2.29(s, 3H), 2.10 (s, 3H), 1.29 (t, J=7.1 Hz, 3H); %). ESI-MS calculated for[M+H]⁺=348.1, observed: 348.2.

Step 6: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-methoxy-2-methyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one

HCl gas was bubbled into a solution of YH13 (35 mg, 0.1 mmol) in CH₃CN(10 mL) for 5 min. The reaction mixture was heated up to 80° C. for 1 h.After the solution was cooled, the volatile was evaporated under vacuumand a solution of NaOH (1 M, 3 mL) was added followed by ethanol (9 mL).The solution was refluxed for 2 h prior to the removal of ethanol. Tothe residue was added 1 M HCl at 0° C. until the pH=4. The precipitatewas filtered, washed with water (2 mL), ethyl acetate (2 mL). The solidwas dried under vacuum and weighed crude 30 mg (88%). ¹H NMR (300 MHz,CD₃OD): 7.06 (s, 1H), 3.61 (s, 3H), 2.41 (s, 3H), 2.32 (s, 3H), 2.13 (s,3H); ESI-MS calculated for [M+H]⁺=343.1, observed: 343.5.

Step 7: Synthesis of4-(4-chloro-5-fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole

A suspension of YH14 (30 mg, 0.09 mmol in POCl₃ (2 mL) was heated at 90°C. for 6 h prior to the removal of the volatile under vacuum. Theresidue was taken up by the ethyl acetate (4 mL) and a saturatedsolution of NaHCO₃ was added until pH=9. The precipitate was filteredand washed with water and ethyl acetate. ¹H NMR (300 MHz, CD3OD): 12.97(s, 1H), 7.44 (s, 1H), 3.48 (s, 3H), 2.68 (s, 2H), 2.37 (s, 3H), 2.16(s, 3H); ESI-MS calculated for [M+H]⁺=361.1, observed: 361.3.

N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 305)

Cpd. No. 305 was synthesized following the same procedure as Cpd. No.304. ¹H NMR (300 MHz, CD3OD): 7.31 (s, 1H), 6.40 (s, 1H), 3.84 (s, 3H),3.76 (s, 3H), 2.69 (s, 3H), 2.40 (s, 3H), 2.23 (s, 3H), 2.08-1.92 (m,1H), 1.14-0.97 (m, 2H), 0.92-0.78 (m, 2H); ESI-MS calculated for[M+H]⁺=462.20, observed: 462.50.

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 306)

YH15 (36 g), 3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (30 g), Pd(OAc)2(2 mg), PCy3 (6 mg), Cs2CO3 (130 mg), and anhydrous THF (2 mL) weremixed and the reaction mixture was heated at reflux for 12 h. The crudemixture was diluted with EtOAc and the organic layer was washed withwater. The solvent was removed and the residue was purified via reversephase HPLC to yield the titled compound in 6 mg. ¹H NMR (300 MHz,CD3OD): 6.03 (s, 1H), 5.41 (s, 1H), 3.75 (s, 3H), 3.73 (s, 3H), 3.71 (s,3H), 2.79 (s, 3H), 2.27 (s, 3H), 2.10 (s, 3H), 1.99-1.80 (m, 1H),1.03-0.84 (m, 2H), 0.74-0.54 (m, 2H); ESI-MS calculated for[M+H]⁺=476.2, observed: 476.3.

Step 1: Synthesis of 2-bromo-3,5-difluoro-1-methoxy-4-nitrobenzene

A solution of 2-bromo-1,3,5-trifluoro-4-nitrobenzene (4.48 g, 17.6 mmol)in methanol (35 mL) was cooled to −30° C. prior to dropwise addition ofa solution of NaOMe in methanol (3.8 g, 25% wt). After the addition wascompleted, the reaction mixture was maintained at the temperature for 1h prior to being allowed to warm to r.t. The solvent was removed undervacuum and the residue was diluted in EtOAc and water. The solution wasextracted with EtOAc (2×50 mL). The organic layers were combined,separated, dried over Na₂SO₄, and concentrated under vacuum. The residuewas purified through column chromatography (eluent: hexanes/EtOAc=8/1)to afford a mixture of YH18a and YH18b (3 g, 64%, ratio YH18a:YH18b=4:1). ¹H NMR (300 MHz, CDCl₃): 6.69-6.59 (m, 1H), 3.99 (s, 3H).

Step 2: Synthesis of4-(2,4-difluoro-6-methoxy-3-nitrophenyl)-3,5-dimethylisoxazole

To a round-bottom flask was charged with a mixture of YH18a and YH18b (3g, 11 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole (3g, 13 mmol), Pd(dppf) CH₂Cl₂ (898 mg, 1.1 mmol), KF (1.4 g, 24 mmol),toluene (22 mL) and water (22 mL). The reaction mixture was heated upunder N₂ at 100° C. for 12 h. The solution was cooled prior to beingextracted with EtOAc (2×100 mL). The organic layers were combined andwashed with brine (50 mL). The organic layer was separated, dried overNa₂SO₄, and concentrated under vacuum. The residue was purified throughcolumn chromatography (eluent: hexanes/EtOAc=2:1) to afford YH19 as asolid (370 mg, 12%). ¹H NMR (300 MHz, CDCl₃): 6.68 (dd, J=11.7, 1.8 Hz,1H), 3.90 (s, 3H), 2.28 (s, 3H), 2.15 (s, 3H); ESI-MS calculated for[M+H]⁺=285.1, observed: 285.1.

Step 3: Synthesis of ethyl2-cyano-2-(4-(3,5-dimethylisoxazol-4-yl)-3-fluoro-5-methoxy-2-nitrophenyl)acetate

To a suspension of NaH (60% in mineral oil, 114 mg, 2.9 mmol) in DMF (6mL) at 0° C. was added ethyl cyanoacetate (294 mg, 2.6 mmol) dropwise.The solution was allowed to warm to r.t. and stirred for 15 minutes.Then the reaction mixture was cooled back to 0° C. prior to the dropwiseaddition of a solution of YH19 (370 mg, 1.3 mmol) in DMF (1 mL). Thereaction was stirred for 1 h at 0° C. prior to being neutralized by 1 MHCl. The reaction mixture was extracted with EtOAc (2×20 mL). Theorganic layers were combined and washed with brine (3×10 mL). Theorganic layer was separated, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified through column chromatography (eluent:hexanes/EtOAc=1/1) to afford YH20 as oil (476 mg, 97%). ¹H NMR (300 MHz,CDCl₃): 7.08 (s, 1H), 5.49 (s, 1H), 4.40-4.20 (m, 2H), 3.96 (s, 3H),2.26 (s, 3H), 2.13 (s, 3H), 1.32 (t, J=7.1 Hz, 3H); ESI-MS calculatedfor [M+H]⁺=378.1, observed: 378.2.

Step 4: Synthesis of ethyl2-amino-6-(3,5-dimethylisoxazol-4-yl)-7-fluoro-5-methoxy-1H-indole-3-carboxylate

To a solution of YH20 (476 mg, 1.26 mmol) in acetic acid (4 mL) wasadded iron powder (424 mg, 7.6 mmol). The reaction was stirred for 12 hprior to being diluted with EtOAc (10 mL) and the suspension wasfiltered. The volatiles were removed under vacuum and the residue wastreated with EtOAc (50 mL) and water (10 mL). The organic layer wasseparated, washed successively with NaOH (1 M, 5 mL), NaHCO₃, and brine.The organic layer was separated, dried over Na₂SO₄, and concentratedunder vacuum. The residue was purified through column chromatography(eluent: DCM/EtOAc=4/1) to afford YH21 as a solid (240 mg, 55%). ¹H NMR(300 MHz, CDCl₃): 9.81 (s, 1H), 7.25 (s, 1H), 6.13 (s, 1H), 4.41 (q, J7.0 Hz, 2H), 3.81 (s, 3H), 2.27 (s, 3H), 2.16 (s, 3H), 1.46 (t, J=7.0Hz, 3H); ESI-MS calculated for [M+H]⁺=348.1, observed: 348.5.

Step 5: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-8-fluoro-6-methoxy-2-methyl-3,9-dihydro-4H-pyrimido[4,5-b]indol-4-one

HCl gas was bubbled into a solution of YH21 (240 mg, 0.7 mmol) in CH₃CN(10 mL) for 10 min. The reaction mixture was heated up to 80° C. for 1h. After the solution was cooled, the volatile was evaporated undervacuum and a solution of NaOH (1 M, 6 mL) was added followed by ethanol(18 mL). The solution was refluxed for 2 h prior to the removal ofethanol. To the residue was added 1 M HCl at 0° C. until the pH=4. Theprecipitate was filtered, washed with water (2 mL), ethyl acetate (2mL). The solid was dried under vacuum and weighed crude 200 mg (83%)¹HNMR (300 MHz, CD₃OD): 12.40 (s, 1H), 7.40 (s, 1H), 3.85 (s, 3H), 2.43(s, 3H), 2.26 (s, 3H), 2.07 (s, 3H ESI-MS calculated for [M+H]⁺=343.1,observed: 343.3;

Step 6: Synthesis of4-(4-chloro-8-fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole

A suspension of YH22 (100 mg, 0.3 mmol in POCl₃ (4 mL) was refluxed for4 h prior to the removal of the volatile under vacuum. The residue wastaken up by the ethyl acetate (4 mL) and a saturated solution of NaHCO₃was added until pH=9. The precipitate was filtered and washed with waterand ethyl acetate to give YH23 (100 mg, 95%). ¹H NMR (300 MHz, CD3OD):7.65 (s, 1H), 3.92 (s, 3H), 2.70 (s, 3H), 2.29 (s, 3H), 2.10 (s, 3H);ESI-MS calculated for [M+H]⁺=361.1, observed: 361.2.

N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 307)

Cpd. No. 307 was synthesized following the same procedure as Cpd. No.304. ¹H NMR (300 MHz, CD3OD): 7.20 (s, 1H), 6.05 (s, 1H), 3.91 (s, 3H),3.74 (s, 3H), 2.65 (s, 3H), 2.31 (s, 3H), 2.15 (s, 3H), 2.04-1.85 (m,1H), 1.14-0.83 (m, 2H), 0.85-0.74 (m, 2H); ESI-MS calculated for[M+H]⁺=462.2, observed: 462.4.

N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 308)

Cpd. No. 308 was synthesized following the same procedure as Cpd. No.306. ¹H NMR (300 MHz, CD3OD): 6.03 (s, 1H), 5.41 (s, 1H), 3.75 (s, 3H),3.73 (s, 3H), 3.71 (s, 3H), 2.79 (s, 3H), 2.27 (s, 3H), 2.10 (s, 3H),1.99-1.80 (m, 1H), 1.03-0.84 (m, 2H), 0.74-0.54 (m, 2H); ESI-MScalculated for [M+H]⁺=476.2, observed: 476.3.

Step 1: Synthesis of tert-butyl3-(4-bromo-3-fluoro-5-methoxy-2-nitrophenyl)-2,4-dioxopiperidine-1-carboxylate

To a round-bottom flask was charged with tert-butyl2,4-dioxopiperidine-1-carboxylate (2.13 g, 10 mmol), K₂CO₃ (2.07 g, 15mmol), DMSO (15 mL). The reaction mixture was stirred for 10 minutesprior to the addition of a mixture of YH18a and YH18b (1.4 g, 5 mmol).The reaction mixture was heated up under N at 60° C. for 2 h. Thesolution was cooled prior to being diluted with water and EtOAc (100mL). The organic layer was separated and washed with water and brine (50mL). The organic layer was separated, dried over Na₂SO₄, andconcentrated under vacuum. The residue was purified through columnchromatography (eluent: hexanes/EtOAc=1:1) to afford YH26 as a solid(820 mg, 45%). ¹H NMR (300 MHz, CDCl₃ □□□ ppm 6.65 (d, J=1.2 Hz, 1H),4.00-3.92 (m, 2H), 3.94 (s, 3H), 2.71-2.53 (m, 2H), 1.55 (s, 9H); ESI-MS(M+H): 461.0 calculated, 461.1 observed.

Step 2: Synthesis of7-bromo-6-fluoro-8-methoxy-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one

To a solution of YH26 (820 mg, 1.7 mmol) in ethanol (10 mL) was addediron powder (952 mg, 17 mmol), FeCl₂ (324 mg, 2.6 mmol) and acetic acid(0.48 mL, 8.5 mmol). The reaction mixture was heated up to reflux for 12h prior to being cooled down to r.t. The reaction mixture was dilutedwith EtOAc (10 mL) and the suspension was filtered. The volatiles wereremoved under vacuum and the residue was treated with EtOAc (50 mL) andwater (10 mL). The organic layer was separated, washed successively withNaHCO₃ and brine. The organic layer was separated, dried over Na₂SO₄,and concentrated under vacuum. The residue was purified through columnchromatography (eluent: DCM/MeOH=9/1) to afford YH27 as a solid (310 mg,59%). ESI-MS (M+H): 313.0 calculated, 313.2 observed.

Step 3: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-fluoro-8-methoxy-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one

To a round-bottom flask was charged with YH27 (150 mg, 0.5 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(223 mg, 1 mmol), Pd(dppf)CH₂Cl₂ (20 mg, 0.025 mmol), dioxane (4 mL) andNa₂CO₃ solution (2 M, 1 mL). The reaction mixture was heated up under Nat 100° C. for 12 h. The solution was cooled prior to being extractedwith EtOAc (2×10 mL). The organic layer was separated and concentratedunder vacuum. The residue was purified through HPLC to afford YH28 as asolid (50 mg, 30%). ¹H NMR (300 MHz, CD₃OD□□□ 7.43 (s, 1H), 3.84 (s,3H), 3.65 (d, J=5.8 Hz, 2H), 3.07 (t, J=6.2 Hz, 2H), 2.26 (s, 3H), 2.11(s, 3H); ESI-MS (M+H): 330.12 calculated, 330.33 observed.

Step 4: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-fluoro-8-methoxy-2,5-dihydro-1H-pyrido[4,3-b]indol-1-one

To a solution of YH28 (50 mg, 0.15 mmol) in dioxane (4 mL) was added DDQ(69 mg, 0.3 mmol). The reaction mixture was refluxed for 6 h. After thesolution was cooled, the reaction was diluted with water (2 mL) andethyl acetate (10 mL). The organic layer was separated, dried overNa₂SO₄, and concentrated under vacuum. The residue was purified throughcolumn chromatography (eluent: DCM/MeOH=9/1) to afford YH29 as a solid(41 mg, 87%). ¹H NMR (300 MHz, CD₃OD) δ ppm 7.67 (s, 1H), 7.39 (d, J=6.9Hz, 1H), 6.66 (d, J=6.9 Hz, 1H), 3.92 (s, 3H), 2.32 (s, 3H), 2.16 (s,3H); ESI-MS (M+H): 328.10 calculated, 328.20 observed.

Step 5: Synthesis of4-(1-chloro-6-fluoro-8-methoxy-5H-pyrido[4,3-b]indol-7-yl)-3,5-dimethylisoxazole

A suspension of 18 (41 mg, 0.13 mmol) in POCl₃ (3 mL) was refluxed for 4h prior to the removal of the volatile under vacuum. The residue wastaken up by the ethyl acetate (4 mL) and a saturated solution of NaHCO₃was added until pH=9. The precipitate was filtered and washed with waterand ethyl acetate to give 19 (12 mg, 29%). ¹H NMR (300 MHz, DMSO) δ12.77 (s, 1H), 8.27 (d, J=5.6 Hz, 1H), 7.81 (s, 1H), 7.53 (d, J=5.6 Hz,1H), 3.93 (s, 3H), 2.30 (s, 3H), 2.10 (s, 3H); ESI-MS (M+H): 346.1calculated, 346.2 observed.

N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-fluoro-8-methoxy-5H-pyrido[4,3-b]indol-1-amine(Cpd. No. 309)

Cpd. No. 309 was synthesized following the same procedure as Cpd. No.304. ¹H NMR (300 MHz, CD₃OD) δ ppm 7.86 (s, 1H), 7.85 (d, J 7.2 Hz, 1H),7.37 (d, J=7.1 Hz, 1H), 6.24 (s, 1H), 3.99 (s, 3H), 3.81 (s, 3H), 2.34(s, 3H), 2.17 (s, 3H), 2.01-1.91 (m, 1H), 1.00-0.95 (m, 2H), 0.87-0.73(m, 2H); ESI-MS (M+H): 447.2 calculated, 447.3 observed.

Step 1: Synthesis of 3-bromo-6-fluoro-2-methoxy-5-nitropyridine

5-bromo-6-methoxy-3-nitropyridin-2-amine (19 g, 80 mmol) was slowlyadded to a solution of HF/pyridine (70% HF, 30% pyridine 77 mL) at 0° C.NaNO₂ (5.8 g, 84 mmol) was added slowly portion wise to the reactionmixture. After the addition is completed, the reaction mixture wasallowed to warm to r.t. The reaction mixture became very hot as thereaction progressed and occasional cooling was applied to keep thetemperature from overheating. The reaction mixture was stirred foranother 1 h prior to being poured into ice. The solution was extractedwith Et₂O (2×200 mL). The organic layers were combined and washedsuccessively with NaOH (1 M, 2×500 mL), saturated NaHCO₃ (100 mL), andbrine (100 mL). The organic layer was separated, dried over Na₂SO₄, andconcentrated under vacuum. The residue was purified through columnchromatography (eluent: hexanes/EtOAc=8/1) to afford YH32 as white solid(16 g, 82%). ¹H NMR (300 MHz, CDCl₃) δ ppm 8.67 (d, J=8.2 Hz, 1H), 4.12(s, 3H).

Step 2: Synthesis of4-(6-fluoro-2-methoxy-5-nitropyridin-3-yl)-3,5-dimethylisoxazole

To a round-bottom flask was charged with YH32 (3.8 g, 15 mmol),3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(3.7 g, 16.5 mmol), Pd(dppf)CH₂Cl₂ (612 mg, 0.75 mmol), KF (1.9 g, 33mmol), toluene (40 mL) and water (40 mL). The reaction mixture washeated up under N₂ at 100° C. for 12 h. The solution was cooled prior tobeing extracted with EtOAc (2×100 mL). The organic layers were combinedand washed with brine (50 mL). The organic layer was separated, driedover Na₂SO₄, and concentrated under vacuum. The residue was purifiedthrough column chromatography (eluent: hexanes/EtOAc=4/1 to 2:1) toafford YH33 as a red solid, which was triturated with diethyl ether,followed by filtration to give YH33 as a yellow solid (2.2 g, 55%)¹H NMR(300 MHz, CDCl₃) δ ppm 8.30 (d, J=8.6 Hz, 1H), 4.06 (s, 3H), 2.33 (s,3H), 2.17 (s, 3H).

Step 3: Synthesis of ethyl2-cyano-2-(5-(3,5-dimethylisoxazol-4-yl)-6-methoxy-3-nitropyridin-2-yl)acetate

To a suspension of NaH (60% in mineral oil, 2.5 g, 63 mmol) in DMF (114mL) at 0° C. was added ethyl cyanoacetate (6.4 g, 57 mmol) dropwise. Thesolution was allowed to warm to r.t. and stirred for 15 minutes. Thenthe reaction mixture was cooled back to 0° C. prior to the dropwiseaddition of a solution of YH33 (7.6 g, 28.5 mmol) in THF (8 mL). Thereaction was stirred for 1 h at 0° C. prior to being neutralized by 2 MHCl. The reaction mixture was extracted with EtOAc (2×200 mL). Theorganic layers were combined and washed with brine (3×100 mL). Theorganic layer was separated, dried over Na₂SO₄, and concentrated undervacuum. The residue was purified through column chromatography (eluent:hexanes/EtOAc=4/1, then DCM) to afford YH34 as oil (10 g, 98%). ¹H NMR(300 MHz, CDCl₃) δ ppm 8.32 (s, 1H), 5.87 (s, 1H), 4.36 (q, J=7.1 Hz,2H), 4.14 (s, 3H), 2.37 (s, 3H), 2.22 (s, 3H), 1.37 (t, J=7.1 Hz, 3H).

Step 4: Synthesis of ethyl2-amino-6-(3,5-dimethylisoxazol-4-yl)-5-methoxy-1H-pyrrolo[3,2-b]pyridine-3-carboxylate

To a solution of YH34 (10.1 g, 28.5 mmol) in acetic acid (99 mL) wasadded iron powder (9.6 g, 171 mmol). The reaction was stirred and thetemperature of the solution rose as the reaction progressed. After thetemperature fell back to r.t, the reaction mixture was diluted withEtOAc (100 mL) and the suspension was filtered. The volatiles wereremoved under vacuum and the residue was treated with EtOAc (500 mL) andwater (100 mL). The organic layer was separated, washed successivelywith NaOH (1 M, 50 mL), NaHCO₃, and brine. The organic layer wasseparated, dried over Na₂SO₄, and concentrated under vacuum. The residuewas purified through column chromatography (eluent: hexanes/EtOAc=2/1,then EtOAc) to afford YH35 as a solid (7 g, 76%). ¹H NMR (300 MHz,CDCl₃) δ ppm 10.19 (s, 1H), 6.72 (s, 1H), 6.52 (s, 2H), 4.40 (q, J=6.8Hz, 2H), 3.89 (s, 3H), 2.05 (s, 3H), 1.91 (s, 3H), 1.44 (t, J=6.8 Hz,3H).

Step 5: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-ol

Ethyl acetimidate hydrochloride (22.2 g, 180 mmol) was added to avigorously stirred solution of K₂CO₃ (24.8 g, 180 mmol) in water (200mL) and DCM (200 mL). After 10 minutes, the organic layer was separatedand dried over MgSO₄. The clear solution was decanted to a flask whereit contained YH35 (2.0 g, 6 mmol). To this solution was added aceticacid (3.4 mL, 60 mmol) and the reaction mixture was stirred for 12 hduring which time precipitate occurred. The solution was filtered andthe filtrate was evaporated to give a crude oil. A solution of NaOH (2.5M, 36 mL) was added to the crude oil followed by the addition of ethanol(80 mL). The reaction mixture was heated up to 80° C. for 4 h. After thesolution was cooled, the ethanol was evaporated under vacuum and theaqueous solution was cooled to 0° C. and 1 M HCl was added slowly untilPH=4. The precipitate was filtered, washed with water (50 mL), ethylacetate (50 mL), and DCM (50 mL). The white solid was dried under vacuumand weighed 1.0 g (50%). ¹H NMR (300 MHz, CD₃OD) δ ppm 7.67 (s, 1H),4.08 (s, 3H), 2.53 (s, 2H), 2.35 (s, 3H), 2.18 (s, 3H); ESI-MS (M+H):323.2 calculated, 323.4 observed.

Step 6: Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-yltrifluoromethanesulfonate

To a suspension of YH36 (2.2 g, 6.8 mmol) and 2-chloropyridine (2.55 mL,27.2 mmol) in THF (200 mL) and DCM (100 mL) at −78° C. was addeddropwise a solution of Tf₂O in DCM (1 M, 13.6 mL). The reaction mixturewas stirred for 10 min, and TLC indicated that some starting materialremained. 2-Chloropyridine (2.55 mL, 27.2 mmol) was added followed bydropwise addition of a solution of Tf₂O in DCM (1 M, 13.6 mL). Afteraddition, the reaction mixture was quenched by saturated NaHCO₃ (20 mL).The organic layer was separated, and the aqueous layer was extractedwith EtOAc. The organic layers were combined, dried over Na₂SO₄, andconcentrated under vacuum. The crude solid was triturated in DCM, andthe white solid was filtered to afford YH37 (1.3 g). The filtrate wasconcentrated and purified through column chromatography (eluent:DCM/EtOAc=3/1, then EtOAc) to afford another batch of YH37 (0.7 g, totalyield 64%). ¹H NMR (300 MHz, CD3OD) δ ppm 7.87 (s, 1H), 4.09 (s, 3H),2.80 (s, 3H), 2.39 (s, 3H), 2.22 (s, 3H). ESI-MS (M+H): 458.1calculated, 458.5 observed.

Synthesis of Cpd. No. 310 and Related Analogs

YH37 (0.1 mmol), amine (0.2 mmol), and anhydrous DMF (1 mL) were mixedand the reaction mixture was heated at 80° C. for 12 h. Solvent DMF wasremoved and the residue was purified via reverse phase HPLC to yield thefollowing compounds:

Cpd. No. Structure Characterization 310

1H NMR (300 MHz, CD3OD) δ ppm 7.87 (s, 1H), 4.09 (s, 3H), 2.70 (s, 3H),2.37 (s, 3H), 2.33 (s, 3H), 2.20 (s, 3H), 1.75 (s, 9H), ESI-MS (M + H):461.54; UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.15 min 311

1H NMR (300 MHz, DMSO) δ ppm 12.06 (s, 1H), 9.01 (s, 1H), 8.70-8.50 (m,2H), 7.81 (s, 1H), 7.24 (dd, J = 7.7, 4.8 Hz, 1H), 4.04 (s, 3H), 4.01(s, 3H), 2.54 (s, 3H), 2.34 (s, 3H), 2.14 (s, 3H); ESI-MS (M + H):456.80; UPLC(10 to 100% CH₃CN: H₂O 10 min): 3.80 min 312

1H NMR (300 MHz, CD3OD) δ ppm 7.86 (s, 1H), 7.52 (s, 1H), 4.70-4.60 (m,1H), 4.13 (s, 3H), 2.65 (s, 3H), 2.38 (s, 3H), 2.21 (s, 3H), 2.14 (m,3H), 1.51 (d, J = 6.7 Hz, 6H); ); ESI-MS (M + H): 447.68; UPLC(10 to100% CH₃CN: H₂O 10 min): 3.99 min 313

1H NMR (300 MHz, DMSO) δ ppm 12.23 (s, 1H), 8.85 (d, J = 0.8 Hz, 1H),7.84 (s, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.70 (s, 1H), 7.32 (t, J = 7.7Hz, 1H), 6.97 (d, J = 7.5 Hz, 1H), 4.10 (s, 3H), 2.63 (s, 3H), 2.37 (s,3H), 2.34 (s, 3H), 2.14 (s, 3H); ESI-MS (M + H): 415.52; UPLC(10 to 100%CH₃CN: H₂O 10 min): 4.99 min 314

1H NMR (300 MHz, DMSO) δ ppm 12.02 (s, 1H), 8.63 (s, 1H), 7.79 (s, 1H),6.42 (s, 1H), 4.07 (s, 3H), 3.75 (s, 3H), 2.55 (s, 3H), 2.32 (s, 3H),2.13 (s, 3H), 1.20 (s, 9H); ESI-MS (M + H): 461.25; UPLC(10 to 100%CH₃CN: H₂O 10 min): 4.64 min 315

1H NMR (300 MHz, CD3OD) δ ppm 7.74 (s, 1H), 5.93 (s, 1H), 3.99 (s, 3H),3.93 (s, 3H), 3.83 (s, 3H), 2.66 (s, 3H), 2.33 (s, 3H), 2.16 (s, 3H),1.24 (s, 9H); ESI-MS (M + H): 475.57; UPLC(10 to 100% CH₃CN: H₂O 10min): 4.77 min 316

1H NMR (300 MHz, CD3OD) δ ppm 7.92 (s, 1H), 5.98 (s, 1H), 4.44 (s, 3H),3.98 (s, 3H), 2.65 (s, 3H), 2.38 (s, 6H), 2.24 (s, 3H), 1.61 (s, 9H);ESI-MS (M + H): 475.50; UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.70 min 317

1H NMR (300 MHz, DMSO) δ ppm 7.64 (s, 1H), 7.19-7.04 (m, 2H), 6.99-6.85(m, 2H), 3.82 (s, 3H), 3.45 (s, 3H), 2.27 (s, 3H), 2.24 (s, 3H), 2.05(s, 3H); ESI-MS (M + H): 429.67; 318

1H NMR (300 MHz, CD3OD) δ ppm 8.53 (dd, J = 4.6, 1.4 Hz, 1H), 7.83 (dd,J = 8.2, 1.4 Hz, 1H), 7.71 (s, 1H), 7.08 (dd, J = 8.2, 4.5 Hz, 1H), 4.20(s, 3H), 4.04 (s, 3H), 2.69 (s, 3H), 2.28 (s, 3H), 2.09 (s, 3H); ESI-MS(M + H): 470.42; UPLC(10 to 100% CH₃CN: H₂O 10 min): 3.86 min 319

1H NMR (300 MHz, CDCl3) δ ppm 7.89 (s, 1H), 7.67 (s, 1H), 4.47 (s, 3H),4.26- 4.20 (m, 1H), 3.99 (s, 3H), 2.61 (s, 3H), 2.37 (s, 3H), 2.23 (s,3H), 1.97 (s, 3H), 1.53 (d, J = 6.7 Hz, 3H), 1.44 (d, J = 6.6 Hz, 3H);ESI-MS (M + H): 461.50; UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.31 min 320

1H NMR (300 MHz, CD3OD) δ ppm 7.85 (s, 1H), 5.97 (s, 1H), 4.19 (s, 3H),3.95 (s, 3H), 3.71 (s, 3H), 2.68 (s, 3H), 2.35 (s, 3H), 2.18 (s, 3H),1.93-1.87 (m, 1H), 1.04- 0.84 (m, 2H), 0.79-0.59 (m, 2H); ESI-MS (M +H): 459.68; UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.24 min 321

1H NMR (300 MHz, DMSO) δ ppm 7.67 (s, 1H), 6.30 (s, 1H), 3.94 (s, 3H),3.31 (s, 3H), 2.44 (s, 3H), 2.31 (s, 3H), 2.12 (s, 3H), 2.05-1.86 (m,2H), 1.85-1.68 (m, 4H), 1.68-1.44 (m, 2H); ); ESI-MS (M + H): 407.50;UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.84 min 322

1H NMR (300 MHz, DMSO) δ ppm 12.2 (s, 1H), 8.74 (s, 1H), 7.81 (s, 1H),6.28 (s, 1H), 4.06 (s, 3H), 3.71 (s, 3H), 2.32 (s, 3H), 2.13 (s, 3H),1.94-1.77 (m, 1H), 0.99- 0.79 (m, 2H), 0.79-0.53 (m, 2H), ; ESI-MS (M +H): 445.4; UPLC(10 to 100% CH₃CN: H₂O 10 min): 4.09 min, 97% purity

Synthesis of Cpd. No. 325 and Related Analogs

Step 1: Synthesis of4-(4-chloro-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole

To a solution of YH37 (635 mg, 1.38 mmol), tetra-butyl ammonium chloride(772 mg, 2.8 mmol) in anhydrous THF (10 mL) was added 4N HCl in dioxane(0.1 mL). The reaction mixture was stirred for 12 h prior to the removalof solvent under vaccum. The residue was diluted with DCM, filtered, andwashed with water to provide YH39 as white solid (398 mg, 84% yield).

Step 2: YH39 (0.1 mmol), borate ester (0.1 mmol), Pd(dppf)Cl2 (8 mg), KF(19 mg) and dioxane/H2O (1 mL/0.5 mL) were mixed and the reactionmixture was heated at reflux for 12 h. The crude mixture was dilutedwith EtOAc and the organic layer was washed with water. The solvent wasremoved and the residue was purified via reverse phase HPLC to yield thefollowing compounds:

Cpd. No. Structure Characterization 325

1H NMR (300 MHz, CDCl3): 9.36 (d, J = 4.8 Hz, 1H), 8.36 (d, J = 8.4 Hz,1H), 8.26 (d, J = 5.1 Hz, 1H), 8.12 (d, J = 7.8 Hz, 2H), 7.90 (s, 1H),7.81 (d, J = 7.5 Hz, 1H), 3.18 (s, 3H), 3.01 (s, 3H), 2.30 (s, 3H), 2.11(s, 3H); ESI-MS (M + H): 437.57; UPLC(10 to 100% CH₃CN: H₂O 10 min):2.88 min 326

1H NMR (300 MHz, CDCl3): 9.90 (s, 1H), 9.01 (d, J = 8.6 Hz, 1H), 8.33(d, J = 7.6 Hz, 1H), 7.93 (d, J = 7.7 Hz, 2H), 7.58 (s, 2H), 7.49-7.38(m, 1H), 4.03 (s, 3H), 3.18 (s, 3H), 3.04 (s, 3H), 2.29 (s, 3H), 2.13(s, 3H); ESI-MS (M + H): 494.50; UPLC(10 to 100% CH₃CN: H₂O 10 min):4.29 min 327

1H NMR (300 MHz, CDCl3) δ ppm 8.74- 8.52 (m, 1H), 8.47 (s, 1H), 7.82 (s,1H), 7.76-7.63 (m, 1H), 7.53 (s, 1H), 3.96 (s, 3H), 3.56 (s, 1H), 3.04(s, 3H), 2.33 (s, 3H), 2.18 (s, 3H), 1.65 (s, 6H); ESI-MS (M + H):444.42; UPLC(10 to 100% CH₃CN: H₂O 10 min): 3.61 min 328

1H NMR (300 MHz, CD3OD) δ ppm 7.99 (s, 1H), 3.97 (s, 3H), 3.86 (s, 3H),2.98 (s, 3H), 2.93-2.80 (m, 2H), 2.80-2.70 (m, 2H), 2.37 (s, 3H), 2.19(s, 3H), 1.10 (d, J = 8.5 Hz, 3H), 1.07 (d, J = 8.5 Hz, 3H); ESI-MS (M +H): 446.83; UPLC(10 to 100% CH₃CN: H₂O 10 min): 3.2 min, 98% purity 329

1H NMR (300 MHz, CD3OD) δ ppm 7.96 (s, 1H), 3.93 (s, 3H), 2.96 (s, 3H),2.37 (s, 3H), 2.36 (s, 3H), 2.19 (s, 3H), 2.25-2.11 (m, 1H), 1.14-1.04(m, 4H); ESI-MS (M + H): 431.58; UPLC(10 to 100% CH₃CN: H₂O 10 min): 3.8min, 99% purity 330

1H NMR (300 MHz, CD3OD) δ ppm 7.93 (s, 1H), 4.03 (s, 3H), 3.90 (s, 3H),2.97 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 2.19 (s, 3H), 2.13-2.07 (m,1H), 1.03-0.72 (m, 4H); ESI-MS (M + H): 444.42; UPLC(10 to 100% CH₃CN:H₂O 10 min): 3.2 min, 95% purity 331

1H NMR (300 MHz, CD3OD) δ ppm 7.98 (s, 1H), 3.93 (s, 3H), 3.89 (s, 3H),2.99 (s, 3H), 2.40 (s, 3H), 2.37 (s, 3H), 2.19 (s, 3H), 2.05-1.84 (m,1H), 0.93-0.75 (m, 4H), ESI-MS (M + H): 444.42; UPLC(10 to 100% CH₃CN:H₂O 10 min): 3.3 min, 99% purity

Example 171 Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4-ol(ZBB261)

To a round-bottom flask, S6 (1 g), MeOCH₂CH₂CN (4 mL) and hydrogenchloride solution, 4 M in dioxane (4 mL) were added at room temperature.The reaction mixture was stirred overnight. The volatile components wereremoved on a rotary evaporator. To this crude mixture, 10% NaOH aqueoussolution (10 mL) and EtOH (20 mL) were added and the solution was heatedat reflux for 8 h. The volatile components were then removed on a rotaryevaporator and the aqueous residue was acidified with 2 N HCl aqueoussolution. The product ZBB261 was allowed to precipitate at 0° C.Filtration of the mixture furnished crude ZBB261 which was purified byHPLC to yield the desired product as a CF₃CO₂H salt in 0.15 g. ESI-MScalculated for C₁₉H₂₁N₄O₄ [M+H]⁺=369.15; Observed: 369.74. ¹H NMR (300MHz, MeOD) δ 7.80 (s, 1H), 7.30 (s, 1H), 3.98-3.79 (m, 5H), 3.40 (s,3H), 3.03 (t, J=6.2 Hz, 2H), 2.33 (s, 3H), 2.17 (s, 3H).

Synthesis of4-(4-chloro-6-methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(ZBB264)

To a round-bottom flask, ZBB261 (0.278 g, 0.8 mmol) and POCl₃ (8 mL)were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished ZBB264 as a brown solid in0.24 g. ESI-MS calculated for C₁₉H₂₀ClN₄O₃[M+H]⁺=387.12; Observed:387.44. ¹H NMR (300 MHz, DMSO) δ 12.56 (s, 1H), 7.82 (s, 1H), 7.43 (s,1H), 3.94-3.84 (m, 5H), 3.27 (s, 3H), 3.18 (t, J=6.4 Hz, 2H), 2.32 (s,3H), 2.12 (s, 3H).

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 287)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB264 (60 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), NaOtBu (100 mg), andtoluene (4 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 287 as a CF₃CO₂H salt in25 mg. ESI-MS calculated for C₂₅H₂₈N₇O₃ [M+H]⁺=488.24; Observed: 488.76.¹H NMR (300 MHz, MeOD) δ 7.49 (s, 1H), 7.46 (s, 1H), 6.14 (s, 1H), 3.91(s, 3H), 3.87 (t, J=5.9 Hz, 2H), 3.78 (s, 3H), 3.36 (s, 3H), 3.22 (t,J=5.9 Hz, 2H), 2.34 (s, 3H), 2.17 (s, 3H), 2.02-1.89 (m, 1H), 1.04-0.94(m, 2H), 0.81-0.69 (m, 2H).

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((2-methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-ol(ZBB266)

To a round-bottom flask, S6 (1 g), MeOCH₂CH₂OCH₂CN (4 mL) and hydrogenchloride solution, 4 M in dioxane (4 mL) were added at room temperature.The reaction mixture was stirred overnight. The volatile components wereremoved on a rotary evaporator. To this crude mixture, 10% NaOH aqueoussolution (10 mL) and EtOH (20 mL) were added and the solution was heatedat reflux for 8 h. The volatile components were then removed on a rotaryevaporator and the aqueous residue was acidified with 2 N HCl aqueoussolution. The product ZBB266 was allowed to precipitate at 0° C.Filtration of the mixture furnished crude ZBB266 in 0.7 g. ESI-MScalculated for C₂₀H₂₃N₄O₅ [M+H]⁺=399.16; Observed: 399.44. ¹H NMR (300MHz, DMSO) δ 12.12 (s, 1H), 12.04 (s, 1H), 7.59 (s, 1H), 7.26 (s, 1H),4.49 (s, 2H), 3.84 (s, 3H), 3.76-3.65 (m, 2H), 3.53 (dd, J=5.6, 3.7 Hz,2H), 3.28 (s, 3H), 2.29 (s, 3H), 2.09 (s, 3H).

Synthesis of4-(4-chloro-6-methoxy-2-((2-methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(ZBB267)

To a round-bottom flask, ZBB266 (0.278 g, 0.8 mmol) and POCl₃ (8 mL)were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished ZBB267 as a brown solid in0.25 g. ESI-MS calculated for C₂₀H₂₂ClN₄O₄[M+H]⁺=417.13; Observed:417.65.

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((2-methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 288)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB267 (60 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), NaOtBu (100 mg), andtoluene (4 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 288 as a CF₃CO₂H salt in23 mg. ESI-MS calculated for C₂₇H₃₂N₇O₄ [M+H]⁺=518.25; Observed: 518.44.¹H NMR (300 MHz, MeOD) δ 7.50 (s, 1H), 7.43 (s, 1H), 6.12 (s, 1H), 4.79(s, 2H), 3.91 (s, 3H), 3.86 (dd, J=4.1, 2.0 Hz, 2H), 3.76 (s, 3H),3.69-3.64 (m, 2H), 3.39 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 1.95 (tt,J=8.4, 5.1 Hz, 1H), 1.04-0.94 (m, 2H), 0.79-0.71 (m, 2H).

Synthesis of 7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((methylsulfonyl)methyl)-9H-pyrimido[4,5-b]indol-4-ol (ZBB271)

To a round-bottom flask, S6 (1 g), MeSO₂CH₂CN (4 mL) and hydrogenchloride solution, 4 M in dioxane (4 mL) were added at room temperature.The reaction mixture was stirred overnight. The volatile components wereremoved on a rotary evaporator. To this crude mixture, 10% NaOH aqueoussolution (10 mL) and EtOH (20 mL) were added and the solution was heatedat reflux for 8 h. The volatile components were then removed on a rotaryevaporator and the aqueous residue was acidified with 2 6dN HCl aqueoussolution. The product ZBB271 was allowed to precipitate at 0° C.Filtration of the mixture furnished crude ZBB271 in 0.8 g. ESI-MScalculated for C₁₈H₁₉N₄O₅S [M+H]⁺=403.10; Observed: 403.55. ¹H NMR (300MHz, MeOD) δ 7.82 (s, 1H), 7.34 (s, 1H), 4.62 (s, 2H), 3.91 (s, 3H),3.25 (s, 3H), 2.33 (s, 3H), 2.17 (s, 3H).

Synthesis of4-(4-chloro-6-methoxy-2-((methylsulfonyl)methyl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole(ZBB273)

To a round-bottom flask, ZBB271 (0.278 g, 0.8 mmol) and POCl₃ (8 mL)were added. The mixture was heated at 90° C. for 6 h. The reactionmixture was cooled to room temperature and the volatile components wereremoved on a rotary evaporator. Water (20 mL) and ethyl acetate (20 mL)were added and the pH was adjusted to 8 using NaHCO₃ saturated aqueoussolution. Filtration of the mixture furnished ZBB273 as a brown solid in0.21 g. ESI-MS calculated for C₁₈H₁₈ClN₄O₄S [M+H]⁺=421.07; Observed:421.44.

Synthesis ofN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((methylsulfonyl)methyl)-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 289)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB273 (60 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (4 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 289 as a CF₃CO₂H salt in27 mg. ESI-MS calculated for C₂₅H₂₈N₇O₄S [M+H]⁺=522.19; Observed:522.44.

Synthesis ofN4-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine(Cpd. No. 290)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB253 (60 mg),3-cyclopropyl-1-ethyl-1H-pyrazol-5-amine (84 mg), K₃PO₄ (130 mg), andtoluene (4 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 290 as a CF₃CO₂H salt in20 mg. ESI-MS calculated for C₂₄H₂₇N₈O₂ [M+H]⁺=459.22; Observed: 459.67.¹H NMR (300 MHz, MeOD) δ 7.56 (s, 1H), 7.34 (s, 1H), 6.04 (s, 1H), 4.07(q, J=7.2 Hz, 2H), 3.90 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H), 1.95 (ddd,J=13.3, 8.4, 5.0 Hz, 1H), 1.44 (t, J=7.2 Hz, 3H), 1.03-0.91 (m, 2H),0.79-0.65 (m, 2H).

Synthesis ofN4-(1,3-dicyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine(Cpd. No. 291)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB253 (60 mg),1,3-dicyclopropyl-1H-pyrazol-5-amine (88 mg), K₃PO₄ (130 mg), andtoluene (4 mL). The mixture was heated at reflux for overnight beforequenching with methanol. The reaction mixture was filtered and themixture was purified by HPLC to yield Cpd. No. 291 as a CF₃CO₂H salt in24 mg. ESI-MS calculated for C₂₅H₂₇N₈O₂ [M+H]⁺=471.22; Observed: 471.33.¹H NMR (300 MHz, MeOD) δ 7.59 (s, 1H), 7.35 (s, 1H), 6.10 (s, 1H), 3.90(s, 3H), 3.44-3.34 (m, 1H), 2.33 (s, 3H), 2.16 (s, 3H), 1.92 (td, J=8.4,4.4 Hz, 1H), 1.16-1.08 (m, 2H), 1.00-0.92 (m, 4H), 0.77-0.71 (m, 2H).

Synthesis of7-(3,5-dimethylisoxazol-4-yl)-N4-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine(Cpd. No. 292)

Pd₂(dba)₃ (18 mg) and BINAP (26 mg) were mixed in anhydrous toluene. Andthe mixture was heated at reflux for 3-4 minutes. This mixture wastransferred into a round-bottom flask containing ZBB253 (60 g),2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (88 mg),K₃PO₄ (130 mg), and toluene (4 mL). The mixture was heated at reflux forovernight before quenching with methanol. The reaction mixture wasfiltered and the mixture was purified by HPLC to yield Cpd. No. 292) asa CF₃CO₂H salt in 24 mg. ESI-MS calculated for C₂₅H₂₉N₈O₂ [M+H]⁺=473.24;Observed: 473.56. ¹H NMR (300 MHz, CDCl₃) δ 7.47 (s, 1H), 7.35 (s, 1H),4.65-4.45 (m, 1H), 3.87 (s, 3H), 2.77 (t, J=7.2 Hz, 2H), 2.58 (t, J=6.9Hz, 2H), 2.49-2.36 (m, 2H), 2.31 (s, 3H), 2.13 (s, 3H), 1.51 (d, J=6.7Hz, 6H).

Synthesis of3-(3-Cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]-indol-4-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carbaldehyde(Cpd. No. 293)

Cpd. No. 163 (50 mg), formic acid (13.8 mg), EDCI-HCl (76 mg), and HOBt(54 mg) were dissolved in anhydrous DMF (3 mL). EtN(i-Pr)₂ (0.1 mL) wasadded via a syringe and the reaction mixture was stirred at roomtemperature for overnight. The reaction mixture was the purified byreverse phase HPLC to yield the titled compound in 24 mg as a salt ofCF₃CO₂H. ¹H NMR (300 MHz, MeOD): 8.01 (s, 1H), 7.47 (s, 1H), 6.07 (s,1H), 5.30-5.15 (m, 1H), 4.70-4.50 (m, 2H), 4.40-4.20 (m, 2H), 3.89 (s,3H), 2.68 (s, 3H), 2.31 (s, 3H), 2.13 (s, 3H), 2.10-1.90 (m, 1H),1.10-0.90 (m, 2H), 1.80-1.70 (m, 2H). ESI-MS calculated for C₂₇H₂₉NO₃[M+H]⁺=513.24, observed: 513.67.

Synthesis ofN-(3-Cyclopropyl-1-(oxetan-3-ylmethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 294)

Step 1: 3-Cyclopropyl-1-(oxetan-3-ylmethyl)-1H-pyrazol-5-amine

3-(Bromomethyl)oxetane (0.5 g, 3.3 mmol) and hydrazine (250 mg, 5.0mmol) were dissolved in ethanol (20 mL) and the mixture was heated atreflux for overnight. To the reaction mixture,3-cyclopropyl-3-oxopropanenitrile (540 mg) was added and the reactionwas heated at reflux for 12 h. The mixture was purified by reverse phaseHPLC to yield the titled compound in 198 mg. ESI-MS calculated forC₁₀H₁₆N₃O [M+H]⁺=194.13, Observed: 194.58.

Step 2

The titled compound was prepared from S13 (180 mg) and3-cyclopropyl-1-(oxetan-3-ylmethyl)-1H-pyrazol-5-amine (198 mg)following the similar procedure for preparation of Cpd. No. 135. Thetitled compound was obtained in 15 mg as a salt of CF₃CO₂H. ¹H NMR (300MHz, MeOD): 8.00 (s, 1H), 7.46 (s, 1H), 6.41 (s, 1H), 4.80-4.70 (m, 1H),4.65-4.45 (m, 2H), 4.45-4.30 (m, 1H), 3.94 (s, 3H), 3.85-3.75 (m, 2H),3.65-3.50 (m, 1H), 2.73 (s, 3H), 2.32 (s, 3H), 2.15 (s, 3H). 2.20-2.05(m, 1H), 1.40-1.25 (m, 2H), 1.10-0.90 (m, 2H). ESI-MS calculated forC₂₇H₃₀N₇O₃ [M+H]⁺=500.24, observed: 500.50.

Synthesis ofN-(3-cyclopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine(Cpd. No. 295)

Step 1: 3-Cyclopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-amine

1-Bromo-2-(methylsulfonyl)ethane (1.87 g, 10 mmol) and hydrazine (4.8mL, 10 mmol) were dissolved in ethanol (50 mL) and the mixture washeated at reflux for overnight. To the mixture,3-cyclopropyl-3-oxopropanenitrile (810 mg) was added and the reactionwas heated at reflux for 12 h. Ethanol was then removed and the mixturewas neutralized with 2 N NaOH aq. solution. The aq. phase was extractedwith ethyl acetate and the product was purified by flash columnchromatography to yield the titled compound in 733 mg. ESI-MS calculatedfor C₉H₁₆N₃O₂S [M+H]⁺=230.10, Observed: 230.67.

Step 2

The titled compound was prepared from S13 (547 mg) and3-cyclopropyl-1-(2-(methyl sulfonyl)ethyl)-1H-pyrazol-5-amine (773 mg)following the similar procedure for preparation of Cpd. No. 135. Thetitled compound was obtained in 90 mg as a salt of CF₃CO₂H. ¹H NMR (300MHz, MeOD): 7.63 (s, 1H), 7.47 (s, 1H), 6.17 (s, 1H), 4.54 (t, J=6.14Hz, 2H), 3.75 (t, J=5.98 Hz, 2H), 3.92 (s, 3H), 2.84 (s, 3H), 2.71 (s,3H), 2.32 (s, 3H), 2.15 (s, 3H), 2.00-1.90 (m, 1H), 1.00-0.90 (m, 2H),0.80-0.70 (m, 2H). ESI-MS calculated for C₂₆H₃₀N₇O₄S [M+H]⁺=536.21,observed: 535.83.

Synthesis of4-(4-chloro-6-methoxy-9H-pyrido[3,4-b]indol-7-yl)-3,5-dimethylisoxazole

Step 1: synthesis of 5-chloro-N-methylnicotinamide. 5-chloronicotinicacid (25 g) and anhydrous DMF (0.1 mL) was dissolved in anhydrous1,2-dichloroethane (250 mL). SOCl₂ (34.8 mL) was added via a syringe andthe reaction mixture was heated at reflux for 5 h. The volatilecomponents were removed on a rotary evaporator. Dichloromethane (200 mL)was added and the volatile components were removed on a rotaryevaporator. This process was repeated twice and the remaining solid wasdissolvent in anhydrous THF (250 mL). Me-NH₂ solution in THF (2 M, 240mL) was added at 0° C. via a dropping funnel and the reaction mixturewas stirred at ambient temperature for overnight. Water was added andthe aqueous phase was extracted with ethyl acetate. The combined organiclayers were combined, dried over anhydrous sodium sulfate, andconcentrated on a rotary evaporator. The solid was dried under vacuumfor overnight affording 5-chloro-N-methylnicotinamide as dry powder in25.73 g. ESI-MS calculated for C₇H₈ ³⁵ClN₂O [M+H]⁺=171.0, Observed:171.1.

Step 2: synthesis of 5-chloro-4-(3-methoxyphenyl)-N-methylnicotinamide(YJ3). Dry 5-chloro-N-methylnicotinamide (6.8 g, 40 mmol) was dissolvedin anhydrous THF (100 mL). (3-Methoxyphenyl)magnesium bromide (1.0 M inTHF, 200 mL) was added via a dropping funnel while the reaction flaskwas cooled with a water bath. The reaction was stirred at ambienttemperature for 8 h. Methanol (11.4 mL, 280 mmol) was added at 0° C. viaa syringe followed by addition of NCS (6.91 g, 52 mmol) in smallportions. The reaction was stirred at ambient temperature for overnight.The reaction was then quenched with NIH aqueous solution (15%). Theaqueous phase was extracted with ethyl acetate and the combined organiclayers were combined and dried over anhydrous sodium sulfate. Thesolvent was removed on a rotary evaporator and the remaining residueswas purified by flash column chromatography. The titled compound (YJ3)was isolated in 8.0 g. ESI-MS calculated for C₁₄H₁₄³⁷ClN₂O₂[M+H]⁺=279.07, Observed: 279.42.

Step 3: synthesis of 5-chloro-4-(3-methoxyphenyl)nicotinic acid (YJ4).YJ3 (8.0 g), Boc₂O (9.8 g), and Et₃N (10 mL) were dissolved in anhydrousTHF (40 mL). DMAP (366 mg) was added in small portions and the mixturewas stirred at ambient temperature for 6 h. The mixture was concentratedon a rotary evaporator and the residue was dissolved in THF (40 mL) andwater (40 mL). LiOH—H₂O (7.14 g, 170 mmol) was added and the mixture wasstirred at ambient temperature for overnight. t-BuOMe (150 mL) was addedand the organic layer was extracted with NaOH (0.5 M, 3×40 mL). Theaqueous layers were combined and acidified with 10% citric acid. Theaqueous layer was then extracted with ethyl acetate/THF (2:1, 7×40 mL).The combined organic layer was dried over anhydrous sodium sulfate andconcentrated on a rotary evaporator to yield the titled compound (YJ4)in 7.03 g. The crude was used without further purification. ESI-MScalculated for C₁₃H₁₁ ³⁵ClNO₃ [M+H]⁺=264.04, Observed: 263.83.

Step 4: synthesis of 5-chloro-4-(2,4-dibromo-5-methoxyphenyl)nicotinicacid (YJ5). YJ4 (7.03 g) was dissolved in AcOH/H₂O (30 mL: 20 mL).PyHBr₃ (15.5 g, 1.8 equiv.) was added in small portions. The reactionmixture was stirred at ambient temperature for 4 h. The reaction mixturewas quenched with NaHSO₃ (gas evolve) and filter through a pad ofCelite®. The Celite® was washed with methanol and all the solvents wereremoved on a rotary evaporator. Water (100 mL) was added and the mixturewas extracted with ethyl acetate (3×100 mL). The organic layers werecombined and dried over anhydrous sodium sulfate. The solvents wereremoved on a rotary evaporator to yield4-(2-bromo-5-methoxyphenyl)-5-chloronicotinic acid. The crude materialwas dissolved in AcOH/water (50 mL/33 mL). PyHBr₃ (12.8 g, 40 mmol) wasadded in small portions. The mixture was stirred at ambient temperaturefor overnight. The reaction was then extracted with ethyl acetate (3×100mL). The organic layers were combined and dried over anhydrous sodiumsulfate. The remaining residues were purified by reverse phase HPLC toyield the titled compound (YJ5) in 1.03 g. ¹H NMR (300 MHz, MeOD-d4):9.10 (s, 1H), 8.91 (s, 1H), 7.76 (s, 1H), 6.66 (s, 1H), 3.82 (s, 3H).ESI-MS calculated for C₁₃H₉ ⁷⁹Br₂ ³⁵ClNO₃ [M+H]⁺=421.86, Observed:422.33.

Step 5: synthesis of tert-butyl(5-chloro-4-(2,4-dibromo-5-methoxyphenyl)pyridin-3-yl)carbamate (YJ6).YJ5 (1.03 g, 2.5 mmol) and EN (1 mL, 7.17 mmol) were dissolved in t-BuOH(20 mL). DPPA was added via a syringe at ambient temperature and themixture was stir for 4 h at ambient temperature before heated at refluxfor overnight. Solvent was removed on a rotary evaporator and residueswas purified by flash column chromatography to yield the titled compound(YJ6) in 673 mg. ¹H NMR (300 MHz, CDCl₃): 9.28 (s, 1H), 8.53 (s, 1H),7.90 (s, 1H), 6.68 (s, 1H), 3.88 (s, 3H), 1.46 (s, 9H). ESI-MScalculated for C₇H₁₈ ⁷⁹Br₂ ³⁵ClN₂O₃ [M+H]⁺=492.94; Observed: 493.25.

Step 6: synthesis of 7-bromo-4-chloro-6-methoxy-9H-pyrido[3,4-b]indole(YJ7). YJ6 (673 mg), NaH (60% in mineral oil, 109 mg), and CuI (400 mg)were weighted into a dry round-bottom flask. Anhydrous diglyme (5 mL)was added and the system was degassed and refilled with nitrogen. Thereaction heated at 120° C. for 2 h. The reaction mixture was then pourinto 5% NH₃ aqueous solution and the aqueous layer was then extractedwith ethyl acetate. The solvent was removed on a rotary evaporator andthe remaining residues was purified by flash column chromatography toyield the titled compound (YJ7) in 347 mg. ¹H NMR (300 MHz, DMSO-d6):11.92 (s, 1H), 8.89 (s, 1H), 8.41 (s, 1H), 8.10 (s, 1H), 7.94 (s, 1H),3.95 (s, 3H).

Step 7: synthesis of4-(4-chloro-6-methoxy-9H-pyrido[3,4-b]indol-7-yl)-3,5-dimethylisoxazole(YJ8). YJ7 (135 mg, 0.44 mmol) and3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(196 mg, 0.88 mmol) were mixed with DME (6 mL) followed by addition ofNa₂CO₃ (2 M aqueous solution, 3 mL). The system was degassed andrefilled with nitrogen. Pd(dppf)Cl₂-DCM (33 mg) was added and the systemwas degassed and refilled with nitrogen. The reaction mixture was thenheated at reflux for overnight. The aqueous layer was then extractedwith ethyl acetates and the combined organic layers were dried andconcentrated on a rotary evaporator. The remaining residues werepurified by flash column chromatography to yield the titled compound(YJ8) in 40 mg. ¹H NMR (300 MHz, CDCl₃): 9.83 (s, 1H), 8.83 (s, 1H),8.41 (s, 1H), 8.09 (s, 1H), 7.32 (s, 1H), 3.95 (s, 3H), 2.35 (s, 3H),2.22 (s, 3H). ESI-MS calculated for C₁₇H₁₅ ³⁵ClN₃O₂[M+H]⁺=328.09,observed: 328.42

Synthesis ofN-(3-Cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrido[3,4-b]indol-4-amine(Cpd. No. 323)

Pd₂(dba)₃ (45 mg) and BrettPhos (sigma-aldrich, 107 mg) were mixed inanhydrous toluene. The mixture was heated at reflux for 10 min. Thepreformed catalyst solution was cooled and transferred into a degassedand nitrogen-filled flask containing YJ8 (80 mg),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (83 mg), t-BuONa (100 mg), andanhydrous toluene (10 mL). The reaction mixture was heated at reflux forovernight. The crude mixture was quenched with methanol, acidified, andpurified by reverse phase HPLC to yield the titled compound in 3 mg as asalt of CF₃CO₂H. ¹H NMR (300 MHz, MeOD): 8.74 (s, 1H), 7.69 (s, 1H),7.62 (s, 1H), 7.58 (s, 1H), 5.78 (s, 1H), 3.88 (s, 3H), 3.79 (s, 3H),2.35 (s, 3H), 2.17 (s, 3H), 2.00-1.80 (m, 1H), 1.00-0.80 (m, 2H),0.70-0.50 (m, 2H). ESI-MS calculated for C₂₄H₂₅N₆O₂ [M+H]⁺=429.20,observed: 429.75.

Alternate Route to PrepareN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethyl-isoxazol-4-yl)-6-methoxy-9H-pyrido[3,4-b]indol-4-amine(Cpd. No. 323)

Step 1: 5-Bromonicotinic acid (25 g, 124 mmol) was dissolved in1,2-dichloroethane (200 mL). SOCl₂ (27 mL, 371 mmol) was added at 0° C.followed by anhydrous DMF (0.2 mL) to initiate the reaction. Thereaction mixture was heated at reflux for 5 h then concentrated on arotatory evaporator. CH₂Cl₂ (100 mL) was added and removed on a rotatoryevaporator and this process was repeated once. The remaining residueswere dissolved in THF (100 mL) and methyl amine (124 mL, 2 M in THF) wasadded. Volatile components were removed on a rotatory evaporator and theremaining residues were dissolved in ethyl acetate followed by additionof water. The aqueous layer was extracted with ethyl acetate, thecombined organic layers were washed with brine, then dried overanhydrous Na₂SO₄. The ethyl acetate was removed on a rotary evaporatoraffording ZYJ22 as a solid in 25.3 g. ¹H NMR (300 MHz, DMSO-d6): 8.94(d, J=1.73 Hz, 1H), 8.83 (d, J=2.17 Hz, 1H), 8.72 (br, 1H), 8.37 (t,J=1.93 Hz, 1H), 2.79 (s, 1.5H), 2.78 (s, 1.5H). ESI-MS calculated forC₇H₈ ⁷⁹BrN₂O [M+H]⁺=214.98; Observed: 215.0.

Step 2: 1-(Benzyloxy)-4-bromo-2-methoxybenzene (30.5 g, 104 mmol) inanhydrous THF (100 mL) reacted with magnesium turning (3.0 g, 125 mmol)in the presence of catalytic iodine provided the corresponding Grignardreagents. The Grignard reagents was transferred into a THF solution ofZYJ22 (5.09 g, 49 mmol) and the reaction was stirred at ambienttemperature for overnight. The reaction was then quenched with methanol(5.9 mL, 146 mmol) at 0° C. After 20 min, NCS (6.5 g, 49 mmol) was addedin small portions. The reaction was stirred at ambient temperature forovernight and then quenched with 7% ammonia solution. Ethyl acetate wasadded to aqueous solution and the solid was collected affording thedesired ZYJ23 (2.06 g). The aqueous layer was extracted with ethylacetate, the combined organic layers were washed with brine, then driedover anhydrous Na₂SO₄. The ethyl acetate was removed on a rotaryevaporator and the remaining solid was mixed with diethyl ether.Filtration provided another portion of ZYJ23 in 4.57 g. ¹H NMR (300 MHz,DMSO-d6): 8.85 (s, 1H), 8.51 (s, 1H), 8.34-8.22 (m, 1H), 7.54-7.30 (m,5H), 7.12-7.08 (m, 1H), 6.89 (s, 1H), 6.82-6.72 (m, 1H), 5.10 (s, 2H),3.72 (s, 3H), 2.52 (d, J=4.50 3H). ESI-MS calculated for C₂₁H₂₀⁷⁹BrN₂O₃[M+H]⁺=427.07; Observed: 427.17.

Step 3: ZYJ23 (6.63 g, 15.5 mmol) and Boc₂O (7.0 g, 32 mmol) wasdissolved in anhydrous THF (40 mL). DMAP (1.95 g, 16 mmol) was added insmall portions. The reaction was stirred at ambient temperature forovernight. LiOH—H₂O (6.72 g, 160 mmol) and water (40 mL) were added tothe reaction mixture and it was stirred for overnight. Water (100 mL)was added and the aqueous layers were extracted with diethyl ether (100mL×2). The aqueous layer was acidified with citric acid and extractedwith THF/ethyl acetate (4:1, 5×50 mL). The combined organic layers weredried over anhydrous sodium sulfate and concentrated on a rotatoryevaporator affording ZYJ24 in 6.60 g. ¹H NMR (400 MHz, DMSO-d6): 8.95(s, 1H), 8.83 (s, 1H), 7.52-7.46 (m, 2H), 7.46-7.40 (m, 2H), 7.40-7.34(m, 1H), 7.14 (d, J=8.30 Hz, 1H), 6.90 (d, J=1.83 Hz, 1H), 6.78 (dd,J=8.22, 1.86 Hz, 1H), 5.13 (s, 2H), 4.09 (br, 1H), 3.76 (s, 3H), 3.32(br, 1H).

Step 4: ZYJ24 (6.60 g, 16 mmol) was mixed with AcOH-water (200 mL, 6:4).PyHBr₃ (5.12 g, 16 mmol) was added in small portions and the mixture wasstirred at ambient temperature for overnight. Additional 5 g of PyHBr₃was added and the reaction was heated at 75° C. until conversioncompleted (>6 h). The reaction mixture was diluted with water (400 mL)and cool with ice-water bath for 15 min. The solid was collected byfiltration and washed with cool ether (40 mL) affording the desiredproduct ZYJ25 in 5.90 g. ¹H NMR (400 MHz, DMSO-d6): 9.04 (s, 1H), 9.02(s, 1H), 7.54-7.48 (m, 2H), 7.48-7.40 (m, 2H), 7.40-7.36 (m, 1H), 7.36(s, 1H), 6.91 (s, 1H), 5.15 (s, 2H), 3.72 (s, 3H). ESI-MS calculated forC₂₀H₁₆ ⁷⁹Br₂NO₄ [M+H]⁺=491.94; Observed: 492.0.

Step 5: ZYJ 25 (5.90 g, 12 mmol) was mixed with t-BuOH (30 mL). EN (4.3mL, 30 mmol) was added via a syringe, followed by addition ofdiphenylphosphoryl azide (4.13 mL, 19.2 mmol) via a syringe. The mixturewas stirred at ambient temperature for 3 h then heated at reflux for 24h. The reaction was cooled to ambient temperature for 6 h and dilutedwith MeOH (200 mL). The solid was collected by filtration to give ZYJ26in 5.60 g. The mother liquid was concentrated and purified by flashcolumn chromatography to give ZYJ26 in 0.33 g. ¹H NMR (400 MHz,MeOD-d4): 8.56 (s, 1H), 7.56-7.34 (m, 5H), 7.28 (s, 1H), 6.68 (s, 1H),5.96 (s, 1H), 5.21 (s, 2H), 3.89 (s, 3H), 1.50 (s, 9H). ESI-MScalculated for C₂₄H₂₅ ⁷⁹Br⁸¹BrN₂O₄[M+H]⁺=565.02; Observed: 565.42

Step 6: ZYJ26 (5.93 g, 10.5 mmol) was mixed with anhydrous diglyme (40mL). NaH (840 mg, 21 mmol, 60% in mineral oil) was added in smallportions followed by addition of CuI (3.04 g, 16 mmol). The system wasdegased and refilled with nitrogen, followed by heating at reflux for 4h. The reaction was quenched with 50 mL concentrated ammonia and 150 mLwater. The solid was collected by filtration and dissolved in CH₂Cl₂ (40mL) and CF₃CO₂H (15 mL) following stirring at ambient temperature for 2h. The desired product ZYJ27 was collected by filtration as a greensolid, which is 4.23 g after drying in high vacuum overnight. ¹H NMR(400 MHz, DMSO-d6): 12.32 (s, 1H), 8.03 (s, 1H), 7.56-7.50 (m, 2H),7.48-7.40 (m, 2H), 7.40-7.36 (m, 1H), 7.35 (s, 1H), 5.31 (s, 2H), 3.92(s, 3H). ESI-MS calculated for C₁₉H₁₆ ⁷⁹BrN₂O₂[M+H]⁺=383.04; Observed:383.50.

Step 7: ZYJ27 (2.0 g, 4.5 mmol) mixed with anhydrous CH₂Cl₂ and themixture was cooled to −78° C. BBr₃ (7.65 mL, 1.0 M in CH₂Cl₂) was addedvia a syringe and the reaction was monitored by HPLC and completed inabout 3 h. The reaction was quenched with MeOH (20 mL) at −78° C. andthen water was added at room temperature. Solid was collected and washedwith diethyl ether to provided ZYJ28 as a solid in 1.41 g. ¹H NMR (400MHz, DMSO-d6): 12.47 (s, 1H), 9.09 (s, 1H), 8.68 (s, 1H), 8.02 (s, 1H),7.19 (s, 1H), 3.94 (s, 3H). ESI-MS calculated for C₁₂H₁₀ ⁷⁹BrN₂O₂[M+H]⁺=292.99; Observed: 292.25.

Step 8: Pd₂(dba)₃ (184 mg, 0.2 mmol) and BINAP (248 mg, 0.4 mmol) weremixed in anhydrous 1,4-dioxane (10 mL). The mixture was heated at refluxfor 5 minutes. This clear, orange-red color solution was transferredinto a round-bottom flask containing ZYJ28 (620 mg, 2.2 mmol),3-cyclopropyl-1-methyl-1H-pyrazol-5-amine (602 mg, 4.4 mmol), LiHMDS(13.2 mL, 1.0 M in toluene), and anhydrous 1,4-dioxane (20 mL). Themixture was heated at reflux for overnight before quenching withmethanol. The reaction mixture was concentrated, filtered, and purifiedby HPLC to yield ZYJ29 in 340 mg as a CF₃CO₂H salt. ¹H NMR (400 MHz,MeOH-d4): 8.65 (s, 1H), 7.84 (s, 1H), 7.15 (s, 1H), 7.06 (s, 1H), 5.65(s, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 1.95-1.83 (m, 1H), 1.00-0.90 (m,2H), 0.70-0.62 (m, 2H). ESI-MS calculated for C₁₉H₂₀N₅O₂ [M+H]⁺=350.16;Observed: 350.25.

Step 9: ZYJ29 (287 mg, 0.62 mmol) was dissolved in anhydrous THF (10mL). NaH (180 mg, 3.0 mmol, 60% in mineral oil) was added in smallportions at 0° C. followed by addition of PhN(Tf)₂ (428 mg, 1.2 mmol) inone portion. The reaction warmed up to ambient temperature over 4 hbefore quenching with water. The aqueous layer was extracted with ethylacetate, the combined organic layers were washed with brine, then driedover anhydrous Na₂SO₄. The ethyl acetate was removed on a rotaryevaporator and the remaining residues containing ZYJ30 were used forSuzuki coupling without further purification.

Step 10: The crude ZYJ30 and3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoxazole(401 mg, 1.8 mmol) were dissolved in DME (9 mL) followed by addition ofNa₂CO₃ (2 M aqueous, 6 mL). The system was degased followed by additionof Pd(PPh₃)₄ (80 mg, 0.06 mmol) and the reaction was heated at refluxfor overnight. The aqueous layer was extracted with ethyl acetate, thecombined organic layers were washed with brine, then dried overanhydrous Na₂SO₄. The ethyl acetate was removed on a rotary evaporatorand the remaining residues were purified by reverse phase HPLC to yieldCpd. No. 323 in 60 mg as a salt of CF₃CO₂H.

Example 172 Competitive Fluorescence-Polarization (FP) Assays

Fluorescence Polarization (FP) competitive binding studies were carriedout using a FAM labeled fluorescent probe (ZBA248 or BRD-1F) todetermine binding affinities of representative Compounds of theDisclosure for recombinant BRD4 BD1 and BRD4 BD2 proteins. For example,equilibrium dissociation constants (K_(d)) values of ZBA248 to these sixproteins were determined from protein saturation experiments bymonitoring the total fluorescence polarization of mixtures composed withthe fluorescent probe at a fixed concentration and proteins withincreasing concentrations up to full saturation. Serial dilutions oftesting protein were mixed with ZBA248 to a final volume of 200 μl inthe assay buffer. In order to achieve large dynamic rages, particularlyfor BD1 bromodomains, 100 mM phosphate buffer (pH=6.5, 0.01% TritonX-100 (Sigma, 282103) being added right before assays) was used as theassay buffer. Final ZBA248 concentration was 1.5 nM for all proteins.Plates were incubated at room temperature for 30 minutes with gentleshaking to assure equilibrium. FP values in millipolarization units (mP)were measured using the Infinite M-1000 plate reader (Tecan U.S.,Research Triangle Park, N.C.) in Microfluor 1 96-well, black,round-bottom plates (Thermo Scientific, Waltham, Mass.) at an excitationwavelength of 485 nm and an emission wavelength of 530 nm. IQ values ofZBA248 were calculated by fitting the sigmoidal dose-dependent FPincreases as a function of protein concentrations using Graphpad Prism6.0 software (Graphpad Software, San Diego, Calif.).

The IC₅₀ and K_(i) values of representative Compounds of the Disclosurewere determined in a competitive binding experiment as described above.Mixtures of 10 μl of the tested compounds in assay buffer with 40%Ethylene Glycol and 190 μl of preincubated protein/probe complexsolution in the assay buffer (100 mM potassium phosphate, pH 6.5, 0.01%Triton X-100) were added into assay plates which were incubated at roomtemperature for 30 minutes with gentle shaking. Final concentrations ofproteins were 10 and 6 nM in assays for BD1 and BD2 of BRD4,respectively. Final probe concentration is 1.5 nM in all assays.Negative controls containing protein/probe complex only (equivalent to0% inhibition), and positive controls containing only free probes(equivalent to 100% inhibition), were included in each assay plate. FPvalues were measured as described above. IC₅₀ values were determined bynonlinear regression fitting of the competition curves. Instead of beingcalculated from IC₅₀ values as described before, K, values ofcompetitive inhibitors were obtained directly by nonlinear regressionfitting as well, based upon the K_(d) values of the probe to differentproteins, and concentrations of the proteins and probes in thecompetitive assays (Wang, FEBS Lett. 360; 111 (1995); Zhang et al.,Analytical Biochemistry, 331; 138 (2004)).

Binding affinities of representative Compounds of the Disclosure to BRD4BD1 and BRD4 BD2 proteins in competitive, fluorescence-polarizationassays are presented in Table 2.

TABLE 2 IC₅₀ (nM) Cpd. No. BRD4 BD1 BRD4 BD2 1 na 21.8 2 na 41.9 3 540183 4 52.9 21.7 5 340 381 7 365 198 8 9.7 8.0 9 6.1 6.3 10 21.5 43.3 11240 235 12 na 28.2 13 >1000 >1000 14 14.6 22.6 15 10.1 18.8 16 248 19417 16.7 82.3 18 211 1159 19 200 613 21 13.3 34.6 22 49.1 40.623 >1000 >1000 24 >1000 >1000 25 >1000 >1000 26 >1000 >100027 >1000 >1000 29 >1000 >1000 32 26.5 39.4 33 24.5 21.5 34 30.2 28.7 3520.4 42.9 36 68.5 92.6 37 12.1 6.5 58 11 22.6 59 90.5 174 63 15.7 8.6 656.1 4.1 76 29.4 23.7 77 64.4 168 78 16 63.5 79 9.3 1.8 80 6.5 18.5 815.1 19.6 82 4.6 3.3 95 >1000 >1000 96 864 379 97 34 8 98 76 13 99 47 87100 99 89 101 978 786 102 18 17 103 29 38 104 >1000 810 105 >1000 868106 1414 619 107 92 33 108 58 21 109 284 253 110 73 33 111 312 218 112460 395 113 582 564 115 23.2 136 116 14 9.6 117 62.4 na 118 4.2 3.4 11911.4 10.6 120 9.6 5.8 121 1.6 3.2 122 4.3 2.3 123 257 483 124 5 29.5 1254.4 2 126 11 32.8 127 24.5, 55 133, >1000 129 105 202 131 9.6 51.4 13268.6 718 133 >1000 >1000 134 40.2 30.5 135 5.6 1.3 136 10.5 6.9 137 4.51.2 138 4.2 1.2 139 16.3 16.5 140 39.3 95 141 4.6 1.1 142 4.5 0.5 14327.9 57.7 144 2.1 0.7 145 18.9 56.9 146 13.7 7.7 147 59.9 93.7 148 7.9 5149 6.8 5.4 150 9.6 7.2 152 10.6 5.6 160 14.1 na 163 8.8 na 166 119 161169 14.3 23 170 44.9 56.5 171 153 79.5 172 57.2 49.5 173 31.7 25.1 174142 117 175 28.7 6.9 176 13.7 10.3 177 7.9 13.2 178 9 0.6 179 166 116181 4.4 10.2 182 15.6 23.6 183 9.6 6.1 185 4.9 12.3 186 33.9 55.1 18710.5 10.9 188 2.1 3.7 192 30.1 114 193 3.6 2.7 194 10.1 14.2 195 16.614.4 196 10 7.5 197 70.1 69.9 198 6.9 3.6 199 13.3 14.5 200 10.9 5.9 2065.6 na 207 2.9 1.3 210 >1000.0 >1000.0 211 16 17 212 18 8 213 54 28 214855 348 215 128 57 216 19 35 217 165 68 218 17 15 219 219 365 220 17 9221 49 57 222 183 276 223 47 55 224 105 33 225 213 108 226 21 20 227 1422 228 25 26 229 24 22 230 13 8 231 35 44 232 29 52 233 69 38 234 25 25235 41 52 236 14 59 237 10 5 238 5 3 239 19 28 240 13 20 241 16 29 242 912 243 15 14 247 165 121 248 70 79 249 29 99 250 12 14 251 9 5.5 25510.5 8.5 258 8.1 2.8 266 10.3 3.1 269 21.9 35.1

Binding affinities to BRD2 BD1 and BD2, BRD3 BD1 and BD2, and BRD4 BD1and BD2 can also be determined by a label free binding assay using theOctetRED label free biolayer interferometry (BLI) binding assay.

Example 173 Cell Growth Inhibition

Cell growth inhibitory activity of representative Compounds of theDisclosure was determined using CellTiter-Glo® Luminescent CellViability Assay. For leukemia cell lines MV-4-11 (ATCC, Manassas, Va.)and MOLM-13 (DSMZ, Germany), cells were seeded in 96-well white opaquecell culture plates at a density of 10,000 cells/well with seriallydiluted compounds and incubated at 37° C. in an atmosphere of 95% airand 5% CO2 for 4 days. Cell viability was determined using theCellTiter-Glo® Luminescent Cell Viability Assay Kit (Promega, Madison,Wis.) according to the manufacture's instruction. Briefly, a volume ofCellTiter-Glo® Reagent equal to the volume of cell culture medium wasadded to each well, and then the plates were incubated at roomtemperature for 10-20 minutes. The luminescent signal was measured usinga Tecan Infinite M1000 multimode microplate reader (Tecan, Morrisville,N.C.). The half maximal inhibitory concentration (IC50) was calculatedusing the GraphPad Prism 5 software (GraphPad Software, La Jolla,Calif.).

For breast cancer cell lines, cells were seeded in 96-well cell cultureplates at a density of 5,000-10,000 cells/well with serially dilutedcompounds and incubated at 37° C. in an atmosphere of 95% air and 5% CO2for 4 days. All the breast cancer cell lines were obtained from theATCC. Cell viability was determined using the WST-8(2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium,monosodium salt) based Cell Counting-8 Kit (Dojindo MolecularTechnologies, Inc., Rockville, Md.) according to the manufacture'sinstruction. Briefly, WST-8 was added to each well at a finalconcentration of 10% (v/v), and then the plates were incubated at 37° C.for 1-2 hours for color development. The absorbance was measured at 450nm using a SPECTRAmax PLUS plate reader (Molecular Devices, Sunnyvale,Calif.). The IC₅₀ was calculated using the GraphPad Prism 5 software.

For prostate cancer cell lines, VCaP prostate cancer cells were grown inDMEM with Glutamax (Gibco) supplemented with 10% FBS (Invitrogen) in 5%CO2 cell culture incubator. All cell lines were tested and found to befree of mycoplasma contamination. Cells were seeded in 96-well plates at2,000-10,000 cells per well (optimum density for growth) in a totalvolume of 100 ml media containing 10% FBS. Serially diluted compounds in100 ml media were added to the cells 12 h later. After 96 h incubation,cell viability was assessed by Cell-Titer GLO (Promega). The values werenormalized and IC₅₀ was calculated using GraphPad Prism software.

Cell growth inhibition of representative Compounds of the Disclosure inMOLM13 leukemia and MDA-MB-436 breast cancer cell lines are presented inTable 3, and in VCaP prostate cancer cell lines presented in Table 4.

TABLE 3 IC₅₀ (nM) MOLM-13 Cell Line MDA-MB-436 Cell Line Cpd. No.(CellTiter-Glo assay) (WST assay) 1 29.8 148.0 2 68.0 246.0 3 38.4 386 469.3 249 5 475 719 6 52.6 1522.0 7 56.3 142.0 8 10.3 55.1 9 5.0 29.6 1045.6 138 11 23.9 398.0 12 15.2 59.6 13 107.8 1077.0 14 23.7 83.3 15 5.133.7 16 14.6 529.0 17 28.4 51.0 18 86.2 140.6 19 108.6 323.3 21 21.952.7 22 77.5 84.8 29 82.1 1106.0 32 40.9 155.2 33 2419.0 302.7 34 32.797.6 35 38.9 88.9 36 103.3 236.2 37 54.1 56.2 58 32.0 54.6 59 401.0535.0 63 22.8 46.1 65 11.7 26.0 76 117.1 155.9 77 242.1 350.6 78 97.4271.0 79 43.9 121.3 80 26.1 55.2 81 22.9 67.0 82 10.5 13.8 97 43.0 180.098 171.0 380.0 99 206.0 307.0 100 147.0 235.0 101 266.0 811.0 102 510.0363.0 103 39.0 120.0 104 603 3.4 105 371 885 106 56.0 618.0 107 8.0229.0 108 19.0 181.0 109 12.0 679.0 110 16.0 354.0 111 7.0 1100.0 11215050.0 2429.0 113 853.0 1100.0 115 30.7 81.1 116 15.4 26.3 117 90.9177.0 118 17.7 25.0 119 38.8 26.0 120 23.0 23.5 121 11.7 11.2 122 6.07.8 123 759.0 1420.0 124 41.9 58.3 125 11.3 17.5 126 65.3 140.0 127178.0 508.0 129 144.0 201.0 131 32.7 97.6 132 97.5 224.0 133 433.047870.0 134 32.0 128.0 135 30.2 57.6 136 26.6 63.2 137 4.3 11.3 138 5.730.3 139 49.2 110.2 140 120.0 210.0 141 1.6 13.6 142 1.1 7.3 143 98.0175.0 144 3.0 14.5 145 69.5 170.0 146 26.0 39.2 147 201.0 319.0 148 3.420.4 149 7.2 14.2 150 7.2 29.8 152 19.0 34.0 166 503.5 1425.0 169 63.393.9 170 131.2 222.0 171 609.0 1533.0 172 453.2 634.0 173 121.3 197.6174 108.2 118.0 175 40.5 71.0 176 52.9 83.3 177 78.6 109.6 178 22.5 52.9179 2083.0 329.5 181 22.2 22.9 182 34.8 98.0 183 29.7 83.7 185 17.0 71.0186 27.1 132.3 187 38.8 121.4 188 3.2 12.8 192 114.0 422.0 193 8.1 47.5194 13.2 59.6 195 29.1 75.1 196 32.7 52.5 197 357.0 511.0 198 25.7 58.7199 30.5 67.9 200 25.4 40.0 210 1130.0 na 211 76.0 57.0 212 103.0 112.0213 103.0 211.0 214 208.0 249.0 215 318.0 360.0 216 220.0 292.0 217498.0 1930.0 218 9340.0 na 219 912.0 849.0 220 37.0 72.0 221 189.0 209.0222 629.0 731.0 223 115.0 152.0 224 192.0 740.0 225 189.0 315.0 226 94.091.0 227 31.0 62.0 228 87.0 129.0 229 69.0 88.0 230 71.0 123.0 231 28.079.0 232 62.0 238.0 233 101.0 222.0 234 34.0 139.0 235 74.0 146.0 23649.0 117.0 237 41.0 72.0 238 39.0 61.0 239 22.0 43.0 240 20.0 46.0 24133.0 76.0 242 24.0 47.0 243 61.0 162.0 247 113.0 115.0 249 159.0 302.0250 21.0 67.0 251 11.0 23.0 255 12.0 26.0 269 97.4 154.4

TABLE 4 IC₅₀ (nM) VCaP Cell Line Cpd. No. (CellTiter-Glo assay) 137 23.4141 19.3 144 53.8 185 64.7

Additional biological data from the assays described above are providedin Table 5.

TABLE 5 Cellular data (nM) Binding affinities (FP) MDA- BRD4BD1 BRD4BD2MB-436 LNCaP Cpd. IC50 K_(i) IC50 K_(i) IC₅₀ IC₅₀ No. (nM) (nM) (nM)(nM) (nM) (nM) 281 6.1 2.0 3.6 5.7 351 116 282 6.1 1.3 0.5 1.0 33 22 2834.5 0.6 5.0 0.9 19 12 284 10 3.0 10.6 2.6 268 105 285 18.9 3.7 9.8 2.1286 28.7 5.1 18.5 4.6 287 3.1 <1 1.4 <1 58 81 288 4.9 <1 1.6 <1 13 37289 2.4 <1 2.2 <1 57 130 290 4.8 <1 4.5 <1 19 12 291 5.2 1.5 4.9 1.0 3720 292 2.0 <1 2.3 <1 12 7 304 63 15 318 94 N/A N/A 305 >5000 N/A 850 3421193 1165 306 129 30 43 10 67 534 307 16 3.8 18 4.3 130 59 308 23 5.0 255.3 181 106 309 18 4.1 40 13 141 136 310 378 143 313 113 1280 N/A 3111087 602 >1000 N/A 1100 N/A 312 378 140 346 101 1055 N/A 313 4067 11984073 1144 >2000 N/A 314 457 146 986 209 >2000 N/A 315 28 7.8 16 4.7 164N/A 316 317 106 311 106 1018 N/A 317 74 27 139 44 1138 N/A 318 35 12 10834 299 N/A 319 102 38 92 27 646 N/A 320 10.2 1.8 7 1.3 85 N/A 321 482171 796 239 4428 N/A 322 199 68 214 67 646 674 323 11.8 1.6 5.9 1.2 1521

Example 174 AR Signaling is Blocked by BET Bromodomain Inhibitors

A panel of 5 prostate cancer and 1 benign prostate cell line was treatedwith the JQ1. Three of the AR-signaling positive cells were found to besensitive to JQ1, though all six cell lines express high levels of itstarget proteins (FIG. 1). Next, knockdown of BRD2/3/4 (data not shown)showed significant inhibition of cell proliferation/invasion,phenocopying JQ1-treatment (data not shown). Further, JQ1-treatmentinduced G₀-G₁ arrest, apoptosis and associated transcriptionaldownregulation of the anti-apoptotic BCL-x1 protein in AR-positive cells(FIG. 2) (Filippakopoulos, P. et al., Nature 468:1067-1073 (2010);Mertz, J. A. et al., Proc Natl Acad Sci USA 108:16669-16674 (2011)).Similar to BCL2 down-regulation by the BET-inhibitor, I-BET151, inleukemia (Dawson, M. A. et al., Nature 478:529-533 (2011)); reduction inBCL-x1 by JQ1 could in part be explained by the observation of loss ofBRD2/3/4 recruitment to its promoter region (data not shown). Even at100 nM, long term colony-formation of AR-positive cells were severelyinhibited with JQ1 (FIG. 3) with no apparent effect on JQ1 targetproteins (data not shown). As AR-positive cells were preferentiallysensitive to JQ1, it was examined whether JQ1 has an effect on AR-targetgenes. VCaP cells, which harbor the TMPRSS2-ERG gene fusion and ARamplification (Tomlins, S. A. et al., Science 310:644-648 (2005)),displayed a dose-dependent decrease in PSA and ERG-both at the mRNA andprotein level (FIGS. 4 and 5). Similar effects of JQ1-treatment wereseen in LNCaP and 22RV1 cells (data not shown). Furthermore, bortezomibdid not reverse the JQ1-mediated PSA and ERG protein loss, indicatingthat these genes are regulated at the transcriptional level (data notshown). Microarray analysis was performed to examine changes in globalgene expression upon JQ1-treatment. Gene Set Enrichment Analysis (GSEA)using the AR-gene signature (Table 6), revealed these genes weresignificantly repressed in AR-positive cells (FIG. 6) suggestingBET-protein regulation of AR-mediated transcription. Additionally, aloss of the MYC associated gene signature was observed in AR-positivecell lines upon JQ1-treatment (Table 7). MYC is a known transcriptionaltarget of BET-inhibition in hematological cancers (Delmore, J. E. etal., Cell 146:904-917 (2011); Mertz, J. A. et al., Proc Natl Acad SciUSA 108:16669-16674 (2011)). MYC levels were attenuated by JQ1 in cellswhich are AR-positive and sensitive to JQ1 inhibition, but not inAR-negative cells (data not shown). Thus, high expression of MYC per se(data not shown) does not confer sensitivity to JQ1 in prostate cancercells. Time-course experiments with JQ1 demonstrated loss of MYC (datanot shown), and cyclohexamide had no additional effect on MYC protein(data not shown), ruling out a post-translational mode of JQ1 action onMYC proteins. Phenotypically, knockdown of MYC did not affect cellinvasion (data not shown), while JQ1-treatment inhibited invasion (datanot shown). Additionally, exogenous expression of MYC did not result ina rescue of JQ1-mediated inhibition of cell growth (data not shown).Thus, while MYC levels may be repressed by JQ1 in AR-positive cells, andmay have a role in proliferation, MYC does not appear to be the primarytarget for the anti-neoplastic effects of JQ1.

JQ1 block or AR target gene transcription (FIGS. 4-6) suggested that ARmay interact with BRD4 which is known to engage sequence-specific DNAbinding proteins (Wu, S. Y. et al., Mol Cell 49:843-857 (2013)).Gel-filtration-chromatography were performed and it was found that ARand BRD4 predominantly eluted together in a high-molecular weightcomplex (FIG. 7). Moreover, RNA PolII which was reported as a target forphosphorylation by BRD4 (Devaiah, B. N. et al., Proc Natl Acad Sci USA109:6927-6932 (2012)) also co-eluted in the same complex, suggestive ofthe existence of a large multi-protein complex consisting of AR, BRD4and RNA PolII. Immunoprecipitation experiments further confirmed anendogenous association between AR and BRD4 (FIG. 8). Additionally, aninteraction between AR and BRD2/3 (FIG. 8) was observed, implying acommon region in BRD2/3/4 proteins responsible for AR interaction. Inorder to map the region mediating this interaction, the ability ofdifferent deletion variants of BRD4 to pull-down AR in 293T cells (FIG.9) was tested. It was found that truncated version of BRD4 whichcomprised BD1-BD2 domains maintained the ability to pull-down AR even athigh salt concentrations (FIGS. 10 and 11). To determine whether theBD1-BD2 domains directly interact with AR, quantitative assessment ofthe binding affinity using the Octet-RED system was carried out. Varyingconcentrations of BD1-BD2 protein were applied to biosensors withimmobilized AR, and it was found that BRD4 interacts with AR in aconcentration dependent fashion, with an estimated Kd of 70 nM,supporting a high affinity interaction (FIG. 12). This interaction wasfine-mapped to create a series of Halo-AR and GST-BRD4 constructs for invitro pull-down studies that demonstrated that the BD1, and to a lesserextent the BD2, of BRD4 bind directly to NTD-domain of AR, which wasfurther mapped to a 38 amino acid region NTD1b of AR (FIGS. 13-15).Subsequently, the disruption of BD1-AR and BD1-NTD1b interactions by JQ1(FIG. 16) was observed. Likewise, JQ1 treated VCaP displayed loss of theendogenous BRD4-AR interaction (data not shown). Together, these datasuggest that BET protein inhibition leads to disruption of the AR-BRD4interaction and may account for the preferential activity of JQ1 inAR-positive prostate cancer cells.

Ubiquitously expressed BRD2/3/4 proteins are suggested to haveoverlapping functions (Dawson, M. A. et al., Nature 478:529-533 (2011);Filippakopoulos, P. et al., Nature 468:1067-1073 (2010); Belkina, A. C.and Denis, G. V., Nat Rev Cancer 12:465-477 (2012) and consistent withthis, AR interaction with BRD2/3/4 was observed. BET-inhibitors such asJQ1 and I-BET762 are known for their high affinity binding towardBD1/BD2 domain of BRD2/3/4 proteins (Dawson, M. A. et al., Nature478:529-533 (2011); Delmore, J. E. et al., Cell 146:904-917 (2011);Filippakopoulos, P. et al., Nature 468:1067-1073 (2010)). This suggeststhat BET-inhibitors might affect genome-wide recruitment of all thethree BET-proteins. Towards this end, ChIP-seq with antibodies againstBRD2/3/4 in VCaP cells treated with JQ1 or I-BET762 (Table 8) wasperformed. A high genome-wide overlap between BRD2/3/4 (62-86% peakoverlap) was observed (data not shown). JQ1 or I-BET762 treatment led toa reduction in the recruitment of all three proteins to the chromatin(data not shown). Moreover, this reduced BRD2/3/4 recruitment wasequally distributed for regions with or without AR (data not shown).

Binding of androgen (DHT) to AR leads to its activation/translocationfrom the cytoplasm to the nucleus where it binds to regions of DNAcomprising AREs and results in subsequent recruitment of proteinsinvolved in transcriptional activation or suppression in a gene-specificmanner. BRD4 interacts with acetylated histones as well as DNA bindingtranscription factors, leading to context-dependent transcriptionalactivation or inhibition of target genes (Jang, M. K. et al., Mol Cell19:523-534 (2005); Wu, S. Y. et al., Mol Cell 49:843-857 (2013);Belkina, A. C. and Denis, G. V., Nat Rev Cancer 12:465-477 (2012)).Since the AR-BRD4 interaction is disrupted by JQ1 (FIGS. 7-16), it wasexplored whether this affects AR localization in a genome-wide context.ChIP-seq with antibodies against AR, BRD4, and RNA PolII in cells thatwere either starved, treated with DHT, or DHT plus JQ1 (Table 8) wereperformed. Two anti-androgens, bicalutamide and MDV3100 were used forcomparison. The average ChIP-seq signal for AR was highly enriched inDHT-treated cells (FIG. 17). Recruitment of AR to target loci wasmarkedly attenuated by MDV3100 and less so by bicalutamide. JQ1 couldblock AR recruitment to a level almost equivalent to MDV3100 (FIG. 17).Furthermore, a co-recruitment of AR and BRD4 at 2031 sites was observed.The strongest association is observed within promoters of AR-regulatedgenes (502 promoters, p=4e-49), and for the highest AR peaks (1112sites, p=le-38) (FIG. 18). Limiting the evaluation to AR and BRD4coincident peaks, it was observed that DHT can mediate AR recruitment tothese loci which was inhibited by MDV3100 and to a lesser extent by JQ1(FIG. 19). By contrast, JQ1 almost completely abrogated DHT induced BRD4recruitment to the AR-BRD4 shared loci (FIG. 20). Examples of genetracks for AR and BRD4 associated genomic regions such as enhancers andsuper-enhancers (Loven, J. et al., Cell 153:320-334 (2013)) and theeffects of different treatments on their levels are shown in FIG. 21. Incorroboration with the ChIP-seq data, gene expression analysis in VCaPand LNCaP cells displayed efficient repression of DHT-induced AR-targetgenes by JQ1 than MDV3100 or bicalutamide (data not shown).

Next, the oncogenic ERG expression in VCaP cells was explored sinceJQ1-treatment had a marked effect on its expression (FIGS. 4 and 5). Theattenuation of DHT induced ERG expression by JQ1 was due tode-recruitment of RNA PolII from ERG gene body and reduced binding of ARand BRD4 on the TMPRSS2 promoter/enhancer (data not shown). Thisefficient ERG downregulation by JQ1 is compelling considering that theTMPRSS2-ERG gene fusion product is a key oncogenic driver in 50% ofprostate cancers (Tomlins, S. A. et al., Science 310:644-648 (2005);Chen, Y. et al., Nat Med 19:1023-1029 (2013)). Next, the effect of JQ1on ERG mediated transcription was investigated. Towards this, ERGChIP-seq in cells treated with JQ1 for 12 h was performed; a time windowwhere ERG protein levels were still unaffected by JQ1 (data not shown).A significant loss in the -top 4% ERG enriched peaks was observed (datanot shown). Next, the functional consequence of ERG de-recruitment bytesting the expression of several of its target genes afterJQ1-treatment was determined (data not shown). The ERG activated geneswere down-regulated and ERG repressed genes were de-repressed by JQ1(data not shown). To confirm the BET-inhibitors role in blocking ERGmediated oncogenic function in an isogenic setting, RWPE and PC3 cellsoverexpressing ERG were tested (data not shown). Treatment of JQ1 orI-BET762 led to attenuation of ERG-mediated invasion (data not shown)and GSEA demonstrated a highly significant negative enrichment for ERGtarget genes in these cells upon BET-inhibitor treatment (data notshown). Next, it was investigated whether ERG is involved in thetranscriptional regulation of MYC. ERG was found to be highly enrichedon the known distal-enhancer of MYC; but was reduced upon JQ1-treatment(data not shown). Likewise, ETV1 occupies the same distal-enhancerregion in ETV1 fusion positive LNCaP (Chen, Y. et al., Nat Med19:1023-1029 (2013). Knockdown of ERG and ETV1 along with AR led to MYCdown-regulation, implicating ETS transcription factors in the regulationof MYC in fusion-positive prostate cancer cells (data not shown).ChIP-seq analysis of AR and RNA PolII enrichment at the MYC locuspresented an interesting pattern where DHT treatment led to increased ARand reduced RNA PolII binding on the MYC distal-enhancer and gene bodyrespectively, that was reinstated in the presence of MDV3100 orbicalutamide but not by JQ1 (data not shown), and this result wassupported by the observed concomitant reduction in MYC expression uponDHT treatment that was de-repressed in the presence of MDV3100 but notby JQ1 (data not shown). Lack of de-repression of MYC by JQ1 in thissetting could be explained by the fact that both AR and ERG are absentfrom the MYC distal-enhancer leading to net loss of MYC expression. Thisdata also suggests a mechanism by which CRPC may become resistant toanti-androgen therapy by maintaining expression of the MYC oncogene.

JQ1 efficacy in comparison to MDV3100, a direct AR antagonist usedclinically for advanced CRPC, was studied (Scher, H. I. et al., N Engl JMed 367:1187-1197 (2012)). Before embarking on the in vivo experiment,JQ1 and MDV3100 were tested on VCaP cells in vitro for 8 days. Marginalcell death for MDV3100 versus suppression of cell growth atsub-micromolar concentrations by JQ1 was observed (FIG. 22). No effecton physiologic androgen-regulated processes was found suggesting thatJQI does not act a generic anti-androgen However, JQ1 reduced testessize in mice as reported earlier (Lin, T. H. et al., Cell Death Dis4:e764 (2013)). (data not shown). Treatment of VCaP tumor-bearing micewith JQ1 led to significant reduction in tumor volume/weight (FIGS.23-25). However, MDV3100 had a less pronounced effect. Recently, severalstudies described the pro-metastatic effects of MDV3100 in pre-clinicalmodels (Lin, T. H. et al., Cell Death Dis 4:e764 (2013)). WhetherMDV3100 treatment leads to spontaneous metastasis in the VCaP xenograftmodel was tested. Towards this, femur, liver and spleen from MDV3100treated mice were isolated, and evidence of metastases in femur andliver was observed (data not shown). By contrast, JQ1 treated micedisplayed no evidence of metastasis (data not shown). Taken together,these pre-clinical studies suggest that the use of MDV3100 in clinicallylocalized prostate cancer may potentiate the formation ofmicro-metastases, which would not be the case with BET-inhibitors.Consistent with previous reports JQ1 and MDV3100 were well tolerated bymice (data not shown). Although VCaP cells were originally derived froma patient with CRPC, VCaP tumor xenograft respond to castration in mousemodels. Whether JQ1 would still have a growth inhibitory effect incastration-resistant VCaP tumor xenografts was studied, and a 50%reduction in these castration-resistant tumors by JQ1-treatment wasobserved (FIG. 26).

Maintenance of AR signaling has been identified as the most commonresistance mechanism that patients with advanced prostate cancer developafter conventional hormonal treatments (Harris, W. P. et al., Nat ClinPract Urol 6:76-85 (2009)). AR amplification, mutation, and alternativesplicing have all been suggested as potential resistance mechanisms toanti-androgen treatments (Chen, C. D. et al., Nat Med 10:33-39 (2004);Taplin, M. E. et al., Cancer Res 59:2511-2515 (1999); Sun, S. et al., JCln Invest 120:2715-2730 (2010)). Over half of CRPC patients have atleast one of these aberrations in the AR pathway (Grasso, C. S. et al.,Nature 487:239-243 (2012). As BET-inhibitors function “downstream” of ARitself (FIG. 27), these data suggest that these compounds may beeffective in the context of AR directed resistance mechanisms includingcompensatory mechanisms involving related steroid hormone receptorswhich are also likely to require BET bromodomain function. Byfunctioning downstream of AR, BET-inhibition is less likely to beaffected by acquired resistance associated with AR antagonists,including the recently identified F876L mutation of AR (Balbas, M. D. etal., Elife 2:e00499 (2013)). While both MDV3100 and JQ1 block ARrecruitment to target loci on a genome-wide scale (the “AR cistrome”),it was found that JQ1 likely has an enhanced effect by fully abrogatingco-recruitment of BRD4, which is required for mobilization of thetranscriptional machinery (Jang, M. K. et al., Mol Cell 19:523-534(2005); Yang, Z. et al., Mol Cell 19:535-545 (2005)). A recent studydemonstrated that BET-inhibition leads to preferential loss of BRD4 at“super-enhancers” and consequent transcriptional elongation defects(Loven, J et al. Cell 153:320-334 (2013)). These super-enhancers wereoften associated with key oncogenic drivers in a variety of cancers.Tumor cells are thought to become addicted to selected oncogenes, andbecome unusually reliant on their high expression which may explain thepreferential sensitivity of BET-inhibition in cancer versus normaltissues. While MYC and its association with multiple myeloma washighlighted as a super-enhancer dependent cancer (Loven, J. et al. Cell153:320-334 (2013)), this framework likely applies to key transcriptionfactors involved in the development of CRPC including AR, ETS, and MYC(FIG. 27). Taken together, these data strongly suggest the clinicalevaluation of BET-inhibitors is warranted in CRPC, either as monotherapyor in combination with second generation anti-androgens.

Methods Cell Culture

VCaP prostate cancer cells were grown in DMEM with Glutamax (Gibco),LNCaP, 22RV1, DU145 and PC3 prostate cancer cell lines were grown inRPMI 1640, all were supplemented with 10% FBS (Invitrogen) in 5% CO₂cell culture incubator. The immortalized benign prostate cell lineRWPE-1 was grown in keratinocyte media with supplements (Lonza). Allcell lines were tested and found to be free of mycoplasma contamination.

Cell Viability Assay

Cells were seeded in 96-well plates at 2000-10,000 cells/well (optimumdensity for growth) in a total volume of 100 μl media containing 10%FBS. Serially diluted compounds in 100 μl media were added to the cells12 h later. Following 96 h. incubation, cell viability was assessed byCell-Titer GLO (Promega). The values were normalized and IC50 wascalculated using GraphPad Prism software. For long-term colony formationassay, 10,000-50,000 cells/well were seeded in six-well plates andtreated with either 100 nM or 500 nM of JQ1 or DMSO. After 12 days cellswere fixed with methanol, stained with crystal violet and photographed.For colorimetric assays, the stained wells were treated with 500 μl 10%acetic acid and the absorbance was measured at 560 nm using aspectrophotometer.

Cell Cycle Analysis

Cells were grown in 6 well plates and treated with varyingconcentrations of JQ1. For cell cycle analysis, cells were washed 48 hpost-treatment with PBS and fixed in 70% ethanol overnight. The cellswere washed again with PBS, stained with propidium iodide and analyzedby flow cytometry.

RNA Interference

For knockdown experiments, cells were seeded in six-well plates andtransfected with 100 nM ON-TARGETplus SMARTpool siRNA (ThemoScientific)targeting BRD2, BRD3, BRD4, MYC or non-targeting control usingoligofectamine (Invitrogen) according to the manufacturer'sinstructions. Cells were trypsinized 24 h post-transfection and used incell proliferation and matrigel invasion assays as well as for RNAextractions to determine the knockdown efficiency. AR, ERG and ETV1knockdown was achieved by transfecting 100 nM specific ON-TARGETplusSMARTpool siRNA using oligofectamine.

Cell Proliferation Assay

For cell proliferation assays post siRNA knockdown, 20,000 cells/wellwere seeded in 24-well plates (n=3), and cells were harvested andcounted at the indicated time points by Coultercounter (Beckman Coulter,Fullerton, Calif.).

VCaP, LNcaP and 22RV1 cells were transduced with either Ad-c-MYC (VectorBiolabs, cat. No. 1285) or LacZ control Adeno viral particles. 24 h postinfection; equal number of cells were seeded in 24 well plates andtreated with vehicle, JQ1 or I-BET762 at 500 nM concentration. Cellswere counted at the indicated time points by Coulter Counter.

Matrigel Invasion Assays

Twenty-four hours post-infection with siRNA or 500 nM JQ1 treatment,0.2×10⁶ VCaP or 0.1×10⁶ LNCaP cells were seeded in a transwell chamberpre-coated with Matrigel (BD Biosciences). Medium containing 10% FBS inthe lower chamber served as chemoattractant. In the case of JQ1, 500 nMcompound was added to both upper and lower chambers. After 48 h, thenon-invading cells and EC matrix were gently removed with a cotton swaband invasive cells located on the lower side of the chamber were stainedwith crystal violet, air dried, photographed and counted.

PC3 and RWPE cells were treated with JQ1 or I-BET762 at 500 nMconcentration along with DMSO control for 24 h prior to seeding 50,000cells/well in a transwell chamber pre-coated with Matrigel along withthe corresponding drugs used for treatment. Medium containing 10% FBS inthe lower chamber served as chemoattractant. After 48 h, thenon-invading cells and EC matrix were gently removed with a cotton swaband invasive cells located on the lower side of the chamber were stainedwith crystal violet, air dried and photographed. For colorimetricassays, the inserts were treated with 150 μl of 10% acetic acid and theabsorbance measured at 560 nm using a spectrophotometer (GE Healthcare).

RNA Isolation and Quantitative Real-Time PCR

Total RNA was isolated from cells using RNeasy Mini Kit (Qiagen) andcDNA was synthesized from 1,000 ng total RNA using SuperScript IIIFirst-Strand Synthesis SuperMix (Invitrogen). QPCRs were performed induplicate or triplicate using Taqman assays (Applied Biosystems) orstandard SYBR green reagents and protocols on a StepOnePlus Real-TimePCR system (Applied Biosystems). The target mRNA expression wasquantified using ΔΔCt method and normalized to GAPDH expression. Allprimers were designed using Primer 3 (http://frodo.wi.mit.edu/primer3/)and synthesized by Integrated DNA Technologies (Coralville, Iowa). Theprimer sequences for the SYBR green and catalogue numbers for TaqManassays used are provided in Table 9.

Antibodies and Immunoblot Analyses

Antibodies used in the study are listed in Table 10. All antibodies wereemployed at dilutions suggested by the manufacturers. For Western blotanalysis, 200 ug total protein extract was boiled in sample buffer and10-20 g aliquots were separated by SDS-PAGE and transferred ontoPolyvinylidene Difluoride membrane (GE Healthcare). The membrane wasincubated for one hour in blocking buffer [Tris-buffered saline, 0.1%Tween (TBS-T), 5% nonfat dry milk] followed by incubation overnight at4° C. with the primary antibody. Following a wash with TBS-T, the blotwas incubated with horseradish peroxidase-conjugated secondary antibodyand signals were visualized by enhanced chemiluminescence system as permanufacturer's protocol (GE Healthcare).

Immunoprecipitations

For endogenous immunoprecipitation experiments, nuclear extracts wereobtained from VCaP and LNCaP cells using NE-PER nuclear extraction kit(Thermo Scientific). Nuclear pellet was then lysed in IP buffer (20 mMTris pH7.5, 150 mM NaCl, 1% Triton-X 100, Protease Inhibitor) bysonication. Nuclear lysates (0.5-1.0 mg) were pre-cleaned by incubationwith protein G Dynabeads (Life Technologies) for 1 h. on a rotator at 4°C. 5 μg antibody was added to the pre-cleared lysates and incubated on arotator at 4° C. overnight prior to the addition of protein G Dynabeadsfor 1 h. Beads were washed thrice in IP buffer and resuspended in 40 μLof 2× loading buffer and boiled at 90° C. for 10 minutes for separationof the protein and beads. Samples were then analyzed by SDS-PAGE andwestern blotting as described above. For endogenous competitive assays,the VCaP cells were incubated with 5 or 25 μM JQ1 for 6 h prior tonuclear protein extractions.

For co-immunonoprecipitation experiments in 293T cells, plasmidsencoding different deletions of BRD4 in pCDNA4c, (Addgene) and fulllength AR in pFN21 plasmid (Promega) were transfected using Fugene 6.0HD (Roche) according to the manufacturer's instruction. Twenty four hpost transfection; total proteins were extracted using IP buffersupplemented with protease inhibitor cocktail mix (Sigma), and checkedfor the expressions of the corresponding proteins by immunoblotting.Immunoprecipitation using Halo-beads followed by immunoblotting withanti-His antibody were performed as described above.

Cell Free Protein-Protein Interaction Studies

In vitro protein expression was carried out by cloning the desiredexpression cassettes downstream of a Halo- or GST-tag to create fusionproteins. Briefly, AR and its sub-domains were cloned into the pFN2Kvector containing N-terminal GST sequence (Cat.# G1891, Promega); BRD4and its sub-domains were cloned into the pFN19A vector containingN-terminal Halo sequence (Cat.# C8461, Promega). After cloning, thefusion proteins were expressed using the cell-free transcription andtranslation system (Cat.# L5030, Promega) following the manufacturer'sprotocol. For each reaction, protein expression was confirmed by Westernblot.

A total of 10 μl cell-free reaction containing halo- and GST-tag fusionproteins were incubated in PBST (0.1% tween) at 4° C. overnight. Tenmicroliter HaloLink beads (Cat.# G931, Promega) were blocked in BSA at4° C. for overnight. After washes with PBS, the beads were mixed withAR-BRD4 mixture and incubated at RT for 1 h. Halolink beads were thenwashed with PBST for 4 times and eluted in SDS loading buffer. Proteinswere separated on SDS gel and blotted with anti-GST Ab (GE healthcare).For competitive assay, AR-BD1, NTD1b-BD1 and AR-BD2 mixture wasincubated in the presence of different dose of JQ1.

AR:BRD4 Direct Interaction Assays by OctetRED

The binding affinity between AR and BRD4 was determined by biolayerinterferometry technology using the OctetRED system (ForteBio).Recombinant AR protein (Cat.# AR-8486H, Creative Biomart) wasbiotinylated by EZ-Link NHS-PEG4 Biotinylation Kit (Cat.#21329, ThermoScientific) following the manufacturer's protocol and any unincorporatedbiotin was removed from the reactions with Zeba 2 ml desalt columns.Biotinylated proteins (5 μg/ml) were then incubated with superstreptavidin biosensors (Cat.#18-5057, ForteBio) in binding buffer (20mM HEPES pH 7.4, 150 mM NaCl) and washed three times in binding buffer.BRD4 (BD1-BD2) protein (Cat.#31047, BPS Biosciences) was seriallydiluted in binding buffer, and the AR:BRD4 association/dissociation wasmonitored by OctetRED for 10 min at 25° C. Non-specific binding wascontrolled by subtracting the signal obtained from AR:RNF2 interactionsfrom that of AR:BRD4 interactions and baseline signal drift wascontrolled by monitoring immobilized AR without BRD4. OctetRED analysissoftware was used to analyze the data.

Gene Expression Array Analysis

VCaP, LNCaP, 22RV1 and DU145 cells were treated with 500 nM JQ1 for 24 hand total RNA extracted using RNeasy Mini Kit (Qiagen) for geneexpression array analysis. For anti-androgen comparative study, VCaP andLNCaP cells were grown in media containing 10% charcoal-striped serumfor 48 h followed by pre-treatment with 500 nM JQ1, 10 μM MDV3100 or 25μM Bicalutamide for 6 h and stimulated with 10 nM DHT (androgen) for 18h. Cells treated with only vehicle or 10 nM DHT served as controls. Forthe effect of BET inhibitors in isogenic ERG system, RWPE-ERG andPC3-ERG cells were treated with 500 nM JQ1 or I-BET762 for 24 h.Expression profiling was performed using the Agilent Whole Human GenomeOligo Microarray (SantaClara, Calif.) according to the manufacturer'sprotocol. All samples were run in technical duplicates or quadrupletsagainst control. Over- and under-expressed gene sets were generated byfiltering to include only 2-fold average over- or underexpression (Logratio with p<0.001) in all hybridizations. Gene Set Enrichment Analysis(GSEA) was performed using the JAVA program(http://www.broadinstitute.org/gsea) as described in Subramanian, A. etal., Proc Natl Acad Sci USA 102:15545-15550 (2005).

The AR target gene signature used in GSEA analysis was generated fromcommon up-regulated genes in VCaP and LNCaP upon DHT treatment and thegene list is provided in Table 6.

The ERG gene signature was generated by extracting 2-fold up genes fromRWPE and PC3 cells stably expressing ERG compared to respective LacZexpressing cells. GSEA was performed using this gene set on geneexpression data obtained from the JQ1 and I-BET762 treated RWPE and PC3cells. GSEA using gene set that were not changed upon expression of ERGto exclude the possibility that treatment with JQ1 and I-BET762 maychange gene expression in a non-specific fashion was also tested.

Chromatin Immunoprecipitation (ChIP) and ChIP-Seq

The ChIP assays for BRD2, BRD3, BRD4, AR, RNA PolII, ERG and H3K27acwere performed using HighCell ChIP kit (Diagenode) according tomanufacturer's protocol. For BRD2/3/4 ChIP-seq experiments with BETinhibitors, VCaP cells were treated with 500 nM JQ1 or I-BET762 for 12h. For AR signaling ChIP-seq experiments, VCaP cells were grown incharcoal-stripped serum containing media for 48 h followed by 6 hpre-treatment with vehicle or 500 nM JQ1 or 10 M MDV3100 or 25 μMBicalutamide and then stimulated with 10 nM DHT for 12 h. For ERGChIP-seq studies, VCaP cells were treated with 500 nM JQ1 or vehicle for12 h. Next, cells were cross-linked for 10 min. with 1% formaldehyde.Cross-linking was terminated by the addition of 1/10 volume 1.25 Mglycine for 5 min. at room temperature followed by cell lysis andsonication (Bioruptor, Diagenode), resulting in an average chromatinfragment size of 200 bp. Chromatin equivalent to 5×10⁶ cells were usedfor ChIP using different antibodies. ChIP DNA was isolated (IPure Kit,Diagenode) from samples by incubation with the antibody at 4° C.overnight followed by wash and reversal of cross-linking. The ChIP-seqsample preparation for sequencing was performed according to themanufacturer's instructions (Illumina). ChIP-enriched DNA samples (1-10ng) were converted to blunt-ended fragments using T4 DNA polymerase, E.coli DNA polymerase I large fragment (Klenow polymerase) and T4polynuleotide kinase (New England BioLabs, NEB). A single A-base wasadded to fragment ends by Klenow fragment (3′ to 5′ exo minus; NEB)followed by ligation of Illumina adaptors (Quick ligase, NEB). Theadaptor-modified DNA fragments were enriched by PCR using the IlluminaBarcode primers and Phusion DNA polymerase (NEB). PCR products were sizeselected using 3% NuSieve agarose gels (Lonza) followed by gelextraction using QIAEX II reagents (QIAGEN). Libraries were quantifiedwith the Bioanalyzer 2100 (Agilent) and sequenced on the Illumina HiSeq2000 Sequencer (100 nucleotide read length).

ChIP-Seq Analysis

ChIP-Seq Enrichment Levels:

ChIP enrichment levels within a peak (or site) were calculated from thesequencing data as follows: (1) reads were aligned to the HG19 referencegenome using Bowtie2 (Langmead, B. and Salzberg, S. L., Nat Methods9:357-359 (2012)) with all default settings. (2) Aligned reads weresorted using NovoSort and exact duplicates were removed using Samtools(Li, H. et al., Bioinformatics 25:2078-2079 (2009)). (3) For each peak(site) overlapping reads were counted and this count was divided by thelength of the peak or site. (4) To correct for differences in sequencingdepth and alignment coverage the values are further normalized by thenumber of aligned reads per million.

ChIP-Seq Reproducibility Plots:

To assess the biological variability of AR and ERG ChIP-seq experiments,the enrichment levels of their respective replicates were compared. Foreach replicate peaks were called using MACS with all default settingagainst an IgG control. Peaks within genomic regions prone totechnical-artifacts were exclude (Pickrell, J. K. et al., Bioinformatics27:2144-2146 (2011)). For each replicate pair, a set of concordant peaksas those overlapping in both replicates was defined. For each concordantpeak, enrichment levels within the union of the two overlapping peakswere calculated. The scatter plots include all peaks with enrichmentlevels up-to the 99th percentile.

Overlaps of Bromodomain Proteins:

The genome-wide distribution of BRD2, BRD3, and BRD4 peaks in DMSOtreated VcaP cells was compared. First, peaks for each of the proteinsusing MACS with all default settings and IgG control were called. Amoderately stringent significance cut-off (MACS score >100) was used.Next, all genomic regions that were enriched for at least one of theproteins were identified. Specifically, all stringent peaks were“reduced” using GenomicRanges (Lawrence, M et al., PLoS Comput Biol9:e1003118 (2013)). For each of those regions, it was established whichof the Bromodomain proteins were enriched to count the number ofoverlaps.

Drug-Induced Changes of Bromodomain Protein Enrichment Levels

For each protein (BRD2, BRD3, BRD4), quantitative changes in theirrespective enrichment levels upon drug treatment (I-BET762, JQ1)relative to the levels in the DMSO control were assessed. First, for allconditions and proteins, peaks were called as in Overlaps of bromodomainproteins were called. Next, for each protein separately, genomic thatwere enriched in any (union) of the treatment conditions (DMSO,I-BET762, or JQ1) were identified. Within those regions enrichmentlevels as described in (ChIP-seq enrichment levels) were quantified.Since enrichment levels of different proteins are not directlycomparable, all enrichments to the median level of the (DMSO) controlwere normalized.

Differential AR-BRD4 Enrichment and AR-BRD4 Overlap

HPeak, a Hidden Markov model (HMM)-based peak-calling software (Qin, Z.S. et al., BMC Bioinformatics 11:369 (2010)) designed for theidentification of protein-interactive genomic regions, was employed forChIP-seq peak determination. For enrichment plots shown in FIGS. 17, 19and 20, identified peaks for each sample are centered by peak summit andaverage coverage per million was counted within 1500 bp relative to thepeak center. The overlap of AR and BRD4 enriched regions were calculatedby BEDtools (Quinlan, A. R. and Hall, I. M., Bioinformatics 26:841-842(2010)) The significance of overlap between AR and BRD4 binding wascalculated using hypergeometric test based on the derived number ofassociated genes. The heatmap for AR peak enrichment was generated usingpython-based script on raw data and visualized using JavaTreeView(Saldanha, A. J., Bioinformatics 20:3246-3248 (2004)).

Differential ERG Enrichment:

Sites with significant differences in ERG levels between DMSO and JQ1treated cells were identified. First, concordant peaks (see ChIP-seqreproducibility plots) that were overlapping or in the +/−5 kbpproximity of annotated gene loci were identified. A gene locus wasdefined as the union of all of its known transcripts (Ensembl Genes 73).DESeq2 was used to assess the statistical significance of differences inERG enrichment levels. Although DESeq2 was originally developed forRNA-seq its statistical model is well-suited to count data in general.The tools' default multiple hypothesis correction method and reportpeaks with significant differences in ERG levels (adjusted P-value <0.1)was used. To assess quantitative differences in ERG levels atsignificantly “gained” (positive difference in ERG levels upon JQ1treatment) and “lost” (negative difference in ERG levels upon JQ1treatment) the same procedure as in ChIP-seq enrichment levels wasfollowed.

Murine Prostate Tumor Xenograft Model

Four week-old male SCID C.B17 mice were procured from a breeding colonyat University of Michigan. All procedures involving mice were approvedby the University Committee on Use and Care of Animals (UCUCA) at theUniversity of Michigan and conform to all regulatory standards. Micewere anesthetized using 2% Isoflurane (inhalation) and 2×10⁶ VCaPprostate cancer cells suspended in 100 μl of PBS with 50% Matrigel (BDBiosciences) were implanted subcutaneously into the dorsal flank on bothsides of the mice. Once the tumors reached a palpable stage (100 mm³),the animals were randomized and treated with either 10 mg/kg body weightMDV3100 or 50 mg/kg body weight (doses previously used in mouse prostatecancer and multiple myeloma models) (Delmore, J. E. et al., Cell146:904-917 (2011); Tran, C. et al., Science 324:787-790 (2009)) by oralgavage or intraperitonially respectively for five days a week. Growth intumor volume was recorded using digital calipers and tumor volumes wereestimated using the formula (π/6) (L×W²), where L=length of tumor andW=width. Loss of body weight during the course of the study was alsomonitored. At the end of the studies mice were sacrificed and tumorsextracted and weighed. Additionally, femur bone marrow, liver and spleenwere harvested to examine spontaneous metastasis by detecting human-Alusequence. Briefly, genomic DNA from femur bone marrow, liver and spleenwere prepared using Puregene DNA purification system (Qiagen), followedby quantification of human ALU sequence by human Alu specificFluorogenic TaqMan qPCR probes as described (Tran, C. et al., Science324:787-790 (2009); van der Horst, E. H. et al., Biotechniques37:940-942, 944, 946 (2004)). For CRPC experiment, VCaP tumor bearingmice were castrated when the tumors were approximately 200 mm³ in sizeand randomized later once the tumor grew back to the pre-castration sizeand treated with JQ1 or vehicle (D5W) control. All procedures involvingmice were approved by the University Committee on Use and Care ofAnimals (UCUCA) at the University of Michigan and conform to allregulatory standards.

Prostate Histology and Hormone Measurement

Four to five weeks old male SCID C.B17 mice were administered vehicle,10 mg/kg MDV3100 or 50 mg/kg JQ1, by oral gavage or intraperitonially,respectively for five days a week. Highly hormone responsive seminalvesicles attached to prostate were harvested from mice after four weeksof injection. Prostate were fixed in formalin solution and processed forsectioning. Standard H&E staining was achieved on the formalin fixedsections and were used to image the different lobes of the gland. Todetermine the testosterone levels, blood samples were collected bycardiac puncture from mice anesthetized with isoflurane. The serum wasseparated from the blood and stored at −80° C. until assayed. Serumtestosterone levels were measured by the Ligand Assay at University ofMichigan-ULAM Pathology Cores for Animal Research.

TABLE 6 AR target gene list: Common upregulated genes upon DHTstimulation in VCaP and LNCaP cells used for GSEA analysis shown in FIG.6. ABCC4 B3GAT1 ChGn FRK LOX PER1 STEAP4 ABHD2 BC039021 CHIA FZD5 LRCH1PFKFB2 STK17B ACSL3 BC041926 CHKA GADD45G LRIG1 PGC TACC1 ADARB2BC041955 CHST2 GIPR LSS PHACTR3 TBRG1 AF349445 BC055421 CLDN12 GREB1 MAFPNPLAB TBX15 AFF4 BC062780 CLDN14 GSR MAK PPP2CB TG AI089002 BG462058CLDN8 HERC3 MALT1 RAB27A TGFB2 AI207522 BG618474 CTBP1 HLA-DRB3 MAP1BRAB4A TIPARP AI570240 BI710972 CUTL2 HOMER2 MAP7D1 RASD1 TLOC1 AK023880BM469851 CXorf9 HPGD MBOAT2 RHOU TMCC3 AK025380 BMPR1B CYP1A1 HS3ST4MFSD2 RUNX1 TMPRSS2 AK055915 BQ017638 CYP2U1 HSD17B2 MICAL1 S100A5TNFAIP3 AK057576 BQ706282 DDR2 IFI6 MLPH SCRG1 TPD52 AK074291 BRP44DHCR24 IGF1 MOGAT2 SGK TRIM36 AK092594 BU567141 DKFZp761PG IGF1R MPZL1SHROOM3 TRIM63 AK093002 BU753102 DNAJB9 IL20RA MTMR9 SLC16A6 TTNAK098478 BX099483 DOCK11 IMPAD1 NANOGP1 SLC26A2 TUBA3D AK124281C10orf114 DOCK8 INPP4B NAT1 SLC26A3 WIPI1 AK124426 C14orf162 EAF2 KCNMA1NCAPD3 SLC2A14 WNT7B AL533190 C16orf30 EDG7 KLF15 NDFIP2 SLC2A3 WWTR1AL713762 C18orf1 ELL2 KLK3 NDRG1 SLC38A4 X03757 ALDH1A3 C1orf108 ELOVL5KLK4 NEBL SLC41A1 ZBTB1 AMAC1L2 C1orf113 ELOVL7 KLK5 NEK10 SLC45A3ZBTB16 ANKRD37 C1orf26 EMP1 KRT18 NFKBIA SLITRK6 ZBTB24 ANXA2 C20orf112ENDOD1 KRT19 NNMT SMC4 ARSG C6orf81 ENST000003 KRT72 NR4A1 SMOC1 ASRGL1CA314451 ERN1 LAMA1 NY-REN-7 SNAI2 ATP10A CA414006 ERRFI1 LDLR ODC1SNTG2 ATP1A1 CBLL1 F2RL1 LIFR OLAH SOCS2 ATP1A4 CCDC4 FAM13A1OSLOC205251 ORM1 SPDEF ATRNL1 CDC14B FER1L3 LOC401708 ORM2 SPDYA AUTS2CDC14C FGD4 LOC641467 OTUD7B SPINK5L3 AW029229 CDYL2 FKBP5 LOC646282PACS1 SPOCK1 AW389914 CEBPD FLJ31568 LOC730498 PDLIM5 SPTB AZGP1 CENPNFLJ39502 LONRF1 PECI ST6GALNAC1

TABLE 7 GSEA showing loss of MYC signature (4 gene set) in AR-positivecells but not AR-negative DU145 cells after JQ1 treatment. P- FDR-qSample Gene set Size NES value value VCaP MYC_UP.V1_UP 113 −2.265 0 0SCHUHMACHER_MYC_TARGETS_UP 70 −2.275 0 0SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 39 −1.824 0 0.028SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 28 −1.818 0 0.029 LNCaPMYC_UP.V1_UP 113 −2.068 0 0.001 SCHUHMACHER_MYC_TARGETS_UP 70 −2.403 0 0SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 39 −1.957 0 0.005SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 28 −1.751 0 0.026 22RV1MYC_UP.V1_UP 113 −1.712 0 0.011 SCHUHMACHER_MYC_TARGETS_UP 70 −1.851 00.079 SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 39 −1.353 0.066 0.278SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 28 −1.521 0.025 0.195 DU145MYC_UP.V1_UP 113 −0.952 0.574 0.753 SCHUHMACHER_MYC_TARGETS_UP 70 −1.0860.285 0.521 SCHLOSSER_MYC_TARGETS_AND_SERUM_RESPONSE_UP 39 −0.734 0.8980.988 SCHLOSSER_MYC_AND_SERUM_RESPONSE_SYNERGY 28 −1.085 0.319 0.523size—number of genes in each set; NES—normalized enrichment score; p-and FDRq, test of statistical significance.

TABLE 8 High-throughput sequencing read information for ChIP librariesof BRD2, BRD3, BRD4, AR, RNA Pol.II, ERG, H3K27ac and IgG. Total readsMapped reads unique reads # ChIP-seq sample (millions) (millions)(millions) % unique 1 BRD2_VEH 57.15 51.32 50.78 88.86 2 BRD2_JQ1 83.5675.03 74.10 88.68 3 BRD2_I-BET762 72.05 64.55 63.91 88.70 4 BRD3_VEH50.59 46.55 46.11 91.14 5 BRD3_JQ1 62.88 57.24 56.66 90.11 6BRD3_I-BET762 64.46 58.68 58.12 90.17 7 BRD4_VEH 68.56 66.93 64.24 93.698 BRD4_JQ1 50.21 46.21 45.74 91.08 9 BRD4_I-BET762 61.21 56.28 55.5690.78 10 AR_VEH_Exp.1 73.98 68.90 57.52 77.75 11 AR_VEH_Exp.2 84.6973.54 41.45 48.94 12 AR_VEH_DHT_Exp.1 69.98 65.52 44.71 63.89 13AR_VEH_DHT_Exp.2 57.58 53.14 38.40 66.69 14 AR_DHT_JQ1_Exp.1 73.86 69.7464.23 86.97 15 AR_DHT_JQ1_Exp.2 57.51 53.64 40.42 70.29 16AR_DHT_MDV3100_Exp.1 79.23 74.48 58.89 74.33 17 AR_DHT_MDV3100_Exp.271.52 60.62 37.44 52.35 18 AR_DHT_Bicalutamide_Exp.1 82.22 76.46 64.4678.40 19 AR_DHT_Bicalutamide_Exp.2 112.46 97.64 48.51 43.13 20 BRD4_VEH34.31 32.50 30.60 89.20 21 BRD4_DHT 35.37 33.47 31.59 89.30 22BRD4_DHT_JQ1 36.16 34.07 32.81 90.75 23 BRD4_DHT_MDV3100 41.23 38.2937.25 90.34 24 BRD4_DHT_Bica1utamide 40.83 37.75 36.35 89.03 25 RNA PolII_VEH 72.24 67.17 65.32 90.43 26 RNA Pol II_DHT 65.89 61.97 59.18 89.8327 RNA Pol II_DHT_JQ1 64.11 60.53 59.23 92.39 28 RNA Pol II_DHT_MDV310065.18 62.01 60.60 92.97 29 RNA Pol II_DHT_Bicalutamide 69.77 65.88 63.9691.67 30 ERG_VEH_Exp.1 59.42 56.18 38.54 64.86 31 ERG_VEH_Exp.2 50.7949.20 45.53 89.64 32 ERG_JQ1_Exp.1 62.22 59.81 50.07 80.48 33ERG_JQ1_Exp.2 55.83 52.71 38.56 69.07 34 H3K27ac 59.31 57.99 56.26 94.8535 IgG 64.80 49.27 12.98 20.03

TABLE 9 PCR primers. SYBR QPCR primers BRD2_Fwd BRD2_Rev BRD3_FwdBRD3_Rev BRD4_Fwd BRD4_Rev ERG_Fwd ERG_Rev PSA_Fwd PSA_Rev TMPRSS2_FwdTMPRSS2_Rev FKBP5_Fwd FKBP5_Rev SLC45A3_Fwd SLC45A3_Rev MYC_Fwd MYC_RevAR_Fwd AR_Rev ETV1_Fwd ETV1_Rev GAPDH_Fwd GAPDH_Rev gMYC dis.Enh_FwdgMYC dis.Enh_Rev gMYC upstream_Fwd gMYC upstream_Rev TaqMan QPCR probeTDRD1 CACNA1D ARHGDIB NDRG1 VCL KRT8 MALAT1 BCL-XL WNT2 CRISP3

TABLE 10 Antibodies. Antibody Use Supplier Cat. No. AR_PG-21 ChIP-seqMillipore 06-680 AR IP, IB Abcam ab74272 RNA Pol II IB, ChIP-seq Abcamab5408 BRD2 IB Abnova PAB3245 BRD2 IB, ChIP-seq Bethyl A302-583A BRD3 IBSanta Cruz sc-81202 BRD3 IB, ChIP-seq Bethyl A302-368A BRD4 IB, ChIP-seqBethyl A301-985A ERG IB Epitomics 2805-1 MYC IB Sigma M5546 PSA IB DakoA0562 GST IB GE Life Science 27-4577-01 Halo IP, IB Promega G9281 PolyHistidine IP, IB Sigma H1029 BCL-X1 IB Cell Signaling 2762 cPARP IB CellSignaling 9541 GAPDH(14C10) IB Cell Signaling 3683SIP—Immunoprecipitation IB—Immunoblot analysis ChIP-seq—ChromatinImmunoprecipitation followed by sequencing

Having now fully described the methods, compounds, and compositions ofmatter provided herein, it will be understood by those of skill in theart that the same can be performed within a wide and equivalent range ofconditions, formulations, and other parameters without affecting thescope of the methods, compounds, and compositions provided herein or anyembodiment thereof. All patents, patent applications and publicationscited herein are fully incorporated by reference herein in theirentirety.

1-48. (canceled)
 49. A method of treating a patient comprisingadministering to the patient a therapeutically effective amount of thecompound having Formula I:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein: B¹ is —N═ or —C(R^(1b))—; B² is —N═ or —C(R^(1c))—; Y¹ isselected from the group consisting of —C(R^(2a))═ and —N═; Y² isselected from the group consisting of —C(R^(2b))═ and —N═; Y³ isselected from the group consisting of —C(R^(2c))═ and —N═; G is selectedfrom the group consisting of halo, hydroxy, cyano, optionallysubstituted cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl, aralkyl, (heteroaryl)alkyl, —OS(═O)₂CF₃, and—Z—R³; R^(1a) and R^(1b) are each independently selected from the groupconsisting of hydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio,amino, and halo; R^(1c) is selected from the group consisting ofhydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, andfluoro; R^(2a) and R^(2c) are independently selected from the groupconsisting of hydrogen, halo, alkyl, and carboxamido; R^(2b) is selectedfrom the group consisting of hydrogen, amino, optionally substitutedalkyl, hydroxyalkyl, alkoxyalkyl, heteroalkyl, (heterocyclo)alkyl,(amino)alkyl, optionally substituted cycloalkyl, optionally substitutedheterocyclo, and carboxamido; R³ is selected from the group consistingof optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, and optionally substitutedheterocyclo; A is optionally substituted 5-membered heteroaryl; X¹ isselected from the group consisting of —O—, —S—, and —N(R^(5a1))—; Z isselected from the group consisting of —C(═O)—, —O—, —S—, —SO₂—, and—N(R^(5b1))—; R^(5a1) is selected from the group consisting of hydrogenand alkyl; and R^(5b1) is selected from the group consisting of hydrogenand alkyl, with the provisos that: a) when G is halo, hydroxy, cyano,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, (heteroaryl)alkyl, or—OS(═O)₂CF₃ then either B¹ or B², or both, is —N═; or b) when G is halo,hydroxy, cyano, optionally substituted cycloalkyl, optionallysubstituted aryl, optionally substituted heteroaryl, aralkyl,(heteroaryl)alkyl, or —OS(═O)₂CF₃ then either R^(1b) or R^(1c), or both,is hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, carboxamido, orfluoro; and c) A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein: R^(4a) and R^(4b) are each independently selected from thegroup consisting of hydrogen, halo, haloalkyl, and alkyl; and X⁵ isselected from the group consisting of —O— and —S—, wherein the patienthas cancer, a chronic autoimmune disorder, an inflammatory condition, aproliferative disorder, sepsis, or a viral infection.
 50. The methodclaim 49, wherein the patient has cancer.
 51. The method of claim 50,wherein the cancer is selected from the group consisting of adrenalcancer, acinic cell carcinoma, acoustic neuroma, acral lentigiousmelanoma, acrospiroma, acute eosinophilic leukemia, acute erythroidleukemia, acute lymphoblastic leukemia, acute megakaryoblastic leukemia,acute monocytic leukemia, acute promyelocytic leukemia, adenocarcinoma,adenoid cystic carcinoma, adenoma, adenomatoid odontogenic tumor,adenosquamous carcinoma, adipose tissue neoplasm, adrenocorticalcarcinoma, adult T-cell leukemia/lymphoma, aggressive NK-cell leukemia,AIDS-related lymphoma, alveolar rhabdomyosarcoma, alveolar soft partsarcoma, ameloblastic fibroma, anaplastic large cell lymphoma,anaplastic thyroid cancer, angioimmunoblastic T-cell lymphoma,angiomyolipoma, angiosarcoma, astrocytoma, atypical teratoid rhabdoidtumor, B-cell chronic lymphocytic leukemia, B-cell prolymphocyticleukemia, B-cell lymphoma, basal cell carcinoma, biliary tract cancer,bladder cancer, blastoma, bone cancer, Brenner tumor, Brown tumor,Burkitt's lymphoma, breast cancer, brain cancer, carcinoma, carcinoma insitu, carcinosarcoma, cartilage tumor, cementoma, myeloid sarcoma,chondroma, chordoma, choriocarcinoma, choroid plexus papilloma,clear-cell sarcoma of the kidney, craniopharyngioma, cutaneous T-celllymphoma, cervical cancer, colorectal cancer, Degos disease,desmoplastic small round cell tumor, diffuse large B-cell lymphoma,dysembryoplastic neuroepithelial tumor, dysgerminoma, embryonalcarcinoma, endocrine gland neoplasm, endodermal sinus tumor,enteropathy-associated T-cell lymphoma, esophageal cancer, fetus infetu, fibroma, fibrosarcoma, follicular lymphoma, follicular thyroidcancer, ganglioneuroma, gastrointestinal cancer, germ cell tumor,gestational choriocarcinoma, giant cell fibroblastoma, giant cell tumorof the bone, glial tumor, glioblastoma multiforme, glioma, gliomatosiscerebri, glucagonoma, gonadoblastoma, granulosa cell tumor,gynandroblastoma, gallbladder cancer, gastric cancer, hairy cellleukemia, hemangioblastoma, head and neck cancer, hemangiopericytoma,hematological malignancy, hepatoblastoma, hepatosplenic T-cell lymphoma,Hodgkin's lymphoma, non-Hodgkin's lymphoma, invasive lobular carcinoma,intestinal cancer, kidney cancer, laryngeal cancer, lentigo maligna,lethal midline carcinoma, leukemia, leydig cell tumor, liposarcoma, lungcancer, lymphangioma, lymphangiosarcoma, lymphoepithelioma, lymphoma,acute lymphocytic leukemia, acute myelogeous leukemia, chroniclymphocytic leukemia, liver cancer, small cell lung cancer, non-smallcell lung cancer, MALT lymphoma, malignant fibrous histiocytoma,malignant peripheral nerve sheath tumor, malignant triton tumor, mantlecell lymphoma, marginal zone B-cell lymphoma, mast cell leukemia,mediastinal germ cell tumor, medullary carcinoma of the breast,medullary thyroid cancer, medulloblastoma, melanoma, meningioma, merkelcell cancer, mesothelioma, metastatic urothelial carcinoma, mixedMullerian tumor, mucinous tumor, multiple myeloma, muscle tissueneoplasm, mycosis fungoides, myxoid liposarcoma, myxoma, myxosarcoma,nasopharyngeal carcinoma, neurinoma, neuroblastoma, neurofibroma,neuroma, nodular melanoma, ocular cancer, oligoastrocytoma,oligodendroglioma, oncocytoma, optic nerve sheath meningioma, opticnerve tumor, oral cancer, osteosarcoma, ovarian cancer, Pancoast tumor,papillary thyroid cancer, paraganglioma, pinealoblastoma, pineocytoma,pituicytoma, pituitary adenoma, pituitary tumor, plasmacytoma,polyembryoma, precursor T-lymphoblastic lymphoma, primary centralnervous system lymphoma, primary effusion lymphoma, preimary peritonealcancer, prostate cancer, pancreatic cancer, pharyngeal cancer,pseudomyxoma periotonei, renal cell carcinoma, renal medullarycarcinoma, retinoblastoma, rhabdomyoma, rhabdomyosarcoma, Richter'stransformation, rectal cancer, sarcoma, Schwannomatosis, seminoma,Sertoli cell tumor, sex cord-gonadal stromal tumor, signet ring cellcarcinoma, skin cancer, small blue round cell tumors, small cellcarcinoma, soft tissue sarcoma, somatostatinoma, soot wart, spinaltumor, splenic marginal zone lymphoma, squamous cell carcinoma, synovialsarcoma, Sezary's disease, small intestine cancer, squamous carcinoma,stomach cancer, T-cell lymphoma, testicular cancer, thecoma, thyroidcancer, transitional cell carcinoma, throat cancer, urachal cancer,urogenital cancer, urothelial carcinoma, uveal melanoma, uterine cancer,verrucous carcinoma, visual pathway glioma, vulvar cancer, vaginalcancer, Waldenstrom's macroglobulinemia, Warthin's tumor, and Wilms'tumor.
 52. The method of claim 51, wherein the cancer is selected fromthe group consisting of acute monocytic leukemia, acute myelogenousleukemia, chronic myelogenous leukemia, chronic lymphocytic leukemiamixed lineage leukaemia, NUT-midline carcinoma, multiple myeloma, smallcell lung cancer (SCLC), neuroblastoma, Burkitt's lymphoma, cervicalcancer, esophageal cancer, ovarian cancer, colorectal cancer, prostatecancer, and breast cancer.
 53. The method of claim 50, wherein thecancer is breast cancer having active androgen receptor signaling. 54.The method of claim 50, wherein the cancer is prostate cancer havingactive androgen receptor signaling.
 55. The method of claim 50 furthercomprising administering a therapeutically effective amount of a secondtherapeutic agent useful in the treatment of the disease or condition.56-67. (canceled)
 68. A kit comprising the compound having Formula I:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein: B¹ is —N═ or —C(R^(1b))—; B² is —N═ or —C(R^(1c))—; Y¹ isselected from the group consisting of —C(R^(2a))═ and —N═; Y² isselected from the group consisting of —C(R^(2b))═ and —N═; Y³ isselected from the group consisting of —C(R^(2c))═ and —N═; G is selectedfrom the group consisting of halo, hydroxy, cyano, optionallysubstituted cycloalkyl, optionally substituted aryl, optionallysubstituted heteroaryl, aralkyl, (heteroaryl)alkyl, —OS(═O)₂CF₃, and—Z—R³; R^(1a) and R^(1b) are each independently selected from the groupconsisting of hydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio,amino, and halo; R^(1c) is selected from the group consisting ofhydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, andfluoro; R^(2a) and R^(2c) are independently selected from the groupconsisting of hydrogen, halo, alkyl, and carboxamido; R^(2b) is selectedfrom the group consisting of hydrogen, amino, optionally substitutedalkyl, hydroxyalkyl, alkoxyalkyl, heteroalkyl, (heterocyclo)alkyl,(amino)alkyl, optionally substituted cycloalkyl, optionally substitutedheterocyclo, and carboxamido; R³ is selected from the group consistingof optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, and optionally substitutedheterocyclo; A is optionally substituted 5-membered heteroaryl; X¹ isselected from the group consisting of —O—, —S—, and —N(R^(5a))—; Z isselected from the group consisting of —C(═O)—, —O—, —S—, and —SO₂— and—N(R^(5b1))—; R^(5a1) is selected from the group consisting of hydrogenand alkyl; and R^(5b1) is selected from the group consisting of hydrogenand alkyl, with the provisos that: a) when G is halo, hydroxy, cyano,optionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, aralkyl, (heteroaryl)alkyl, or—OS(═O)₂CF₃ then either B¹ or B², or both, is —N═; or b) when G is halo,hydroxy, cyano, optionally substituted cycloalkyl, optionallysubstituted aryl, optionally substituted heteroaryl, aralkyl,(heteroaryl)alkyl, or —OS(═O)₂CF₃ then either R^(1b) or R^(1c), or both,is hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, carboxamido, orfluoro; and c) A is not 1,3-dimethyl-1H-pyrazol-4-yl, or:

wherein: R^(4a) and R^(4b) are each independently selected from thegroup consisting of hydrogen, halo, haloalkyl, and alkyl; and X⁵ isselected from the group consisting of —O— and —S—, and instructions foradministering the compound, or a pharmaceutically acceptable salt,hydrate, or solvate thereof, to a patient having cancer, a chronicautoimmune disorder, an inflammatory condition, a proliferativedisorder, sepsis, or a viral infection. 69-72. (canceled)
 73. A methodof preparing having Formula II:

or a pharmaceutically acceptable salt, hydrate, or solvate thereof,wherein: R¹ is selected from the group consisting of hydrogen, hydroxy,alkyl, haloalkyl, alkoxy, alkylthio, amino, and halo; R² is selectedfrom the group consisting of hydrogen, amino, alkyl, hydroxyalkyl,alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl, optionally substitutedcycloalkyl, optionally substituted heterocyclo, and carboxamido; R³ isselected from the group consisting of optionally substituted cycloalkyl,optionally substituted aryl, optionally substituted heteroaryl, andoptionally substituted heterocyclo; A is optionally substituted5-membered heteroaryl; X¹ is selected from the group consisting of —O—,—S—, and —N(R^(5a1))—; Y¹ is selected from the group consisting of —CH═and —N═; Z is selected from the group consisting of —O—, —S—, —SO₂—, and—N(R^(5b1))— R^(5a1) is selected from the group consisting of hydrogenand alkyl; and R^(5b1) is selected from the group consisting of hydrogenand alkyl, with the proviso that A is not 1,3-dimethyl-1H-pyrazol-4-yl,or:

wherein: R^(4a) and R^(4b) are each independently selected from thegroup consisting of hydrogen, halo, haloalkyl, and alkyl; and X⁵ isselected from the group consisting of —O— and —S—, the methodcomprising: a) reacting a compound of Formula VII:

wherein: L is a leaving group; R¹ is selected from the group consistingof hydrogen, hydroxy, alkyl, haloalkyl, alkoxy, alkylthio, amino, andhalo; R² is selected from the group consisting of hydrogen, amino,alkyl, hydroxyalkyl, alkoxyalkyl, (heterocyclo)alkyl, (amino)alkyl,optionally substituted cycloalkyl, optionally substituted heterocyclo,and carboxamido; A is optionally substituted 5-membered heteroaryl; X¹is selected from the group consisting of —O—, —S—, and —N(R^(5a1))—; Y¹is selected from the group consisting of CH and N; and R^(5a1) isselected from the group consisting of hydrogen and alkyl, with acompound having Formula VIII:H—Z—R³  VIII wherein: Z is selected from the group consisting of —O—,—S—, and —N(R^(5b1))—; R³ is selected from the group consisting ofoptionally substituted cycloalkyl, optionally substituted aryl,optionally substituted heteroaryl, and optionally substitutedheterocyclo; and R^(5b1) is selected from the group consisting ofhydrogen and alkyl, and b) isolating the compound having Formula II. 74.The method of claim 73, wherein the reacting is carried out in asolvent.
 75. The method of claim 74, wherein the solvent is selectedfrom the group consisting of dimethylformamide, acetonitrile, dimethylsulfoxide, and N-methyl-2-pyrrolidone.
 76. The method of claim 73,wherein the reacting is carried out at a temperature of about 50° C. toabout 200° C.
 77. The method of claim 73, wherein L is a leaving groupselected from the group consisting of Cl, I, Br, and OSO₂R⁶, wherein R⁶is selected from the group consisting of alkyl, haloalkyl, andoptionally substituted aryl.
 78. The method of claim 49, wherein: A isselected from the group consisting of:

R^(4a), R^(4b), and R^(4c) are each independently selected from thegroup consisting of hydrogen and alkyl; X² is selected from the groupconsisting of —O—, —S—, and —N(R^(5c1))—; and R^(5c1) is selected fromthe group consisting of hydrogen and alkyl.
 79. The method of claim 78,wherein A is A-3 and X² is —N(R^(5c1))—.
 80. The method of claim 49,wherein Z is —NH—.
 81. The method of claim 49, wherein Y² is —C(R^(2b))═and R^(2b) is alkyl.
 82. The method of claim 49, wherein Y¹ is —N═. 83.The method of claim 80, wherein R³ is optionally substituted heteroaryl.84. The method of claim 49, wherein said compound having Formula I isselected from the group consisting of:7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-phenyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;4-(4-((4-Isopropyl-5-methyl-4H-1,2,4-triazol-3-yl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-5-methyl-3-phenyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(5-methyl-4-phenyl-1H-pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)-4-phenylthiazol-5-amine;N-(1-(3-chlorophenyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,3-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3-c]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(5-chloro-1-methyl-1H-indazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyrimidin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-2-isopropyl-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(6-methoxy-1-methyl-1H-indazol-3-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(1-methyl-1H-indazol-3-yl)-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;4-(4-((2-chlorophenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((3-chlorophenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((2-isopropylphenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((1H-indol-3-yl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((3-(tert-butyl)phenyl)thio)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;(R)—N-(chroman-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-1H-1,2,4-triazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-(tert-butyl)-1,5-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(5-(tert-butyl)-1,3-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(4-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;4-(tert-butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)thiazol-5-amine;N-(1,3-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;3-(4-chlorophenyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-methylisoxazol-4-amine;3-(3-chlorophenyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-methylisoxazol-4-amine;4-(3-chlorophenyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)thiazol-5-amine;4-(4-chlorophenyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-(oxazol-2-yl)thiazol-5-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-isopropyl-4-phenylthiazol-5-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(5-methyl-2-phenyl-1H-pyrrol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(2-(3-chlorophenyl)-5-methyl-1H-pyrrol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;4-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-N,2-dimethyl-5-phenyl-1H-pyrrole-3-carboxamide;(4-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-2-methyl-5-phenyl-1H-pyrrol-3-yl)(morpholino)methanone;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(5-methoxy-[1,1′-biphenyl]-2-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(4′-chloro-5-methoxy-[1,1′-biphenyl]-2-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(4-((dimethylamino)methyl)-5-methoxy-[1,1′-biphenyl]-2-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(7-phenyl-2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-methyl-7-phenyl-3,4-dihydro-2H-benzo[b][1,4]oxazin-6-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(6-methoxy-4-phenylpyridin-3-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(4-methoxy-2-(pyridin-2-yl)phenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(4-methoxy-2-(pyridin-4-yl)phenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(4-methoxy-2-(oxazol-2-yl)phenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(4-ethoxynaphthalen-1-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(6-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(5-methoxy-1-methyl-1H-indazol-3-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-3-yl)-2-isopropyl-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine;N-(1-(tert-butyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-2-isopropyl-N-(1-isopropyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;2-(5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-3-methyl-1H-pyrazol-1-yl)ethan-1-ol;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-methyl-1-(pyridin-4-yl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(1,3-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)-6-methoxy-2-methyl-N-(pyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethyl-1H-pyrazol-4-yl)-N-(1,3-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;7-(3,5-dimethylisoxazol-4-yl)-2-isopropyl-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-2-(tetrahydro-2H-pyran-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-methyl-1H-pyrazol-5-yl)-6-methoxy-9H-pyrimido[4,5-b]indol-4-amine;N-(1,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,4-dimethyl-1H-pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(4-isopropyl-1-methyl-1H-pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(4-isopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,4-trimethyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,3-diisopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-isopropyl-2-methylthiazol-5-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-methylthiazol-2-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-methylthiazol-2-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-5-methyl-1H-imidazol-2-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-4-methyl-1H-imidazol-2-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-1H-imidazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-isopropyl-3-methylisoxazol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3-isopropyl-5-methylisoxazol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-isopropyl-2-methyloxazol-5-amine;4-(4-((3-chlorophenyl)sulfonyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((4-isopropyl-4H-1,2,4-triazol-3-yl)sulfonyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-(3-chlorophenoxy)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(6-methoxy-2-methyl-4-(pyridin-3-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;N-(3-chlorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-5-methyl-3-phenylisoxazol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(imidazo[1,2-a]pyridin-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(4-methoxynaphthalen-1-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1H-pyrrolo[2,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)thieno[2,3-b]pyridin-3-amine;4-(6-methoxy-2-methyl-4-(quinolin-4-yloxy)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;4-(4-((5-bromopyridin-3-yl)oxy)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole;N-(5-chloropyridin-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-chloro-4-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(5-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4-methylpyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4-methylpyridin-2-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(6-methylpyridin-2-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-cyclohexyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,5-dimethyl-1H-pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-methyl-i1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-(tert-Butyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclopentyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclobutyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-tert-butyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methyl-2,4,5,6-tetrahydrocyclopenta-[c]pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-(tert-butyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(5-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(7-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;2-(3-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-indazol-1-yl)ethanol;7-(3,5-dimethylisoxazol-4-yl)-N-(4-fluoro-1-methyl-1H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;3-(tert-butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)isothiazol-5-amine;N-(5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclopentyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclobutyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(4,5,6,7-tetrahydropyrazolo[1,5-a]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(4-cyclopropyl-1,3-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-ethyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-ethyl-4,5,6,7-tetrahydro-2H-indazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(4-cyclopropyl-1-ethyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-ethyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-(trifluoromethyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(2-cyclopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;2-(3-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-5,6-dihydrocyclopenta[c]pyrazol-2(4H)-yl)ethanol;7-(3,5-dimethylisoxazol-4-yl)-N-(2-(2-fluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,3-dicyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;1-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)ethanone;ethyl3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazole-1-carboxylate;N-(3-cyclopropyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-(2,2,2-trifluoroethyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;2-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)ethanol;N-(3-cyclopropyl-1-(2-fluoroethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(2-(dimethylamino)ethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(1,1,1-trifluoro-2-methylpropan-2-yl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;tert-butyl3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carboxylate;N-(1-(azetidin-3-yl)-3-cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-imidazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethyl-1,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,5-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1,2-dimethyl-1H-imidazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1-methyl-1H-pyrazole-4-carbonitrile;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2,4-dimethylthiazol-5-amine;N-(1-cyclopentyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-isopropyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-(tert-butyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-(tert-butyl)-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3,4-dimethyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclobutyl-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclopropyl-3,4-dimethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-2-isopropyl-4-methylthiazol-5-amine;N-(1-cyclopropyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-(tert-butyl)-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-isopropyl-1,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-(tert-butyl)-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclopropyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclobutyl-4-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-isopropyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclobutyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclobutyl-1-ethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;2-(tert-butyl)-N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4-methylthiazol-5-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-isopropyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(1-cyclopropyl-3-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N4-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(methoxymethyl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-8-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-m-tolyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-methoxyphenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(3-(trifluoromethyl)phenyl)-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,5-dimethylisoxazol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3-ethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-chloro-2-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-methoxy-5-methylphenyl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-3,4-dimethylisoxazol-5-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(isoquinolin-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-4,5-dimethylisoxazol-3-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(isoquinolin-8-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(5-chloro-2-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-chloro-5-fluorophenyl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-phenyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylquinolin-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)benzo[d]thiazol-7-amine;N1-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)-N3,N3-dimethylbenzene-1,3-diamine;7-(3,5-dimethylisoxazol-4-yl)-N-(indolin-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methylindolin-6-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1H-indol-6-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(2,3-dihydrobenzofuran-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-indol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(3,5-dimethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2,5-dimethylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3,5-dicyclopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3,5-diethyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1,3,5-triethyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3,5-diisopropyl-1-methyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropylphenyl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(2-methylpyridin-4-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-4-fluoro-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-ethyl-4-fluoro-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-ethyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-4-fluoro-1-isopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;N-(1-cyclopentyl-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-5H-pyrido[4,3-b]indol-1-amine;N-(3-cyclopropyl-1-(1-methylazetidin-3-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2,9-trimethyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1H-pyrrolo[2,3-c]pyridin-3-yl)-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N-(3-(1-methoxycyclopropyl)-1-methyl-1H-pyrazol-5-yl)-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;2-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)-N-ethylacetamide;N-(3-cyclopropyl-1-(piperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(1-ethylpiperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;1-(4-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)piperidin-1-yl)ethanone;N-(3-cyclopropyl-1-(2-methoxyethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(1-methylpiperidin-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;1-(4-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1-methyl-1H-pyrazol-3-yl)ethanone;2-(4-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1-methyl-1H-pyrazol-3-yl)propan-2-ol;N-(3-tert-butyl-1,5-dimethyl-1H-pyrazol-4-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;methyl5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1-methyl-1H-pyrazole-3-carboxylate;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-3-(prop-1-en-2-yl)-1H-pyrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((2-methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-amine;1-(3-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)azetidin-1-yl)ethanone;methyl3-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)azetidine-1-carboxylate;N-(3-cyclopropyl-1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;(2S)-4-(3-cyclopropyl-5-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-ylamino)-1H-pyrazol-1-yl)butane-1,2-diol;(S)-3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)propane-1,2-diol;N-(1-((1,4-dioxan-2-yl)methyl)-3-cyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(2-morpholinoethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-(2-methoxyethyl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((2-methoxyethoxy)methyl)-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-((methylsulfonyl)methyl)-9H-pyrimido[4,5-b]indol-4-amine;N4-(3-cyclopropyl-1-ethyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine;N4-(1,3-dicyclopropyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine;7-(3,5-dimethylisoxazol-4-yl)-N4-(2-isopropyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-6-methoxy-9H-pyrimido[4,5-b]indole-2,4-diamine;3-(3-cyclopropyl-5-((7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-yl)amino)-1H-pyrazol-1-yl)azetidine-1-carbaldehyde;N-(3-cyclopropyl-1-(oxetan-3-ylmethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[3′,2′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-5-fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-fluoro-6-methoxy-2-methyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-8-fluoro-6-methoxy-N,2-dimethyl-9H-pyrimido[4,5-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-fluoro-8-methoxy-5H-pyrido[4,3-b]indol-1-amine;N-(1-(tert-butyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-N-(m-tolyl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(1-(tert-butyl)-3-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-N-(m-tolyl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-N-(1-methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;7-(3,5-dimethylisoxazol-4-yl)-N-(1-isopropyl-4-methyl-1H-pyrazol-5-yl)-6-methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-N,2-dimethyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrido[3,4-b]indol-4-amine;N-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-9H-pyrido[2,3-b]indol-4-amine;4-(6-methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole;methyl4-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-yl)-1-naphthoate;2-(3-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)propan-2-ol;4-(4-(3,5-diethyl-1-methyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole;5-cyclopropyl-4-(7-(3,5-dimethylisoxazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-4-yl)-3-methylisoxazole;4-(4-(5-cyclopropyl-1,3-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole;4-(4-(3-cyclopropyl-1,5-dimethyl-1H-pyrazol-4-yl)-6-methoxy-2-methyl-9H-pyrido[2′,3′:4,5]pyrrolo[2,3-d]pyrimidin-7-yl)-3,5-dimethylisoxazole;andN-(3-cyclopropyl-1-methyl-1H-pyrazol-5-yl)-6-methoxy-2-methyl-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-9H-pyrimido[4,5-b]indol-4-amine.